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Abstract 
 
Breast cancer is the most common cancer in women worldwide, accounting for a quarter of 
all female cancer cases. Despite improvements in early diagnosis and treatment, the mortality 
rate for breast cancer has remained stubbornly high, with some subtypes unresponsive to 
current treatments. One reason for this is the metabolic heterogeneity of breast cancer, with 
some sub-types having poor treatment options. Breast cancer may be considered as a 
metabolic disease due to the high metabolic demand associated with tumour growth. This 
raises the possibility of targeting cancer metabolic vulnerabilities.  
 
We present a systems biology approach to identify novel drug targets through analysing the 
metabolism of breast cancer and the exploration of novel combination therapies. We explore 
the combination of metabolism-modulating drugs Metformin and GW4064 with 
chemotherapeutic agents in vitro and find some of the combinations are synergistic in breast 
cancer cell lines.  
 
To identify novel drug targets for altering metabolism a novel dynamic computational model 
representing a breast cancer cell integrating genome-scale metabolism is developed, a gene 
and signalling regulatory network and a kinetic cell cycle model. Using the congruency 
approach, we develop context-specific models for breast cancer cell lines and through in 
silico analysis, identify metabolic choke-points as potential drug targets. Two predictions 
were selected for in vitro investigation: IMPase and Serotonin signalling. We demonstrate 
synergy between these targets and traditional cancer chemotherapeutics in causing cell death.  
 
In conclusion, a systems biology approach can enhance and accelerate the identification of 
novel drug targets and aid development of network targeting treatments. The work presented 
here provides an important proof-of-concept to show that computer modelling can predict 
novel drug combinations that increase the ability of currently approved drugs to kill cancer 
cells. As such, it offers new opportunities to optimise breast cancer treatment and move 
toward the goal of making breast cancer a fully treatable disease.  
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Chapter 1 
1 Introduction 
 
 
1.1 General introduction 
 
Breast cancer is the most common cancer in women worldwide, accounting for a quarter of 
all female cancer cases (International Agency for Research on Cancer, 2012). It is the second 
most common cancer in the world: the global age standardised rate (ASR) is 46.3 per 100,000 
people. Notably, ASR of breast cancer differs widely according to income levels; World 
Health Organisation (WHO) defined ‘high income countries’ have an average ASR or 78.3 
per 100,000 people, whereas ‘low income countries’ have an average ASR of 28.6 per 
100,000 (Bray et al., 2018). ASR in the UK and USA is particularly high; 93.6 and 84.9 cases 
per 100,000 respectively (Bray et al., 2018).  
 
Age standardised global mortality rate for breast cancer is 11.2 per 100,000 (Bray et al., 
2018). Trends in death rate from breast cancer remained stable between 1930 and 1990, but 
have seen a steady decrease since 1990. From 2006 to 2015, breast cancer death rates in the 
USA have declined 2.6% annually; seeing almost a 25% decrease in mortality over a decade 
(National Cancer Institute, 2018). However, prognosis largely depends on a number of 
variables, notably; stage at diagnosis, grade and breast cancer subtype. The stage at diagnosis 
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refers to the extent to which the cancer has spread. The stage can be determined using a 
rating system such as ‘TNM’, which considers spread of the primary tumour within the breast 
and neighbouring tissue (T), spread to nearby lymph nodes (N) and distant metastases (M). 
The cancer is given a stage between 0, no spread and IV, advanced disease (Edge and 
Compton, 2010). For patient groups, this staging system accurately predicts prognosis and 
outcome: for advanced disease (stage IV), the 5-year relative survival rate is just over 25% of 
patients, whereas for localised disease (stage o), 5-year relative survival is 99% (SEER, 
2016). However, recent interrogation of the system found less accurate predictions when 
applied to individual patients. This is because there are a number of other confounding 
variables that effect patient survival including menopausal status, age at diagnosis, body mass 
index, comorbidities and the presence or absence of mutations in tumour suppressor genes 
(Ess et al., 2018; Siotos et al., 2018; Cacho-Díaz et al., 2019; Sønderstrup et al., 2019).  
 
This prompted recent updates to the system to incorporate biological factors such as hormone 
receptor status in the staging and to fine tune definitions within TNM, such as that of primary 
tumours (Giuliano et al., 2017). Breast cancer subtype can refer to a number of distinguishing 
features but the five main intrinsic or molecular subtypes are: Luminal A, Luminal B, Triple-
negative/basal-like, HER2-enriched and Normal-like. These are based on the genes that the 
cancer expresses (Haque et al., 2012). While progress has been made in treating breast 
cancer, there are still a large number of women who die from the disease. This is in part due 
to the stage at diagnosis, but also on the breast cancer sub-type. The treatment options for the 
different subtypes vary greatly in efficacy and it is therefore important to design optimal 
treatments for all sub-types. 
 
Breast cancer is a heterogonous disease, clinically, histologically and genetically. Developing 
robust subtypes that can be identified at diagnosis is critical to accurately predict prognosis 
and disease development and to tailor treatment plans. Thus, there are a number of ways in 
which breast cancer subtypes are defined.  
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1.2 Hallmarks of cancer 
 
Breast cancer, as with other cancers, is a complex genetic disease that arises through a 
number of cellular alterations that in combination drive malignant transformation. The 
alterations give rise to distinct cellular capabilities that are characterised as hallmarks of 
cancer. The six hallmarks of cancer were defined in 2000 by Hanahan and Weinberg and 
remain a useful means for understanding the biology of this complicated neoplastic disease. 
The hallmarks are: 1) sustaining proliferative signalling, 2) resisting cell death, 3) inducing 
angiogenesis, 4) enabling replicative immortality, 5) evading growth suppressors and 6) 
activating invasion and metastasis (Hanahan and Weinberg, 2000). 
 
 Sustaining proliferative signalling 
 
The replication of non-cancerous cells within the body is dictated by growth signals that 
control progression through the cell cycle. The production of these signals is tightly regulated 
and thus tissues in the body remain stable in size and structure. Cancer cells, contrastingly, 
are able to stimulate their own growth by maintaining aberrant expression of proliferation 
signals in a number of ways. Methods include overexpression of cell surface receptors for 
growth factors or of the growth factors themselves. Additionally, mutations in cancer cells 
may enable the prolonged activation of downstream growth pathways such as MAP-kinase 
without a requirement for growth factor signalling (Davies and Samuels, 2010). 
 
 Evading growth suppressors 
 
As a balance to the positive growth regulators mentioned above, there are a series of negative 
regulators present in the cell to prevent uncontrolled cell division. These negative regulators 
are often termed as tumour suppressors, and their inactivation results in tumour formation 
(Harris, 1995). The first tumour suppressor gene identified was Retinoblastoma (Rb) and 
subsequently a number of different tumour suppressor genes have been characterised. Work 
has found that inhibition of the majority of these tumour suppressor genes can be implicated 
in both heritable and non-heritable forms of cancer (Cooper, 2000). Generally, tumour 
suppressor proteins act as negative regulators of cellular proliferation and thus their 
inactivation results in uncontrolled cell growth and division.  
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 Resistance of cell death 
 
The ability of the body to promote programmed cell death via the apoptotic pathway is 
critical in preventing cancer development and maintaining tissue homeostasis. The process of 
apoptosis refers to programmed cell death and was first described in 1842 by Carl Vogt and 
has been researched extensively since. Apoptosis can be triggered through two distinct, but 
convergent, mechanisms: the extrinsic apoptotic pathway detects signals, typically cytokines, 
from outside of the cell via cell surface receptors; in contrast, the intrinsic pathway triggers 
apoptosis in response to stimuli from within the cell such as DNA damage (Adams and Cory, 
2007). Tumour cells often develop means to evade apoptosis, which leads to malignantly 
transformed cells not being destroyed. Mechanisms by which tumour cells inactivate 
apoptosis include: loss of damage sensors; increasing expression of anti-apoptotic regulators; 
or, circumventing the ligand induced pathway.  
 
 Enabling replicative immortality  
 
The majority of cells within the body have a limited number of cell division cycles, termed 
the Hayflick Limit. Once a cell passes the Hayflick limit it enters replicative senescence and 
no longer divides. This occurs due to progressive the telomere shortening that occurs with 
each cell division and acts as a mechanism of tumour suppression (Campisi, 2001). 
Telomeres protect the ends of DNA against damage during replication and are made up of 
hexanucleotide repeats and the length of a telomere determines the number of cell divisions a 
cell can safely undertake. During cancer, cells can evade senescence by preventing the 
incremental loss of telomere length, and hence the entry into senescence. Telomerase is a 
reverse transcriptase that generates a new strand of telomeres by adding T2AG3 units using an 
inbuilt RNA template (Sandin and Rhodes, 2014), (Yang et al., 2016). In the majority of 
human cells there is insufficient telomerase to counter telomere shortening. In contrast, 
almost 90% of cancer cell lines express telomerase in levels sufficient to prevent telomere 
shortening during cell replication (Hanahan and Weinberg, 2011). This prevents the cell 
reaching the Hayflick limit and entering senescence, and enables the growth of tumours from 
a small cell population (Yang et al., 2016).  
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 Inducing angiogenesis 
 
Proliferation of newly formed tumours depends upon sufficient energy and oxygen as well as 
a means to remove potentially harmful metabolic by-products. To achieve this, tumours must 
primarily possess a good blood supply, with good access to lymph channels also 
advantageous. Angiogenesis is the process by which new blood vessels are formed and 
lymphogenesis is the development of new lymph channels. Both of these processes are 
stimulated by signals produced within a tumour during rapid growth (Folkman et al., 1971). 
These signals are regulators of angiogenesis and include: basic fibroblast growth factor 
(bFGF), transforming growth factor (TGF) and vascular endothelial growth factor (VEGF), 
which is found in approximately half of all human cancers examined (Salven et al., 1998).  
 
 Activating invasion and metastasis 
 
Cancer metastasis is the transfer of cancer cells from their place of origin to another tissue, 
whereupon they may form a secondary tumour. This process was first described by Paget in 
the Lancet in 1989 as the seed and soil hypothesis (Paget, 1989). Further examination of this 
process has revealed its complexity and the plethora of processes required for it to occur 
(Mollabashy and Scarborough, 2000). A generalised process of the stages metastasis is 
illustrated in Figure 1-1. The primary tumour initially invades neighbouring tissues and 
traverses basement membranes until a blood vessel or lymph vessel is reached. At this stage, 
isolated cancer cells may break off from the tumours and enter the circulatory or lymphatic 
system. These cells then have the capacity to invade different organs in the body and begin 
proliferating at a new site (Hunter et al., 2008), (Talmadge and Fidler, 2010). Understanding 
the ability of cancer cells to metastasise and form disseminated disease is critical in 
developing treatment plans and estimating prognosis. These signals can be stimulated by 
rapid cellular proliferation or through environmental cues such as detection of hypoxic 
conditions. 
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Figure 1-1. Pictorial representation of the process of metastasis (Saxena and Christofori, 2013) 
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1.3 Aetiology and epidemiology of breast cancer 
 
 Epidemiology  
 
The identification of breast cancer risk factors continues to evolve as the general 
understanding of the molecular mechanisms behind the disease improve. Well characterised 
risk factors include age (National Cancer Institute, 2018), with the risk of breast cancer in 
women over 70 years old almost eight times higher than in women under the age of 49. 
Reproductive activity is another factor that contributes to breast cancer risk (Kelsey, 
Gammon and John, 1993). Women who are younger than 12 at menarche or older than 55 at 
menopause have a 1.3 and 1.5 times higher relative risk of developing breast cancer. Lower 
age at first pregnancy and breast feeding can confer protective effects against developing 
breast cancer (Newcomb et al., 1994). Family history is also a well characterised risk of 
breast cancer development, with the population prevalence of hereditary breast cancer 
phenotypes approximately 6% (Hughes et al., 2003; Pharoah et al., 2000; Palomaki et al., 
2006; Palmero et al., 2009). This familial risk is conferred in some cancers through BRCA1 
and BRCA2 genetic mutations (Loman et al., 2001). Two tumour suppressors BRCA1 and 
BRCA2 have been strongly associated with the development of inherited breast cancer. 
BRCA1 protein, aids DNA damage repair and thus conserves genetic stability. The protein 
associates with others to form the BASC complex (BRCA1 – associated genome surveillance 
complex). Mutations in this gene account for 40% of inherited breast cancer cases (Clark et 
al., 2012).  
 
Aside from the aforementioned risks for breast cancer, a number of additional risk factors 
have been identified in recent years, including exposure to estrogen. Estrogen as a contributor 
to carcinogenesis explains why early first menarche and late menopause can result in 
increased cancer risk through prolonged exposure to elevated estrogen levels. The effect of 
elevated estrogen and androgens in post-menopausal women was examined in a large-scale 
prospective cohort study by Kaaks et al in 2005. They took blood samples to test for 
endogenous hormone levels and looked at breast cancer incidence in follow up 
questionnaires. The study concluded that there is a direct link between circulating androgen 
and estrogen levels with breast cancer risk. The risk estimates for testosterone were 1.85 
(1.33–2.57) and for estradiol 2.28 (1.61–3.23) (Kaaks et al., 2005).  
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Estrogens are endogenous chemicals with important roles in normophysiology. However, 
they are also used in a number of medical scenarios, including the oral contraceptive pill and 
hormone-replacement therapy. Hence, individuals may be exposed to increased levels of 
estrogens directly via these routes; in addition, the potential for inadvertent exposure through 
estrogen contamination in water and food sources exists. The level of exposure to exogenous 
hormones has been related to breast cancer risk but the link appears less robust than with 
endogenous estrogens. For example, early studies found estrogen-containing contraceptive 
use for 49 to 96 monthswere associated with a 1.4-fold increase in the risk of developing 
breast cancer. However, the risk was only conferred whilst the contraceptive was taken, with 
no increased risk observed in studies carried out 10 years after stopping oral contraceptive 
use (Collaborative Group on Hormonal Factors in Breast Cancer, 1996). Furthermore, recent 
studies did not find the use of oral contraceptive to be a significant risk factor for breast 
cancer development in the general population, only in those with a first degree relative who 
had been diagnosed with breast cancer (Grabrick et al., 2000). 
 
With increasing understanding of breast morphology and availability of mammogram data, 
breast morphology has been examined and linked to breast cancer risk. High breast density 
observed in a mammogram being associated with an increased risk of hormone-receptor 
positive tumours (Tice et al., 2015). Night-shift work was recently identified as a potential 
carcinogen by the WHO (Straif et al., 2007). The link between breast cancer specifically and 
night-shift work was explored in a meta-analysis by Kamdar et al in 2013, who found there 
was a weak association between this work and breast cancer (Kamdar et al., 2013). 
 
Knowledge of the mechanisms behind these breast cancer risk factors has the potential to 
enable preventative measures to be taken with the hope of reducing overall breast cancer 
incidence. Furthermore, identifying high risk groups could allow targeted mammography 
screening and genetic testing for those most vulnerable (Vogel, 2018). 
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 Aetiology  
 
  Breast cancer oncogenes and tumour suppressor genes 
 
Breast carcinogenesis occurs in a number of stages often beginning with genetic alterations or 
expression abnormalities in genes associated with cellular development. A large proportion 
of breast cancers in humans originate from epithelial cells, referred to as human mammary 
epithelial cells (HMEC). Different subtypes of cancer are thought to originate from different 
epithelial cell populations, luminal or ductal cells, although it has been postulated that some 
arise from stem cell populations rather than differentiated cells. The majority of the HMEC 
cell population grow for a fixed number of cell divisions and then senesce due to tight 
controls of cell division. Loss of these control mechanisms results in unrestricted cell 
proliferation and other stages of oncogenic transformation as described in detail in Sustaining 
proliferative signalling of the ‘Hallmarks of Breast Cancer’.  Work to understand the role of 
HMECs in oncogenic development in the breast have been undertaken through genetic 
analysis of tumours and HMEC transformation models (Dimri, Band and Band, 2005). The 
process of immortalising HMECs in cell culture has been achieved by selecting those that 
grow beyond senescence when subject to a number of conditions. This may include 
upregulation of notable oncogenes or treatment with gamma radiation. Immortalisation is a 
critical step in malignant transformation and allows genetic alterations to arise that result in 
further malignant traits. Through mouse transgenic models, a number of critical genes 
implicated in mammary development and malignant transformation have been identified 
(Dimri, Band and Band, 2005).  
 
The following are all classed as oncogenes, whose activation result in gain of function effects 
that contribute to cancer progression or tumour suppressor genes, whose loss of function 
promoted oncogenic transformation (Osborne et al., 2004; Elenbaas et al., 2001).  
 
(i) The p53 gene is regarded as an exemplar tumour suppressor, with mutations in this 
gene observed in approximately 30% of breast cancers. The protein has been 
described as a gatekeeper of the cell due to its role in a regulating a number of key 
cellular processes: cellular metabolism, apoptosis and cell cycling. p53 mutations 
therefore, provide a three-fold advantage to cancer cells: It drives the hyper 
metabolism required to fuel rapid cell division, supports evasion of apoptosis, and 
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allows cells to avoid cell cycle checkpoints and rapidly proliferate (Levine and Oren, 
2009).  
(ii) Another tumour suppressor gene mutated frequently in breast cancer is the 
retinoblastoma protein (pRB), approximately 25% in primary breast tumours and 17% 
in metastatic breast cancer (Berge et al., 2011). pRB is a member of the 
retinoblastoma family of genes and the proteins are responsible for an important 
mechanism of cell cycle inhibition; repression of gene transcription required for G1 to 
S-phase transition. Loss of pRB function often results in cancer development and a 
high prevalence of pRB loss is observed in triple negative breast cancers (Trere et al., 
2009).  
(iii) Wnt-1 is a mammary proto-oncogene identified in the 1980s (Nusse and Varmus, 
1982). The gene encodes cysteine-rich signalling molecules involved in proliferation 
(Mak et al., 1998) and activation of this pathway through genetic mutation has been 
observed in a large number of breast carcinomas (Lin et al., 2000).  
(iv) Growth factor receptors are often implicated as oncogenes. Human epithelial receptor 
2 (HER2) is a well characterised oncogene in breast cancer, as are the estrogen 
receptor and progesterone receptors. 
(v) Cell cycle-related genes and cell cycle regulators are another group of oncogenes 
implicated in breast cancer development. These include BRCA1/2, cyclins, CDKs, 
ErbB2, c-Myc (Elenblaas et al., 2001). 
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1.4 Classification of Breast Cancer  
 
  The importance of classification  
 
The classification of breast cancer has been extensively explored as a tool to improve clinical 
outcome. Accurate classification can aid rapid diagnosis, provide clear prognosis and enable 
prediction of disease progression, which treatment to utilise, and treatment responsiveness. 
 
 Histological classification 
 
Historically, classification of breast cancer was based solely on histological properties of 
tumours; both the properties of the individual cells and gross structure of the tumour(s). 
Breast cancers are first classed as either in situ carcinomas or invasive cancers, which 
differentiate between tumours contained within the structure of the breast and those that have 
spread to surrounding tissue (Rosen, 2001). The breast structure is shown in Figure 1-2. The 
two most prevalent histological types of in situ breast cancer are lobular and ductal 
carcinomas, which differ in cytological features. Ductal carcinomas form gland-like 
structures and contrastingly lobular carcinomas tend not to form particular structures and 
typically have small, round cells (Rosen, 2001). Ductal carcinoma accounts for 
approximately 75% of all US breast cancer cases and can be sub-categorised into further 
subtypes: Comedo, cribiform, micropapillary, papillary and solid. Comedo ductal carcinoma 
is characterised by the presence of central necrosis or apoptotic cell death (Shekhar et al., 
2008). Cribiform histology is gaps between the cancer cells within ducts of the breast, 
(micro) papillary tumours have cancer cells in a finger-like pattern whereas solid tumours 
contain cancer cells filling the ducts of the breast. Invasive cancers fall into six main groups; 
infiltrating ductal, invasive lobular, ductal/lobular, mucinous, tubular, medullary and 
papillary (Malhotra et al, 2010). Infiltrating ductal and lobular carcinomas are defined by 
their origin: ductal tumours begin in the milk ducts, and often escape the wall of the duct to 
begin growing in neighbouring tissue. In contrast, invasive lobular cancer begins in breast 
lobules and spreads to the surrounding breast tissue. The other four types of invasive breast 
cancers are defined by their pathology: Medullary tumours are fleshy and soft, papillary 
tumours are characterised by growth patterns of epithelial cells linking fibrovascular stalks 
(Pal et al., 2010), Mucinous tumours are so called due to the large amounts of mucous 
present, and tubular carcinomas are made up of elongated or oval tubules (Makki, 2015). 
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Figure 1-2. Structure of the human breast including a detailed view of the terminal duct lobular unit. 
 
 
Tumour histology was the basis for the WHO classification of tumours of the breast, a 
common reference used by oncologists and pathologists (Lakhani et al, 2012). Whilst useful 
to a certain extent, it has become clear that there is insufficient resolution using histological 
classification alone to striate breast cancer into clinically distinguishable subgroups. This is 
evidenced by the fact that approximately 80% of breast cancer tumours are classified as 
‘invasive ductal carcinoma, not otherwise specified’ (Selvi, 2015). This histological grading 
system is often supported by morphological and molecular assessments such as the 
Nottingham Prognostic Index (NPI) (Fong et al., 2015). This grades tumours based on 
mitotic rate, nuclear morphology and tubule formation, which refers to how much of the 
tumour tissue has normal ductal structures (Rakha et al., 2008). Longitudinal studies have 
found significant prognostic value in the NPI (Elston and Ellis, 1991) and it has been used 
extensively by pathologists and clinicians (Royal College of Pathologists, 2005). A review in 
2006 performed by Komaki et al, however, found that of the three informants of tumour 
grade, only nuclear morphology provided information on rate of recurrence (Komaki et al., 
2006).  Histological classification and grading systems evidently possess value in predicting 
prognosis, however without molecular understanding, the capacity for directed treatment 
development and administration is limited. Furthermore, more recent molecular 
characterisation of gene expression has illustrated that histologically indistinguishable breast 
cancers can be molecularly distinct (Perou et al., 2000; Sørlie et al., 2001). 
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 Molecular classification 
 
The prognostic power of histological and morphological/molecular classification of breast 
cancer tumours is limited. This is problematic as it can negatively impact patient prognosis 
due to sub-optimal or incorrect therapeutic interventions being employed. This has been a 
catalyst for the development of new approaches to classify tumours, which seek to define the 
molecular underpinning of breast cancer heterogeneity to allow better prediction of treatment 
responsiveness and disease progression.  
 
Gene expression profiles allow the detailed exploration of differences between tumours at a 
molecular level. Seminal studies examining gene expression profiles identified five major 
breast cancer groups: luminal A, luminal B, HER2-type, basal and normal-like. These 
subtypes were initially defined through hierarchical clustering of gene expression data 
obtained through microarray analysis of 115 malignant breast tumours (Perou et al., 2000). 
Sørlie et al additionally carried out experiments of this kind and classified tumours according 
to a ‘molecular portrait’ obtained by examining 456 cDNA clones (Sørlie et al., 2001). These 
groups have shown to be distinct in clinical outcome and robust in accurately striating 
different patient samples even when using different gene signatures. Luminal A versus B, 
found B represent a clinically distinct group with worse disease course and greater chance of 
relapse. Basal-like and ERBB2-positive subtypes were associted with the shortest relapse-
free survival and overall shortest survival times. Notably, basal-like subtypes have high 
levels of TP53 mutations; loss of a tumour suppressor protein function. ERBB2 is an 
oncoprotein, whose overexpression is associated with poor patient outcome (Sørlie et al., 
2001). Other early gene expression profiling studies include work by Zhiyan Hy et al in 
2006, who used cDNA microarrays to identify a list of 1300 intrinsic genes to be used in the 
prospective classification of tumours (Hu et al., 2006). This study, in agreement with Sørlie 
et al’s work, identified the same subgroups with similar trends of clinical outcome; Luminal 
A group had the best outcome. The conclusions from these early cDNA expression analyses 
have been confirmed using different analysis platforms. A team from the Cancer Genome 
Atlas Network examined breast cancer samples in terms of mRNA and protein arrays, DNA 
methylation status as well as microRNA and exome sequencing (Koboldt et al., 2012). 
Widespread use of tissue microarray analysis has enabled the examination of protein 
expression profiles to identify subgroups. Abd El-Rehim et al applied this method to more 
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than 1000 cases of breast cancer and found 5 distinct groups that broadly agreed with 
previous classifications from cDNA microarray screens (Abd El-Rehim et al., 2005). 
Agreement of the subtypes across different platforms and between genetic profiles and at a 
translational level ratify their clinical relevance. Additional measurements of morphological, 
genetic and translational characteristics confirm the validity of these core measurements. 
 
It should be noted that whilst many studies broadly agree with these intrinsic subtypes, other 
classifications have been proposed. In 2007, a new intrinsic subtype was identified: Claudin-
low. These were unique in the low level expression of a particular set of genes, including 
those responsible for cell-cell adhesion (Herschkowitz et al., 2007).  
 
Intrinsic subtype Clinico-pathalogic definition Type of therapy recommended 
Luminal A Luminal A 
ER+ and or PR+ 
HER2- 
Ki-67 low 
Endocrine therapy alone 
Luminal B Luminal B (HER2-) 
ER+ and or PR+ 
HER2- 
Ki-67 high 
Endocrine therapy  cytotoxic therapy 
Luminal B (HER2-) 
ER+ and or PR+ 
HER2 overexpressed 
Ki-67 any level 
Cytotoxics with anti-HER2+ endocrine 
therapy 
ERBB2-overexpression HER2 positive (non-luminal) 
ER- and PR- 
HER2 overexpressed 
Cytotoxics with anti-HER2+  
Basal-like Triple negative (ductal) 
ER- and PR- 
HER2- 
Cytotoxics 
 
Table 1-1. Intrinsic vs clinio-pathologic definitions of breast cancer subtypes and the type of therapy 
recommended as discussed at the St. Gallen International Expert Consensus on the Primary Therapy of Early 
Breast Cancer 2011 (Goldhirsch et al., 2011). 
 
 Immunohistochemistry to identify molecular groups 
 
An alternative to microarray-based classification of molecular subtypes is the use of 
immunohistochemistry (IHC) to identify molecular groups. This method has been 
investigated as a means to allow the use of molecular classification routinely in the clinic, 
where histological services are routinely available. Examination of ER, HER2, PR and Ki67 
status can be used to and enable the classification of a population of tumours into four 
subtypes of breast cancer: triple negative, HER2, luminal A and luminal B. Hugh et al find 
these classifications to be prognostically significant for overall survival and disease free 
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survival (Hugh et al., 2009). However, discrepancies have been observed between IHC 
determined subtypes and molecularly defined intrinsic subtypes. Kim et al analysed over 600 
patients to using both IHC and PAM50 subtyping to define tumour subtype. They found 
38.4% of patients saw discrepancies between PAM50 defined intrinsic subtype and IHC 
subtype, noting that survival rate analysis according to IHC subtypes could result in poor 
treatment choices and negatively affect patient outcomes (Kim et al., 2018). One challenge 
around the use of IHC is the subjective nature of scoring a tumour as hormone receptor 
positive. This highlights the need for standardisation between laboratories (Kurosumi., 2003). 
 
ER Status 
The correlation between ER expression and responsiveness to endocrine therapy has been 
known for a number of years. Therefore, identifying accurately the ER status of a tumour 
may improve treatment planning and outcomes (Harvey et al., 1999). The ER status of a 
tumour is most reliably determined using IHC techniques on paraffin embedded cancer 
tissue. The methods and consequently results, have been found to differ largely across 
different clinics. In controlled laboratory studies, the duration of sample fixation and method 
of antigen retrieval were separately examined for effect on tumour scoring for ER status. 
Both of these factors were found to affect classification of tumours, with shortened fixation 
times resulting in strongly positive ER tumours being classified as ER-negative (Goldstein et 
al., 2003).  
 
PR Status 
Approximately 50% of breast cancers test positive for PR (Elwood and Godolphin, 1980; 
Nadji et al., 2005). The PR status of a tumour is often considered in combination with ER 
status and consequently, ER and PR testing are often undertaken concomitantly. While ER 
status is essential to determine therapeutic care of breast cancer patients, the prognostic value 
of PR testing remains questionable. Robertson et al find that considering ER and PR status in 
combination improve the accuracy of predictions of clinical outcome but has no benefit in 
effectively determining which patients should receive endocrine therapy (Robertson et al., 
1996).  
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The majority of ER+ breast cancers are also PR+, however, even when a tumour is ER+ but 
PR-, endocrine therapy is recommended in both cases. Therefore, the value to individual 
patients of knowing PR status may be limited (Elwood and Godolphin, 1980). However, ER+ 
PR- patients may have a poorer response to this treatment, meaning PR status may be an 
important predictor for treatment outcomes (Robertson et al., 1996). Furthermore, some 
research finds that patients with IHC results of ER- and PR+ may still be responsive to 
endocrine therapy (McGuire, 1975; Knox et al., 2008).  
 
HER2 Status 
HER2 overexpression in breast cancer is associated with poor patient prognosis (Slamon et 
al., 1988). Accurate determination of HER2 status of a breast cancer is important in directing 
treatment decisions. HER2+ tumours are candidates for HER2-targeted therapy and IHC is a 
means utilised to determine this status in breast cancer tumours. As with ER and PR IHC 
testing, standardisation of these methods are important in optimising the usefulness of HER2 
as a prognostic marker (Hicks and Schiffhauer., 2011). 
 
The importance of standardisation and utilisation of approved methodologies of IHC is 
highlighted by Vyberg et al’s findings that of 1703 tests performed between 2008-2012, 11% 
of false negative results occurred (Vyberg et al., 2015). The implications of this being 
patients receiving incorrect treatment regimens, potentially resulting in poorer patient 
outcomes. This is observed in research by Slamon et al, who found that treatment with 
HER2-directed Trastuzumab therapy for 1 year following standard chemotherapy resulted in 
significant clinical benefit. Of patients receiving adjuvant Trastuzumab, 78.6% reached 4-
years disease free survival compared with 72.2% of patients who received standard 
chemotherapy but no follow up with adjuvant Trastuzumab (Gianni et al., 2011). 
 
Ki67 Status 
Ki67 is a nuclear protein present in all proliferating cells and present in all phases of the cell 
cycle aside from G0 and thus has been noted as a proliferation marker. The protein is not on 
the list of the American Society of Clinical Oncology recommendations for tumour markers 
(Harris et al., 2007), but is recognised by others as an important marker for early stage breast 
cancer (Yerushalmi et al., 2010) and has been included as one of the 21 genes in the 
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Oncotype DX assay (Paik et al., 2004) as a means to predict risk of breast cancer recurrence. 
Ki67 has also been noted as a predictor of chemotherapy resistance, encodrine therapy 
resistance and general responsiveness to treatment regimen (Soliman and Yussif, 2016). 
Cheang et al utilise Ki67 levels to striate luminal breast cancers into luminal A (KI67 <14%) 
and luminal B (KI67>14%), with luminal B significantly worse 10-year breast cancer 
survival rates (Luminal A 92% (95% Confidence Interval (CI) 90–94), Luminal B 79% (74–
85) P<0.001) (Cheang et al., 2009). 
 
The quantification if Ki67 levels is achieved most commonly using IHC with the MIB-1 
antibody (Yerushalmi et al., 2010). The Ki67 score is the percentage of positively stained 
cells within a population of malignant cells tested (Yerushalmi et al., 2010). This 
quantification, similarly to HER2, ER and PR status is limited by the availability and 
utilisation of standardised methods and analysis. Whilst appearing to provide little predictive 
value in determining treatment responsiveness, in combination with the above, KI67 is 
gaining favour as an additional prognostic marker to further striate groups of tumours into 
useful subgroups (Cheang et al., 2009). 
 
Criticism of IHC method of defining breast cancer subtypes 
Aside from the intra- and inter-laboratory differences in IHC determination of hormone 
receptor status, there are other criticisms to this approach. For example, genetic screening of 
breast cancer cells has identified that there are a great number of molecular differences 
between ER positive and negative cancers and even within an ER positive group. This 
questions the usefulness of hormone receptor status when considered alone as a diagnostic 
tool or in the planning of treatment courses (Pusztai et al., 2006). Generation and utilisation 
of standardised, reproducible IHC methodologies and test results is essential for the 
usefulness of this means of classifying breast cancers. Standardisation will move towards 
more accurate diagnostic outcomes and allow the selection of the most beneficial treatment 
regimens for different breast cancer types.  
 
 
 
 Conclusion of molecular subtyping  
 
Several means of molecular classification have been explored and their limitations 
highlighted. Whilst promising, molecular classification approaches have a number of 
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difficulties that must be overcome before their widespread use clinically. The standing query 
over the fixed number of intrinsic subtypes of breast cancer is one such difficulty, with 
Luminal A, Luminal B, HER2 and basal like subtypes relatively well established, there is still 
question over further subtypes including claudin-low and normal-like. Whilst normal-like 
tumours appear clinically and molecularly distinct from other subtypes, there is still question 
over whether normal like cells are purely an artefact from tumours contaminated with normal 
tissue (Weigelt et al., 2010). 
 
The microarray-based gene expression method of tumour classification proved promising, 
however, without standardisation, it cannot be used to reliably classify individual tumours. 
An example of where standardisation is needed is study design. Differences in microarray 
study design can alter results obtained from the same samples, for example, class discovery 
method does not involve the use of a hypothesis or pre-defined groups whereas class 
comparison compares microarray profiles of unknown samples to those of pre-defined groups 
(Weigelt et al., 2010). This represents the evolution of the classification approaches, utilising 
modern techniques to re-examine the key targets to use for classification. Practically, this has 
been a move from histology to gene expression. This approach is promising, but requires 
more work to ensure reproducible and clinically useful stratification of individuals into 
groups and to inform treatment regimen.  
 
Recent advancements in molecular analysis of tumours have accelerated the understanding of 
the biology underpinning breast cancer. While this provides new avenues for novel drug 
targets, the current molecular classification systems currently show limited clinical value and 
thus this new understanding has not yet been fully utilised. In order to optimise the usefulness 
of the subtyping of breast cancer, pathologists should incorporate IHC-determined receptor 
status, histopathological classification, and molecular information gleaned from genomic 
screening.  
 
There is no single system of breast cancer classification that can consistently and discretely 
sort tumours whilst capturing the extent of the heterogeneity of the disease. However, several 
the systems discussed above can provide useful and robust ways of categorising tumours to 
optimise clinical usefulness and inform treatment decisions.  
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 Biomarkers 
 
For breast cancer diagnosis and treatment decisions, pathologists often use the expression 
status of three receptors: the estrogen receptor (ER), progesterone receptor (PGR) and human 
epidermal growth factor receptor (HER2). 
 
 Estrogen receptor and progesterone receptor 
 
ER and PGR are members of the nuclear receptor (NR) superfamily of transcription factors 
that bind and functionally respond to ligands including hormones and vitamins (Huang et al., 
2010). These proteins are responsible for regulating the expression of genes whose protein 
products affect many aspects of metabolism, development and cellular differentiation. 
Nuclear receptors exist as either monomers, homodimers or heterodimers and all bind to 
hormone response elements (HRE) on DNA. These nuclear receptors are grouped based on 
mode of action into type I, II, III and IV (Conzen, 2008). Type I includes ER and PR (Huang 
et al., 2010). 
 
Type I nuclear receptors include the estrogen and progesterone receptors. These are secured 
in the cytoplasm by proteins including HSP90 until ligand-mediated activation releases the 
receptors for homodimerisation. Following this, the receptors can translocate into the nucleus 
(Echeverria and Picard, 2010). The nuclear receptors localised in the nucleus can then alter 
target gene expression, with the majority of target sites residing in enhancer elements (Glass 
and Rosenfeld, 2000). Type II nuclear receptors include the thyroid hormone and are 
generally permanently localised in the nucleus where they form heterodimers with the 
retinoid X receptor. Without ligand binding, the heterodimers are active repressors of gene 
function. This is achieved through association of the receptors with the Nuclear Receptor co-
repressor and the Silencing-Mediator for Retinoid/Thyroid hormone receptors (SMRT). 
These in turn are associated with histone deacetylases (Chen and Evans, 1995; Watson et al., 
2012). Upon ligand binding, triggers co-repressor dissociation and co-activator binding. 
Examples of co-activators include histone acetyl transferases, increasing the access to nuclear 
receptor target genes (Glass and Rosenfeld, 2000). Type III are similar to type I in that both 
classes form homodimers. However, Type III nuclear receptors bind to different types of 
hormone response elements, direct repeat versus inverted repeat (Mangelsdorf et al., 1995). 
Type IV nuclear receptors can bind as monomers or as dimers. Regardless of this, a single 
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DNA-binding domain will associate with a single half site of the hormone response element 
on DNA (Sever and Glass, 2013). The general modular structure is similar across all 
receptors; six regions A-F shown in Figure 1-3. 
 
 
Figure 1-3. Structural organisation of nuclear receptors - the general modular structure (Mosselman et al., 
1996). 
 
The ligand binding domain (LBD) is a binding pocket for interactions with the hormone or 
ligand. It is made up of 12 alpha helices that fold into helical sheets, the binding pocket is 
located within this tertiary structure. The size of the LBD can vary greatly between NRs, with 
some having a relatively small chemical space that will bind, such as HER2, whereas others 
will accept a high degree of diversity in the ligands they bind, such as PXR NR (Rastinejad et 
al., 2013)s share. There is some overlap between ligands, such that one may bind to more 
than one NR, albeit with differing binding affinities (Kds). This, alongside the sharing of co-
regulators and target genes, allows NRs to work together to coordinate biological responses 
to chemical exposure (Robyr et al., 2000).  
 
The LBD is also implicated in recruiting co-activator proteins to enhance transcriptional 
activation by the NR. The DNA binding domain (DBD) interacts with elements in the DNA 
called nuclear receptor response elements (NREs), present in promotors or enhancers, upon 
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which the NR carries out transcriptional activation. The classical binding for NRs is as a 
dimer (homo- or hetero-) or a monomer, against a consensus half site of 5′-AGGTCA-3′. 
These half sites are presented as pairs separated by a number of nucleotides, and can be 
direct, everted or inverted repeats (DR1, DR2, IR6, ER6). The Kd of nuclear receptors to 
NREs is generally in the nanomolar range (Keller and Wahli, 1997). The LBD and DBD are 
linked via a hinge region. N-terminal to the DBD there is an amino acid sequence (AF-1), 
which is highly variable between NRs. This, in certain circumstances, can function as a 
ligand-independent transcriptional activator (Bain et al., 2007). 
 
The Estrogen Receptor 
 
In humans, there are two estrogen receptors, ER⍺ and ER, which are encoded by separate 
genes on separate chromosomes (Patel and Bihani, 2017). The primary ligand for ERs is the 
endogenous chemical 17-estradiol (E2), with approximate kd values of 0.1nM and 
0.4nM for ER⍺ and ER, respectively (Mosselman et al., 1996; Kuiper et al., 1997).  
 
ER⍺ is localised primarily in the mammary gland, ovary and uterus, ER is found 
primarily in the prostate and liver (Heldring et al., 2007). ER⍺ regulated genes include those 
involved in proliferation and differentiation and consequently, the deregulated action of ER-
mediated cell signalling in the breast has been implicated in the development of a number of 
breast cancers types. Furthermore, ER⍺ is implicated in post translational modifications and 
extra-nuclear signalling and dysregulation of these pathways is also correlated with breast 
cancer development. ER has greater effect in immune function and the central nervous 
system (Heldring et al., 2007). 
 
Estrogen Receptor signalling 
ER-dependent genomic signalling involves the following stages: E2 bind to ER in the 
nucleus, leading to a structural change that promotes association of the receptor to forms a 
homodimer. This homodimer is structurally optimised for binding to a region of DNA called 
the estrogen response element (ERE), the consensus sequence for which is ERE: 5′-
GGTCAnnnTGACC-3′ (Klein-Hitpass et al., 1986; Klinge, 2001). 
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The signalling can then follow the classical or tethered pathway. The classical pathway 
involves direct binding of ER to the aforementioned EREs, which are located in the 
promotors of certain target genes of ER (Kumar and Chambon, 1988). The bound ER 
homodimer will recruit coregulatory proteins to the site and form a transcriptional complex. 
The composition of the transcriptional complex dictates whether ER activity is stimulated or 
repressed by coactivators (CoA) or corepressors (CoR), respectively, this occurs in a ligand-
specific manner. Estrogen receptor target genes have been elucidated by a number of groups 
using integrated computational genomics and chromatin immunoprecipitation microarray (Jin 
et al., 2004; Lin et al., 2004; Welboren et al., 2007). Table 1-2 shows some examples of 
estrogen receptor regulated genes and their associated cellular functions.   
 
 
Accession 
number 
Symbol Gene name Ontology Up/down 
regulated 
M62403 IGFBP4 Insulin-like growth 
factor binding protein 4 
 
Signal transduction 
[0007165] 
Up 
AF245389 GREB1 GREB1 protein High-affinity zinc ion 
transport [0006830] 
 
Up 
NM_002894 RBBP8 Retinoblastoma binding 
protein 8 
DNA repair [0006281] 
 
Up 
U16752 CXCL12 Chemokine (C-X-C 
motif) ligand 12 
(stromal cell-derived 
factor 1) 
 
Immune response 
[0006955] 
 
Up 
NM_000926 PGR Progesterone receptor  Signal transduction 
[0007165] 
 
Up 
NM_003489 NRIP1 Nuclear receptor 
interacting protein 1 
Transcription regulation 
[0006355]  
 
Up 
     
NM_012342 NMA Putative transmembrane 
protein 
Melanin biosynthesis 
from tyrosine [0006583] 
 
Down 
NM_001719 BMP7 Bone morphogenetic 
protein 7 (osteogenic 
protein 1) 
Cell growth and/or 
maintenance [0008151] 
 
Down 
 
Table 1-2. Some example up and down regulated estrogen receptor target genes and their gene ontology (Lin et 
al., 2004).  
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In addition to direct interaction with DNA to regulate gene expression (ER-dependent 
genomic signalling), ER is able to regulate gene expression indirectly (tethered or non-
genomic signalling). In this pathway, gene expression is altered through interaction of the ER 
with other transcription factors following interaction with E2, which in turn interact with 
DNA and elicit changes in gene expression. Plasma membrane associated ERs facilitate the 
non-genomic pathway of ER signalling. This pathway is relatively poorly understood, at least 
in comparison to direct genomic signalling, but can stimulate signalling cascades that effect 
their changes without using gene regulation, for example through alterations to ion channels 
(Marino et al., 2006). A representation of this pathway is seen in Figure 1-4. A key pathway 
of non-genomic ER regulated gene expression is: estradiol causes 1) ERK signalling, which 
increases transcription mediated by the c-Fos promoter (Watters et al., 1997) or 2) PKA 
signalling, which increases transcription from promotors that possess a cAMP response 
element (Watters and Dorsa, 1998).  
 
The biological functions of non-genomic signalling include allowing the activation of genes 
that do not possess classical EREs. One such example of this is the induction of PKA 
signalling by estradiol in a neuronal cell line which resulted in neurotensin gene activation 
(Watters and Dorsa, 1998). Another biological function of non-genomic estrogen signalling is 
to enhance transcription from genes with EREs in their promotors, which could be achieved 
by estradiol activated ERK signalling resulting in the phosphorylation of ER-alpha and 
increased transcription (Clark et al., 2014) 
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Figure 1-4. Pictorial representation of non-genomic and genomic estrogen signaling. Creb1, SP1 and Stat1 are 
examples of transcription factors recruited in non-genomic estrogen signalling. Pathways for figure obtained 
from Reactome (Fabregat et al. 2018).  
   
 
The regulation of gene expression by E2 is multifaceted. The complexity role of ER in cell 
signalling is evidenced by the number of known ER target genes and the distinct roles of the 
two nuclear ERs. The number of ER target genes is in the region of several thousand, which 
underpins the diverse role of ER within the cell and in driving breast cancer progression 
(Carroll et al., 2006). ER⍺ and ER show differing transcriptional roles and can form both 
homodimers: ER⍺:ER⍺ or ER: ER and heterodimers: ER⍺:ER (Marino et al., 2006). 
Furthermore, the cellular environment; cell type, level of ER expression, presence of ligands 
can all greatly influence the signalling cascades and resulting transcriptional changes.  
 
Amongst the diverse range of roles performed by the ER is mammary gland development. At 
the onset of puberty, E2 stimulates signalling resulting in the maturation of the mammary 
gland. This includes growth and morphogenesis of the breast including the development of 
terminal end buds and ducts (Howard and Gusterson, 2000). See section 1.4.2 for detail on 
morphology of the breast.  
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Estrogen Receptor signalling in cancer 
The expression of ER⍺ has been closely associated with tumour development in the breast. A 
link between ER and cancer was initially defined in 1971 by Jensen et al, who discovered an 
ER expressed in breast tumours that correlated to hormonal changes (Jensen et al., 1971). 
One means by which ER⍺ affects tumour development is by altering the transcription of 
genes associated with proliferation and metastasis. Altered expression of genes associated 
with mammary gland development can result in breast cancer onset. Specific examples of 
these genes include: FOXM1, PELP1 and GREB1, all target genes of ER and additionally 
associated with the positive regulation of ER activity (Lin et al., 2004; Madureira et al., 
2006). This is an example of a feed-forward mechanism, where the target stimulates ER 
expression and in turn this stimulates the further expression of target genes. FOXM1 is a 
transcriptional activator and is involved in cellular proliferation. It is a known physiological 
regulator of ER⍺ expression in breast cancer, and its pharmacological repression has been 
shown to reduce levels of ER⍺ (Madureira et al., 2006). Interestingly, more recent work has 
identified reciprocal regulation of FOXM1 by ER⍺; ER⍺ activation modulates mRNA levels 
and protein expression of FOXM1 (Millour et al., 2010). Concordantly, high expression of 
FOXM1 is associated with poor prognosis for breast cancer patients (Madureira et al., 2006). 
PELP1, similarly to FOXM1 is both a coactivator and a genomic target of ER⍺. GREB1 
(Growth regulation by estrogen in breast cancer) is associated with E2-stimulated 
proliferation in breast cancer cells. Its transcription is activated by ER⍺ interaction with any 
one of three EREs at the gene locus (Sun, Nawaz and Slingerland, 2007). MTA3 (metastatic 
tumour antigen 3) was identified as an ER⍺ regulated gene by Fujita et al 2004. Suppression 
of MTA3 is correlated with increased levels of tumour metastasis and survival via promotion 
of epithelial-to-mesenchymal transition (Fujita et al., 2004). 
 
As mentioned previously, the actions of ER⍺ are tempered or enhanced via corepressors or 
coactivators. These proteins generally have a conserved structure that allows them to 
associate with ER⍺’s LBD. The action of CoAs and CoRs can be conferred through enzyme 
activity that allows changes to chromatin structures (Green and Carroll, 2007). Suppression 
of ER⍺ CoRs or overexpression of CoAs have been shown to induce carcinogenesis. BRCA1 
and 2 and ATBF1 are examples of corepressors that are dysregulated in breast cancer. SCR3 
and BCAS3 are coactivators observed in high levels in some breast cancers (Huen, Sy and 
Chen, 2010).  
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E2 signalling and the cell cycle in breast cancer 
As explored in the seminal paper ‘Hallmarks of Cancer’, lack of cell cycle control points can 
lead to malignant transformation (Hanahan and Weinberg, 2000). A key cell cycle regulatory 
protein is Cyclin D1 as shown in Figure 1-5. It has been postulated as an oncogene as 
overexpression of the Cyclin D1 protein is associated with tumorigenic changes in breast 
tissues (Wang et al., 1994). ER⍺ regulates the expression of Cyclin D1 through a non-
genomic pathway, via the recruitment of associated transcription factors such as ATF-2. 
Recruitment of ATF-2 is necessary because Cyclin D1 lacks an ERE (Sabbah et al., 1999). 
The impact of ER regulation on cyclin D1 is the promotion of cycling, which contributes to 
cell cycle progression. Additionally, Zwijsen et al identify a role for Cyclin D1 in ER 
activation. Cyclin D1 binds directly to the hormone binding domain of the ER, increases ER 
binding to estrogen response elements and ultimately upregulates estrogen-mediated 
transcription (Trowbridge et al., 1997; Zwijsen et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5. Hochegger, H., et al. Overview of the eukaryotic cell cycle. The cycle comprises four main phases, 
G1, S, G2 and M. Cell cycle progression is controlled through positive and negative regulators. Cyclin-
dependent kinases (CDKs) prompt the transition from G1-S phase and G2-M phase through the phosphorylation 
of different substrates. Cyclin D, CDK4 and CDK6 regulate events in G1. Cyckin E and CDK2 trigger S-phase. 
Cyclin A-CDK2 trigger the end of S-phase. Cyclin B-CDK1 triggers mitosis or M-phase (Hochegger, H., et al, 
2008). 
 
 
 
Additional cell cycle interaction occurs between ER⍺ and CDK2 (Manavathi et al., 2013). 
Trowbridge et al observe an upregulation of ER-dependent transcription following cyclin 
A/cdk2 mediated phosphorylation of the ER (Trowbridge, Rogatsky and Garabedian, 1997). 
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Deregulated ER⍺ expression breast cancer  
 
In breast cells, ER⍺ activity is tightly regulated at a number of levels to prevent abnormal 
activity that could promote carcinogenic progression.  
(i) The methylation state of the chromatin closely dictates the level of ER⍺ 
expression in breast cells.  Methylation of DNA at CpG islands acts to block 
transcription factor binding and gene expression. ER positive breast cancer cell 
lines and normal breast cells lack methylation of the ER gene promoter, allowing 
ER expression. In contrast, ER negative breast cancers exhibit high levels of 
methylation at the same sites (Lapidus et al., 1998), repression expression of ER, 
and hence ER target genes as well.  
(ii) The hormones present within a cell also effect ER expression. As noted above, a 
number of ER target genes also activate ER gene expression. Therefore, estradiol 
levels regulate ER⍺ levels via EREs found in a large number of ER⍺ promotors in 
breast and other estrogen responsive tissues (Donaghue, R Westley and E. B. 
May, 1999). In addition, progesterone also affects ER levels within breast cells 
and acts as a repressor (Pinzone et al., 2004). Vitamin D (1,25-dihydroxyvitamin 
D3) display an anti-proliferative effect associated with ER suppression. Later 
experiments identified a response element for Vitamin D on the ER promoter 
(Stoica et al., 1999).  
(iii) Growth factors such as insulin growth factor (IGF-I) have been shown to increase 
levels of ER in certain breast cancer cell lines. Insulin treatment of MCF7 cells for 
example, resulted in upregulation of both ER levels and their capacity for binding 
(Pinzone et al., 2004). 
 
The Progesterone Receptor 
 
The progesterone receptor (PR), like the ER, belongs to the nuclear receptor family of ligand-
dependent transcription factors. It responds to binding of the steroid hormone, progesterone 
with an approximate Kd of 2nM (Mockus et al., 1982). Similar to ER, there are two isoforms 
of PR; PR-A and PR-B (Sampayo, Recouvreux and Simian, 2013), however unlike the ER 
isoforms, these arise from the same gene but are expressed from different promoters. The 
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isoforms have similar functions, with PR-Bs effects as a transcription factor being observed 
as more potent. In the breast, it holds a key role in the differentiation of the lobuloalveoli. 
 
In parallel to the scenario seen with ER, both genomic and non-genomic pathways are active 
for PR. For genomic pathways, ligand-bound PR associates with progesterone response 
elements (PREs) on the promotor regions of certain genes occurs via the following 
mechanism (Scarpin et al., 2009). Progesterone binds the LBD of the PR, a conformational 
change occurs allowing receptor dimerisation, PRE-association and coactivator recruitment.  
 
Non-genomic pathways of PR-mediated transcriptional regulation are also utilised in breast 
cells and include the activation of growth factor signalling pathways (Lange, 2008). One such 
example is the activation of the MAPK pathway by PR, which, in contrast to transcriptional 
changes, occurs within minutes of an increased level of progesterone in the cell. There are 
approximately 25,000 PR binding sites in the human genome. PR direct mediation of gene 
expression can occur through binding to these sites. Interestingly, only 1% of PR binding 
sites are occupied by direct PR binding in breast cancer, suggesting there is some cooperative 
activity of PR with other transcription factors. The level of chromatin organisation can 
influence the readiness with which ligand bound PR binds to PREs on gene promotors. 
Ballaré et al proposed that nucleosomes may have a positive role in determining the level of 
PR binding through the recruitment of nucleosome remodelling complexes (Ballaré et al., 
2013). 
Progesterone Receptor signalling in cancer 
 
Ligand activated PR is a well characterised breast mitogen and has been found to have a 
direct role in breast cancer proliferation. Progesterone and progestins, synthetic progesterone, 
acting through PR-B stimulate proliferation of breast cancer cells (Conneely, Mulac-Jericevic 
and Lydon, 2003). PR recruits a number of coregulators, including SRC-3 and corepressors 
such as SMRT that have been identified in the mammary gland.  
 
As discussed previously, dysregulation of coregulators can result in cancer development. In 
breast cancer, overexpression of PR coactivators is often observed and their increased 
availability is thought to amplify PR transcriptional activity. The aforementioned SRC-3 
protein is present at elevated levels in breast cancers (List et al., 2001). 
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 HER2 Receptor 
 
The Human Epidermal growth factor Receptor (HER2) Receptor is the third receptor 
commonly used as a diagnostic biomarker in breast cancer. It has also become a recent 
therapeutic target.  
 
HER2 is a member of a family of tyrosine kinases that have a conserved structure including a 
cytoplasmic domain containing tyrosine kinase, an extracellular ligand binding domain and a 
region spanning the plasma membrane. HER2 is activated upon ligand binding to the LBD, 
followed by homo- or hetero-dimerisation (with Epidermal Growth Factor Receptor (EGFR) 
or HER3) and begins with the phosphorylation of the cytoplasmic tyrosine kinase. This 
phosphorylation in turn activates signalling pathways associated with cell survival and 
growth such as the phosphatidylinositol-3-kinase pathway (PI3K/Akt) (Schlessinger, 2004). 
As such, HER2 signalling can be predominantly defined as an indirect (or non) genomic 
pathway of regulation. However, some direct genome effects have been noted. 
 
HER2 signalling in cancer 
HER2 gene is a known oncogene with levels amplified in 15-20% of breast cancers (Wolff et 
al., 2013). The gold standard for HER2 amplification assessment is, using fluorescence in 
situ hybridisation (FISH), to calculate the ratio of HER2 to chromosome enumeration probe 
(CEP). A mean ratio of >2.0 is classed as amplification and <2.0 as HER2 negative cells. 
Overexpression of the receptor results in increased tumour invasiveness and metastasis 
(Sledge, 2018).  
 
Amplification of the HER2 gene results in an increased number of HER2 homodimers and an 
increased proportion of HER2-containing heterodimers. One means by which this results in 
transformation is that said dimers (HER2-EGFR or HER2-HER3) maintain signalling activity 
for longer and can evade degradation and thus increase signal strength and duration. 
Downstream signalling pathways consequently see prolonged activation (Karunagaran et al., 
1996). Amongst these signalling pathways is the PI3k/Akt pathway, which has been 
implicated in tumorigenesis. Therefore, constitutive activation of PI3k/Akt signialling via 
overexpressed HER2 is a clear mechanism underlying HER2-mediated cancerous 
transformation (Zhou et al., 2004).  
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Direct HER2 target genes 
As noted in the previous section, the principle method by which HER2 contributes to 
tumorigenesis is through intracellular signalling (i.e. indirect genomic activation). However, 
Wang et al reported in 2004 that HER2 could localise to the nucleus following activation, 
and that HER2 binding to promotors can activate gene transcription.  
 
Full length HER2 is present in the nucleus of breast cancer cells, where it regulates biological 
responses through direct binding to promotors or enhancers of target genes (Tan et al., 2002; 
Kim et al., 2009; Wang et al., 2010). The receptor is translocated from the plasma membrane 
through the process of endocytic internalisation and endosomal sorting. This involves the 
association of HER2 with nuclear transport machinery, specifically with importin-1. 
HER2/importin-1 associates with the nuclear pore protein and is translocated to the nucleus  
 
Examples of direct target genes for HER2 include cyclooxygenase-2 (COX-2), whose 
expression has been reported as upregulated in a number of HER2 positive cancers. COX-2 is 
a known regulator of tumour growth and metastasis in breast cancer, the cyclooxygenase is 
correlated with aggressive breast cancer subtypes. COX-2 positive tumours are proportionally 
higher in patients over 50 years old, advanced stage of disease and in ER and PR-negative 
cancers (Jana et al., 2014). Furthermore, COX-2 promotes aromatase transcription, resulting 
in increased growth of ER-positive breast cancer (Hoellen et al., 2011). 
Chemokine receptor CXCR4 is also upregulated in a number of HER2 positive cancers, this 
receptor drives the metastatic phenotype in breast tumours  (Müller et al., 2001). The 
expression of CXCR4 induces expression of a number of cytokines including interleukin-6, 
chemokine ligand 2 and Granulocyte-macrophage colony-stimulating factor. These are 
implicated in recruiting myeloid cells to the tumour and the drive of metastasis (Sobolik et 
al., 2014).  
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Summary of biomarkers 
 
Nuclear receptors have long been known as regulators of physiological, developmental and 
disease processes. Consequently, they are key targets for drug development in the treatment 
of cancer and specifically breast cancer. For breast cancer, the estrogen and progesterone 
receptors remain important and a combination of PR and ER signalling, crosstalk and 
transcriptional activation is required for both normal breast development and breast tumour 
progression (Lange, 2008). More recent research has identified roles for other nuclear 
receptors in breast cancer progression, notably HER2. As mechanisms of action are better 
elucidated, the clinical relevance of these is highlighted, emphasising their potential role 
in cancer treatment.  
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1.5 Breast cancer heterogeneity 
 
As detailed in section 1.5, attempts to classify breast tumours has been confounded by the 
heterogeneous nature of the disease. There is a high degree of diversity between and within 
tumours as well as among cancer-bearing individuals, and all of these factors contribute to 
differences in aggressiveness, prognosis and therapeutic response, complicating treatment. 
Inter-tumour heterogeneity is explored in 1.6.1.5 Clinical implications of intra-tumour 
heterogeneity, and details the attempted classification of tumours by their overall phenotype. 
In this section, intra-tumour heterogeneity in breast cancer will be explored, whereby there is 
a heterogeneous pool of tumour cells within an individual tumour. It has been observed that 
cells within one tumour can display vast genetic and morphological variability. Cells may be 
different sizes, proliferate at different rates, have differing abilities for metastasis and vary in 
drug sensitivity. Specifically, intra-tumour heterogeneity describes the presence of different 
sub populations of breast cancer cells within one tumour and between one tumour and 
metastatic tumours (Martelotto et al., 2014). A number of studies have found human breast 
tumours comprise many genetically distinct subpopulations. These genetic differences 
include levels of ER, PR and HER2 gene amplification (Davis et al., 1984; Pertschuk et al., 
1999). Heterogeneity may reflect the physical position of cells within a tumour, or may 
reflect temporal heterogeneity with cells altering their phenotype over time (Shah et al., 
2012). The mechanisms by which this heterogeneity develops have been explored in a 
number of studies and have resulted in two main theories: the cancer stem cell (CSC) 
hypothesis and the clonal evolution or selection model. Initially, these were seen as 
competing theories, but further research has suggested they represent complementary 
mechanisms. Identifying the means by which intra-tumour heterogeneity arises can allow 
better prediction of disease progression and treatment planning. 
 
  The cancer stem cell hypothesis 
 
The human breast undergoes periods of cell growth and apoptosis during development and 
also in the adult human to allow structural changes in the breast. To facilitate this, the breast 
retains undifferentiated cells that have unrestricted proliferative potential, to allow regrowth 
of the mature mammary gland; as such these are breast stem cells. Kordon & Smith found 
that single mammary stem cells were capable of generating in the region of 1012 multipotent 
cells. These retained breast stem cells may provide a mechanism for malignant 
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transformation in the breast (Kordon and Smith, 1998). The cancer stem cell (CSC) 
hypothesis proposes that a tumour arises from a single stem cell type within which a tumour 
initiating mutation arises. Tumour growth and development is facilitated by this small 
population of CSCs as they persist and can reproduce themselves. In addition, the hypothesis 
states that CSCs can drive tumour heterogeneity by retaining the potential to differentiate into 
many different cell types. These cells in the breast are referred to as breast cancer stem cells 
(BCSCs). In the CSC hypothesis, Figure 1-6B, the tumour is organised hierarchically, where 
BCSCs would form the top and terminally differentiated cells form the base. Thus, the 
asymmetric and symmetrical renewal of BCSCs maintain the tumour growth and the 
differentiated cells form the heterogeneous tumour (Allegrucci and Shah, 2012).  
 
The properties of cell plasticity and self-renewal possessed by breast stem cells are shared by 
BCSCs where they are used to drive tumour initiation and growth. The relationship between 
breast stem cells and BCSCs is seen through a number of similarities between these cell 
populations. The two cell populations share many molecular networks as observed through 
similar transcriptomic profiles (Liu, S et al., 2014). Additionally, there are a number of 
shared pathways, all implicated in maintaining the stem cell phenotype, which include 
Hedgehog, JAK-STAT and Wnt (Pattabiraman and Weinberg, 2014). Additionally, breast 
stem cells can exist as epithelial-like or mesenchymal-like stem cells, and this ability is 
maintained by BCSCs (Liu, S et al., 2014).  
  
 
Figure 1-6. The clonal evolution model and the cancer stem model. A. The clonal evolution model in brief states that normal cells (blue) 
undergo a number of mutations that result in the formation of a cancer cell (orange) that eventually expands to form a tumour. B. The cancer 
stem cell hypothesis proposes cancer stem cell to be the origin of cancer (shown in red). These cells are self-renewing, pluripotent, 
tumourigenic and can form new cancer stem cells that form a differentiated cancer. (Bradshaw, et al., 2016). 
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 The clonal evolution model 
 
This model was initially developed by Peter Norwell in 1976 (Nowell, 1976). He postulated 
that most cancers arise from an individual cell, and that a number of incremental steps must 
occur, shown in Figure 1-6. The amassing of a series of individual mutations results in 
carcinogenic transformation. The model postulates that tumour heterogeneity arises through a 
number of rounds of clonal expansion from different cancer cells, all possessing different 
mutations that confer a proliferative advantage. Further heterogeneity is observed when non-
genetic cell differences result in clonal expansion. These may include epigenetic events such 
as altered DNA methylation or histone modifications that bestow a survival advantage or 
increase proliferative ability. Alongside the mutations providing such advantage, clones may 
accumulate neutral mutations that may become advantageous in different conditions, for 
example when under treatment.  
 
This results in increased diversity in the population of clones within a tumour. Alterations to 
the tumour microenvironment can then result in different clones making up different 
proportions of cells the tumour (Hanahan and Weinberg, 2011).  Recent experiments 
undertaken to further explore this model of tumorigenesis created patient derived xenografts 
(PDXs), where tumour cells are injected into mice, and the resulting tumour progression was 
observed. Eirew et al in 2014 created PDXs based on 15 primary breast tumours and found 
the tumours observed in the mice consistently developed in a way that reflected the clonal 
heterogeneity observed in the primary tumour (Eirew et al., 2014), thus supporting the clonal 
evolution model.  
 
 Temporal heterogeneity 
 
As cancer progresses, some tumours remain dynamic and continue to evolve. This is as a 
response to external pressures, such as drug treatments or internal pressures such as nutrient 
or oxygen supply. Internal pressures also drive spatial heterogeneity described in the next 
section. Genomic differences are seen between cells from biopsies taken at early stage and 
later stages of cancer progression and notably, genetic differences are observed between the 
primary tumour and metastases (Torres et al., 2007). Almost one third of primary breast 
cancers differ significantly in regard to genetic copy numbers from their metastases as 
measured in studies using comparative genomic hybridisation (CGH) (Kuukasjärvi et al., 
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1997). As treatment design is driven by specific genetic markers of breast cancer tumours, 
these differences may mean treatment effective for the primary tumour would have reduced 
efficacy in metastatic tumours. Examining this effect in colorectal cancer, Vakiani et al 
propose genetic testing of metastatic tumours as well as primary tumours to best inform 
treatment plans (Vakiani et al., 2012).  
 
 Spatial heterogeneity  
 
There are also distinguishable differences between cells within a tumour according to the area 
in which they are localised. The intra-tumour heterogeneity according to location is often 
associated with histological differences in areas of the tumour. Geyer et al observe this 
histological diversity is a result of differences in genetic abnormalities (Geyer et al., 2010). 
Although spatial heterogeneity is commonly linked to histological heterogeneity, this is not 
always the case: distinct genetic populations have been observed in different regions of the 
tumour that appear morphologically homogeneous (Navin et al., 2010).  
 
 
 Clinical implications of intra-tumour heterogeneity 
 
The clinical implications of the existence of intra-tumour heterogeneity are two-fold. First, 
given the heterogenity between different areas of one tumour, and between a primary tumour 
and metastasis, biopsy sampling must be adjusted. For example, to take into account spatial 
and temporal heterogeneity, biopsies should be taken from multiple sites through the course 
of disease progression. Second, a single therapeutic treatment regime is unlikely to result in 
complete tumour regression of a heterogeneous tumour. As different drugs will be effective 
against cells in a heterogeneous tumour, combination therapies are likely to be most effective 
in the treatment of breast cancer.  
 
 Summary of breast cancer heterogeneity 
 
Understanding the intra-tumour heterogeneity of breast cancer is critical to allow effective 
classification and treatment. The level of difference between cells within a tumour mean 
combination therapies may be most effective, treating each subpopulation of cells (Allegrucci 
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and Shah, 2012). Identifying the mechanisms that result in the emergence of heterogeneous 
cell populations in different cancers also provides key insights into disease progression. The 
two theories explored above are no longer considered to be mutually exclusive, but 
identifying which tumours follow which model of development most closely is likely to aid 
specialised treatment and potentially prognosis. The use of PDXs have increased 
understanding of tumour development and could potentially aid clearer diagnosis in the 
future (Shackleton et al., 2009).    
 
1.6 Summary of epidemiology and aetiology of breast cancer  
 
Breast cancer is a highly heterogenous disease, with a high degree of diversity seen both 
within and between tumours. The diversity results in differences in aggressiveness, prognosis 
and therapeutic response and increases the importance of developing accurate subtype 
classifications to guide treatment development. Breast cancer is the most common form of 
invasive cancer in women, with prevalence highest in regions of America, Western Europe 
and Northern Europe. A number of breast cancer risk factors include, a first degree relative 
with breast cancer (familial breast cancer), age, exogenous hormones and lifestyle factors 
including smoking cigarettes. Worldwide incidence of female breast cancer is approximated 
to reach more than 3million new cases by 2050. This highlights the need for the development 
of preventative strategies as well as treatment improvements (International Agency for 
Research on Cancer, 2012). It has been predicted that the worldwide incidence of female 
breast cancer will reach approximately 3.2 million new cases per year by 2050 (Hortobagyi et 
al., 2005). These numbers reflect the magnitude of breast cancer incidence, its effect on 
society worldwide and the need for urgency for preventive and treatment measures. 
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1.7 Treatment 
 
Treatment of breast cancer depends largely on its stage and type. The treatment methods can 
be split broadly into two categories: local and systemic. Local treatments are confined to the 
region of the tumour itself, with minimal effects outside of this area: The primary means of 
localised treatment are surgery and radiation therapy. In contrast, systemic treatment reaches 
all parts of the body and can act to treat residual primary tumours and metastases: Chemical 
and biological therapeutic agents are used for systemic treatment.  
 
 Local Treatment 
 
 Surgery  
 
Some type of surgical procedure is included in the majority of breast cancer treatment. The 
goal of most surgeries is to remove the entire tumour and a small area of healthy tissue 
surrounding it. This is generally breast conserving surgery (BCS), but occasionally a simple 
or full mastectomy or a modified radial mastectomy (RM) with axillary lymph node sampling 
is used, where the entire breast and adjacent tissue is removed.  
 
Early stage breast cancers can often be successfully treated with BCS in combination with 
radiation therapy (RT), referred to as breast conserving therapy (BCT). Where biopsy reveals 
that lymph nodes are clinically negative for cancer, a simple mastectomy or BCT will be 
undertaken.  However, if malignant cells are found in the lymph nodes, a RM with axillary 
lymph node sampling is the most commonly chosen option. A number of other factors can 
also disqualify patients from BCT, these include: pregnancy, previous courses of RT and 
large tumour size. 
 
Veronesi et al studied early breast cancer patient outcomes for 20 years after BCT or RM and 
found there was only 0.5% difference in the rate of death from cumulative causes (41.7 for 
patients who underwent BCT and 41.2% for patients who underwent a RM (Veronesi et al., 
2002). 
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 Radiation Therapy 
 
Radiation therapy functions through causing high levels of damage to DNA in cancer cells 
that ultimately results in cell death through apoptosis. Tissues absorb radiation, causing 
ionisation of atoms that in turn result in the formation of free radicals. These highly reactive 
free radicals will spontaneously react with cellular macromolecules and cause DNA damage. 
If the damage is irreparable through DNA damage mechanisms in the cell, cell death will 
occur (Evans and Staffurth, 2018). Two primary means of delivering radiotherapy are 
external beam radiation therapy (EBRT) and internal radiation (brachytherapy). EBRT is a 
beam of radiation generated outside of the patient’s body and targeted to the specific area of 
the tumour. Brachytherapy is the placement of a radioactive source inside the body, close to 
the tumour for a period of time. The majority of RT used to treat breast cancer is EBRT and it 
is primarily used in combination with some kind of resection surgery. Side effects of EBRT 
include localised swelling, skin damage, and tiredness. This treatment may also damage 
lymph nodes and can limit a woman’s future ability to breast feed. The ability to precisely 
direct the beam onto the tumour limits the side effects to being primarily localised (Evans and 
Staffurth, 2018). Brachytherapy also has the potential to cause side effects including localised 
bruising, pain, damage to the adipose tissue and infection can occur (American Cancer 
Society, 2017). General side effects for all RT treatments include fatigue, and other short-
term side effects such as erythema skin rash, hair loss and desquamation or skin peeling. 
Later side effects include tissue necrosis, myelitis; spinal cord inflammation and damage to 
nerves (Evans and Staffurth, 2018).  
 
 Systemic treatment  
 Chemotherapy 
 
Chemotherapy is the treatment of cancer cells with cytotoxic drugs which exert their effects 
by interfering with the cell cycle or mitosis. These agents mainly target rapidly dividing cells 
and therefore a larger proportion of cancer cells are killed over normal cells. Chemotherapy is 
considered a systemic treatment as they are not locally targeted and can influence cells 
throughout the body. While this has the disadvantage of an increased adverse side effect 
profile, it has the advantage of being able to treat all tumours, both known and currently 
undetected.  
Introduction 
 
54 
 
The mechanisms underlying breast cancer heterogeneity, both inter- and intra-tumoral are 
discussed in section Breast cancer heterogeneity. A major consequence of this is that multiple 
treatment options must exist as no one chemotherapeutic agent or treatment plan will be 
effective against every breast tumour subtype, or indeed against every cell within an 
individual tumour (Henry et al., 2016). The American Society of Clinical Oncology has 
defined a number of factors to consider when creating a treatment plan for breast cancer. It is 
important to note that treatment plans must consider both beneficial (efficacy) and negative 
(adverse side effect) profiles. The characteristics of the cancer must first be considered, for 
example, the stage at diagnosis, hormone receptor status, tumour grade. Second, 
consideration of the patient is important in terms of age, overall health, likely benefit and 
potential side effects. Third, utilising tools such as PAM50 screening can aid understanding 
of the genomics of cancer and further inform decisions on optimal chemotherapy plans. 
Fourth, patient outcomes have been seen to improve with the use of dose-dense 
chemotherapy; shorter intervals between treatments when compared with traditional interval 
lengths. However, given this increase in efficacy must be balanced against the likelihood of 
an increased adverse effect profile.  
 
Chemotherapy drugs are given orally or intravenously and can be administered after surgery 
(adjuvant chemotherapy) or prior to surgery (neoadjuvant chemotherapy). Neoadjuvant 
chemotherapy is primarily used to shrink breast cancer tumours to improve outcomes of 
surgery. Adjuvant chemotherapy is used to ensure any cancerous cells that may have been 
left in the body after surgery are killed and cannot form secondary tumours. Chemotherapy is 
the primary means by which advanced stage breast cancers are treated. The rationale for this 
is that in advanced stage breast cancer the risk of metastasis is high, and when cancer has 
spread outside of the localised area of the breast, only a systemic agent will treat these 
(unknown) secondary tumours (Holland et al., 2003).  
 
Chemotherapeutic agents    
 
Neoadjuvant and adjuvant chemotherapy generally uses a combination of: anthracyclines, 
taxanes, 5-fluorouracil, cyclophosphamide and carboplatin. When treating advanced or 
metastasised breast cancer, in addition to those listed above, the following may be used: 
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platinum agents, vinorelbine, capecitabine, gemcitabine, ixabepilone and eribulin. These 
agents are used the provision of second-line or third-line treatments have been shown to 
increase time of disease control in patients with metastatic breast cancer (Dufresne et al., 
2008). The above agents can be categorised by broad mechanism of action into: alkylating 
agents, anti-metabolites, anti-tumour antibiotics, topoisomerase inhibitors and tubulin-
binding drugs. Those agents most used widely in breast cancer treatment will be discussed in 
more detail below.  
 
Anthracyclines 
 
This class of chemotherapeutics includes doxorubicin, essential in the treatment of a number 
of breast cancers. Anthracyclines were initially obtained from Streptomyces peucetius in the 
1960s and since then, many attempts to alter these compounds to improve efficacy and 
reduce toxicity have been made through slight structural alterations. The mechanism of action 
of anthracyclines in cancer treatment have been studied extensively. Gewirtz et al in 1999 
examined a number of proposed mechanisms, three of which are generally accepted as the 
primary means by which anthracyclines confer anti-tumour effects (Gewirtz, 1999). The 
primary mode of action of anthracyclines is that they initiate DNA damage through the 
inhibition of topoisomerase II. Topoisomerases create nicks in one strand of DNA, allowing 
the strand to swivel around the other strand, adding/removing coils into the DNA. The 
enzymes are responsible for opening and closing DNA during transcription and replication. 
 
Topoisomerase II has roles in DNA repair, transcription and chromosomal segregation in cell 
division (Thakur, 2011). Anthracyclines inhibit the topoisomerase II from completing its full 
catalytic cycle. An intermediate in the topoisomerase II reaction cycle is where DNA strands 
are cut and linked to topoisomerase II. Anthracyclines fix the enzyme and DNA in this 
formation, which prevents reannealing of the DNA and release of the topoisomerase enzyme. 
The DNA damage resulting from topoisomerase II poisoning causes cell cycle arrest at G1 
and G1 and following this, apoptosis (Minotti et al., 2004). Other mechanisms by which 
anthracyclines can cause cytotoxicity are through: activation of the p53 tumour suppressor 
gene, leading to initiation of apoptosis in cancer cells (Hollstein et al., 1991); the generation 
of reactive oxygen species (ROS), which again stimulating apoptosis in cancer cells (Wang et 
al., 2004).  
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Anthracyclines are very effective chemotherapeutics in the treatment of breast cancer. 
However, these drugs can induce cardio-toxicity through long term administration, which 
limits their utility both in terms of duration of treatment and for specific sub-populations (i.e. 
those with a history of heart disease). Resultantly, alternative topoisomerase II inhibitors 
have been widely explored, as well as modifications to the structure of doxorubicin itself. 
However, doxorubicin still remains a primary chemotherapeutic used in the treatment of 
breast cancer (Minotti et al., 2004).  
 
Taxanes 
 
Taxanes were established as a promising treatment for metastatic breast cancer in the 1990s 
and in 1996 Docetaxel; a semisynthetic analogue of the original taxane Paclitaxel, was 
approved for the treatment of advanced or metastatic breast cancer (US Food and Drug 
Administration, no date). In more recent years, taxanes have become widely used for the 
adjuvant treatment of early breast cancer cases (Bevers et al., 2013). The mechanism of 
action of taxanes is primarily as mitotic inhibitors, where cells are prevented from entering 
mitosis and therefore completing cell division. Taxanes achieve this by inhibiting the 
depolymerisation of microtubules in the cell. Microtubules are akin to a dynamic skeleton in 
the cell and are important in the process cell division as they form the spindles that allow 
separation of chromosomes during anaplase. Microtubule function relies on a dynamic 
process of polymerisation and depolymerisation and therefore the inhibition of 
depolymerisation inhibits normal function and prevents cell death (Gradishar, 2012). The 
consequence of disrupting microtubule dynamics and spindle formation is that chromosome 
segregation does not occur correctly during mitosis, leading to aneuploidy (the incorrect 
number of chromosomes in a cell). Aneuploidic cells are identified and destroyed through 
apoptosis (Zhang et al., 2012) 
 
Antimetabolites  
 
This class of chemotherapeutic agents function through inhibiting biosynthesis of key 
molecules, most notably nucleotides. Antimetabolites can also be incorporated into the 
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structure of DNA/RNA and prevent normal functioning. 5-Fluorouracil (5-FU) functions as a 
cytotoxic agent through both of these mechanisms (Longley, Harkin and Johnston, 2003).  
 
5-FU enters cancer cells via the same transport pathway as uracil. It is a potent inhibitor of 
the enzyme thymidylate synthase, which provides thymidylate for DNA repair pathways 
(Santi, McHenry and Sommer, 1974). In addition, a metabolite of 5-FU (FUTP) can be 
incorporated into RNA molecules, where it inhibits the conversion of pre-rRNA into mature 
rRNA by blocking pre-mRNA splicing. The effects of this misincorporation of 5-FU are 
widespread and ultimately impede cell viability, causing apoptosis (Kufe and Major, 1981).  
 
Alkylating agents  
 
Alkylating agents are capable of forming covalent bonds with the nucleophilic centres of 
some macromolecules. These agents generally interact with DNA through an alkyl group, 
creating DNA adducts. At low levels, DNA adducts can be repaired by the cellular DNA 
repair mechanisms, at doses used for chemotherapy, the rate of adduct formation is such that 
cells are targeted for destruction. A common refinement for alkylating agents is to make them 
bifunctional, such that they can form covalent bonds at two nucleophilic centres on separate 
bases. This generates cross links in the DNA molecule, which is more difficult to repair and, 
thus, more likely to lead to cell death. Examples of classical alkylating agents include as 
Cyclophosphamide (Moore, 1991)nt and Ifosfamide (Zalupski and Baker, 1988) 
 
Platinum-containing chemotherapeutics are also alkylating agents, but covalently link to an 
adenine or guanine base via a platinum atom not an alkyl group. The resulting effect of the 
cell is the same, with high levels of DNA adducts/cross-links leading to cell destruction 
(Lawley and Brookes, 1965). Cisplatin is a platinum based drug with potent anti-tumour 
properties characterised in the late 1960s by Rosenberg et al (Rosenberg, 1980). Cisplatin in 
its activated form reacts preferentially with N7 of guanine. The resulting structure is a 
monofunctional platinated DNA adduct, but this is insufficient to prevent ribonucleotide 
synthesis. The inhibition of DNA synthesis requires interaction with another nucleophilic 
site, which requires the hydrolysis of the chlorine within cisplatin. This final structure forms 
DNA-DNA or DNA-protein links, preferentially between two guanine bases either intra-
strand or inter-strand (Corda et al., 1991). The cross-links cause DNA to unwind or 
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structurally deform, which inhibits DNA synthesis and activates DNA repair pathways within 
the cell. Incomplete or unsuccessful DNA repair results ultimately in the triggering of the 
apoptotic pathway and cell death (Siddik, Siddik and H., 2005).   
 
Endocrine therapy  
 
Aside from the traditional chemotherapeutic drugs used in the treatment of a number of 
different cancers, including breast cancer, another category of anti-cancer drugs are those 
which target the endocrine system of the cells. For tumours that are positive for a particular 
hormone receptor, there are a number of endocrine therapies that can be used to inhibit 
growth. Modern approaches to endocrine therapy were pioneered by Harper and Walpole in 
the late 1960s (Harper and Walpole, 1967) and the first use of endocrine therapy to 
successfully treat patients with breast cancer was in 1971 reported by Cole et al in a clinical 
appraisal (Cole, Jones and Todd, 1971). There are now a number of different endocrine 
therapies used to treat breast cancer with different mechanisms of action, they include 
Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors (AI).  
 
SERMs have a complicated mechanism of action that varies according to cell and tissue type. 
This is largely due to the complexity of the pharmacology of the estrogen receptor. ER 
conformation is determined by its binding to a particular ligand and subsequent association 
with different co-regulators. SERMs are neither pure agonists nor antagonists, and cause ER 
interaction with different combinations of coactivators and corepressors according to the cell 
type (Baumann and Castiglione-Gertsch, 2007). SERMs therefore result in altered ER 
activity in cells, including the disruption of ER-dependent cell proliferation in ER-positive 
breast tumours.  
 
Tamoxifen is a first generation SERM and is the most widely used and extensively 
researched to date. It received FDA approval for metastatic breast cancer treatment in the late 
1970s and remains the drug of choice for ER positive breast cancer (Maximov, Lee and 
Jordan, 2013). Tamoxifen is a triphenylethylene and the structure of its active metabolite 
permits its association with the ligand-binding domain of ER with an affinity of Kd 4.8 nM 
(Coezy et al.,1982) compared with 0.1nM for estradiol (Mosselman et al., 1996). 
Tamoxifen binding therefore precludes the association of estrogen with the ER, acting as a 
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competitive inhibitor. In addition, association of tamoxifen with ER promotes a 
conformational change to the receptor, which inhibits activation factor recruitment including 
activation factor 2 (AF-2). Together, these mechanisms inhibit estrogen mediated growth of 
ER positive breast cancers (Komm and Mirkin, 2014). 
 
In addition to tamoxifen, a number of other SERMs have been developed for breast cancer 
treatment. Notably, a slightly different class of drugs; Selective Estrogen Receptor Down-
regulators (SERDs) have also been developed and provide clinically favourable outcomes in 
some settings. A significant advantage of SERDs over first generation SERMs is that they 
block both AF-2 and Activation Function-1 (AF-1) domains of the ER. AF-1 is linked to the 
binding of alternative co-activators of ER including the p160 family and steroid receptor 
RNA activator. AF-1 and AF-2 functioning in combination maximise the transcriptional 
activity of the ER (Shao and Brown, 2003), and hence their combined disruption maximises 
inhibition of activity. The first SERD developed was Fulvestrant. Unlike Tamoxifen, 
Fulvestrant shows no level of agonist effects on the ER.  
 
Fulvestrant differs structurally from tamoxifen and is a steroidal analog of estradiol. The drug 
has higher affinity for the ER compared with Tamoxifen, with Fulvestrant possessing almost 
90% of the binding affinity of estradiol, and Tamoxifen only 2.5% of the binding affinity of 
estradiol (Wakeling, Dukes and Bowler, 1991). As well as a complete inhibition of estrogen 
signalling through the ER, Fulvestrant also reduces cellular ER and PR levels, which has 
been observed in breast cancer cell lines (McClelland et al., 1996) and clinically (Gandhi et 
al., 2000). This occurs as when Fulvestrant binds to the ER, it forms an unstable complex, 
which causes increased degradation of the ER when compared with estradiol-bound ER 
(Robertson et al., 1996). 
 
The efficacy and tolerability of Tamoxifen versus Fulvestrant was examined in patients with 
advanced breast cancer in a multicentre, double-blind, randomised trial. After 14.5 months 
follow-up, no significant difference was found between the two drugs for primary end point 
to time to progression (Fulvestrant 6.8 months and Tamoxifen 8.3 months; hazard ratio, 1.18; 
95% CI, 0.98 to 1.44; P =.088). Hazard ratio measures the effect of the drug over time and is 
a ratio of the effects seen in the treatment condition to the effects seen in the control 
condition. (Hazard ratio = effect in the intervention group  effect in the control group). The 
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objective response rate was found to be 31.6% with Fulvestrant treatment and 33.9% with 
Tamoxifen treatment, with both drugs being tolerated well (Howell et al., 2004). Fulvestrant 
has been explored in clinical trials as a second-line treatment for advanced breast cancer. In 
the early 2000s was licenced by the Food and Drug Administration as well as the European 
Union for treatment of postmenopausal women with ER-positive breast cancer following 
disease relapse or continued progression following treatment with Tamoxifen or another 
SERM (Howell, 2006). In patients for whom prior endocrine treatment has failed to treat 
breast cancer, Osbourne et al compared the effect of Fulvestrant with anastrozole in a double-
blind, parallel-group study of postmenopausal patients (Osborne et al., 2002). Anastrozole, is 
a non-steroidal aromatase inhibitor. The drug has been used for decades as a second-line 
treatment for breast cancer (Wiseman and Adkins, 1998). Objective response rate for both 
treatments was 17.5% and duration of response longer for Fulvestrant-treated patients; 19.0 
months versus 10.8 months for anastrozole-treated patients (Osborne et al., 2002). 
 
Aromatase Inhibitors  
 
SERMs and SERDs lessen the effect of estrogen on cancer cells by disrupting estrogen 
receptor function. The aromatase inhibitor class of drugs function differently, through 
preventing the production of estrogen in somatic cells. Aromatase, a P450 enzyme complex, 
catalyses the production of estrogen through the aromatisation of androgen hormones 
(Brueggemeier, Hackett and Diaz-Cruz, 2005). The two categories of aromatase inhibitors 
are non-steroidal and steroidal. The steroidal category has an affinity for the binding site of 
aromatase and act as suicide substrates through irreversible binding to the active site. Non-
steroidal AIs efficacy is reliant on the maintenance of high intracellular concentrations as 
their binding to aromatase, is reversible, and they act as competitive inhibitors 
(Brueggemeier, Hackett and Diaz-Cruz, 2005). Aromatase inhibitors have no effect on 
estrogen production in the ovaries, thus this class of drugs are only effective in post-
menopausal women. For pre-menopausal women, Luteinizing Hormone-Releasing Hormone 
Agents (LHRHs) can be utilised, as these agents prevent estrogen production in the ovaries 
(Spicer and Pike, 2000). These drugs are only effective in the subset of breast cancer cases 
that are ER+ and the development of resistance of cancers to them continues to be an issue in 
their effectiveness and improvement of long-term survival.  
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1.8 Drug resistance  
 
Resistance to anticancer drugs greatly limits the long-term efficacy of chemotherapy in a 
number of cancers including breast cancer. Chemotherapeutic resistance can develop before 
exposure to drugs or during a course of chemotherapy, referred to as innate or acquired 
resistance respectively. The development of resistance to one or more chemotherapeutic 
agents can occur through a number of different mechanisms, many of which have been 
elucidated in the past two decades (Giaccone and Pinedo, 1996).  
 
The mechanisms can be categorised into three main types: kinetic resistance, 
pharmacological resistance and cellular resistance. Kinetic reasons for the development of 
resistance refer to the growth of a tumour. A large proportion of chemotherapeutic agents 
preferentially act on rapidly proliferating cells, as this is a hallmark of tumour cells. 
However, within a tumour, subpopulations of slowly proliferating cells may develop, which 
will be more resistant to such chemotherapeutic intervention. Pharmacological resistance 
refers to the reduced ability of particular drug molecules to penetrate cells or diffuse within a 
tumour according to their chemical structure (Filipits, 2004). Finally, cellular resistance 
mechanisms include: a reduction in the intracellular drug concentration via reduced uptake or 
increased efflux utilising transport proteins, a reduction in the concentration of active drug in 
the cell via decreased activation or upregulated inactivation and increases in repair pathways 
to compensate for drug-induced damage (Giaccone and Pinedo, 1996). It can be seen that 
these three definitions are over-lapping, with resistance often occurring through more than 
one route. The described mechanisms of drug resistance often affect more than one (class) of 
therapeutic agent, leading to the development of multi-drug resistance (MDR), a phenomenon 
that contributes to poor treatment responsiveness of breast cancer. Multidrug resistance is the 
process by which cancer cells develop resistance to a number of structurally and functionally 
diverse chemotherapeutic agents (Gillet and Gottesman, 2010).   
 
 Mechanisms of drug resistance  
 
Resistance to anticancer drugs greatly limits the long-term efficacy of chemotherapy in a 
number of cancers including breast cancer. Chemotherapeutic resistance can develop before 
exposure to drugs or during a course of chemotherapy, referred to as innate or acquired 
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resistance respectively. The development of resistance to one or more chemotherapeutic 
agents can occur through a number of different mechanisms, many of which have been 
elucidated in the past two decades. The mechanisms include reducing intracellular drug 
concentration, drug metabolism alterations, apoptosis suppression, and enhanced DNA repair 
(Ali et al., 2017) . These strategies can be used individually or synergistically, whereby 
Multi-drug resistance (MDR) can develop (Gillet and Gottesman, 2010). 
 
 Reducing intracellular chemotherapeutic concentration 
 
There are two types of mechanism to reduce intracellular drug combinations, either reduction 
of drug influx to the cell or maximisation of drug efflux out of the cell or additionally. The 
ultimate outcome of these mechanisms is reduced drug absorption. 
Reductions in uptake  
 
Solute carrier family (SCL)  
 
The solute carrier family of includes 360 uptake transporters including ion-coupled 
transporters and passive transporters (Hediger et al., 2004). Some members of this family are 
implicated in drug resistance. For example, it has been well examined that polymorphisms in 
the gene encoding Reduced folate carrier SLC19A1/hRFC1 inhibit patient responses to some 
chromotherapeutic agents including methotrexate (Assaraf, 2007).  
Additionally, SLC28 and 29 transporters have been shown to alter the cellular uptake of 
chemotherapeutic agents. Specifically, SLC29A1 is implicated in the transport of 
gemcitabine (Mackey et al., 1998) and the role of this in resistance development is further 
highlighted by work showing SLC29A1 levels are a marker for overall prostate cancer patient 
survival treated with gemcitabine (Farrell et al., 2009). This suggests low SLC29A1 levels 
may be associated with resistant phenotypes. 
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Increase in efflux 
 
Breast Cancer Resistance Protein 
 
Control over the transport of drug molecules is a key means by which cancer cells can reduce 
the levels of drugs they are exposed to. Breast cancer resistance protein (BCRP) is a member 
of the ATP-binding cassette (ABC) transporter superfamily (Higgins, 1995) and was first 
identified in the breast cancer cell line MCF-7/AdrVp which possesses a MDR phenotype 
(Doyle et al., 1998). BCRP is an efflux transporter that homodimerises to function at the 
plasma membrane of cells and transports a wide variety of molecules including natural 
substrates such as folate, urea and steroid hormones as well as anti-cancer drugs (Nakanishi 
et al., 2003). BCRP is overexpressed in a number of human cancers including breast cancer 
and said overexpression can occur both through gene amplification and post translational 
modifications. For example, prolonged exposure of the breast cancer cell lines MCF-7 to the 
chemotherapeutic agent mitoxantrone  results in BCRP gene amplification (Kawabata et al., 
2003), and leads to drug resistance. Epigenetic reprogramming such as demethylation and 
histone deacetylation have been explored as means by which BCRP is upregulated 
(Nakanishi et al., 2003).   
 
Multidrug resistance 1/P-glycoprotein 
 
Another ABC protein implicated in MDR is Multidrug resistance 1/P-glycoprotein 
(MDR1/Pgp) (Gottesman, Fojo and Bates, 2002). Pgp has a number of diverse substrates, 
including chemotherapeutic agents such as topoisomerase inhibitors (e.g. doxorubicin) and 
tyrosine kinase inhibitors (e.g. gefitnib) (Nanayakkara et al., 2018). In many cancers 
MDRP/Pgp is expressed at high levels, causing resistance to a number of chemotherapeutics. 
In breast cancer, basal MDRP/Pgp levels are relatively low but expression is amplified 
following exposure to chemotherapy, suggesting it contributes to acquired resistance (Trock, 
Leonessa and Clarke, 1997). The active transport of anti-cancer drugs by MDRP/Pgp from 
the cytosol to extracellular space results in a reduction of intracellular drug concentration to 
insufficient to confer cytotoxic effects, and resistance is then observed.  
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 Drug metabolism 
 
Altered metabolism of drugs inside tumour cells can affect levels of active compound 
available and contribute to resistance development.  
Phase I and Phase II Metabolic Enzymes  
 
Cyctochrome P450 enzymes (CYPs) are involved in the regulation of oxidative metabolism 
(Phase I). Accordingly, CYPs reside in the mitochondria and endoplasmic reticulum (ER). 
Those in the ER can metabolise exogenous compounds such as therapeutic drugs. In 
combination with epoxide hydrolase enzymes, drugs can be metabolised from cytotoxic 
compounds to metabolites that can be exported through ABC-mediated drug transport 
(Brown, Reisfeld and Mayeno, 2008). Although initially characterised in the liver, the 
presence of extra-hepatic CYPs is well established (Oyama et al., 2004; Purnapatre et al., 
2008). Polymorphisms in these genes may result in increased metabolic activities of the 
proteins (Housman et al., 2014), with some polymorphisms predictors of treatment outcomes 
(van Schaik, 2008). Specifically, polymorphisms in CYP2B6 increase the metabolism of 
chemotherapeutic agent cyclophosphamide (Xie et al., 2006). In breast cancer, the efficacy of 
Tamoxifen has been found to be dependent upon polymorphisms of CYP2D6. Tamoxifen (a 
pro-drug) is metabolised through this enzyme to be active as endoxifen (Stearns et al., 2003). 
Further metabolism of Tamoxifen is controlled by sulfotransferases and UDP 
glucuronotransferases (Majumder et al., 2017). The enzymes above are highly polymorphic, 
with genetic differences resulting in differential metabolism of the drug. Consequently, the 
co-administration of drugs that can alter CYP2D6 are targets of interest for enhancing the 
efficacy of Tamoxifen (Jin et al., 2005).  
 
Uridine diphosphate glycosyltransferases 
 
Beyond reducing the concentration of chemotherapeutics within cancer cells, another cellular 
mechanism of resistance development is the reduction of active drug due to altered drug 
metabolism. Uridine diphosphate glycosyltransferases (UDGs) are a group of enzymes 
capable of catalysing glucuronidation; the transfer of glycosyl groups onto intracellular 
molecules, including drugs. This process increases compound solubility and aids expulsion 
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from the cell (Starlard-Davenport et al., 2010). A particular family of UGTs is the UGT1As, 
which are upregulated in a range of breast cancer cell lines including MCFB7 and 
MDABMBB468 cells. UGT1A protein upregulation provides cancer cells with an increased 
capacity to metabolise drugs, enhancing their excretion from the body. This effectively 
reduces the intracellular concentration and reduces the capacity for drugs to elicit their 
therapeutic potential (de Almagro et al., 2011). Epigenetic changes can result in the 
upregulation of particular UGTs such as UGT1A1 that also confer resistance (Housman et 
al., 2014).  
 
Phase II enzymes 
 
These enzymes include glutathione-s-transferase and UDP-glucuronosyltransferases, 
involved in glutathionylation and sulfation (Hemmerich, Verdugo and Rath, 2004; Ghezzi 
and Di Simplicio, 2007). Amongst others, these enzymes metabolise reactive drugs and 
cytotoxic metabolites into non-toxic metabolite conjugates (Deeley, Westlake and Cole, 
2006). therefore, these are implicated in resistance development, with upregulation or some 
genetic polymorphisms conferring resistance to tumour cells (Ekhart et al., 2009). 
 
 Apoptosis suppression 
 
Evasion of drug induced apoptosis is a key contributor to cancer drug resistance and a major 
blocker to effective chemotherapy treatment. This resistance is achieved through the 
mitochondrial Bcl2-mediated pathway. Bcl2 mutations have been shown to impede treatment 
success (Viktorsson, Lewensohn and Zhivotovsky, 2005). Some correlation has been 
observed between bcl2 expression and response to chemotherapy with Bonetti et al observing 
this gene has a role in predicting resistance development (Bonetti et al., 1998).  
 
 Enhanced DNA Damage repair 
 
Chemotherapeutic agents possess a number of mechanisms of action, but converge to cause 
DNA damage and consequent cell death (Martin et al., 2008). The effectiveness of these 
treatments is impaired by the DNA damage repair machinery within cells including pathways 
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such as: mismatch repair, nucleotide excision repair, non-homologous end joining and 
homologous recombination (Hakem, 2008). The extent of activity in a particular repair 
pathway such as nucleotide excision repair is correlated with increased survival of ovarian 
(Dabholkar et al., 1992) and colorectal cancer cells (Metzger et al., 1998).  
 
Additionally, resistance to particular alkylating agents through methylguanine 
methyltransferase-mediated DNA repair has been characterised in glioma patients (Verbeek 
et al., 2008). DNA-dependent protein kinase catalytic subunits are key in the process of non-
homologous end joining DNA repair (Ciszewski et al., 2014). In breast cancer, low levels of 
this subunit is correlated with high tumour grade and poor survival. Furthermore, 
upregulation of non-homologous end joining is implicated in chemotherapeutic resistance 
and inhibiting DNA-dependent protein kinase catalytic subunits increases the sensitivity of 
breast cancer cells to doxorubicin (Moll et al., 1999). 
 
 Summary of drug resistance 
 
The above examples illustrate the range of gene expression differences between drug 
resistant and sensitive breast cancer cells. The numerous pathways altered as a result of these 
are extensive. The various methods of acquired and intrinsic resistance have a significant 
effect on drug effectiveness and rate of cancer recurrence. Understanding these mechanisms 
is critical in order to prevent its occurrence or address its effect and thus enable the 
development of more successful treatments.  
 
Aside from the well characterised mechanisms of drug resistance described above, additional 
factors contributing to its development are the efficiency of an individual’s liver to clear 
chemotherapeutics and the tolerance of adverse effects limiting the dose that can be 
administered (Ali et al., 2017). 
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1.9  Metabolism 
 
Metabolic reprogramming: an emerging hallmark of cancer 
 
It is becoming increasingly clear that the sustained cell division observed in tumours has a 
high metabolic demand. To support cell division, cells must be able to generate all the 
components required, including nucleotides, amino acids, lipids, energy etc., and this requires 
active cellular metabolism. Cancer cells have the capacity to alter their metabolism to confer 
a proliferative advantage, enhancing growth capacity and promote survival. The mechanisms 
of metabolic reprogramming are diverse and can be mediated by genetic or epigenetic effects.  
 
 The Warburg Effect 
 
One of the first identified mechanisms of metabolic reprogramming was an alteration in the 
utilisation of energy producing pathways. Glucose metabolism is the the process most 
commonly used cells capture to capture energy in the form of adenosine triose phosphate 
(ATP). In normal cells, mammalian energy production occurs through glycolysis, forming 
pyruvate, which then undergoes oxidative phosphorylation through the tricarboxylic acid 
cycle. In 1924 Otto Warburg defined The Warburg Effect as the reliance of malignant cells 
on glycolysis without subsequent oxidative phosphorylation, event in the presence of excess 
oxygen, to provide the majority of their energy requirements (Warburg et al., 1924). 
Observations in cancer cells have seen levels of glycolysis 200-fold higher than oxidative 
phosphorylation. In tumours, therefore, glucose uptake is increased and high levels of lactate 
are produced despite maintenance of metabolism and an abundance of oxygen (Vander 
Heiden, et al., 2009).  
 
That cancer cells make this metabolic switch has been observed for a number of years. 
However, the reason underlying this switch is less well understood. Oxidative 
phosphorylation is well defined as a more efficient means of ATP production than glycolysis: 
where oxidative phosphorylation can generate over thirty ATP molecules per glucose 
molecule, glycolysis generates only two. The switch to glycolytic-predominant energy 
metabolism has been observed in differentiated cells under hypoxic conditions (Lunt and 
Vander Heiden, 2011), suggesting that oxygen tension may be a driver for this switch. A 
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number of theories for the preferential use of glycolysis in tumours have been postulated: 
first, ATP generation through glycolysis may act to increase reactive oxygen species (ROS) 
levels, which allows for ROS-mediated cell signalling (Locasale and Cantley, 2011); second, 
the Warburg Effect may actively create a hypoxic microenvironment that enhance the ability 
for cells to invade surrounding tissue (Estrella et al., 2013); third, the effect has been 
postulated as a mechanism to provide a carbon source for the biosynthesis needs of a rapidly 
proliferating cell, as glucose molecules that enter into glycolysis can be subverted into 
pathways for protein and lipid synthesis (Liberti and Locasale, 2016).  
 
 Further metabolic reprogramming 
 
Another metabolic alteration observed in cancer cells linked to the requirement for 
biosynthesis is the upregulation of the tricarboxylic acid (TCA) cycle. There is experimental 
evidence showing the transport of a proportion of pyruvate from glycolysis into the TCA 
cycle to maintain the activity of this pathway (Cheng et al., 2011). This observation is in 
direct conflict to the Warburg effect, as that requires the minimisation of the TCA cycle. 
 
Other alterations to cellular metabolism have been noted in cancer cells, all supporting 
increased rates of cell proliferations. These include: upregulation of nutrient transporter 
expression; increased expression of glycolysis-related genes; higher rates of protein 
synthesis; and, upregulation of enzymes required for glycolysis. Alterations in key signalling 
pathways have also been reported, including phosphatidylinositol 3-kinase (PI3K), 
mammalian target of rapamycin (mTOR) and protein kinase B (Akt). Many cancer-specific 
alterations to signalling pathways are controlled by oncogenes or mutations in tumour 
suppressor genes. HER2 for example mediates a proportion of the changes to 
PI3K/Akt/mTOR pathways (Ogrodzinski et al., 2017). 
 
Breast cancer, as other cancers, can alter cellular metabolism to either better support cell 
proliferation or to reduce therapeutic efficacy. Notably, different subtypes of breast cancer 
have been shown to exhibit different metabolic alterations (Ogrodzinski et al., 2017). The 
understanding could also aid in more useful subtyping of different breast cancers, discussed 
in detail in 1.5.3.1. Breast cancer subtypes display different metabolic alterations. Triple 
negative breast cancers (TNBCs) do not express ER, PR or HER2. The metabolic phenotype 
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of TNBCs includes an increase in glucose metabolism through glycolysis; The Warburg 
Effect. Contrastingly, ER positive cell lines have been observed to obtain ATP primarily 
through oxidative phosphorylation. TNBCs display increased levels of glutamine metabolism 
compared to non-transformed cells (Dang, 2012) and compared to other breast cancer 
subtypes. This has been observed in vitro using cell line models, and is further evidenced in 
vivo by observed sensitivity of TNBCs to inhibitors of the glutaminase enzymes (Gross et al., 
2014). Differences in lipid metabolism have also been observed in TNBCs compared with 
hormone receptor positive breast cancers. The breast cancer cell line MCF-7, which is ER 
positive, displays lower levels of lipid accumulation and storage of cholesterol when 
compared with triple negative breast cancer cell lines.  
 
Understanding breast cancer sub-type specific metabolic reprogramming is not only 
beneficial for tumour sub-typing,but could enable the identification and subsequent targeting 
of metabolic vulnerabilities. These vulnerabilities may occur in all breast cancers, or be 
specific to certain sub-types, potentially aiding treatment of breast cancers that are currently 
poorly served by therapeutic options.  
 
 
 Metabolism as a target for breast cancer treatment  
 
For cells to divide there is an energy cost associated with the production of building blocks 
for cell division (e.g. amino acids, nucleotides, lipids etc.).  As cancer is, essentially, a 
disease of uncontrolled cell division, there is a high energy demand to drive this cell division. 
Antimetabolites, described in Section 1.8.2.1, which alter the ability of cells to perform 
nucleotide metabolism, have formed an important part of cancer treatment for many years 
(Heidelberger et al., 1957; Wagner et al., 2006). Research has now shown that there are 
many other metabolic requirements of cancer cells that are critical to cell survival and 
proliferation and are distinct from the requirements of non-cancerous cells (Lunt and Van 
Heiden, 2011). As such, cancer metabolism has been studied to provide information on 
disease progression and to identify potential therapeutic targets to treat a number of cancers, 
including breast cancer. 
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As previously discussed, Otto Warburg identified altered metabolism amongst cancer cells 
over 90 years ago; notably increased aerobic consumption of glucose and lactate production 
(Warburg et al., 1924). While the full biological rationale for all metabolic reprogramming 
that occurs during cellular transformation is still be elucidated, it is clear that there are two 
main outcomes: first, to provide the metabolic components that are required for high levels of 
cell proliferation (e.g. nucleotides, amino acids, lipis, energy etc.); second, to reduce the 
sensitivity of the cancer to cell to agents (both xenobiotic and endogenous in nature) that 
might destroy it. Regardless of the biological rationale, if these changes occur to support cell 
survival and tumour growth, then it is logical to presume that targeting these adaptations may 
be a novel avenue for treating cancer. 
 
Within breast cancer research, recent work has identified further metabolic differences 
between normal and malignant cells, as well as differences between tumour subtypes. The 
field of metabolomics has provided a means for large scale investigation of breast cancer 
metabolic profiles using methods including liquid chromatography-mass spectrometry (LC-
MS) and nuclear magnetic resonance spectroscopy (NMR) coupled with statistical analysis to 
investigate networks of metabolic pathways. Willmann et al in 2015 used such techniques to 
compare metabolic profiles of three breast cell lines and observed significant differences 
between them. This highlights the potential use of metabolomics in the identification of 
breast cancer subtypes or in assisting diagnosis (Willmann et al., 2015). 
 
 
 
 Bile acid metabolism  
 
Physiologically, Bile acids (BAs) are terminal products of cholesterol metabolism, with 
primary bile acids (e.g. cholic acid) being actively secreted into the intestinal lumen, where 
they are further metabolised to form secondary bile acids (e.g deoxycholic acid and 
lithocholic acid). Enteroheptic recirculation of biles acids means that intestinal BA 
concentrations are significantly higher than the rates of biosynthesis. BAs are physiologically 
important as they are able to aid solubilisation of lipophilic molecules in the intestine through 
micelle formation. As such, they aid the absorption of lipophilic vitamins (e.g. vitamins A, K, 
E, and D), and the excretion of lipophilic chemicals such as cholesterol and bilirubin. 
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However, in elevated concentrations, BAs can cause cytotoxic effects, and as such their rate 
of biosynthesis, processing and recirculation are tightly regulated.  
 
A role for bile acid metabolism has been identified in breast cancer, with bile acids 
influencing the ER and ER-regulated proteins (Baker et al., 1992). Bile acid metabolism is 
key for the maintenance of normal cellular function in a number of tissues including the liver 
and intestine. A dysregulation of bile acid metabolism has been found to sensitise hepatic 
cells to cancer development (Huang et al., 2015) and a protein critical for the maintenance of 
normal bile acid metabolism is the farnesoid X receptor. 
 
The Farnesoid X Receptor  
 
The Farnesoid X receptor (FXR) is part of a large family of nuclear receptor transcription 
factors, first isolated in 1995 (Forman et al., 1995). As with other nuclear receptors, FXR 
possesses an N-terminal DBD and C-terminal LBD. The primary endogenous ligands of the 
FXR are bile acids (BAs) (Makishima et al., 1999), which are the final product of hepatic 
cholesterol catabolism and are steroid acids involved in digestion, lipid absorption and 
cholesterol homeostasis (Staels and Fonseca, 2009). In humans, the principal sites of FXR 
expression are the liver, kidney, intestine and adrenal gland. Lower levels of expression are 
also seen in adipose tissue (Forman et al., 1995). FXR can be activated through binding of 
bile acid ligands to the LBD, which promotes the heterodimerisation of FXR and the retinoid-
X-receptor (RXR). Functions of the FXR are propagated through binding of the DBD of the 
Heterodimerised FXR:RXR nuclear receptors to cis-acting elements in FXR response 
elements located on promotors of particular target genes (Edwards et al., 2002). The roles are 
far reaching and include: hepatoprotection, liver regeneration and metabolic control including 
lipoprotein metabolism, bile acid homeostasis and glucose homeostasis (Cariou and Staels, 
2007). 
 
FXR regulates levels of BAs through regulating gene expression (Cariou and Staels, 2007). 
BAs are ligands for FXR with Kds in the order of 10s-100sµM. Once activated, FXR 
regulates the expression of a range of genes, including another nuclear receptor, the Small 
Heterodimer Partner (SHP). SHP inhibits expression of Cyp7a1, the gene that encodes 
cholesterol-7-alpha hydroxylase, the rate-limiting enzyme cholesterol metabolism and 
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biosynthesis of BAs. This creates a negative feedback loop; as BA levels increase, the rate of 
their production is decreased (Lee et al., 2006). An additional mechanism of FXR-mediated 
bile acid homeostasis is the induction of the multi-drug resistance protein (MDR3). MDR3 
can reduce the levels of free bile acids in a tissue through altering bile acid transport, which 
results in the micelles formed in the intestine to contain more bile acids. Ligand-bound FXR 
can also inhibit the uptake of BAs into tissues such as the liver. This occurs through the 
indirect inhibition of the expression of OATP1B1, the organic anion transporter polypeptide 
involved in the transport of BAs into the liver (Eloranta and Kullak-Ublick, 2008).  
 
FXR in the breast and breast cancer 
 
In addition to the sites of primary expression above, FXR is also expressed in breast tissue. 
Swales et al in 2006 analysed the expression of FXR in a number of patient samples from 
both infiltrating ductal carcinoma and normal breast tissue using immunohistochemistry and 
Western blotting. They demonstrated higher levels of FXR-specific staining in tumour 
samples compared to controls, although all samples demonstrated some expression (Swales et 
al., 2006a). Increased expression of FXR in breast cancers has been confirmed in subsequent 
studies (Journe et al., 2009), raising interest in a potential role of FXR in cancer propagation 
or disease progression. Journe et al found FXR expression in ER-positive tumours was higher 
than in ER-negative tumours, which is consistent with expression levels in ER-positive MCF-
7 breast cancer cell line compared with ER-negative MDA-MB-231 breast cancer cell lines 
(Journe et al., 2009).  
 
There are a number of ways in which increased FXR activity could influence tumour growth 
in breast cancer:  
(i) Cell proliferation: FXR antagonists result in cyclin D downregulation at both 
transcript and protein level (Journe et al., 2009). As cyclin D has a role in G1/S 
progression (Sherr and Roberts, 1999), its inhibition can lead to cellular arrest in 
G0/G1. FXR expression is also linked to that of c-myc, another proliferation 
marker (Journe et al., 2009). 
(ii) Drug Resistance: FXR regulates the expression of a number of transporter 
proteins in cells. Amongst these, are members of the MDR and MRP families of 
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drug transporters that have been implicated in the development of multidrug 
resistance in cancer.  
(iii) Cell death: FXR activators cause apoptosis in FXR positive breast cancer samples 
(Swales et al., 2006a), and in breast cancer cell lines (Mohan et al). 
 
 
The mechanisms by which FXR is proposed to promote cell cycle are explored by You et al, 
who found to have a critical role specifically in G1/S transition. You, et al found that 
treatment of lung cancer cell lines with FXR inhibitors increased the proportion of cells in 
G0/G1 and decreased the proportion in S and G2/M phases (You et al, 2017). FXR inhibition 
resulted in downregulation of cyclin D1 and retinoblastoma proteins, which suggests FXR 
may positively regulate the transcription of these proteins (You et al, 2017). Within the cell 
cycle, Cyclin D1 synthesis is initiated in G1 phase and promotes G1/S transition. Therefore, 
downregulation of Cyclin D1 via the inhibition of FXR impedes cell cycle progression (You 
et al, 2017). 
 
The findings by Journe et al that FXR promotes cell proliferation in breast cancer and 
findings by Swales et al that FXR activation causes apoptosis presented here are conflicting. 
This may be due to differences in experimental method and culture conditions. Swales et al 
use 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays to measure 
cell viability, whereas Journe et al utilise crystal violet staining. Where MTT assays examine 
the metabolic capacity of cells, crystal violet staining measures the ability of cells to form 
colonies. Furthermore, Swales et al serum starve cells for 24 hours prior to treatment and the 
treatment in in serum free conditions, whereas Journe et all do not serum starve cells. Journe 
et al propose that this experimental condition is likely to compromise proliferation and 
therefore mask interactions between the estrogen receptor and FXR in mediating cell 
proliferation. 
 
The usefulness of FXR as a biomarker for cancer progression and prognosis was assessed by 
Journe et al who examined the correlation between FXR and survival in 120 breast cancer 
patients. Whilst no significant correlation was observed between FXR expression and 
prognosis in patients, there were clear correlations between its expression and the expression 
of a number of different proliferation markers such as Ki-67. In vitro experiments exploring 
interactions between FXR and ER in MCF-7 cells highlight their role in promoting cell cycle 
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progression through a number of proposed mechanisms (Journe et al., 2008). The 
proliferative effect of FXR on some breast cancer cells has highlighted this nuclear receptor 
as a potential drug target for breast cancer (Journe et al., 2008). 
 
 Glucose metabolism 
 
Glucose homeostasis 
 
FXR has been implicated in a number of studies as contributing to the maintenance of stable 
in vivo glucose levels. FXR achieves these effects in a number of ways. One such means is 
through altered expression of genes involved in gluconeogenesis. For example, increased 
levels of ligand-bound FXR result in decreased phoshphoenolpyruvate carboxykinase and 
glucose-1-6-phosphate expression (Cariou et al., 2005). Additionally, experiments involving 
FXR knockout mice demonstrate that without functional FXR, gluconeogenesis is 
dysregulated and animals display reduced insulin sensitivity in muscle (Cariou and Staels, 
2007). These mechanisms are not clearly understood and there are key differences in the 
results from different published studies, which may be due to the nutritional state of the study 
subjects or the ligand utilised to activate FXR (Kim et al., 2007). 
 
 
1.10 Drugs that modulate the metabolic activity of cells  
 
Two main metabolism modulating drugs are explored in the research of this thesis, GW4064 
a Farnesoid X receptor agonist and Metformin, a biguanide and the primary treatment for 
Type II diabetes mellitus.  
 
 GW4064 
 
As discussed in the introduction section 1.10.2, the Farnesoid X receptor (FXR) is a ligand-
activated transcription factor expressed in a number of human cell types, including within 
breast tissue. It is known primarily for its function in the liver, where it regulates a number of 
biological pathways involved in bile acid metabolism. However, in recent years, FXR 
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expression has been identified in the breast, and specifically in ductal epithelial cells of both 
normal and cancerous breast tissue. Additionally, studies have confirmed the expression of 
FXR in a number of specific breast cancer cell lines including MCF-7, MDA-MB-231 and 
MDA-MB-468 (Swales et al., 2006a), (Mohan et al., 2015). FXR is not only present in breast 
tissue and breast cancers, but it has been proposed as a prognostic marker for disease-free 
patient survival in patients with invasive breast carcinomas. In one study of 115 patients, 
those expressing high levels of FXR were found to have a significantly disease-free survival 
of 150 months, which was 30% higher than in patients expressing low levels of FXR. 
Additionally, none of the patients with low FXR saw 200 months disease free survival, 
compared with 80% of patients with high FXR expression (Giaginis et al., 2017).  
 
FXR was originally described for its role in regulating bile acid metabolism in the liver 
Figure 1-7, (Forman et al., 1995; Chiang, 2017). However, subsequent work identified a 
multitude of biological actions, including glucose homeostasis and cellular repair (Cariou and 
Staels, 2007). As a result of this mechanistic diversity, the potential link to breast cancer 
disease progression could occur through several different pathways. Regardless of the exact 
mechanism, activation of FXR in breast cancer cell lines has been observed to reduce cell 
proliferation (Mohan et al., 2015). The expression of FXR in a number of breast cancers, 
along with its potential to negatively impact on tumour growth has raised interest in the 
potential role of FXR as a therapeutic target (Journe et al., 2009). 
 
 
 
 
 
 
 
 
 
Figure 1-7. Regulation of bile acid metabolism by FXR. In the liver, FXR is activated by primary bile acids, the 
final products in the catabolism of cholesterol, chenodeoxycholic acid and cholic acid. The enzyme Cholesterol 
7α-hydroxylase (CYP7A1) is the first enzyme in the bile acid synthesis pathway. Via a feedback mechanism, 
FXR inhibits bile acid synthesis. Activated FXR inhibits CYP7A1 via the induction of the small heterodimer 
partner (SHP), a negative nuclear receptor, which inhibits the transcription of CYP7A1.  
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GW4064 is a potent FXR agonist discovered by GSK (Maloney et al., 2000), whose structure 
is shown in Figure 1-8. Swales et al observed concentration-dependent cell death in breast 
cancer cell lines treated with GW4064 following drug-dependent activation of FXR (Swales 
et al., 2006a).  Studies using GW4064 have identified a large set of genes that are regulated 
by FXR. A number of these genes encode protein products that have been implicated in 
breast cancer progression and multidrug resistance development. These include including a 
gene expression a cationic amino acid transporter: Solute carrier family 7, member 5 
(SLC7A5) and two ATP binding cassette proteins; ATP binding cassette subfamily B 
member 4 (MDR3) and ATP Binding Cassette Subfamily C Member 1 (MRP-1).  The 
apoptotic effect of FXR combined with its down-regulation of key genes in breast cancer 
development further the potential importance of FXR as a therapeutic target for breast cancer. 
Furthermore, FXR has been shown to reduce levels of endogenous aromatase in breast cancer 
cells, a key enzyme in the biosynthesis of estrogen and a well-established target of drugs 
treating estrogen receptor (ER) positive breast cancer (section 1.10.2.1). Therefore, FXR-
mediated aromatase suppression could be a means by which the receptor inhibits cellular 
proliferation in ER positive breast cancers and cell lines (Swales et al., 2006a).  
 
 
 
 
 
 
 
 
 
Figure 1-8. Molecular structure of GW4064. 
 
Another mechanism by which the upregulation of FXR could reduce disease progression in 
breast cancer patients is through promoting changes to the tumour microenvironment. Cancer 
associated fibroblasts (CAFs) comprise a large proportion of the tumour microenvironment 
and have been observed to promote cancer progression in a number of animal models 
(Aboussekhra, 2011). The main pathway through which this is achieved is leptin signalling. 
Leptin is a cytokine, secreted by adipocytes that is correlated with occurrence of breast 
cancer. Recent research has shown that CAFs also secrete leptin (Barone et al., 2012). Leptin 
acts on tumour cells through binding to the OBR receptor and activating signalling pathways 
including MAP-kinase, PI3K/AKT and JAK-STAT, which stimulate cell growth. Growth 
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stimulation by leptin in breast cancer cell line T-47D can be inhibited by MAP-kinase and 
STAT inhibitors (Miyoshi et al., 2006), suggesting activation of both of these signalling 
pathways result in growth signal transduction in breast cancer. Miyoshi et al used univariate 
analysis to identify a number of prognostic factors in breast cancer including mRNA levels of 
short and long isoform leptin receptors, PR status and tumour size (Miyoshi et al., 2006). 
Myoshi et al observed that levels of leptin mRNA are significantly higher in ER-positive 
compared to ER-negative tumours. Another mechanism by which leptin is thought to 
stimulate tumourigenesis specifically in ER-positive breast cancers is through autocrine 
signalling.  
 
Fuqua et al identified cross-talk between CAFs and ER positive breast cancers via leptin 
signalling. They proposed that leptin and estrogen in combination supported the maintenance 
of breast cancer cellular growth, with leptin and associated receptors often overexpressed in 
breast cancers (Fuqua et al., 2000). Mechanistically, this occurs in two main ways: First, the 
leptin (LEP) promotor has been long known to contain estrogen response elements (EREs), 
and O’Neil et al in 2001 showed that estrogen activates the LEP promotor via direct ligand-
bound receptor binding to the ERE (O’Neil et al., 2001). Second, leptin has been shown to 
enhance aromatase expression in ER-positive breast cancer cell lines via an associated 
transcription factor Activating Protein 1 (AP1). Leptin increases mRNA expression through a 
leptin-activated promoter, which has been demonstrated to result in increased aromatase 
enzyme activity in MCF-7 cells (Giordano et al., 2011). Increased aromatase activity would 
increase estrogen generation, and thus tumour growth in ER positive breast cancer cell lines 
(Catalano et al., 2003). Activated FXR should affect these pathways, inhibiting breast cancer 
cell growth and motility. Despite the observed association between leptin signalling and ER 
positive breast cancers, treatment with leptin results in increases in both motility and 
proliferation in both ER-positive and ER-negative breast cancer cell lines, an effect which is 
reversed by concomitant treatment with FXR agonist GW4064 (Giordano et al., 2016). The 
mediating effect of active FXR on the ability of leptin to stimulate growth and motility in 
breast cancer cell lines is achieved through a reduction in leptin-activated signalling 
pathways, as evidenced by a tempering of leptin-mediated phosphorylation of AKT, JAK2 
and STAT3 and the expression of leptin target genes including Cyclin D1 and Survivn with 
cells treated with GW4064 (Giordano et al., 2016). Furthermore, a target gene of FXR, 
SOCS3 (Cirillo et al., 2008), has been characterised as a negative feedback regulator of leptin 
signalling (Xu et al., 2012).  
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Activation of FXR has been suggested to promote apoptosis in breast cancer cell lines in a 
mechanism linked to the generation of reactive oxygen species. ROS-stimulated apoptosis 
and the relation of this to a number of cancers been studied (Chung, Bae and Lee, 2003; 
Donadelli et al., 2007; McLean et al., 2007). Mohan et al studied the effects of FXR agonists 
on the generation of ROS in breast cancer cell lines MCF-7 and MDA-MB-231. Menadione, 
a cytotoxic quinone known to generate ROS in breast cancer cell lines irrespective of ER-
status (Wang et al., 2009) was used as a positive control to generate maximal H2O2 activity 
(Mohan et al., 2015). The FXR agonist GW4064 increased ROS activity significantly relative 
to control (p < 0.0001) in both cell lines as measured using a luminescence assay (Mohan et 
al.,2015). Mohan et al propose that the effects of ROS on breast cancer cell lines are 
achieved through its promotion of the permeability transition pore formation, which results in 
release of cytochrome c and activation of the intrinsic pathway of apoptosis (Martinou and 
Youle, 2011). Observations of cytochrome c release and the activation of caspase 9 following 
FXR activation in MCF-7 and MDA-MB-231 cell lines support this hypothesis, 
demonstrating that FXR stimulates ROS-mediated mitochondrial dependent caspase 
activation (Mohan et al., 2015). 
 
The activation of FXR by GW4064 has been demonstrated to inhibit cell growth and motility 
in both ER positive and negative breast cancer cell lines (Swales et al., 2006a). In addition, 
GW4064 can inhibit cellular growth of breast cancer cell lines with resistance to tamoxifen 
treatment (Giordano et al., 2011a). This is particularly important given the failure of 
endocrine therapeutics to effectively combat breast cancer due to resistance development to 
one or multiple drugs (Gottesman, 2002; Ring and Dowsett, 2004). Giordano et al. found that 
activation of FXR by GW4064 resulted in reduced HER2 expression in MCF-7 cells and a 
tamoxifen resistant derivative cell line (Giordano et al., 2011).  
 
The potential of a combination treatment using tamoxifen and GW4064 has been explored, 
with a synergistic effect identified in breast cancer cell lines (Mohan et al., 2015). Tamoxifen 
has been used clinically for more than 30 years as a treatment for breast cancer (Jordan, 
1992) but there are a number of issues with its use (Ring and Dowsett, 2004). These include 
resistance development during treatment with Tamoxifen, potential for disease relapse, and 
ineffectiveness of Tamoxifen treatment in breast cancers without ER (Dorssers et al., 2001; 
Shastry and Yardley, 2013). Separately, GW4064 and Tamoxifen have been shown to induce 
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concentration-dependent cell death in both MCF-7 and MDA-MB-231 cells, through 
induction of ROS-mediated apoptosis (Kallio et al., 2005; Mohan et al., 2015). The pairwise 
combination of GW4064 and Tamoxifen has been shown to induce cell death in MCF-7 and 
MDA-MB-231 cell lines in a strongly synergistic manner (Mohan et al., 2015) 
 
The efficacy of a combination of GW4064 and Tamoxifen in cell lines suggests this as a 
promising alternative to Tamoxifen treatment alone and could provide therapeutic benefits in 
treating both ER-positive and ER-negative breast cancers (Mohan et al.,2015).  
 
 
 Metformin 
 
Metformin is currently the primary therapy used for the treatment of type 2 diabetes mellitus 
(TIIDM), where it acts to reduce blood glucose levels (Gong et al., 2012). Metformin is a 
biguanide, being comprised of two connected guanidine groups (Figure 1-9), and was 
isolated from galegine sourced from the plant Galega officinalis. Hesse and Taubman first 
linked the compound to the lowering of blood glucose in 1929 (Hesse and Taubmann, 1929). 
Clinical uptake was slow, and it was not until the late 1950s that the drug was introduced to 
treat diabetes in the UK following a publication by Sterne (Sterne, 1957) and in the early 
1990s in the USA (Bailey, 2017). Today, the drug has been used clinically for over 50 years 
and displays high levels of safety as well as having minimal effect on patients’ weight (Rena, 
Pearson and Sakamoto, 2013). Metformin has effects beyond its primary use, controlling 
TIIDM, for example, long-term treatment with metformin is associated with a reduction in 
the incidence of cardiovascular disease (Turner, 1998) (Griffin, Leaver and Irving, 2017).  
 
 
Figure 1-9.a. Biguanide structure of metformin made up of two b. guanidine groups. 
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The mechanism of action of metformin is multifaceted and is still not fully characterised 
(Rena et al., 2013). The primary sites of action of metformin in humans are the liver, kidney 
and intestines. Within the liver, metformin acts to control levels of glucose production via 
indirectly inhibiting gluconeogenesis. As gluconeogenesis requires high levels of ATP, any 
reduction in the ability of hepatocytes to produce ATP will limit gluconeogenic flux. 
metformin achieves this reduction in available ATP through three, linked actions: First, a 
reduction in cellular ATP by accumulating within hepatic mitochondria and inhibiting 
Complex I of the respiratory chain (Owen et al., 2000). Second, metformin inhibits 
mitochondrial glycerophosphate dehydrogenase, diminishing the ability of mitochondria to 
convert lactate into glucose (Madiraju et al., 2014). Third, the resultant alteration of 
AMP:ATP ratios increases the expression of 5' adenosine monophosphate-activated protein 
kinase (AMPK) (Kahn et al., 2005), stimulating increased ATP levels. While this may seem 
counterproductive, one of the mechanisms to achieve AMPK-meditated ATP increase is the 
suppression of gluconeogenesis, through an inhibition of the expression of glucose-6-
phosphatase (Lochhead et al., 2000), and enhanced glucose catabolism through glycolysis 
(Towler and Hardie, 2007). An additional mechanism by which metformin influences blood 
glucose levels that has been proposed in recent years is that the elevated levels of AMP 
caused by metformin reduce cyclic AMP (cAMP) levels. This leads to a suppression of 
protein kinase-A function, and inhibits glucagon-dependent production of glucose from 
hepatocytes (Miller et al., 2013). Further effects of metformin are achieved through its action 
on the intestines, where it stimulates the utilisation of glucose (Rena, Pearson and Sakamoto, 
2013).  
 
A number of longitudinal studies have identified a reduced risk of cancer development in 
patients taking metformin at an average daily concentration of 1875mg, which is below the 
maximum prescribed dose (2000mg/day). Libby et al in 2009 performed an observational 
cohort study among people with type 2-diabetes. They used a survival analysis to compare 
cancer risk in individuals exposed to metformin versus those not exposed to the drug. The 
groups were matched for a number of variables and the study found that metformin uses are 
at a lower absolute risk of cancer compared with the non-users; 7.3% diagnosed with cancer 
versus 11.6% respectively. After adjusting for variables including sex, age, BMI, smoking, 
and other drug use, there was still a significantly reduced risk of cancer associated with use of 
metformin, 0.63. Individuals who had taken metformin for greater than three years were 
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found to have a significant reduction in cancer risk (ORs with 95% CI 0.40; 0.21 to 0.57, 
p=0.004) (Monami et al., 2009); higher levels of exposure conferred a greater protective 
effect (Libby et al., 2009; Evans et al., 2005). In breast cancer specifically, an 
epidemiological study was carried out in 2009 examining patients split into groups of diabetic 
patients taking metformin, diabetic patients not taking metformin and non-diabetic patients 
not taking metformin. The responsiveness of each group to neoadjuvant therapy was 
examined, demonstrating that the pathological complete response of diabetic patients taking 
metformin was 16% higher than diabetic patients not receiving metformin and 8% higher 
than non-diabetic patients (P=0.02) (Jiralerspong et al., 2009).   
 
 
Numerous mechanisms by which metformin acts upon breast cancer cells have been 
hypothesised and tested experimentally, but no definitive mechanism(s) have been 
established for its anti-cancer properties to date. In vitro, metformin has been found to inhibit 
the growth of certain cell lines in culture. For example, Zhang et al demonstrated that  MCF-
7 and MDA-MB-231 exposure to 5-20mM metformin for 48 hours significantly inhibited cell 
proliferation, invasion and migration as well as inducing apoptosis (Zhang et al., 2017). 
Marinello et al proposed that metformin reduces cell survival by increasing the number of 
reactive oxygen species (ROS) present within cells. Increased ROS can induce DNA damage 
and resultantly apoptosis (Marinello et al., 2016). The group found MCF-7 cells to be more 
sensitive to the effect of metformin on cell metabolism than MDA-MB-231 cells. In both cell 
lines, however, the mechanism of action was found to be due to oxidative stress-induced 
DNA damage (Marinello et al., 2016). Another mechanism of metformin-induced breast 
cancer suppression is via the inhibition of protein kinase A. As discussed above, metformin 
inhibits ATP generation resulting in AMP increase. In turn, this decreases cAMP production. 
As cAMP activates PKA, reduced cAMP levels result in reduced PKA. PKA is implicated in 
breast cancer for a number of reasons including the promotion of mammary tumourigenesis 
through proto-oncogene, non-receptor tyrosine kinase (Src) (Beristain et al., 2015). It is 
found in particularly high levels in triple negative breast cancers and has been observed to 
promote resistance to tamoxifen through preventing the required tamoxifen-induced 
conformational change in ERα (Michalides et al., 2004). 
 
The identification of the protective effect of long-term metformin exposure against cancers 
including breast cancer, coupled with the identification of a number of putative mechanisms 
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by which the drug inhibits cancer growth and stimulates apoptosis mean metformin is a 
promising novel treatment for breast cancer. However, the concentrations utilised in cell-line 
experimentation are often not clinically viable. Thus, the potential for the utilisation of 
metformin in combination with conventional chemotherapeutics is explored here in MCF-7 
and MDA-MB-231 cell lines. If synergy is achieved, concentrations of both drugs can be 
lowered to achieve efficacy at clinically tractable concentrations, as well as limiting toxic 
liability. 
 
Metabolically, tumour cells differ from normal cells as detailed above and in the introduction. 
These differences, surrounding increased demand for energy, result in tumour cells having a 
higher sensitivity to metabolic disruptions such as changing energy homeostasis (Bost, F., et 
al, 2016). 
 
 
 
1.11 Summary 
 
A major roadblock in the effective treatment of breast cancer is the heterogeneity, with 
multiple molecular landscapes classified as a single disease (Turashvili and Brogi, 2017). 
Traditional approaches to understanding and treating breast cancer have focused on 
exploring individual events; genes, specific mutations or the result of perturbing individual 
reactions. However, this approach has resulted in high failure rates in cancer-drug 
discovery (>90%) and high levels of resistance development of cancer to treatments. The 
Cancer Genome Project identified the majority of patients, even those with the same 
cancer type, do not share the same genetic aberrations; differences in oncogenic mutations 
likely mean differences in optimal drug targets and treatment (Stephens et al., 2012). 
 
Further issues with cancer drug development arise as the pathways used during oncogenic 
transformation, are also critical for normal cellular homeostasis and regeneration. 
Therefore, targeting these pathways has a significant negative effect on healthy cells. this 
contributes to intolerable off-target toxicities of a number of potential cancer drugs, 
resulting in failure at the stage of clinical trial.  
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A key contributor to the failure of current cancer therapeutics is the lack of understanding 
of the biological underpinning of cancer development and progression. Oncogenic 
transformation can be the result of multiple genetic aberrations resulting in whole-cell 
alterations occur across multiple scales of biological organisation.  
 
Such diverse cellular alterations are unlikely to respond to single agent chemotherapeutics 
and therefore examining differences across all of these scales is key for effective cancer 
treatment development. Novel approaches to treating cancer surround a multi-pronged 
approach, where different points in a cellular network are perturbed concomitantly. Such 
approaches present the potential advantages of more targeted treatment for cancer cells, 
and reduced off-target toxicities and a reduction in resistance development, through the 
removal of biological redundancies (Mokhtari et al., 2017). Utilising drug combinations 
can mitigate off target toxicities through exploitation of potentially synergistic interactions 
between two agents. For example, synergistic combinations allow the reduction of 
individual drug concentration without reducing combined efficacy. Therefore, patients 
receive the therapeutic effect with lower doses of each drug (Wei, et al., 2016). The design 
of such treatments requires a deep understanding of cancer biology.  
 
Technological developments in -omics data generation and analysis are increasing the 
availability of information required to do this. A systems biology approach to 
understanding and treating cancer utilises this information to integrate genetic, proteomic 
and metabolomics data, enabling a more holistic examination of cancer initiation and 
evolution. Using an iterative process of experimentation and in silico hypothesis 
generation, systems biology is a logical approach to advance cancer research (Gomez-
Cabrer and Tegnér, 2017).  
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Systems Biology 
 
1.12 General Introduction  
 
Despite improvements to worldwide survival rates for breast cancer in the past 40 years, the 
improvements have slowed and is beginning to plateau. When considering breast cancer as a 
whole, the survival rate has remained at approximately 80% since the early 2000s (Figure 
1-10) with a stubborn 20% of cases unresponsive to current treatments. This in part is due to 
the heterogeneity of breast cancer. As discussed in 1.6.1.1, there is a high degree of diversity 
both between different tumours and within individual tumours, as well as among cancer-
bearing individuals. These factors contribute to differences in tumour aggressiveness, 
prognosis and therapeutic response, which all complicate treatment development. 
Conventional therapeutic approaches that tend to focus on an individual target/pathway thus 
face fundamental challenges in the treatment of complex disease such as breast cancer. In 
recent years, the application of systems biology approaches to complex diseases has gained 
increasing traction, allowing multiple factors (and their interactions) to be considered at once.   
 
 
 
Figure 1-10. Trends in net 10-year survival for breast cancer from 1971 to 2011. 
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Systems biology is a holistic method for understanding multifaceted, intricate biological 
systems and contrasts the historically reductionist methodology of molecular biology. The 
approach was developed based on the knowledge of emergent properties in biology; where 
observed phenotypes are greater than the sum of genetics and the environment (Bruggeman 
and Westerhoff, 2007). There are two key approaches in systems biology; top down, where 
networks are defined by examining patterns and correlations in transcriptomics, 
metabolomics and proteomics data. Contrastingly, the bottom up approach explores different 
interactions between defined molecules and the way in which these lead to observed 
phenotypes (Bruggeman and Westerhoff, 2007). Increasingly, a third approach (often termed 
‘middle out’) is being utilised. In this approach top-down and bottom-up approaches are 
integrated, allowing enhanced mechanistic information to be included around biologically 
important hubs. 
 
Traditional research approaches tend to focus on individual molecules or reactions, while 
systems biology explores whole networks with the aim of discovering the design principles of 
how the network interacts to produce the observed emergent biological phenotype. This 
approach has been catalysed in recent years by the development of high throughput 
techniques such as genome sequencing, microarray analysis and analysis tools under the 
umbrella of bioinformatics (Foulkes et al., 2017). Central to the systems biology approach is 
the utilisation of computational models and simulations in understanding biological networks, 
which is necessary to explore biological networks that encompass high numbers of molecules 
interacting in a non-linear fashion (Kitano, 2002).  
 
Systems biology can be seen as an iterative cycle. First, analysis of novel and/or literature 
datasets to observe patterns and generate predictive models. Second, models are used to 
generate novel hypotheses. Third, further in vitro/in vivo experiments are undertaken to test 
the hypothesis. Fourth, the outcome of wet-lab experiments feedback into the predictive 
model, refining it to increase prediction robustness. Through this cyclical testing-refining 
paradigm, models will move closer to biological reality and provide novel biological insights 
on how the total system interacts to produce the emergent biological phenotype. Figure 1-11 
illustrates this process. 
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Figure 1-11. The iterative process of systems biology experimentation and modelling, which involves data 
generation, integration, model development and then validation which then can be in turn used for data 
generation.  
 
 
There is a plethora of different types of computational models that can be built for use in in 
silico experimentation as well as a number of different methods utilised in producing and 
validating such models. A move towards standardisation has resulted in the development of a 
universal language (Systems Biology Mark-up Language; SBML), universal graphical format 
(Systems Biology Graphical Notation; SBGN), and open software platforms that utilise these 
formalism to allow easier collaboration and cross examination of model predictions. (Kitano, 
2002b).  
 
 Standardisation of systems biology 
 
To unify different models and ensure they are comparable and reproducible, the Minimum 
Information Requested In the Annotation of biochemical Models (MIRIAM) standard was 
developed. Primary guidelines it incorporates include: the modelling language used must be a 
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standardised and publically available language such as SBML, there must be a description of 
the model, quantitative attributes must be defined including initial conditions and the model 
must be named according to standards (Le Novère et al., 2005). In addition to MIRIAM 
standards, the community has also adopted Minimum Information About a Simulation 
Experiment (MIASE), which aims to standardise the process of simulations and how the 
information regarding these is shared. MIASE standards include: description of each 
simulation experiment, details on the simulation algorithm used, information about any post-
simulation processing (Waltemath et al., 2011). The standardisation of model annotations can 
further aid the comparison of models. Systems Biology Ontology (SBO) is a specific way to 
denote reaction parameters and kinetics within a model (Le Novère, 2006). Biochemical 
species annotation is standardised by the use of particular ontologies including UniProt and 
KEGG (Degtyarenko et al., 2008). Implementation of these standards will improve how 
understandable papers published containing computational systems biology models are to 
both experts and non-experts.  
 
 Systems biology markup language (SBML) 
 
The SBML was generated at Caltech in 2000 as a relatively simple language that met the 
requirements of scientists developing computational models. It was developed to allow ease 
of moving models between different simulation tools. The basis of SBML is the widely used 
eXtensible markup language (XML) and it displays models as a catalogue of chemical or 
biochemical reactions (Achard, Vaysseix and Barillot, 2001). SBML was developed by 
examining a number of different languages previously or currently used in different 
simulation tools, incorporating stochastic simulators and ordinary differential equation 
(ODE) simulators (Hucka et al., 2003). SBML lists chemical reactions incorporating a 
number of elements: reactant and product species, the compartment in which they are 
localised, reaction parameters and any mathematical rules that relate said parameters (Hucka 
et al., 2003). A species represents any molecule involved in a reaction (e.g. substrate, co-
factor, enzyme etc.), and contains name and initial amount present attributes. A reaction is 
any transition that results in the change of at least one species (e.g. enzymatic conversion, 
sub-cellular translocation, transport reactions etc.). SBML encodes reactions as a list of 
reactants, list of products and the stoichiometric coefficient; the number of molecules of 
reactant involved in the reaction, as well as the kinetic parameters of the reaction. Finally, 
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compartments within SBML denote a particular area within which a species exists. These 
may or may not represent a particular biological compartment such as an organelle. 
Compartments must have unique names and can be assigned volumes to enable calculation of 
the concentration of species within the cpmpartment (Hucka et al., 2003). SBML is now used 
widely within the systems biology community, enabling compatibility between different 
models and simulation tools as well as reproducibility and transparency in modelling for 
systems biology.  
 
 Systems Biology Graphical Notation (SBGN) 
 
The SBGN project was initiated in 2005 and aimed to provide a standardised and systematic 
graphical notation for the use in molecular and systems biology (Novère et al., 2009). The 
group identified inconsistencies in non-standardised notations, citing use of multiple symbols 
in the literature to represent the same thing, and multiple representations of the same 
biological pathway (e.g. MAP kinase cascade). While approaches such as Molecular 
Interaction Maps were popular (Kohn, 1999), none became established as a standard for the 
molecular and systems biology community. 
 
Novère et al recognised the need of SBGN to satisfy diverse requirements of a number of 
groups, from biologists to geneticists to computer scientists and thus outlined a number of 
requiremens the notation should meet. These requirements include: freedom from intellectual 
property restrictions, the ability to model numerous common biological species and their 
interactions, visual and semantic consistency and unambiguity and the ability to be utilised in 
mathematical modelling software. 
Within SBGN there are three independent diagram types, which represent three alternative 
representaions of complex biology. These are i) process diagrams, ii) entity relationship 
diagrams and iii) activity flow diagrams.  
i) Process diagrams depict all of the molecular intreactions occurring between 
biochemical species and the results of these interactions, allowing the 
temporal portrayal of reactions.  
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ii) Entity relationship diagrams focus on mapping the influence of entities on the 
transformation of other entities. This allows the representation of variable 
states of entities and therefore the modelling of certain processes such as 
allosteric regulation.  
 
iii) Activity flow diagrams allow simplification of complex biochemical networks 
and effective modelling even if knowledge is incomplete. This is achieved 
through flow diagrams using modulatory arcs instead of precise processes to 
link species. 
 
 
 
 
Figure 1-12. SBGN in use: Simple example of protein phosphorylation catalysed by an enzyme and modulated 
by an inhibitor. Three independent diagram types i) Process diagrams ii) Entity relationship diagrams iii) 
Activity flow diagrams.  
 
Figure 1-12 shows SBGN in use, representing enzyme mediates protein phosphorylation that 
is modulated by an inhibitor using the three independent diagram types. SBGN is now widely 
used in molecular and systems biology as a community standard (Novère et al., 2009). 
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  Desired features of computational models 
 
The usefulness of a computational model is dependent upon its ability to reproduce known 
biology (i.e. to be validated), and to generate useful and novel predictions (i.e. hypothesis 
generation) that can be tested experimentally. In doing so, in silico testing can reduce the 
number of in vitro or in vivo experiments that are required, reducing time and cost, and 
meeting the aims of the 3Rs (replacement, reduction and refinement) (Russel and Birch, 
1959). The ultimate utility of a computational model will be its ability to aid the 
understanding of intricate biological processes.  
 
Robustness in computational systems biology  
 
Robustness describes the ability of a system to reproduce/maintain a particular function or 
phenotype in the presence of perturbations and alterations. From a technical aspect the 
definition of robustness within a computational model may be defined as the extent to which 
the predictions made by said models are reliable (Weisberg, 2006). Robustness analysis can 
distinguish the whether a particular prediction arises from key aspects of the model or from 
oversimplifications or poor representation of biology (Levins, 1966). A key method of 
robustness analysis is to examine a number of different models representing the same 
biological process in different way and observe whether they generate common predictions or 
results (Wimsatt, 1981). Robustness analysis as a means for determining reliability of model 
predictions has been criticised, most notably by Orzack and Sober. Their criticisms centre 
around the idea that robustness analysis is a non-empirical means of confirming predictions 
and just because a number of models generate the same prediction does not mean it is correct 
(Weisberg, 2006). Orzack and Sober postulate that there is a need for knowledge that one 
model in the comparison set provides reliable predictions (Orzack and Sober, 1993). 
Robustness analysis, on balance is a means to identify robust theories and predictions but 
cannot be utilised in validating them; for this, empirical evidence is required.  
 
Apart from the technical definition of robustness, there is an important biological definition 
of robustness: the ability of a biological system to maintain, or recover, its biological 
phenotype following perturbation. In general, biological systems are highly robust, being able 
to maintain homeostasis for many species within the network. It should be noted that in 
biological terms a robust system is often also a dynamic one; effectively, the system is able to 
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adapt to perturbations until steady-state conditions are returned. For example, exposure of a 
cell to cholesterol, elicits a dynamic change in cholesterol metabolism, allowing the levels of 
cholesterol in the cell to be tightly regulated. Computational models are often used to explore 
how biological models are able to demonstrate robustness. Within any network some areas 
will be robust to perturbation, while others may readily flip between different states in 
response to perturbation. These so-called fragile nodes represent areas of the biological 
network that are most sensitive to perturbation, and their targeting is most likely to cause a 
change to the biological phenotype. This change may be adverse (e.g. disease development) 
or beneficial (e.g. targets for therapeutic intervention).  
 
 
1.13 Systems biology and therapeutic approaches 
 
The use of computational systems biology to progress therapeutic options has the potential to 
be multifaceted. A model can allow; 
(i) a deeper understanding of a particular system  
(ii) to predict the effectiveness of a particular drug on a system and compare different 
treatment approaches, 
(iii) to identify potential novel drug targets  
(iv) to aid exploration of network targeting therapeutics.  
 
 
 
 Understanding a system  
 
A traditional reductionist approach to understanding biological systems often results in a 
deep understanding of a series of reactions or metabolite interactions. This, however, often 
fails to explain an entire network and thus cannot account for emergent properties or 
phenotypes. Essentially, studying single pathways will not provide a full understanding on 
how the cell balances the requirements of the pathway under study against the cellular 
requirements; for example, if the pathway required ATP, then using it will not only require 
the cell to generate ATP, but could also negatively impact on other cellular pathways that 
also require ATP through competition for a limited resource. Utilising molecular 
understanding of individual reactions in combination with large data sets with information on 
cellular genetics or proteomics can develop a more holistic picture of a cell, organism or 
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other system. A milestone study in the development and utilisation of such large datasets is 
the Metabric (Molecular Taxonomy of Breast Cancer International Consortium) study. The 
study sourced 2,000 clinically annotated primary fresh-frozen breast cancer samples from 
biobanks in Canada and the UK (Curtis et al., 2012). Each sample was profiled to determine 
genetic and transcriptomic identities and the dataset was split into two independent datasets, a 
discovery set and a validation set. These were used to cross-validate findings (Curtis et al., 
2012). 
 
Understanding metabolism 
 
As described in Section 1.10, metabolic reprogramming is becoming a well-defined hallmark 
of cancer. Malignant transformation includes the accrual of genetic alterations that confer 
subtle or marked differences in several cellular processes, including metabolism, and these 
provide the proliferative advantage that is a hallmark of cancer. Given the multifactorial 
nature of these alterations and their impacts, it is logical to use a systems biology approach to 
understanding their role in cellular transformation, (Hornberg et al., 2006). As discussed 
previously, the mechanisms of metabolic reprogramming are diverse and can be mediated by 
genetic or epigenetic effects. As a result of this complexity, culminating differential datasets 
and pathways onto one network model is of particular importance when building 
computational models to aid the understanding of metabolism. Utilising such an approach, 
Leoncikas et al utilise the aforementioned Metabric dataset in the context of a genome scale 
network of human metabolism. The large-scale dataset is used to generate personalised 
metabolic landscapes for each individual tumour in the discovery set. These individual 
landscapes are then classified based on the activity of the metabolic reactions within the 
landscape and using K-means clustering (Leoncikas et al., 2016). Using clinical data for each 
patient, survival curves were also calculated for each cluster. The group identify a poor 
prognosis group, which is metabolically statistically significantly different. Personalised 
metabolic landscapes were then created for the validation dataset, which when clustered, 
reproduce a group associated with poor prognosis (99% congruency with differentially 
activated reactions). In addition, the group generate mechanistic hypotheses as reasons for the 
poor prognosis cluster such as active serotonin production and propose the investigation of 
serotonin-specific uptake inhibitors as an adjuvant treatment for breast cancer (Leoncikas et 
al., 2016). 
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 Aid exploration of network targeting therapies 
 
The understanding that many malignancies including breast cancer are the culmination of a 
number of changes that shift cellular homeostasis highlights the potential of network 
targeting therapeutic strategies. Traditional drug development centred around one drug with 
one cellular target often fails in effective cancer treatment due to the high number of 
redundant pathways present within cellular networks. Network targeting of cancer cells 
inhibits or impedes the function of two or more vulnerabilities within a system with the hope 
of killing the cell or shifting its phenotype back to that of normal physiology (Kolodkin et al., 
2012). Network targeting with the aim of restoring cellular homeostasis is an emerging 
strategy for cancer treatment, in general, and breast cancer in particular.  
 
Network targeting effectiveness is based on the concept of synthetic lethality. Synthetic 
lethality was first observed in studies involving Drosophila melanogaster (Bridges, 1922) 
and refers to a genetic, or occasionally molecular, interaction where the concomitant presence 
or absence of two genes or molecules results in cellular death. In Figure 1-13, this 
phenomenon is illustrated; the inhibition of gene A or B does not result in cell death, whereas 
the simultaneous inhibition of their expression is lethal (Nijman, 2011). Initially, the concept 
referred to genetic events, but the definition has subsequently been widened to incorporate 
other perturbations including drug treatment.  
 
Figure 1-13. Diagram showing the phenomenon of synthetic lethality, whereby the inhibition of gene (or 
protein) A or B does not result in cell death, but the simultaneous inhibition of their expression does result in 
cell death (Nijman, 2011).  
 
The divergence of cancer cell genetics, metabolism and signalling from that of non-malignant 
cells means there is a potential for synthetic lethal partner genes or molecules that are not 
synthetically lethal in non-transformed cells (Nijman, 2011). The advantage of this would be 
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to allow the development of targeted therapeutics that only or preferentially affect cancer 
cells. Identifying pairs or groups of genes or molecules with combined synthetic lethality in 
breast cancer cells provides new opportunities for treatment development.  
Synthetic lethality exists due to the in-built redundancy of many biological system, which is 
essential to create robustness within living systems. Robustness can be defined as the ability 
of a cell or organism to preserve functionality despite system perturbations (Stelling et al., 
2004). Robustness exists in many levels of biological organisation including cell cycle 
regulation (Borisuk and Tyson, 1998) and numerous signalling pathways (Lee et al., 2003). 
As such, it is likely that cancer chemotherapeutics will act on biological targets that have 
possess a high degree of robustness around their functionality. Practically, robustness occurs 
when there is redundancy within a network. At a genetic level, this would be two or more 
different genes whose products perform overlapping functions (Hartman, Garvik and 
Hartwell, 2001). At a molecular level within a cell, this could be two enzymatic reactions 
whose action result in the same or sufficiently similar product (Stelling et al., 2004). In this 
example, significant perturbations to one of the two enzymatic reactions would have little 
impact on cellular function. However, altering the two reactions concomitantly could render 
the cell unable to generate a product critical for cellular function. 
 
The best example of the application of synthetic lethality in drug design is the interaction 
between BRCA mutations and PARP inhibitors, which is now an effective clinical treatment 
for a number of cancers. While this is a drug-genotype, not drug-drug interaction, it does 
provide the proof of concept for the utilisation of the approach of synthetic lethality 
clinically. PARP, or Poly (ADP-ribose) polymerase, is in an enzyme family that catalyses 
poly ADP-ribosylation, the transfer of ADP-ribose to different proteins. Depending on the 
target protein, PARP activity has a range of physiological effects including cell proliferation, 
cell death and DNA synthesis and repair (Amé, Spenlehauer and de Murcia, 2004). The 
inhibition of PARP cellular activity has been shown clinically to be an effective synthetic 
lethal strategy for the effective treatment of cancers that possess genetic defects in DNA-
repair pathways such as BRCA1 and BRCA2. Olaparib is a pharmacological PARP inhibitor 
and has been tested in human clinical trials. Doses of between 200mg twice daily and 800mg 
twice daily resulted in PARP inhibition and antitumor activity in carriers of BRCA1 or 
BRCA2 mutations diagnosed with breast, ovarian, or prostate cancer (Fong et al., 2009).  
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The concept of network targeting drugs also overcomes the issue of redundant pathways as 
compensatory mechanisms used by cells to overcome drug effects (i.e. drug resistance). The 
effect of blocking an individual component within a network will depend largely on the 
number of alternative or compensatory pathways available (Axelrod et al., 2013). Figure 1-13 
illustrates that in scenario A, inhibition of pathway X with the aim of reducing production of 
species X will only be partially effective. As X is blocked, the cellular machinery can 
circumvent the block and utilise routes W, Y or Z to retain production of species X. 
Furthermore, in a comparison of scenario C vs D, the inhibition of pathway X will have a 
greater effect in C as it carries more weight in terms of creation of product X than it does in 
D.  
 
Metabolic vulnerabilities 
Metabolic vulnerabilities or chokepoints are points within a network that if perturbed will 
have a large effect on a particular output or phenotype. This can be for a plethora of reasons. 
Chokepoints occur in areas of the network where there is little redundancy and thus less 
opportunity for circumventing perturbed reactions. They may also be present where a number 
of reactions converge onto one point or where only one enzyme for example is responsible 
for the catalysis of a reaction critical to a fundamental cellular process.  
 
Metabolic vulnerabilities and cancer 
Cancer cell metabolism undergoes rewiring in a number of ways, which largely confer a 
proliferative advantage (Liberti and Locasale, 2016). In the process of alterations, however, 
inactivation of gene expression can occur. Although this inactivation does not negatively 
affect cancer cells, it can reduce genetic redundancies that can be exploited as described 
above (Cereda, Mourikis and Ciccarelli, 2016).  
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1.14 Computational methods 
 
Computational models exist representing many different levels of biological organisation. By 
default, higher levels of organisation are represented by a more reductionist approach, due to 
lack of data and knowledge. The choice of approach and level of biological organisation to 
model depends largely on the question being asked. However, a longer-term goal of systems 
biology is the creation of digital organisms where all levels of organisation are represented. 
This will most likely be through the combination of models of different levels of detail and 
underlying formalisms (so-called multi-formalism models).  
 
 Physiologically based pharmacokinetic (PBPK) models 
 
Physiologically based pharmacokinetic (PBPK) models are a means to predict the 
pharmacokinetics of a molecular (Jones, Gardner and Watson, 2009). These models 
incorporate data relating to two key factors: 1) the anatomy and biology of an organism or 
system and 2) properties of a particular drug (Kuepfer et al., 2016). PBPK models are made 
up of a number of different compartments that correspond to different organs. These models 
allow the inclusion of know physiological parameters gleaned from first hand experiments or 
from published data. There is a large body of work describing these physiological parameters 
for different populations (e.g. children, geriatrics, obese, animal models). This increases the 
utility of the models by letting the stratify predictions to particular populations. Utilising a 
PBPK model, metabolic clearance, absorption and distribution kinetics can be predicted for a 
given molecule.  
 
PBPK modelling uses a reductionist approach to represent biological systems. Utilising little 
mechanistic information, PBPK models can produce meaningful predictions regarding drug 
metabolism. The limitations of these models arise from the simplification of intricate 
biological processes such as molecular transport to individual mathematical formulas, where 
in reality they represent a number of chemical and molecular processes (Kuepfer et al., 
2016).  
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 Applications of PBPK models  
 
PBPK models have been utilised by a number of groups to predict optimal concentrations of 
drugs in the different disease states including breast cancer.  
 
Tamoxifen is a first line treatment for ER-positive breast cancer. Its intracellular metabolism 
into secondary metabolites including endoxifen is an important contributor to its therapeutic 
effect. This metabolism requires action from cytochrome P450 (CYP2D6), with patients 
possessing reductions in CYP2D6 correspondingly see reduced plasma concentrations of 
endoxifen. These differences complicate treatment and Dickschen et al use PBPK modelling 
to determine the impact of CYP2D6 on generation of endoxifen in patients receiving 
endocrine Tamoxifen therapy for the treatment of breast cancer. The model was used to 
simulate pharmacokinetics of Tamoxifen metabolism in patients with different CYP2D6 
status (Dickschen et al., 2012).  
 
Malik et al utilise a PBPK modelling framework, also to determine pharmacokinetic 
variability between individuals. This group study differences in the metabolism of 
trastuzumab, an anti-HER2 agent. The PBPK model built here accounts for alternative 
mechanistic causes of the differential pharmacokinetics. The alternative differences were 
caused by factors such as differential HER2 concentration and differential endocytic transport 
rates for trastuzumab. In combination with the PBPK model, the group used population data 
from the literature for variability around the factors responsible for differential trastuzumab 
metabolism. They found output from the model could accurately predict patient variability 
across four virtual populations, demonstrating population-PBPK modelling can be utilised to 
understand mechanisms behind pharmacokinetic variability (Malik et al., 2017).  
 
Another example of PBPK utilisation to investigate mechanisms behind drug 
pharmacokinetics is seen in the work carried out by Wang et al. The group specifically use 
PBPK modelling to examine the absorption, distribution and elimination of rosuvastatin, a 
drug in the class of statins used to decrease levels of LDL. Their PBPK model incorporates a 
number of drug transporters and effectively predicts drug-drug interactions of rosuvastatin 
with rifampin (Wang, Zheng and Leil, 2017). 
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 Ordinary Differential Equation (ODE) based modelling 
 
ODEs are equations that contain one or more functions of one independent variable and the 
derivatives of those functions. The equations describe changes in different species over time, 
the changes can be quantity or concentration for example. Mathematical modelling using 
ODEs is applied often to model biological systems such as biochemical reaction networks or 
signalling networks  
 
ODE-based modelling allows these systems to be dynamically modelled and explore 
characteristics such as system robustness (Neelamegham and Liu, 2011). These models can 
contribute to mechanistic understanding of biological systems, enabling meaningful 
conclusions to be cleaned from large data sets. Once information surrounding particular 
model components such as proteins and enzymes is established, the relationships between 
these key elements can be formulated through ODE-based models. Parameterisation of levels 
of key elements or rates of key transitions aids accuracy of in silico investigations and 
resulting hypothesis generation (Neelamegham and Liu, 2011). 
 
As such, ODE-based modelling has applications in understanding cancer biology and has 
been used by a number of groups. Shariapanahi et al develop a mathematical model based on 
four ODEs to explain immunosuppression experienced in myeloma patients. The group 
observed consistency between simulated results and pre-existing experimental data 
particularly surrounding the effectiveness of two agents in the treatment of this (l-arginine 
and 5-fluorouracil). Novel predictions for the combination of these therapeutics were derived 
from in silico investigation (Shariatpanahi et al., 2018). ODE-based modelling can also be 
used to examine relationships between two complex networks, such as the immune system 
and cancer cells (Eftimie et al., 2011). 
 
Assessment of the accuracy of ODE models for describing tumour growth was undertaken by 
Murphy et al. Comparisons of several ODE models used to this effect find discrepancies in 
predicted tumour doubling times, highlighting the importance of conservative examination of 
model assumptions and predictions (Murphy, Jaafari and Dobrovolny, 2016). 
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 Genome scale metabolic networks 
 
A commonly used approach for the study of large-scale biological networks involves the 
reconstruction of genome scale metabolic networks (GSMNs). A GSMN represents all of the 
enzymatically controlled reactions (both metabolic and transport) occurring within a cell, as 
well as some passive diffusion reactions. Generation of a GSMN requires a properly 
annotated genome sequence to enable identification of key network constituents upon which 
the network can be built. Edwards and Palsson in 1999 were the first to publish an entire 
GSMN, which represented Haemophilus influenza. The GSMN contains 343 metabolites and 
488 metabolic reactions (Edwards and Palsson, 1999). GSMNs for several other prokaryotes 
rapidly followed, but the increased complexity of eukaryotic systems meant that it was not 
until 2003 that a GSMN for the single celled eukaryote Saccharomyces cerevisiae was 
published (Forster et al., 2003). In 2007 the first GSMN for Homo sapiens, named Recon 1, 
was produced (Duarte et al., 2007), and comprised 3311 transport and metabolic reactions 
and 2766 metabolites. Recon 1 is curated based on literature data including metabolic genes 
sourced from EntrezGene (Wheeler et al., 2004) and an iteration of Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (Kanehisa et al., 2017). Genes and enzymes were paired using 
the KEGG ligand database (Aoki and Kanehisa, 2005). Further manual curation was 
undertaken using evidence from carefully selected literature articles (Duarte et al., 2007). 
 
There are currently two main reconstructions of human metabolism available. They are 
generic models and can be constrained to represent a specific cell type. The first and that used 
in this research is a second iteration of Recon, which was developed and published in 2013; 
Recon 2 (Thiele, Swainston, Fleming, Hoppe, Sahoo, Aurich, Haraldsdottir, Mo, Rolfsson, 
Stobbe, Thorleifsson, Agren, Bolling, et al., 2013). Recon represents the current most 
comprehensive depiction of human metabolism for use with computational modelling. This 
iteration incorporates 3696 additional reactions and 2766 additional metabolites identified 
from either the literature, or through the incorporation of two other human GSMNs:the 
Edinburgh Human Metabolic Network (EHMN) (Hao et al., 2010), and HepatoNet1, a 
reconstruction developed for the specific analysis of liver physiology (Gille et al., 2010). 
Recon 2 is semantically annotated in line with MIRIAM requirements and is shown to have 
greater predictive potential than Recon 1 with regard to highlighting inborn errors of 
metabolism (IEM) (Sahoo et al., 2012) or predicting drug targets (Folger et al., 2011) This 
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reconstruction, whilst still incomplete is a much closer representation of human metabolism 
(Thiele, Swainston, Fleming, Hoppe, Sahoo, Aurich, Haraldsdottir, Mo, Rolfsson, Stobbe, 
Thorleifsson, Agren, Bolling, et al., 2013).  
  
The second available reconstruction of human metabolism currently available is the Human 
Metabolic Atlas (HMA), developed by a team in Sweden (Pornputtapong, Nookaew and 
Nielsen, 2015). HMA2 iteration is composed of more reactions and metabolites than Recon 
2, yet Recon 2 possesses greater adaptability for use with different formalisms of 
computational systems biology. This is because HMA2 was developed for the specific use 
with the COBRA toolbox (Vlassis, Pacheco and Sauter, 2014), whereas Recon 2 is open 
source.  
 
 
 Tools for the analysis of metabolic networks 
 
 Generation of targeted metabolic networks 
 
As mentioned above, the two main reconstructions of human metabolism available are 
generic. GSMNs generally possess all metabolic reactions within an organism, however not 
all reactions are present in all cell or tissue types (Uhlen et al., 2015). To improve accurate 
modelling of metabolism for these specific cells or tissues, context-specific models are 
created. These are sub-models of the whole GSMN, where those reactions that are inactive 
are removed (Opdam et al., 2017).  
 
Thus to generate cell-type or condition specific models, these GSMNs must be constrained. 
This has been undertaken by a number of groups for both models. HMA2 was utilised by 
Mardinoglu et al to generate a hepatocyte specific model (Adil Mardinoglu et al., 2014) and 
there is also a hepatocyte-specific iteration of Recon 1; Hepatonet 1 (Gille et al., 2010). 
 
Metabolic networks can be constrained based on expression data such as that obtained from 
microarray experiments. A computational tool that utilises expression data to constrain 
metabolic networks is the congruency approach. The approach has been used extensively in 
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the generation of specific metabolic landscapes, tissue specific GSMNs and in addition to 
explore cancer metabolism.  
 
 The congruency approach – methods for generating personalised landscapes 
 
Briefly, the congruency approach predicts a flux distribution for a GSMN using an 
expression dataset as the objective function. Fluxes through reactions mapped to proteins 
marked as absent in the omics dataset are minimised, based on the assumption that if no 
mRNA/protein is present then these reactions should not occur. The output therefore creates a 
scenario specific version of the GSMN, in this case representing specific breast cancer cell 
lines.   
 
Creation of context-specific GSMNs via the congruency approach can be achieved using 
several different methodologies, referred to as model extraction methods (MEMs). These 
include but are not limited to: Integrative Metabolic Analysis Tool (iMAT)/fast iMAT (Zur et 
al., 2010), Gene Inactivity Moderated by Metabolism and Expression (GIMME) (Becker and 
Palsson, 2008), metabolic Context-specificity Assessed by Deterministic Reaction Evaluation  
mCADRE (Wang et al., 2012) and the Model Building Algorithm (MBA) (Jerby et al., 
2010). 
 
The iMAT approach and its derivative fastiMAT are tools is based on a method developed by 
Shlomi et al (Shlomi et al., 2008; Zur et al., 2010). The approach overlays gene expression 
data onto GSMNs and based on levels of expression fluxes through reactions are allowed or 
minimised. Before gene expression data is overlain onto the GSMN, it is necessary to decide 
which transcripts are expressed (present) and which are not expressed (absent). For this, an 
arbitrary threshold can be utilised or can be based on the A/P calls from the initial analysis of 
arrays. iMAT enables the integration of genomic data with a GSMN presented in SBML 
format. Once integrated, the tool allows metabolic flux to be explored in a range of 
conditions. The output of iMAT is flux state for each individual reaction, which, where 
possible is presented as active or inactive and corresponding confidence levels. For some 
reactions, the number of alternative flux pathways with similar overall outputs through the 
network are too great to predict a unique activity state for a particular reaction. The final 
output incorporates confidence values and activity flux for particular genes (Zur et al., 2010). 
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The GIMME algorithm utilises gene expression data with a predefined objective function. 
The algorithm generates a context-specific model that fits said objective and provides a 
quantitative inconsistency score demonstrating consistency of a particular context-specific 
model with the objective function. Use and validation of this approach has been undertaken 
in bacteria and human skeletal muscles (Becker and Palsson, 2008).  
 
mCADRE method was used by Wang et al to generate 126 context-specific reconstructions 
of human metabolism with the basis of Recon 1. The method involves converting input data 
(e.g. gene expression) into binary inputs then determining frequency of expression for 
individual genes across different samples of the same tissues to obtain a ubiquity score. The 
ubiquity scores are used to generate expression-based evidence scores for individual gene 
associated reactions. If these scores are sufficient, the reactions are included in the context-
specific model (Wang et al., 2012).  
 
Jerby et al’s MBA generates contex-specific models by integrating a literature derived 
knowledge as well as transcriptomic and metabolomic data. The approach identified core 
reactions to be included into the model and then sort these based on the probability that they 
will occur in particular tissues. The algorithm generates a tissue-specific model from the 
generic human model by integrating a variety of tissue-specific molecular data sources, 
including literature-based knowledge, transcriptomic, proteomic, metabolomic and 
phenotypic data. The algorithm conservatively generates a model including all tissue-specific 
reactions with a high probability of being present in the tissue of interest (such as human-
curated pathways) and some of the reactions with a moderate probability of being in the 
specific (such as those validates by metabolic data). This method was applied to hepatic 
metabolism and validated through examination of hepatic metabolic functions (Jerby et al., 
2010).  
 
The congruency approach in generating tissue specific GSMNs 
 
The congruency approach has been used by multiple groups to generate tissue specific 
GSMNs. Wang et al’s mCADRE method was used to reconstruct GSMNs representing 126 
different human cell types and tissues, which included 26 tumour tissues and 30 distinct brain 
tissues. The resulting resource is proposed as a useful tool to examine metabolic alterations in 
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human diseases (Wang, Eddy and Price, 2012). Zhao et al also use the congruency approach 
to generate human heart specific GSMNs. The models were then used to explore potential 
biomarkers for the development of cardiovascular disease (Zhao and Huang, 2011).  
 
A human adipocyte-specific GSMN was generated using the congruency approach to 
combine a GSMN with clinical data from adipocyte tissue data in addition to proteome data 
for human adipocytes. The model enabled identification of potential therapeutic targets for 
the treatment of obestity (Mardinoglu et al., 2014). 
 
 
 
The congruency approach in exploring cancer  
 
Amongst the hallmarks of cancer is a divergent metabolism from that of normal non-
transformed cells. These metabolic alterations can be explored using the congruency 
approach. This method of investigation was used by Filippo et al, who generated context-
specific models from lung, breast and liver cancers using GSMNs from the Human Metabolic 
Atlas as a framework (Di Filippo et al., 2016). Leoncikas et al used the congruency approach 
to generate 2,000 patient tumour specific iterations of a GSMN Recon 2 (Leoncikas et al., 
2016). Examining mechanism of cancer metabolic alterations, Schlomi et al use genome 
scale metabolic modelling to elucidate that the Warburg effect observed in cancer cells arises 
directly from increased demands for biomass production in cancer cells (Shlomi et al., 2011). 
 
 Constraint-based modelling approach 
 
As progression is made towards to larger scale models, and eventually digital organisms, it is 
necessary to incorporate data from genomics, kinetics, physiology as well as gene and 
signalling regulatory pathways. The completeness of these data sets for different systems is 
varied, meaning for some networks there is insufficient data to build comprehensive and fully 
quantitative models. For small-scale models, it is practicable to experimentally derive 
missing quantitative parameters, but as the number of different species within a model 
increases, the viability of sourcing thousands of physical parameters reduces. Furthermore, 
parameters are not constant across time nor identical between individuals. This issue 
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catalysed the development of a number of different tools to allow meaningful analysis of 
large-scale models that do not require all quantitative parameters to be known.  
 
Constraint-based modelling (CBM) allows the assimilation of different types of data sets 
from a range of sources. CBM does not require assumptions for all kinetic parameters or 
molecular mechanisms within a given system, yet allows their incorporation if known, where 
they act as constraints on the network behaviour.  
 
When a network is first generated as a model, the potential solutions of the system are 
unbounded. This means that the metabolic landscape of the cell can be examined, but it 
would involve exploring each reaction or combination of reactions in turn. To overcome this 
impractical task, the solution space must be reduced using a number of constraints. The 
nature of the constraints can be stoichiometric, thermodynamic or refer to reaction capacity.  
 
Stoichiometric constraints are utilised to ensure that in a metabolic steady state, reaction 
fluxes remain balanced through a number of mass balance equations. Stoichiometric 
coefficients represent the proportion of reactant to product in a given reaction: for example, 
the reaction 2H + O -> H2O has the stoichiometry that two hydrogen atoms must combine 
with one oxygen atom to produce a single water molecule). For stoichiometric analysis of a 
network, these coefficients are held in a vector for reactants and a vector for products, which 
are combined to create a stoichiometric matrix (Clarke, 1988).  
 
Thermodynamic constraints can shrink the solution space further by specifying the 
directionality of a reaction. Reactions may be unidirectional (e.g. 2H + O -> H2O) or 
bidirectional (e.g. Pyruvatecytosol <-> Pyruvatemitochondria) in nature. An algorithm created by 
Kümmel et al in 2006 incorporates a number of said constraints. Initially irreversible 
reactions are identified by examining Gibbs energies of formation for all species wehre 
eneregies of formation are available. For those species and reactions where kinetics are not 
experminetally known, directionality is determined using information around the geometry of 
the network and through the utilisation of heuristic rules based on thermodynamics (Kümmel, 
Panke and Heinemann, 2006).  
 
Within a GSMN, each reaction is associated with an upper and lower bound (Price, Reed and 
Palsson, 2004). Bounds have two important uses: first, they allow the representation of 
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thermodynamic constraints (e.g. LB=0, UB=1 represents a unidirectional reaction, while 
LB=-1, UB=1 represents a bidirectional reaction). Second, bounds are a type of constraint 
used to limit the ranges of certain variables and when placed on reactions, can limit the level 
of flux or mass that can pass through each individual reaction (Orth et al., 2010). Individual 
flux constraints can be based upon experimental data of the reaction flux, while the 
congruency approach, section 2.3.4 uses -omics data to minimise flux bounds across an entire 
GSMN for reactions catalysed by proteins not active in the omics data set.  
 
 Metabolic Flux and Flux balance analysis  
 
Metabolic flux refers to the movement of molecules through a biological network. There are 
generally multiple pathways that metabolites can take to move through a network and under 
different conditions different routes will be used preferentially. Flux balance analysis (FBA) 
can be understood using the analogy of a SatNav. When using a SatNav, firstly a destination 
is selected, this is analogous of the objective function in FBA. The flux through a system can 
be understood as the flow of traffic along a set of roads and the constraints on the system can 
be compared to restrictions of traffic flow such as road width (e.g single vs dual carriage 
ways). Based on the objective function (desired destination) and constraints (physical road 
limitations), the SatNav will likely present a number of route options from which the ‘final’ 
route is selected. This is analagous to the multiple solutions that may exist for any one 
optimisation of an objective function.  
 
The constraints described above can define or shrink a potential solution space and minimise 
the range of potential solutions, however, it cannot provide unique solutions to the 
mathematically represented network. To achieve this, flux balance analysis (FBA) can be 
used. FBA is a tool that allows the exploration of different unique solutions within a 
stoichiometrically and thermodynamically constrained space, such as a GSMN. In addition to 
the constraints described above, FBA  requires definition of an objective function (Orth, 
Thiele and Palsson, 2010). This is analogous to entering the destination into a SatNav, and 
represents a biological function that you wish to either maximise or minimise. A commonly 
used objective function is biomass, which is a complex reaction containing all the 
components required for cell division. The use of biomass as an objective function reflects 
that the initial GSMNs developed were simple prokaryotes where the ability to increase 
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biomass was a prime function of their existence. In contrast, most cell types in complex 
multicellular organisms have low rates of cell division and hence biomass may not be the 
most appropriate objective function; instead objective functions that represent the unique role 
of that cell type need to be constructed. However, for tumour growth biomass may still be a 
valid objective function as uncontrolled proliferation is a hallmark of malignant cancer.   
 
For a given constrained GSMN, FBA explores the solution space that maximises/minimizes 
the objective function, as specified. As an output it returns the flux through every reaction 
within the GSMN when the objective function is maximised/minimised. Although in some 
instances there will be one unique solution, as the biological system (and thus GSMN) gets 
more complex, it is increasingly likely that more than one alternative flux distribution will 
result in the same maximisation of the objective function (Mahadevan and Schilling, 2003). 
In this case, FBA provides a sample solution, and it must be remembered that there could be 
a number of alternative, equally optimal routes. Lee et al in 2000 presented a scenario where 
number of optimal solutions were generated for a single objective (Lee et al., 2000).  
 
FBA has been used extensively to understand how to optimise a number of biological 
systems. Yang et al utilised FBA in determining optimal concentrations of amino acids 
within a growth medium to maximise growth of hepatocytes in cell culture (Yang, Roth and 
Ierapetritou, 2009). Additionally, FBA has been employed by a number of groups for 
modelling cancer biology. Nilsson et al review the use of genome scale metabolic models 
analysed using FBA for generating quantitative predictions of flux through the network. The 
group conclude that genome scale metabolic modes of cancer can interpret high throughput 
data with the view of identifying therapeutic targets despite challenges regarding incomplete 
parameterisation of the model (Nilsson and Nielsen, 2017). The usefulness of FBA in 
predicting metabolic transformation in cancer cells has historically been limited due to 
requirements for full parameterisation of metabolic uptake rates. Schwartz et al optimise 
FBA by adding a novel flux prediction method. The ability of this approach to predict uptake 
rates for a number of different substrates has been validated and offers a way to explore 
metabolic transformation in cancer cells (Schwartz et al., 2015). 
 
Flux variability analysis (FVA) is a complementary approach to FBA. It utilises FBA to 
identify alternative flux distributions that maximise the objective function (Mahadevan and 
Schilling, 2003). FVA maximises and minimises fluxes through each reaction in turn whilst 
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maintaining this defined system state, and returns the range of fluxes possible for each 
reaction that still allow the objective function to be maximised/minimised. Hence, FVA 
allows the exploration of network redundancy and flexibility, aiding the identification of 
metabolic chokepoints, and view flux distributions across a network (Aurich et al., 2017; 
Asgari et al., 2018)  
 
 
 Dynamic modelling of GSMNs 
 
A major limitation of FBA and FVA is that they can only be utilised on a model assuming a 
steady state. Essentially, this means that they represent a snapshot in time, and do not capture 
the dynamic, temporal changes in biological systems as they respond to perturbations. There 
have been a number of attempts to extend FBA to include gene and signalling regulation. 
Initially, rFBA (Aurich et al., 2017) used Boolean rules to capture relationships between 
network nodes representing genes. An extension of this were iFBA (Covert et al., 2008)and 
idFBA (Min Lee et al., 2008)and QSSPN (Fisher et al., 2013), which allow ODE networks of 
increasing complexity to be coupled to a CBM.   
 
 
 Quasi-steady state Petri nets 
 
Different methods for the representation of molecular interactions within a cell have been 
developed in recent years. The current standard in computational modelling utilises bipartite 
graphs. Bipartite graphs define two vertices, such as different types of molecular species; 
groups 1 and 2, and rules exist within the graph that mean there are no edges or interactions 
within a group, only between members of groups 1 and 2. Bipartite graphs define two groups 
of vertices, and rules exist within the graph that mean that edges can only exist between 
groups, not within a single group (Asratian, Denley and Häggkvist, 1998). An example would 
be two groups representing different types of nodes within a network; group 1 representing 
interactions and 2 representing molecules. Connections can occur between molecules and 
interactions but not molecule to molecule or interaction to interaction.  
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This method has been utilised in a number of molecular network reconstructions (Calzone et 
al., 2008) and is also used in metabolic databases such as KEGG (Kanehisa et al., 2017). In 
addition, bipartite graph representation of molecular interactions is reflected in standardised 
systems biology languages such as SBML (Achard et al., 2001).  
 
Petri nets (PNs) are a tool used to model concurrent systems using bipartite graphs. Petri net 
theory was first described by Carl Petri in 1962 (Brauer and Reisig, 2009) and has been used 
subsequently in the modelling of biological systems, largely in quantitative models 
(Hofestädt and Thelen, 1998). Molecular networks can be converted to Petri net 
representations through abstraction. Petri nets are composed of places, transitions and tokens. 
Places represent a particular resource or species, transitions are actions that consume or 
produce a particular resource and tokens denote the amount of a particular resource. Arcs link 
places and transitions and transitions are fed by input places and feed output places as shown 
in Figure 1-14. When all tokens have been transferred from the input place, the transition can 
no longer fire. The movement of tokens represent flux through a particular reaction and their 
distribution can provide information on the status of a system, (Heiner et al., 2004). 
 
In metabolic petri nets (MPNs), places are metabolites, transitions are biochemical reactions 
and tokens are units of a metabolite. In MPNs, arcs are labelled to represent reaction 
stoichiometries (Koch et al., 2005). Petri nets have traditionally been used for quantitative 
representations of molecular models, however, they have also been used to qualitatively 
model regulatory pathways (Grunwald et al., 2008).  
 
 
Figure 1-14: Petri net elements and their graphical representation.   
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As described above, CBM provides a means to mechanistically simulate genetic and 
biological networks on a large scale (Lewis, Nagarajan and Palsson, 2012), but under the 
assumption of a steady state. QSSPN in one solution used to overcome this limitation (Fisher 
et al., 2013). If a PN model is qualitative in nature, as in work published by Fisher et al 
(Fisher et al., 2013), the QSSPN method uses method uses the Monte Carlo Method (MCM) 
as a means of sampling different trajectories through a model. Here, the progression of a 
signal through a network is stochastic, with a probability assigned to when each reaction will 
fire. Hence, many trajectories must be run to determine which order of reaction firing occurs 
most often.  The MCM broadly involves 1) modelling a system, 2) repeated sampling from 
the system and 3) calculating the statistics of different occurrences (Hollstein et al., 1991). 
The use of MCM in QSSPN involves the following. A set of starting conditions are defined, 
from which a number of simulations are run. These differ based on the different transitions 
and the order in which tokens pass through these transitions. The simulations can allow the 
determination of whether a particular objective function can be achieved through a single 
trajectory in the model. The implications of this are to provide a potential mechanistic 
explanation of a given behaviour that can occur within the constraints and connectivity of the 
model. Monte Carlo sampling then can be used to provide a number of insights. Firstly, the 
probability of a particular trajectory occurring under given conditions can be determined. In 
addition, the influence of changes to the network can be explored by comparing the number 
of trajectories resulting in a particular behaviour prior to and following a network alteration. 
Utilising statistics within the MCM, the extent to which said perturbation influences the 
network can be determined. The QSSPN method has been successfully utilised in a number 
of applications including the qualitative simulation of bile acid homeostasis and prediction of 
the outcomes of in vitro molecular biology experiments (Harrison, 2010). An important 
benefit to QSSPN over other network sampling methods is not only can simulations be run 
without knowledge of full kinetic parameters, if these are known, quantitative data can be 
incorporated into the model. Arbitrary tokens can represent precise molecular levels for 
example, meaning the outputs of QSSPN simulations can generate real quantitative 
predictions potentially over a real timecourse (Fisher et al., 2013).  
 
If however, a PN model is encoded with experimentally determined values as in the case of 
this dynamic multi-scale model of a breast cancer cell and that presented in the MuFINS 
paper (Wu et al., 2016) then the MCM is not required. Here, the experimentally determined 
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values set the probability that a given reaction will fire. This in practice makes the PN 
effectively deterministic, meaning the same model behaviour is observed every time a 
simulation is run. In practice, the underlying algorithm uses the experimentally determined 
numbers as a probability. Therefore, it is possible that two reactions with similar parameters 
may fire in different orders, however, these would be so close to each other that overall 
model behaviour would remain the same.  
 
 Multi-formalism interaction network simulator  
 
In the move towards generating a complete computational reconstruction of a human cell, 
novel methods combining models representing different components has been attempted.  
Improvements in standards for development and annotation of models have increased the 
potential for models from different groups to be combined successfully, this approach is 
termed multi-formalism modelling. Combining models built on different scales and from 
different formalisms requires bespoke tools, and drove development of the Multi-formalism 
interaction network simulator (MuFINS). MuFINS is a software tool that integrated 26 major 
modelling approaches, including the those required for integration of different formalisms 
(e.g. QSSPN). MuFINS simulations are run using SurreyFBA, a flux balance analysis 
software developed at the University of Surrey (Fisher et al., 2013) used to realise a number 
of CBM methods and QSSPN computational engine. This is summarised in Figure 1-15.  
 
In addition to the use of QSSPN to integrate regulatory networks with CBMs, MuFINS 
enables the addition of regulatory networks directly into a CBM, through the use of linear 
inhibitor and activator constraints to reactions. As shown in Figure 1-16, a complex network 
of reactions is represented as linear equations, which in MuFINS can include inhibitor 
constraints (~) and activator constraints (&). An inhibitor constraint denotes that if a 
particular species is present, the reaction cannot occur. An activator constraint means that a 
certain species is required for the reaction to proceed (Wu et al., 2016). 
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Figure 1-15. Overview of MUFINS. Surrey flux balance analysis implements constraint-based modelling methods and the quasi steady 
state petri net algorithm performs QSSPN simulations. A graphical user interface, JyMet, is used to view the GSMN in a spreadsheet format 
and to perform in silico investigations by generating input files for sfba and qusspn. For QSSPN simulations, Snoopy Petri Net editor is 
used. Both JyMet and Snoopy import and export SBML file providing connectivity to other SBML-compliant tools (Gevorgyan et al., 
2011). 
 
 
The incorporation of such a wide range of modelling formalisms enables the move towards 
simulations covering all scales of biological organisation and moves towards accurate 
representations of whole cell or whole organism biology.  
 
A multi-formalism modelling and simulation approach has been utilised for modelling a 
number of biological systems. One such application is to cardiovascular modelling. This 
represents a movement away from the utilisation of 1) solely continuous formalisms for 
cellular modelling, which are computationally very demanding or 2) solely tissue-level 
models based on discrete formalisms, which cannot accurately reproduce known biology. 
Defontaine et al use multi-formalism modelling to create a hybrid model of the above two 
approaches (Wu et al., 2016). The group experience difficulties in applying the multi-
formalism approach but recognise the advantage of such a model in simulating complex 
pathologies  (Defontaine et al., 2004). 
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Figure 1-16. Model of cell signalling in a macrophage demonstrating how a signalling and gene regulatory network can be converted into 
flux balance analysis formalism and linear inhibitor and activator constraints included (Wu et al., 2016).  
 
 
Multi-formalism modelling has also been utilised to understand estradiol biology (Sier et al., 
2017). The diverse roles of estrogen in health and disease as well as the susceptibility of 
estrogen metabolism to both endogenous and external factors mean individual responses to 
this hormone are diverse. The group therefore propose the use of multi-formalism modelling 
to better understand estrogen biology. The multi-formalism model comprises a validated 
physiologically-based pharmacokinetic model (PBPK) of estradiol with a genome scale 
metabolic model of the liver and in addition a kinetic model of estrogen metabolism in the 
liver. The model is then utilised to assess drug-drug interactions and individual metabolic 
alterations that may render an individual susceptible to disease (Sier et al., 2017) including 
both drug-drug interactions and changes to the metabolic landscape that may predispose an 
individual to disease development. 
 
MuFINS specifically has also been used to model diverse systems including the mammalian 
macrophage. The model integrates signalling, regulation and whole cell metabolism and 
notably, includes the capacity to model particular metabolic perturbations via a signalling 
& 
Introduction 
 
113 
network inhibitor. This approach was validated against experimental data and provides a 
means to, through in silico investigation generate hypotheses to inform in vitro experiments 
and improve biological understanding (Wu et al., 2016).  
 
1.15 Summary of systems biology 
 
A systems approach to understanding biology is a movement away from historically 
established reductionist approaches. It enables the examination of emergent properties, 
phenotypes that could not be predicted by solely examining individual components of a 
network. Systems biology has facilitated important developments in disease and treatment 
generation in recent years.  
 
The utilisation of standardised language and modelling techniques facilitates the 
multidisciplinary nature of the systems biology approach, enabling sharing and collaboration 
of models. This contributes to the development computational models, from small (ODE 
fully parameterised models, with as little as four reactions) to GSMNs comprising thousands 
of reactions. 
 
In a movement towards more closely modelling biological organisms, novel algorithms such 
as MuFINS are enabling the development of multi-scale models representing multiple scales 
of biological organisation. Furthermore, the application and value of these models in 
predicting in vitro and in vivo behaviours is enhanced by the utilisation of known biological 
parameters to constrain these networks, generating context-specific iterations of the models.  
 
1.16 Summary of introduction 
 
Breast cancer is the most prevalent cancer in women worldwide and is also the most common 
cause of cancer deaths for females globally. Worldwide survival rates for breast cancer have 
been improving in recent years, largely due to improved diagnosis, screening programs and 
treatment advancements. The rate of improvement to net survival is beginning to plateau, 
with survival rates remaining at approximately 80%, with a stubborn 20% that are 
unresponsive to current treatments.  
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This is largely due to the heterogeneity of breast cancer cases. Breast cancer is a 
heterogeneous disease, with a high degree of diversity both between and within tumours as 
well as amongst cancer bearing individuals. All of these factors contribute to differences in 
aggressiveness, prognosis and therapeutic response, thus complicating treatment.  
 
Chemotherapeutics are traditionally the most common treatment for breast cancer, however, 
their off-target toxicities, adverse side effects and the ability of breast cancer to develop 
resistance against them vastly limit their usefulness as a long-term treatment strategy.  
 
Alternative approaches for breast cancer treatment development are needed to improve 
treatment outcomes for patients and are studied in this research. A network targeting method 
of tackling breast cancer is explored, to exploit the concept of synthetic lethality and is 
approached both from an intuitive study of cancer biochemistry as well as through systems 
biology methodologies.  
 
Systems biology holistic method for understanding intricate biological systems and was 
developed based on the knowledge of emergent properties in biology (Wu et al., 2016). 
Computational systems biology has been used for a number of years as a means to practically 
explore these intricate biological systems. There exists a range of different types of 
computational model developed for network exploration and many different methods utilised 
in producing these models. The movement towards multiformalism simulations that can 
represent multiple scales of biological organisation provide a means to model truer 
representations of human biology. A holistic picture of cancer biology will enable a more 
informed process of treatment development. The use of multiscale models provides novel 
opportunities for in silico testing of cancer cell responsiveness to different experimental 
conditions and thus will enhance the development of selective, network targeting, 
personalised treatments of breast cancer. 
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1.17 Aim, Hypothesis and Objectives 
 
 
Aim: 
The aim of this work was to utilise a systems biology approach to identify novel drug 
combinations for the treatment of breast cancer.  
 
Hypothesis: 
It was hypothesised that the targeted combination therapy of a metabolism-modulating drug 
with a chemotherapeutic agent would be synergistic in breast cancer cell lines. 
 
Objectives:  
 Develop a dynamic, multi-scale computational model of a breast cancer cell, based on 
a genome-scale metabolic network and incorporating select nuclear receptors and a 
kinetic model of the cell cycle 
 Constrain the model using gene expression and metabolomics data  
 Perform in silico investigations to identify metabolic vulnerabilities within the 
network as potential drug targets 
 Validate these predictions in vitro  
 Explore the effect of metabolism modulating drugs in combination with 
chemotherapeutic agents and establish effective novel combinations 
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Chapter 2 
 
2 Materials and Methods 
 
 
 
 
 
 
 
2.1 Materials 
 
Unless otherwise stated, all materials were from Sigma Aldrich and were of molecular 
biology or cell culture grade, as appropriate. 
 
 
 
Materials Supplier Catalogue No. 
Cell lines  
MCF-7 European Collection of Cell Cultures (ECACC) 86012803 
MDA-MB-231 American Type Culture Collection (ATCC) ATCC®HTB-26™ 
MCF-10A American Type Culture Collection (ATCC) 
ATCC® CRL-
10317™ 
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Drugs  
Carbidopa Sigma-Aldrich (Poole, UK) C0460000 
Cisplatin Sigma-Aldrich C2210000 
Doxorubicin Hydrochloride Abcam ab120629 
5-Iodotubercidin Tocris Bioscience (Bristol, UK) 1745 
GW4064 Sigma-Aldrich G5172 
Lithium Chloride Sigma-Aldrich L9650 
Metformin Hydrochloride Sigma-Aldrich PHR1084 
Sorafenib Fisher/ Santa Cruz Biotechnology SC220125 
Tamoxifen Sigma-Aldrich T5648 
 
Cell Culture  
Cholera Toxin Sigma-Aldrich C8052 
Epidermal Growth Factor Pepro-Tech (London, UK) AF-100-15 
Horse Serum Fisher Scientific (Leicestershire, UK) 11510516 
Insulin Solution Sigma-Aldrich I0516 
Trypsin-EDTA Sigma-Aldrich 15400054 
Dulbecco’s Modified Eagle’s  
Medium – high glucose 
Sigma-Aldrich D6171 
Dulbecco’s Modified Eagle’s  
Medium/Nutrient Mixture F-12 
Ham 
Sigma-Aldrich D6434 
Hydrocortisone Sigma-Aldrich H0888 
Penicillin-streptomycin Gibco 15140122 
Countess chamber slides ThermoFisher C10228 
L-Glutamine Solution Sigma-Aldrich G7513 
Trypan Blue Sigma-Aldrich T8154 
Fetal Bovine Serum (FBS) Gibco 11550356 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich D4540 
Phosphate Buffered Saline 
(PBS) 
ThermoFisher BR0014G 
 
 
 
Chapter 3 
 
118 
Cell Viability Assay 
Thiazolyl Blue Tetrazolium 
Bromide (MTT) 
Sigma-Aldrich 298-93-1 
   
Clonogenic Assay 
Crystal Violet Sigma-Aldrich C0755 
   
Metabolite Assays 
Glucose assay kit Abcam Ab65333 
L-Lactate Assay Kit Abcam Ab65331 
Glutamate assay kit Abcam Ab83389 
RPMI 1640 Medium (1X) liquid ThermoFisher 11530406 
 
Seahorse Assays 
Seahorse XFp Cell Energy 
Phenotype Test Kit 
Agilent Technologies LDA UK Ltd 103275-100 
Seahorse XFp Glycolysis Rate 
Assay Starter Pack 
Agilent Technologies LDA UK Ltd S7806A 
Seahorse XFp FluxPak 
Agilent Technologies LDA UK Ltd 
103022-100 
 
 
Table 2-1. Materials used with supplier details and catalogue number. 
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 Reagent preparation – solutions and buffers 
 
Phosphate Buffer Saline (PBS)  
To prepare a 1x PBS solution, one PBS tablet was dissolved in 100ml ddH2O. The solution 
was autoclaved and stored at room temperature.  
 
MCF-7 and MDA-MB-231 growth medium 
MCF-7 (passage 10-30) and MDA-MB-231 (passage 5-30) cell lines were grown and 
maintained in high glucose Dulbecco’s Modified Eagle’s Medium supplemented with 10% 
Fetal Bovine Serum v/v and 100 units/ml penicillin, 0.1mg/ml streptomycin sulphate.  
 
MCF-10A growth medium 
MCF-10A cell line was grown and maintained in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham supplemented with 5% Horse Serum v/v, 20ng/ml 
Epidermal Growth Factor, 0.5mg/ml hydrocortisone 100ng/ml Cholera toxin , 10ng/ml 
Insulin and L-glutamine. 
 
EGF, cholera toxin and insulin were resuspended in sterile ddH2O and stored at -20C, 
hydrocortisone was resuspended in 200 proof ethanol. All components were sterile filtered 
through a 0.2m filter before adding to DMEM-F12.  
 
Cell dissociation medium 
Trypsin EDTA, 10 X was diluted to 1 X with PBS. This is then used in cell culture for 
trypsinization. Stored at 4C.  
 
Cell Viability assay solution 
To perform MTT assay, 5mg tetrazolium dye MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide was dissolved in 1ml of ddH2O. The solution was prepared 
fresh each time.  
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Seahorse assay media  
Medium for cell energy phenotype test: 
Seahorse XF base medium was warmed to 37°C and powdered glucose, glutamine and 
pyruvate were added on the day of use to final concentrations of; 10mM, 2mM 
and 1mM respectively. The pH was adjusted where necessary to 7.4 with NaOH. 
 
Medium for glycolytic rate assay: 
Seahorse XF base medium without phenol red was warmed to 37°C and powdered glucose, 
glutamine and pyruvate were added on the day of use to final concentrations of; 10mM, 2mM 
and 1mM respectively. HEPES was also added to a final concentration of 5mM. The pH was 
adjusted to 7.4 with NaOH. 
 
Crystal Violet solution 
0.5 g crystal violet powder (Sigma-Aldrich) was dissolved in 80 ml distilled H2O, then 20 ml 
methanol was added. The solution was stored at room temperature in the dark. 
 
The drugs used were reconstituted as detailed in Table 2-2 and stored at -20°C. 
 
  
Drug Stock solution 
Carbidopa 15mM in DMSO 
Doxorubicin Hydrochloride 12mM in ddH2O 
5-Iodotubercidin 10mM in DMSO 
GW4064 30mM in DMSO 
Lithium Chloride 1M in ddH2O 
Metformin Hydrochloride 500mM in ddH2O 
Tamoxifen 10mM in ethanol 
 
Table 2-2. Reconstitution of drugs – solvent utilised and stock concentrations prepared. 
 
 
 
Chapter 3 
 
121 
2.2 Methods 
 
 Maintenance of Cell lines 
 
The breast tumour cell lines: MCF-7 (Catalogue no. 86012803) and MDA-MB-
231(Catalogue no 92020525) were purchased from the European Collection of Cell Cultures 
(ECACC).  
  
The breast MCF-10A ATCC® CRL-10317™ was purchased from the American Type 
Culture Collection (ATCC). 
  
 
 Standard Growth Protocol 
 
Cell lines were cultivated in T75 vented, filter flasks in a humidified incubator at 37°C, 5% 
CO2 with a media volume of 10-20mls. Cells were passaged once they reached approximately 
70%-80% confluence, as determined visually under a light microscope. MCF-7 and MDA-
MB-231 cell lines were passaged at a ratio of 1:7 as standard every 3-4 days. MCF-10A cells 
were passaged at a ratio of 1:4 every 3-4 days. The existing medium in the flasks was 
aspirated and disposed of, the cells were then washed with 5mls of pre-warmed (to 37°C) 
phosphate buffered saline. To prepare 1x PBS, one tablet was dissolved in 100 ml of ddH2O 
and autoclaved. Cells were then incubated with 2mls pre-warmed (to 37°C) trypsin-EDTA 
solution for 5 minutes for MCF-7 and MDA-MB-231 cell lines and for 15 minutes for MCF-
10A cell lines or until the cells had visibly detached from the flask. Cells were then 
resuspended in the appropriate volume of pre-warmed media and sub-cultured into new 
plasticware as required. Cells were only used between passages 5-30 to ensure phenotypic 
consistency. After this point, cells were discarded and a fresh stock revived from liquid 
nitrogen 
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 Cryopreservation and thawing 
 
2.2.1.2.1 Cryopreservation 
Cryopreservation medium was prepared by adding dimethyl sulfoxide (DMSO, Catalogue no. 
D4540. Sigma, UK) to complete growth medium at a final concentration of 5% v/v and 
supplementing the medium with additional FBS to a final concertation of 20% v/v. This was 
chilled on ice.  
  
A cell suspension of between 1.5x106 and 2x106 viable cells/ml as described in Section 
2.3.1.1 was prepared using the cryopreservation medium. One millilitre of cell suspension 
was pipetted into each cryovial, which were equilibrated at 2-8°C for approximately 30 
minutes. Cryovials were then transferred to a pre-chilled (2-8°C) 'Mr. Frosty' containing 
250ml isopropanol which was placed into a freezer at -80°C. For long term storage, cells 
were preserved in the vapour phase of liquid nitrogen.  
 
2.2.1.2.2 Thawing and propagation 
  
Complete growth medium was pre-warmed in a 37°C water bath. Frozen vials of cell 
suspensions were retrieved from liquid nitrogen storage and rapidly defrosted by gentle 
agitation in a 37ºC water bath. Once approximately 80% thawed, the cell suspension was 
transferred to a falcon tube containing 10ml of pre-warmed complete growth medium. The 
cell suspension was centrifuged for 7 minutes at 300x g at room temperature to pellet cells. 
The medium was then aspirated and the cell pellet gently resuspended in fresh growth 
medium before transferring to a T25 cell culture flask and placed in an humidified incubator 
at 37°C, 5% CO2 for 24 hours. After this period, the medium was replaced with 10mls of pre-
warmed growth medium and cells cultivated as described in Section 2.3.1.1. 
  
  Cell counting  
  
Cells were counted either using an improved Neubauer-type haemocytometer or an automatic 
cell counter (Countess II. ThermoFisher). 
  
Chapter 3 
 
123 
A cell suspension was prepared by trypsinisation, as detailed in section 2.3.1.1. A 50l 
sample of this suspension was mixed with 50l trypan blue, at a 1:1 ratio v/v. Trypan blue 
stains dead cells and leaves live cells unstained. 10l of the mixture was pipetted either into a 
glass improved Neubauer chamber haemocytometer and counted using a light microscope, or 
pipetted into each side of a disposable counting chamber for use with the automated cell 
counter. 
 
 Cell Viability Assay 
 
 Principle 
The cell viability assay used here is a tetrazolium reduction assay. It is based on the reduction 
of the tetrazolium salt (MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) 
by the NAD(P)H-dependent mitochondrial oxidoreductases in an actively metabolising, 
viable cell (Scudiero et al., 1988). The yellow MTT substrate is reduced to purple formazan 
crystals (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan) with a maximum 
absorbance close to 570 nm, as shown in Figure 2-1 (Riss et al., 2004). The crystals are 
insoluble in water and therefore, are dissolved in organic solvents such as DMSO and 
measured colourimetrically.  
 
As such, it measures mitochondrial activity, a surrogate marker for cell viability. When cells 
cease to metabolise or die, the conversion of MTT to formazan can no longer occur. Hence, 
the MTT  
 
Figure 2-1. Principle of MTT assay. The reduction of MTT (yellow) to Formazan (purple) (Riss et al., 2004) 
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 Protocol  
Breast cell lines were seeded in 96 well plates at an initial density of 5x104 cells per well in 
complete medium. The cells were left for 24 hours to adhere to the plate, after which the 
complete medium was replaced with serum free and the cells serum-starved for 24 hours. 
Cells were then treated with different concentrations of test chemical or vehicle control for 24 
hours at 37°C 5% CO2. Stock solutions were prepared as detailed in Table 2-2 and diluted as 
required in serum free medium.  
 
MTT solution was prepared at 5mg/ml in sterile ddH2O. For the final hour of incubation, 
MTT solution was added to each well at a final concentration of 1mg/ml. At the end of the 
incubation period, liquid was aspirated from each well, and formazan crystals solubilised 
through addition of 100l of 100% DMSO. Plates were gently agitated for 15 minutes to 
ensure even colour dispersion and absorbance read at 540nm using an OmegaTM Fluostar 
spectrophotometer.  
 
Cell viability was calcµated as a percentage of vehicle control. All experiments were 
performed in triplicates to account for technical variability, and undertaken on three 
independent occasions to account for biological variability. Data is presented as the mean 
(±SEM) of the three independent experiments, with each experimental value being the mean 
of the technical repeats (i.e. n=3)  
 
 
 
 Selected drug concentrations 
 
The concentrations for individual treatment of breast cancer cell lines in the MTT assay were 
selected based on previously published IC50 values and preliminary viability experiments to 
optimise the concentration range.  
 
Tam 40mg/d 
The concentration range used for Tamoxifen in the cell viability assays are 1µM-100µM. 
This range was based on work by Mohan et al in 2015 that tested concentrations of 1µM-
15µM and found the IC50 in MCF-7 cells to be approximately 5µM (Mohan, et al., 2015). 
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The cell line specific IC50s published by by Genomics of Drug Sensitivity in Cancer (GDSC) 
at (www.cancerRxgene.org) are 17.71µM for MCF-7 cells and 69.9µM for MDA-MB-231 
cells (Yang, et al., 2013). The dose range used here is extended to test responses of MDA-
MB-231 and MCF-10A cells additionally.  
 
Dox 60mg/21d 
The concentration range tested for Doxorubicin is 0.1µM-20 µM. The GDSC published IC50 
values for MCF-7 and MDA-MB-231 cells are 0.01µM and 1.252µM respectively (Yang, et 
al., 2013).   
 
Cis 60mg/21d 
the cell line specific IC50s for Cisplatin in MCF-7 (97.8µM) and MDA-MB-231 (36.2µM)  
cells are much higher than Doxorubicin and Tamoxifen. Therefore, the concentration range 
explored is greater, 1µM – 500µM. 
 
GW4064  
The concentration range used in these experiments for GW4064 is 0-112µM. This is based on 
work completed by Mohan et al, who determined the IC50 of GW4064 in MCF-7 and MDA-
MB-231 cells to be approximately 25µM. 
 
 
Metformin (1-150mM) 
The metformin concentrations explored here are 0-150mM. This was based on preliminary 
work and represents the lowest dose range that enabled an IC50 curve to be generated. With 
regard to clinical relevance, the daily dose of metformin administered for the treatment of 
diabetes mellitus is 2000mg (Libby, et al., 2009). This translates to an in vitro dose of 
approximately 0.3mM with tissue accumulation doses in the range of 1-5mM. preliminary 
work showed concentrations greater than 1mM are requires to see significant effects on cell 
viability after 24h. 
 
Carbidopa (1–100uM)  
The concentrations of carbidopa testes are 1-100uM, a range based on work by Vytautas 
Leoncikas, who examined the effect of carbidopa on cell viability in MCF-7 cells, and on 
work from Gilbert et al in lung cancer cell lines (Gilbert et al., 2000). 
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Lithium Chloride (50-100uM) 
Lithium Chloride was tested at concentrations between 50 and 200µM, with concentrations 
above 100µM having a significant impact on cell viability. These concentrations are far lower 
than those clinically used in the treatment of bipolar (µM vs mM). Welshons et al found 1-
5mM in vitro concentrations approximates the plasma concentration achieved clinically 
during the treatment of bipolar disorder. However, it should be noted that the clinical 
concentrations reflect plasma concentration and not local concentration. Given the high water 
solubility of LiCl, it is likely that the concentration in fatty tissues such as breast are orders of 
magnitudes lower. 
 
The concentrations for combination studies were chosen based on the IC50s for individual 
treatments found during this work.  
 
 
 
 Clonogenic Assay 
 
 Principle 
The clonogenic assay was used to determine differences in reproductive viability between 
cells under vehicle control and drug treatment conditions. In this assay, cells are plated at a 
very low density such that single cells adhere in isolation. Reproductive viability is defined as 
the number of these single cells to form colonies of at least 50 cells (Puck and Marcus, 1956). 
 
 Protocol 
A single cell suspension is obtained through trypsinisation as described in 2.3.1.1 and cells 
were counted as described in 2.2.2. These were then plated in 6 well plates in complete 
medium at density dependent on both the cell line plating efficiency and predicted effect of 
drug treatment. Plating densities are designed to achieve between 20 and 150 colonies per 
well at the end of the incubation time, which is sufficient for statistical analysis. For MDA-
MB-231 and MCF-7 cells, plating densities for vehicle controls were 500 cells/well and 2500 
cells/well. The cells were left for 24 hours to adhere to the plate, after which the complete 
medium was replaced with serum free and the cells serum-starved for 24 hours. Cells were 
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then treated with different concentrations of test chemical or control for 24 hours at 37°C 5% 
CO2. Treatment medium was then replaced with complete medium and cells incubated for 14 
days with one change of medium after 7 days. Cells were then fixed and stained with crystal 
violet (Catalogue no. C0775. Sigma, UK) prepared as detailed in the section 2.2. Briefly, 
medium was removed and wells rinsed with 5mls PBS. PBS was removed and 2mls of 0.5% 
crystal violet solution added to each well and left for 30 minutes at room temperature. Wells 
then rinsed and allowed to air dry before counting. Colony number per plate was counted 
manually and recorded. 
 
 
 
Plating efficiency (PE) was calculated by: 
PE =
number of colonies
number of cells
 x 100  
 
Surviving fraction (SF) was calculated by:  
SF =
PE of treated sample
PE of control
 x 100  
 
 
 
 Selected drug concentrations 
 
The doses for the clonogenic assay were initially selected based on IC50 values observed in 
MTT assays carries out in this body of work. The sensitivity of cells plated at such low 
seeding densities with prolonged exposure to drug, however was much higher than with the 
conditions of the MTT assay. Therefore the doses were reduced to the highest level where 
cells remained sufficiently viable to count 50 colonies per well.  
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 Measuring consumption and release of molecules in medium 
 
The consumption and release data for glucose, lactate and glutamate from MCF-7 and MDA-
MB-231 cells was measured experimentally.  
 
 Medium sampling 
A single cell suspension was prepared as described in section 2.3.1.1 and cells seeded in a 96 
well plate at a density of 2x104 cells/well; optimisation of seeding densities determined this 
provided 70% confluence in the wells 24h after seeding. After 24 hours, medium was 
aspirated, wells washed twice with 100l PBS and 100l of fresh medium added to each 
well. Cells were incubated for 1h at 37°C 5% CO2. Medium was removed from three sample 
wells, centrifuged at 13000 rcf for 5 minutes to pellet any cellular residue and the supernatant 
frozen at -20°C. This was repeated hourly between 1-8 hours and after 24 hours.  
Medium samples were also collected from cells seeded in T25 flasks. Cells at p30 or lower 
were counted using Countess Automated Cell Counter (Invitrogen), seeded at 30,000 cells 
cm2; 750,000 cells per T25 flask and left for 24 hours.  
Plating in a T25 flask was utilised for a number of reasons. i) Use of a flask enables sampling 
of medium over a longer duration because evaporation of the medium happens less readily ii) 
the samples taken are all from exactly the same place as opposed to different wells within one 
plate, this reduces inaccuracies that may be encountered due to plating or pipetting errors.  
After 24 hours existing medium was aspirated and cells washed twice with 4mls PBS. 4mls 
of fresh medium was then added to each well. After 1 hour, 50l was removed from the flask. 
The samples were centrifuged for 5 minutes at 13000rcf room temperature to pellet any 
cellular residue. The supernatant was then frozen at -20°C. This was repeated each hour for 8 
hours and then at 24 hours.   
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 Quantifying glucose in the medium 
After samples were collected for each time point and condition, glucose levels in each sample 
were assayed using a Glucose Assay Kit (Catalogue no. ab65333. Abcam, UK).  
Glucose is converted to glyconolactonate and hydrogen peroxide (H2O2) in a reaction 
catalysed by glucose oxidase. The hydrogen peroxide then reacts with the probe dye OxiRed 
to form Resorufin in a reaction catalysed by horseradish peroxidase. Resorufin is coloured, 
and also fluoresces, with both measurements proportional to the amount of glucose present. 
The colorimetric change can be measured at λ = 570 nm and fluorescence Ex/Em = 535/587 
nm.  
 
 
Figure 2-2. Reaction for glucose assay kit. 
 
 
 
Standard curve preparation  
Using the glucose standard solution, a set of standards ranging from 0 nmol/well to 10 
nmol/well was prepared as detailed in the kit protocol.   
The assay was performed according to the manufacturer’s instructions. Briefly, each sample 
was prepared in duplicate or triplicate. Using 96 well plates, 1l of each medium sample was 
added the wells in duplicate. The volume was brought to 50l by adding 49l of glucose 
assay buffer. The reaction mix including the glucose oxidase and HRP was prepared 
combining the following in the detailed amounts. A master mix was prepared sufficient for 
all sample wells, each well required 50 μl of the reaction mix containing: Glucose Assay 
Buffer 46 μl, Glucose Probe 2 μl, Glucose Enzyme Mix 2 μl. The mix was vortexed gently 
for 20 seconds.  
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The plate is incubated at 37°C for 30 minutes, protected from light. Fluorometric and 
colourimetric measurements were taken using the FLUOstar® Omega microplate reader. To 
quantify the colorimetric change, the samples are read at OD570nm. Fluorometric 
quantification of glucose levels was also tested, to determine whether the increased 
sensitivity was required to observe differences between samples. However, both colorimetric 
and fluorometric assays were sufficiently sensitive. Fluorometric measurements require black 
walled plates, which are more expensive than their clear counterparts. Therefore, the 
colourimetric measurements were utilised.  
A standard curve was plotted and used to interpolate the amount of glucose in samples. The 
standard curve fit used is linear regression. 
 
Glucose concentrations were calculated by:  
𝑛𝑚𝑜𝑙 𝑔𝑙𝑢𝑐𝑜𝑠𝑒
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
 
 Quantifying lactate in the medium 
Samples were collected as described in section 2.3.6.1, and levels of lactate determined 
assayed using a L-Lactate Assay Kit (Catalogue no. ab65331. Abcam, UK).  
The principle of the kit involves the oxidation of lactate to pyruvate in a reaction catalysed by 
lactate dehydrogenase (LDH). This reaction results in the inter-conversion of NADH to 
NAD+, with a coupled reaction leading to a tetrazolium dye (WST) being reduced to its 
formazan metabolite. This product is coloured and the colorimetric change, which is 
proportional to the amount of lactate present in the sample, can be measured at λ = 450nm.  
 
 
 
 
 
 
 
Figure 2-3. The principle of the Abcam lactate assay kit detection method 
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Standard curve preparation  
Using the lactate standard solution, a set of standards ranging from 0 nmol/well to 10 
nmol/well was prepared as detailed in the kit protocol. 
The assay was performed according to the manufacturer’s instructions. Briefly, each sample 
was prepared in duplicate or triplicate. Using 96 well plates, 1l of each medium sample was 
added the wells in duplicate. The volume was brought to 50l by adding 49l of glucose 
assay buffer.  
The reaction mix is prepared combining the following in the detailed amounts. A master mix 
is prepared sufficient for all sample wells. For each well, prepare a total 50 μl Reaction Mix 
containing: Lactate Assay Buffer 46 μl, Lactate substrate mix 2 μl, Lactate Enzyme Mix 2 μl. 
The mix is vortexed gently for 20 seconds.   The plate is kept protected from light, at 37°C 
for 30 minutes. Colourimetric measurements were taken using the FLUOstar® Omega 
microplate reader. To quantify the colorimetric change, the samples are read at OD450nm.  
A standard curve was plotted and used to interpolate amount of lactate in samples. The 
standard curve fit used is linear regression.  
Lactate concentrations were calculated by:  
𝑛𝑚𝑜𝑙 𝑙𝑎𝑐𝑡𝑎𝑡𝑒
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
 
 Quantifying glutamate in the medium 
For the samples collected as described above section 2.3.6.1, levels of glutamate were also 
assayed using a Glutamate Assay Kit (Catalogue no. ab83389. Abcam, UK).      
The principle of the kit involves the glutamate enzyme mix recognising glutamate as a 
specific substrate leading to proportional colour development the colorimetric change can be 
measured at λ = 450nm. 
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Standard curve preparation  
Using the glutamate standard solution, a set of standards ranging from 0 nmol/well to 10 
nmol/well was prepared detailed in the kit protocol.  
Each sample was prepared in duplicate or triplicate. Using 96 well plates, 10l of each 
medium sample was added the wells in duplicate. The volume was brought to 50l by adding 
40l of glutamate assay buffer.  
The reaction mix is prepared combining the following in the detailed amounts. A master mix 
is prepared sufficient for all sample wells. For each well, prepare a total 50 μl Reaction Mix 
containing: Glutamate Assay Buffer 90 μl, Glutamate developer 8 μl, Glutamate Enzyme Mix 
2 μl. The mix is vortexed gently for 20 seconds. The plate is kept protected from light, at 
37°C for 30 minutes. The plate is kept protected from light, at 37°C for 30 minutes. 
Colourimetric measurements were taken using the FLUOstar® Omega microplate reader. To 
quantify the colorimetric change, the samples are read at OD 450nm.  
 
A standard curve was plotted and used to interpolate amount of glutamate in samples. The 
standard curve fit used is linear regression. 
Glutamate concentrations were calculated by:  
𝑛𝑚𝑜𝑙 𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
 
 
 Metabolic activity analysis 
 
 General principle 
 
The metabolism of the cell lines MDA-MB-231, MCF-7 and MCF-10A was examined using 
the Seahorse XFp analyser from Agilent. Two different assays were used to explore different 
aspects of the cells’ metabolism and included measuring the oxygen consumption rate (OCR) 
and the extracellular acidification fare (ECAR) in real-time. The measurements are taken via 
Chapter 3 
 
133 
probes from a 2l sample of medium above a monolayer of adherent cells. OCR and ECAR 
are calculated from measurements of the concentration of dissolved oxygen and free protons. 
OCR is an indicator of mitochondrial respiration, and ECAR is largely the result of 
glycolysis, thus together these values provide a measure of mitochondrial and glycolytic flux.  
 
Figure 2-4: Agilent Seahorse XF Cell Energy Phenotype Profile. The relative utilisation of the two energy 
pathways of a cell population is determined under both baseline (Baseline Phenotype) and stressed (Stressed 
Phenotype) conditions. The response to an induced energy demand is their Metabolic Potential (Agilent, 2017). 
 
 
The three cell lines were initially examined in untreated conditions to enable the comparison 
of baseline metabolism. The assays were repeated on cells in treated conditions to explore the 
effect of different treatments on the metabolism and identify differential effects.  
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Three assays were undertaken to explore cellular metabolism: New Cell Characterisation, 
Cell Energy Phenotype Test and Glycolytic Rate Assay. The Cell Energy Phenotype Test 
uses carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) to uncouple the 
mitochondria and maximise oxygen consumption rate. The New Cell Characterisation 
involves a titration to determine the concentration of FCCP that drives the maximum oxygen 
consumption rate. 
 
 Seeding cells in XFp cell culture plate 
 
The seeding surface of each well in the XFp cell culture mini plates is approximately 40% of 
a normal 96 well plate, and numbers of cells seeded were scaled appropriately.  
 
A cell suspension was prepared as in section 2.3.1.1 and prepared an appropriate 
concentration to plate 100µl of cells per well, detailed in Table 2-3. Cells were seeded in 
wells B-G taking care to pipette precise volumes to the bottom of each well. 100µl of 
complete medium was pipetted into wells A and H. The moat surrounding the wells were 
filled with 400µl of PBS to prevent evaporation of medium from the wells.  
 
Plates were placed in an incubator at 37°C, 5% CO2 and cells allowed to adhere overnight.  
 
 
Cell line 
Required seeding 
density (cells/well) 
Volume in well (l) 
Concentration to 
plate (cells/ml) 
MCF-7 3.0 x104 100 3x105 
MDA-MB-231 2.0 x104 100 2x105 
MCF-10A 4.0 x104 100 4x105 
 
Table 2-3: Seeding densities required for Seahorse XFp analyser. 
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 Preparing a sensor cartridge for XFp assay 
 
The sensor cartridge has 8 probe tips that can detect pH and O2 concentration, shown in 
Figure 2-5. For accurate readings, the probes must be rehydrated in Seahorse XF Calibrant 
solution before use. Each well of the utility plate is filled with 100µl of the calibrant and the 
moats with 400µl of calibrant. The sensor cartridge is placed onto the utility plate, 
submerging the sensors, and left in a humidified incubator at 37°C, no CO2 for 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. Diagram of a Seahorse XFp microplate. 
 
 
 
 
 New Cell Characterisation Assay 
Principle: 
 
The New Cell Characterisation assay identifies the optimal concentration of FCCP and the 
correct seeding densities for use in the Cell Energy Phenotype Test and Glycolytic Rate 
Assay. This assay identifies the basal and maximal respiration rates in the cell line under 
study for a given set of conditions. Conditions can then be adjusted to ensure that assay 
endpoints are within the dynamic range of the XFp Seahorse machine.  
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Protocol: 
 
MDA-MB-231, MCF-7 and MCF-10A cells were seeded at densities of 2x104, 3x105 and 
4x104 cells/ml, respectively, providing approximately 80% confluence after 20 hours.  
 
An FCCP titration was then carried out as detailed in the assay protocol booklet (Agilent, 
2017), examining concentrations of 0.125, 0.25, 0.5, 1.0, 2.0µM. This allows the empirical 
determination of the FCCP concentration that elicits maximum OCR. This concentration was 
then used in all subsequent experiments.   
 
 
 Cell Energy Phenotype Assay 
Principle: 
 
This assay identifies the energy phenotype of a cell by assessing the levels of mitochondrial 
respiration and glycolysis. Examining these energy producing pathways in combination 
allows the determination of key differences in metabolic profiles between cell lines and 
between treated and untreated cells.  
 
The assay uses an inhibitor of ATP synthase; oligomycin. Oligomycin is an inhibitor of ATP 
synthase. It prevents the function of the Fo proton channel and thus inhibits the oxidative 
phosphorylation of ADP to ATP. This therefore promoting an increase in glycolysis as a 
compensatory energy producing pathway. the decrease in oxygen consumption rate observed 
following oligomycin addition can be used to represent the proportion of basal respiration 
that is used for ATP production. 
 
FCCP is used to depolarise the membrane of the mitochondria. This drives mitochondria to 
restore the membrane potential and oxygen consumption rates are increased (Agilent, 2017).  
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Protocol: 
 
Cells were seeded and the sensor cartridge prepared as described in sections 2.3.7.2 and 
2.3.7.3. On the day of the assay, cells were examined under the microscope to confirm even 
seeding across all wells and at approximately 80% confluence. Seahorse assay medium was 
prepared as described in section Reagent preparation – solutions and buffers - Seahorse Assay 
Media. Complete medium was replaced with seahorse assay medium without phenol red and 
the plate incubated for 60 minutes at 37°C without CO2. The stressor mix was prepared by 
combining oligomycin (10M) and FCCP (5M) 1:1 v/v. Twenty microlitres of this mix was 
loaded into port A for each well, providing for a final concentration in the well of the 1M 
oligomycin and 0.5M FCCP.  
 
The correct program was loaded to the XFp machine (see supplementary material) and the 
assay run.  
 
 
 Glycolytic Rate Assay 
Principle: 
 
This assay measures the rate of glycolysis in cells under basal conditions and cellular stress in 
the form of mitochondrial inhibition. 
   
The glycolytic proton efflux rate is determined by taking measurements of ECAR and OCR. 
As both mitochondrial respiration and glycolysis can contribute to ECAR, the contribution of 
mitochondrial-derived CO2 to ECAR must be determined. To achieve this, a mixture of 
rotenone and antimycin A is used to inhibit complexes II and III of the mitochondria to 
isolate the level of proton efflux generated by respiration. In addition, 2-deoxy-D-glucose is 
used to inhibit glycolysis. The level of mitochondrial proton efflux is then subtracted from 
total proton efflux rate, determining the glycolytic proton efflux rate (Romero et al., 2017).  
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Protocol: 
 
Cells were seeded and the sensor cartridge prepared as described in sections 2.3.7.2 and 
2.3.7.3. On the day of the assay, cells were examined under the microscope to confirm even 
seeding across all wells and approximately 80% confluence. Seahorse assay medium was 
prepared as described in section Reagent preparation – solutions and buffers - Seahorse Assay 
Media. Complete medium was replaced with seahorse assay medium without phenol red and 
the plate incubated for 60 minutes at 37°C without CO2.  
 
Stock solutions of 1:1 v/v rotenone and antimycin A (5M) and 2-deoxy-D-glucose (500mM) 
were prepared. Twenty microlitres of the rotenone:antimycin A stock was loaded into port A 
and 22l of the 2-deoxy-D-glucose stock was loaded into port B of each well, generating 
final well concentrations of 0.5M and 50mM, respectively. Volumes are detailed in Table 
2-4. 
 
 
 
 
 
 
 
 
Table 2-4 – Starting well assay medium volume and compound injection volumes for loading XFp plate for use 
in Seahorse Analyser to examine metabolic activity in cells.  
 
The correct program was loaded to the XFp machine and the assay run. The XFp machine is 
one of the Seahorse XF analysers that analyse mitochondrial respiration and glycolysis in live 
cells using solid-state sensors to simultaneously measure both oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) in every well. 
 
MCF-7 and MDA-MB-231 cells were tested across all assays detailed above and the results 
are presented in Chapters 2 and 3. MCF-10A cells were used in many of the assays, however 
due to technical difficulties with culturing these cells at some time points, they are omitted 
from some assays. 
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 Statistical Analysis  
 
The statistical analysis and graph generation was performed using GraphPad Prism 7 for Mac 
OS X (Version 7.0d, November 16, 2017). Statistical tests used are a one-way or two-way 
ANOVA, with Dunnett’s test post-hoc for multiple comparisons. Statistical significance is 
determined with a P-value of ≤0.05. 
 
Throughout, biological replicates are defined as cells subcultured after trypsinisation. Each 
biological replicate consists of three technical repeats, averaged to obtain the treated or 
vehicle condition value. Results are expressed as ± the standard error of the mean (SEM).  
 
 
 Synergy analysis 
 
Drug-drug interactions can be broadly grouped into three categories: additive, synergistic or 
antagonistic. Additivity describes where the concomitant use of two drugs results in a 
combined efficacy that reflects the efficacy of drug 1 plus the efficacy of drug 2. A 
synergistic drug combination describes a situation where the combined efficacy of drug 1 
plus drug 2 is greater than the sum of the individual efficacies (Loewe, 1953). In contrast, an 
antagonistic combination results in a combination treatment that is less potent the sum of the 
individual drug effects (Sucher, 2014).  
 
SynergyFinder is an R-package that calculates synergy scores for pairwise drug 
combinations. The program calculates separate scores based on four key reference models for 
synergy: Bliss independence model, Highest single agent (HSA) model, Loewe additivity 
model and the Zero interaction policy (ZIP) model. 
 
The HSA and Bliss independence model are effect-based strategies of analysing 
combinations, which compare the impact of the combination directly to the effect of the 
individual components. The HSA model (Lehár et al., 2007)or Gaddum’s non-interaction 
model (Berenbaum, 1989) uses the formula: 𝐶𝐼 =
max(𝐸𝐴, 𝐸𝐵)
𝐸𝐴𝐵
 , where A and B represent the 
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individual drugs and E represents their effect. This is a useful comparison of a single agent 
against a combination, but does not distinguish whether there is an improved effect of the 
combination compared with the additive effect expected when combining the two drugs 
(Foucquier and Guedj, 2015).  
 
The Bliss independence model (Bliss, 1939) assumes drugs will not interact with each other 
and will therefore produce an additive effect in a combination. The expected additive effect 
and the observed combinatorial effect are expressed as probabilities and can be compared to 
one another. Once probabilities are determined, the combination index is then calculated 
using the formula: 𝐶𝐼 =
𝐸𝐴+𝐸𝐵−𝐸𝐴𝐸𝐵
𝐸𝐴𝐵
 . Although a popular method for assessing synergy, 
some limitations of the Bliss Independence model are the requirement for effects to be 
expressed as probabilities and the assumption that both drugs have exponential concentration 
response curves (Goldoni and Johansson, 2007).  
 
The Loewe additivity model is described as a concentration-effect based strategy and was 
defined by Loewe in 1926 (Loewe, 1926; Loewe, 1953). It relies on two principles, one is the 
sham combination principle, which means that if a compound is experimentally combined 
with itself, only additive not synergistic effects should be observed. The second is the 
concentration equivalence principle that just states each concentration of one agent or drug 
can be seen as identical to the concentration of a different agent that leads to the same 
observed effect; concentration a of agent A is equivalent to concentration ba of agent B. This 
can be written as: Effect(a+b) = Ea(a+ab) = EB(ba+b) = EAB. The principle also assumes that 
both drugs have a constant ratio of concentrations for each observed effect; constant potency 
ratio: 𝑅 =
𝐴
𝐵
 . This assumption allows an equation to be written which relates all pairs of 
concentrations between agent a and b. 
𝑎 + 𝑎𝑏 = 𝐴 ↔ 𝑎 + 𝑏 𝑥 𝑅 = 𝐴 ↔ 𝑎 + 𝑏 𝑥 
𝐴
𝐵
= 𝐴 
This forms the basis of the simple equation fundamental to the Loewe Additivity model:    
𝑎
𝐴
+
𝑏
𝐵
= 1 and is how the combination index (CI) is calculated for this model. If the 
combination index is less than one, it suggests that the concentrations of a and b required to 
produce a particular effect when combined are lower than would be expected if the drugs 
were purely additive and suggests a synergistic relationship between the two agents. CI 
greater than 1 suggests the concentrations of a and b required to achieve an effect in 
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combination are higher than would be expected if the drugs were additive and this suggests 
an antagonistic relationship (Berenbaum, 1977). Although superior in some ways to purely 
effect based strategies of examining drug combinations, there are limitations to the Loewe 
additivity method. Practically, a concentration response curve for an agent must be known to 
use this method, which can be time consuming to achieve experimentally or difficult to 
model in silico (Zhao et al., 2014). Additionally, the assumption of a constant potency ratio is 
not always experimentally accurate and thus calculations from the model may not accurately 
represent agent interactions.  
 
The final reference model that SynergyFinder uses is the Zero interaction policy (ZIP) model. 
This is a newly introduced model, designed to overcome some of the limitations described 
above and utilises a combination of elements from Bliss and Loewe models. The model 
evaluates drug interactions by considering the concentration response curves for the 
individual agents as well as for their combinations. By comparing these curves, the model 
can quantify how much the data deviates from the expected zero interaction. Yadav et al 
tested the usefulness of their model with a large dataset and found that synergy was 
effectively highlighted where it existed and false positive scores were minimal. An additional 
advantage is that the whole interaction landscape can be viewed meaning concentrations 
where synergy exists between two agents can be distinguished from concentrations where 
only additivity is observed, thus helping design optimal treatment plans (Yadav et al., 2015). 
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2.3   Computational Methods  
 
 Software packages used: 
Details of the software packages, programs and programming languages used are displayed in 
Table 2-5. 
 
Program/ 
Language 
Version Url Function 
Data analysis 
Matlab Matlab R2014a 
http://www.mathworks.co.uk/ products/ matlab/, 
premium software 
 
R R-studio 1.1.383   
 R Packages: Bioconductor 3.3 https://www.bioconductor.org/, freely available  
 
Bioconductor tools:  
Biobase 2.30.0 
https://www.bioconductor.org/packages/release/ 
bioc/html/Biobase.html, freely available 
Analyse 
microarray data 
   GEOquery 2.36.0 
https://bioconductor.org/packages/release/bioc/ht
ml /GEOquery.html, freely available 
     Limma 3.26.8 
https://bioconductor.org/ 
packages/release/bioc/html/limma.html, freely 
available 
     Bowtie2-2.2.9 
http://bowtie-bio.sourceforge.net/bowtie2/i 
ndex.shtml 
Align sequence 
reads to genome 
 Rsamtools 1.34.0  
http://bioconductor.org/packages/release/bioc/htm
l/Rsamtools.html, freely available 
 
 GenomicFeatures 1.34.1 
(https://www.bioconductor.org/packages/release/b
ioc/html/GenomicAlignments.html, freely 
available), 
Manipulate 
transcript 
annotations 
 GenomicAlignments 1.18.0 
(https://www.bioconductor.org/packages/release/b
ioc/html/GenomicAlignments.html, freely 
available), 
 
 GenomicRanges 1.34.0 
(https://www.bioconductor.org/packages/release/b
ioc/html/GenomicRanges.html, freely available). 
 
Python Python 2.6.6 https://www.python.org/, freely available  
 Python package: MACS-1.4.2 
https://pypi.python.org/pypi/MACS/1.4.2, freely 
available 
Analyse ChIP-
seq data 
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Computational modelling 
Snoopy Snoopy 2 
http://www-dssz.informatik.tu-
cottbus.de/DSSZ/Software/Snoopy, freely 
available 
Petri-net 
modelling  
QSSPN QSSPN_software http://sysbio3.fhms.surrey.ac.uk/, freely available 
QSSPN 
simulations 
Surrey 
FBA 
SurreyFBA 2.0 beta with Jymet http://sysbio3.fhms.surrey.ac.uk/, freely available 
Flux balance 
and flux 
variability 
analysis 
 
Table 2-5: Software packages used in the generation of the in-silico model of breast cancer, detailing name, source and purpose used for in 
this work.  
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 Model development pipeline 
 
The aim of these approaches was to reconstruct a computational model of a breast cancer 
cell, integrating a genome-scale metabolic model, key gene and signal regulatory components 
and a kinetic model of the cell cycle. Once this general model was reconstructed, it would be 
constrained using literature and de novo generated data to represent specific breast cancer cell 
lines or subtypes. The model would be validated against its ability to reproduce known 
biology of the breast cancer cell line under study, and then used to explore metabolic 
chokepoints and vulnerabilities and to identify novel targets for breast cancer treatment.  
 
 Stages of the model development - overview 
 
There are three specific components of the model which needed to be integrated/constrained 
to generate breast cancer cell line-specific reconstructions.  
 
i) Genome-scale metabolic network: The Recon 2 GSMN was used as it is the most 
comprehensive general reconstruction of human metabolism openly available.  
 
ii) Gene and signal regulatory network: Estrogen and progesterone receptors and their 
associated signalling networks were selected for inclusion because of the influence 
hormone receptor status has over breast cancer therapeutic option, as well as tumour 
responsiveness and aggressiveness.  
 
Genes whose expression was differentially regulated in response to estrogen or 
progesterone treatment were identified from the existing microarray data. To 
determine whether expression changes were due to direct interaction of ER/PR with 
the gene, ChIP-Seq data was also analysed and where changes were observed in both 
microarray and ChIP-Seq data, these genes were selected for inclusion in the 
signalling network. The resultant gene and signal regulatory network was integrated 
into the GSMN directly, or thorugh a coupled Petri net representation, as appropriate. 
 
iii) Cell cycle model: A kinetic model of the cell cycle was also incorporated into the 
complete model because: (i) dysregulation of cell cycling is a key phenotype of 
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cancer,  (ii) a number of cell cycle proteins are know to be differentially regulated by 
ER and PR signaling and (iii) a number of drugs are cell cycle specific and function at 
particular stages within the cell cycle or by inhibiting its progression. The cell cycle 
model was reconstructed in Petri net formalism from the published model of Tyson 
and Novak (2001), and validated against the original model behaviour. 
 
 
 Estrogen and Progesterone signaling networks 
 
Initially genes differentially regulated by estradiol or progesterone treatment were identified. 
Microarray data for breast cancer cell lines from NCBI for estradiol or progesterone treated and 
untreated cells was obtained. Using R Bioconductor tools and associated packages, genes whose 
expression altered >2 fold with treatment were identified. Alongside this, ChIP-seq data also from 
NCBI was sourced to identify direct binding sites for either ER or PR. The two lists of genes were 
compared and where gene expression was altered >2fold with treatment and the gene was a direct 
binding site for ER or PR, these were selected for inclusion in the model. 
 
The first step of incorporating these networks into the model was to write a set of linear reactions 
representing the path from receptor to transcription factor and gene. These equations were then 
incorporated in to the GSMN. The up/down regulated genes and proteins are represented in a petri net 
model built in Snoopy representing the transcription factor, gene, mRNA and protein as well as 
transcription and translation reactions. The genes are linked back to the reactions they influence in the 
GSMN and also to the cell cycle model. 
 
The first stage for incorporating the ER and PR gene and signal regulatory network into the 
full reconstruction was to identify the scope of the network to be included. 
 
 
Identification of ER/PR target genes via microarray analysis 
 
Microarray introduction 
 
DNA microarrays allow high through-put parallel gene expression analysis. There are several 
different technologies, but their general approach is to use short oligonucleotides spotted onto 
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slides or beads. These oligonucleotides are approximately 20 bases in length, with each 
‘probe’ exhibiting some specificity toward a target gene. When a number of these probes are 
used together (probe set) it is possible to achieve a high degree of specificity toward a target 
gene.  
 
Tissue samples of interest are processed to isolate messenger RNA (mRNA), which is 
converted into complimentary DNA (cDNA) via reverse transcriptase. The cDNA is 
fluorescently labelled, often using cyanine dyes, before being passed over the chip. 
Hybridisation occurs between cDNA molecules complementary to a probe on the microarray. 
Non-specific binding is reduced by pre-hybridisation with bovine serum albumin or similar. 
Any unhybridised or unbound cDNA samples are washed away and the chip analysed via a 
fluorescent scanner. The scanner identifies patterns of hybridisation by examining fluorescent 
signals from each spot on the slide. The laser excites the fluorescent probe, which results in 
emission measured via a confocal microscope. The microarray is created in a way that each 
place contains a known DNA sequence or a gene and therefore the identifies of cDNA can be 
readily identified (National Human Genome Research institute, 2015). 
 
Microarray data analysis 
 
Data was selected from studies that generated microarray data for MCF-7 and MDA-MB-231 
cell lines in the presence and absence of estrogen or progesterone, or an analogue of these 
hormones. The details of the experiments and data used are presented in Table 2-6 and Table 
2-7. Each data set was paired with an appropriate control, and the two conditions compared in 
terms of the expression level of all genes. This analysis was carried out using the 
programming language R, through the RStudio suite. Packages in R represent collections of 
scripts that perform related analyses. For the current project the Bioconductor package was 
used (Huber et al., 2015). Generalised R-scripts used for the microarray analysis are found in 
the supplementary material (Appendix 1). Bioconductor is an opensource package primarily 
based on R programming language. The collection of tools within Bioconductor allow the 
statistical analysis of genomic data, the generation of reproducible analyses from large data 
sets and the inclusion of important metadata such as that from the literature or annotations 
from within the NCBI Geo database (Huber et al., 2015). The Bioconductor tools Biobase 
2.30.0, GEOquery 2.36.0, limma 3.26.8 were used for the current project. Biobase contains 
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set data structures that can be used to view genomic data such as that obtained from 
microarray experiments (Falcon, Morgan and Gentleman, 2006). GEOquery is described as 
the bridge between the NCBI Gene Expression Omnibus, and BioConductor (Bioconductor, 
2018). Limma is used to identify differential expression for microarray data across different 
conditions (Smyth et al., 2002).  
 
The general workflow is shown in Figure 2-6, with a brief description provided below.  
 
The output of this analysis provides, for each gene measured by the array: the adjusted p-
value for the statistical analysis, the log fold change of gene expression between the control 
and experimental conditions, and annotations including gene symbol and title. Those genes 
with an adjusted p-value 0.05 or lower and displaying a fold change in expression of greater 
than two-fold were selected from each experiment. Details of these are shown in Table 2-6 
and. These were sorted into either positive or negative fold changes and those genes that were 
differentially expressed across three or more microarray experiments were selected for 
comparison with ChIP-Seq analysed data.  
 
 
 
 
Figure 2-6: Flow diagram showing stages of selecting primary target genes for inclusion into the model. 
Microarray and ChIPseq data was selected according to certain criteria, where genes are differentially regulated 
in the microarray data and found to be direct targets through ChIPseq data analysis, they are selected for 
inclusion in the model.  
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GSE Number 
GSM Number  
(GEO Accession No.) 
Cell Line Condition detail Publication reference 
GSE59908 
GSM1453422, 23, 24 
 
MCF7 
Control siRNA 
Vehicle for 3h 
(Antony et al., 2015) 
GSE59908 
GSM1453425, 26, 27 
 
MCF7 
Control siRNA 
Estrogen for 3h 
GSE59908 
GSM1453434, 35, 36 
 
MCF7 
Control siRNA 
Vehicle for 6h 
GSE59908 
GSM1453437, 38, 39 
 
MCF7 
Control siRNA 
Estrogen for 6h 
GSE57935 
GSM1397810, 11, 12 
 
MCF7 
Control siRNA 
Vehicle for 4h 
(Blackmore et al., 2014) 
GSE57935 
GSM1397813, 14, 15 
 
MCF7 
Control siRNA 
Estradiol for 4h 
GSE57935 
GSM1397822, 23, 24 
 
MCF7 
Control siRNA 
0.1% EtOh Vehicle for 24h 
GSE57935 
GSM1397825, 26, 27 
 
MCF7 
Control siRNA 
1nM Estradiol for 24h 
GSE24592 
GSM606107, 08, 09 
 
MCF7 
Control siRNA 
0.1% EtOH for 4h 
(Madak-Erdogan et al., 2011) 
GSE24592 
GSM606110, 11, 12 
 
MCF7 
Control siRNA 
10nM Estradiol for 4h 
GSE24592 
GSM606125, 26 
 
MCF7 
Control siRNA 
0.1% EtOH for 24h 
GSE24592 
GSM606127, 28 
 
MCF7 
Control siRNA 
10nM Estradiol for 24h 
GSE30931 
GSM766676, 77, 78 
 
MCF7 
Control 
No treatment 
 
(Prenzel et al., 2011) 
GSE30931 
GSM766679, 80, 81 
 
MCF7 
 
10 nM 17-estradiol for 6h 
 
GSE85971 
GSM213330, 31, 32, 33, 34 
 
MCF7 
Vehicle 
0.1% ethanol for 24h 
 (Bourdeau et al., 2007) 
GSE85971 
 
GSM213326, 27, 28, 29 
 
MCF7 
Estrogen 
25nM 17beta-estradiol for  4h 
GSE77345 
GSM2049833, 34 
 
T47D 
Control siRNA 
Vehicle 
 
(Aka, Calvo and Lin, 2017) 
GSE77345 
GSM2049835, 36 
 
T47D 
Control siRNA 
E2 treated 
 
GSE70759 
GSM1817471, 88, 93 
 
ZR751 
Vehicle 
6h 
 (Castro et al., 2016) 
GSE70759 
GSM1817479, 83 
 
ZR751 
Estrogen 
1 nM estradiol for 6h 
Table 2-6. The details of the experiments and microarray data sourced from the Gene Excession Omnibus used to identify differentially 
regulated genes for the estrogen receptor 
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GSE 
Number 
GSM Number  
(GEO Accession No.) 
Cell Line Condition detail Reference 
GSE69296 
GSM1697247, 48, 49 
 
ES-2 
Ovarian 
PR-A 
Vehicle for 24h 
(Diep, Knutson and Lange, 
2016) 
GSE69296 
GSM1697250, 51, 52 
 
ES-2 
Ovarian 
PR-A 
R5020 10e-8 M for 24h 
GSE69296 
GSM1697253, 54, 55 
 
ES-2 
Ovarian 
PR-B 
Vehicle for 24h 
GSE69296 
GSM1697256, 57, 58 
 
ES-2 
Ovarian 
PR-B 
R5020 10e-8 M for 24h 
GSE61368 
GSM1503181, 183, 194, 207 
 
ZR-75-1 
Vehicle (ethanol; 2 ppm) 
16h 
(Hagan, Knutson and 
Lange, 2013) 
GSE61368 
GSM1503184, 187, 213, 211 
 
ZR-75-1 
10nM progesterone 
16h 
GSE46850 
GSM1139149, 50, 51 
 
T47D-Y 
Wild Type PR 
Vehicle (ethanol) 6h 
GSE46850 
GSM1139152, 53, 54 
 
T47D-Y 
Wild Type PR 
R5020 10e-8 M 6h 
GSE46715 
GSM1135119, 20, 21 
 
T47D 
PRB 
Vehicle (ethanol)m 6h 
(Dressing et al., 
2014)(Madak-Erdogan et 
al., 2011) 
(Dressing et al., 2014) 
GSE46715 
GSM1135122, 23, 24 
 
T47D 
PRB 
R5020 10e-8 M 6h 
GSE67561 
GSM1649569, 73, 77 
 
T47D Vehicle 24h 
(Chen et al., 2016) 
GSE67561 
GSM1649570, 74, 78 
 
T47D R5020 10nM 24h 
GSE62257 
GSM1524167, 68, 69 
 
T47D 
Control siRNA 
Vehicle Ethanol 6h 
(Ceballos-Chávez et al., 
2015) 
(Ceballos-Chávez et al., 
2015) 
GSE62257 
GSM1524170, 71, 72 
 
T47D 
Control siRNA 
10 nM R5020 6h 
 
Table 2-7. The details of the experiments and microarray data sourced from the Gene Excession Omnibus used 
to identify differentially regulated genes for the progesterone receptor. 
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ChIP introduction 
 
Chromatin Immunoprecipitation (ChIP) is a technique used to identify links between the 
proteome and the genome. ChIP assays can provide a picture of where a particular protein 
binds to DNA within a genome or whether it localised to a particular DNA sequence at a 
particular time point. The primary stages of this technique involve: (i) stabilisation of protein-
DNA interactions via crosslinking, for example with formaldehyde or ethylene glycol bis-
(succinimidyl succinate) (EGS). This allows the examination of unstable or transient protein-
DNA interactions. (ii) cell lysis and differential centrifugation to isolate nuclear contents. (iii) 
fragmentation of isolated nuclear material via enzymatic digestion or shearing. (iv) 
immunoprecipitation using an antibody specific to the target protein isolates the DNA-protein 
complex of interest, which can then be affinity purified. (v) DNA-protein complexes are 
disrupted by reversal of cross-linking using proteinase K or extreme heating, allowing 
isolation of the DNA fragments. (vi) Finally, sequencing of the DNA fragments is used to 
identify all the regions within the genome that the target protein was bound to (Walker, 2009) 
(Wold and Myers, 2008).  
 
 
ChIPseq data analysis 
 
ChIP-Seq data was sourced from the NCBI database, through which SRR files were located 
and downloaded for analysis. Analysis of these ChIP-Seq files was undertaken using 
bowtie2-2.2.9. Bowtie is a short-read aligner that aligns short ChIP-Seq sequence reads to a 
reference genome, in this case the human genome. This tool allows mapping of ChIP-Seq 
sequence reads to the human genome.  
 
Using Python programming language, the output files from bowtie2-2.2.9 were analysed 
using the MACS-1.4.2 tool. MACS stands for Model-based Analysis of ChIP-Seq data and is 
a tool to predict protein-DNA interaction sites from ChIP-seq (Zhang et al., 2008). ChIP-Seq 
experiments isolate regions of the genome enriched for a particular protein of interest. MACS 
is a means to identify these enriched regions in a process called peak finding.  The ChIP-Seq 
data files used are detailed in the supplementary material (Appendix 2). 
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Those genes differentially expressed following treatment of breast cancer cell lines with ER 
or PR ligands, identified by microarray, and identified as having PR/ER protein binding by 
ChIP-Seq experiments were classed as primary target genes. For all primary target genes, as 
search was undertaken to identify whether the encoded proteins were included in Recon 2, 
using the search function on the virtual metabolic human website (Thiele et al., 2013). For 
incorporation of estrogen and progesterone signalling into the model, Petri-Net formalism is 
used via the program Snoopy. 
 
Petri nets (PN) are a tool used to model concurrent systems using bipartite graphs. Although 
different methods for the representation of molecular interactions within a cell have been 
developed in recent years, the current standard in computational modelling utilises bipartite 
graphs. Bipartite graphs define two vertices, such as different types of molecular species; 
groups 1 and 2, and rules exist within the graph that mean there are no edges or interactions 
within a group, only between members of groups 1 and 2 (Asratian et al., 1998). Petri net 
theory was first described by Carl Petri in 1962 (Petri, 1962; Brauer and Reisig, 2009) and 
has been used subsequently in the modelling of biological systems, largely in quantitative 
models (Hofestädt and Thelen, 1998). Molecular networks can be converted to petri net 
representations through abstraction. Petri nets are composed of places, transitions and tokens. 
Places represent a particular resource or species, transitions are actions that consume or 
produce a particular resource and tokens denote the amount of a particular resource. Arcs link 
places and transitions and transitions are fed by input places and feed output places as shown 
in Figure 1-14. When all tokens have been transferred from the input place, the transition can 
no longer fire. The movement of tokens represent flux through a particular reaction and their 
distribution can provide information on the status of a system, (Heiner et al., 2004). 
 
We use PN here to explore the signalling and regulatory network for several reasons. PN 
formalism can bring together different modelling techniques such as stochastic or continuous 
(Heiner, Gilbert and Donaldson, 2008). PNs allow the representation of different levels of 
detail within one coherent model (Marwan et al., 2011), aiding the sound connection of 
different modelling elements. In addition, tools exist to enable the direct execution of PN 
models, such as Snoopy (Heiner et al., 2012). Snoopy is used here as a tool to design and 
simulate direct signalling of ER and PR as activated nuclear receptors binding to DNA and 
altering expression of target genes represented as an extended Petri net. PNs built within 
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Snoopy are saved as specific file formats, .spept for extended PNs, but also allows the import 
of SBML files.  
 
PNs are comprised of the net classes: nodes, arcs and timed transitions. The nodes are places 
or transitions, which are connected by arcs. These are shown in Figure 1-14. Two types of 
nodes exist: places and transitions places generally represent a particular resource or species, 
transitions are actions that consume or produce a particular resource, such as chemical 
reactions. Arcs link places and transitions and transitions to one another, but cannot link two 
places nor two transitions. Arcs can be weighted with specific numbers if reaction 
stoichiometries are known quantitatively or estimated qualitatively. A place can be marked 
with tokens, which can denote the amount of a particular resource available to the system. 
The movement of tokens represent flux through a particular reaction and their distribution 
can provide information on the status of a system (Heiner, Koch and Will, 2004). 
 
Once genes were selected for inclusion into the model, the ER and PR signalling were 
incorporated to the model. This was achieved in two main stages to include indirect and 
direct targeting.  
 
Indirect signalling   
 
The indirect signalling of ER and PR illustrated in Figure 2-7 was included directly into the 
GSMN. The general pathways of ER and PR signalling were obtained from Reactome, a 
curated pathway knowledge base (Fabregat et al., 2018), (Croft et al., 2014). This 
information was used to write linear reactions using MuFINS formalism which is detailed in 
section 1.14.4.7 in the introduction (Wu et al., 2016). The set of reactions written is included 
in the supplementary material (Appendix 4) and was incorporated directly into the tailored 
GSMN. 
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Figure 2-7. Representation of indirect signalling for estrogen receptor. The diagram represents the path from the 
receptor to transcription factor and gene. This pathway was written as a set of linear equations. (ATP = 
Adenosine Triphosphate, ADP = Adenosine Diphosphate, SOS = Son of Sevenless, Akt = Protein Kinase B, Src 
= Src homology 2 domain-containing, CAM = Calmodulin, eNOS = Nitric oxide syntgase, PKA = Protein 
Kinas A, MEK = Mitogen-activated protein kinase kinase, JNK = c-Jun N-terminal kinases, ERK1/2 = proline-
directed kinases, Nup155 = Nuclear Pore Complex, Acyp1 = Acylphosphatase 1, Ppif = Peptidyl-prolyl cis-trans 
isomerase, Atad2 = ATPase Family AAA Domain Containing 2, Mcm4 = Minichromosome Maintenance 
Complex Component 4, Abca1 = ATP-binding cassette, Creb1 = CAMP responsive element binding protein 1, 
SP1 = Sp/KLF transcription factor , Stat1 = Signal transducer and activator of transcription 1). 
 
 
 
Direct signalling (Activated ER and PR binding to DNA)  
 
Direct ER and PR signalling refers to activated nuclear receptors binding to the DNA and 
resulting in alterations to the expression of target genes. This was modelled using the Petri-
net modelling program, Snoopy.  
 
ER and PR have an influence over a number of target genes, both as primary targets of 
ER/PR signally and secondary targets that are altered in response to the effects of the proteins 
Chapter 3 
 
154 
encoded by the primary targets. In order to meaningfully include this receptor signalling into 
the model, it was critical to identify target genes for each receptor, and whether they were 
primary or secondary targets. This was achieved by examining microarray and ChIP-seq data 
for breast cancer cell lines treated with estradiol or progesterone. The methodology for this is 
detailed below in ‘Identification of ER/PR target genes via microarray analysis’. 
 
Once a list of differentially expressed genes in response to estradiol or progesterone treatment 
were identified, these were incorporated into Snoopy as shown below. 
 
First the activation of ER and PR were modelled. Figure 2-8 shows the interaction of ER with 
its ligand estradiol and PR with its ligand progesterone resulting in active ER and PR. The 
nuclear receptors and their ligands are represented as places, white circles, see Figure 1-14 
for details of Petri-net elements and their graphical representations. The activation and 
deactivation of ER and PR are represented as transitions, white squares. Active ER and PR 
are shown as places, grey circles. The nodes are connected by arcs between places and 
transitions.  
 
Figure 2-8: Screenshot from Petri net model built in Snoopy. Activation of ER and PR via interaction with their 
ligands represented in a Petri-net. Circles represent nodes and include ER, estrogen and active ER (with 
estrogen bound) or PR, progesterone and active PR (with progesterone bound). Squares represent transitions, 
ER and PR activation and deactivation.  
 
The nuclear receptors act as transcription factors causing differential regulation of target 
genes. Figure 2-9 shows PR_target_gene_activated is modelled as activating target mRNA, 
yellow and then green places, connected by two transitions. The first transition represents 
basal transcription, which occurs without activated PR. The second represents the level of 
transcription that occurs when PR is activated by progesterone. This transition is informed by 
PR_act, via a read arc that connects PR_act and PRtarget_transcription_PR. On the right-
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hand side of Figure 2-9, the genes inhibited by active PR are modelled. This is achieved in 
the same way for ER signalling.  
 
Figure 2-9: Screenshot from Petri net model built in Snoopy. Nodes representing active PR transcription factor, 
which via transitions activates gene (yellow circle) and subsequently mRNA (green circle) expression. 
 
There are two transitions representing the transcription of PR_target_gene_activated to 
PR_target_mRNA_activated, shown in Figure 2-10. The first PRtarget_transcription_basal, 
represents the level of transcription with no active PR and has a rate of 0.1926. The second, 
PRtarget_transcription_PR, represents transcription with active PR, with a rate of 12. 
 
Where available, the parameters for these rates were determined from the literature. For 
example, basal transcription rate for target genes in the absence of PR/ER signalling 
(Metivier et al, 2003). 
 
Remaining parameters were fitted to the known biological behaviour of the system so the 
system reproduced basal and ER/PR-activated levels of target gene mRNA in the correct time 
window. When examining microarray data, of the genes upregulated in the presence of 
progesterone, the fold changes when compared with expression levels in the absence of 
progesterone range from 1-4 fold and for ER the difference was 1-2 fold. Therefore, the rates 
shown in Figure 2-10 were selected to generate an output for the average increase or decrease 
in gene expression across the genes up or down regulated in the presence of estrogen or 
progesterone. Whilst doing this, care was taken to maintain these parameters within 
biologically realistic bounds. Using these specifications, the model corresponds to the most 
realistic possible scenario considering the current state of knowledge.  
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Figure 2-10. Properties of two transitions defined in Snoopy. PRtarget_transcritpion_PR has a RATE 12 to 
reflect increased transcription caused by active PR compared to PRtarget_transcription_basal with RATE 
0.1926. 
 
The inhibited and activated PR mRNA (PR_target_mRNA_inhibited and 
PR_target_mRNA_activated) is then linked in the PN to proteins down or upregulated by PR. 
Figure 2-11 shows the activated or inhibited PR mRNA is linked to target proteins.  
 
 
 
Figure 2-11. Petri net modelled path from active PR to activated or inhibited target mRNA, which then 
activates or inhibits the expression of target proteins. 
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Proteins associated with reversible reactions are modelled with two separate nodes, 
representing the association with reactions in the forward and reverse directions. Figure 2-12 
shows a screenshot of an example of proteins upregulated by PR. B) shows the properties of 
the ATP1A1 place representing ATP1A1 upregulated by PR signalling. The protein is linked 
back to the reactions it is involved in, with the recon2 reaction ID (R_NaKt) written below 
LIST 1. ACTIVITY 10 represents an activity look up table with 10 steps, which constrain the 
quasi steady state flux. The first column represents the concentation, the middle is the lower 
bounds for the reaction flux and the third the upper flux. As ATP1A1 is only associated with 
unidirectional reactions in Recon2, the bounds are set from 0 to a positive flux. The maximal 
flux through the reaction represents the potential upregulation of protein levels resulting from 
PR signalling. ACOT6 is an example of a protein associated with both unidirectional and 
bidirectional reactions in Recon 2. Figure 2-12 C shows properties of the ACOT6 place 
representing ACOT6 upregulated by PR signalling. The protein is linked back to the 
reactions it is involved in, with the Recon2 reaction IDs written below LIST 2. This 
represents only the unidirectional reactions ACOT6 influences within recon2. Figure 2-12 D, 
window showing properties of the ACOT6r place representing ACOT6 upregulated by PR 
signalling. The protein is linked back to the reactions it is involved in, with the Recon 2 
reaction IDs written below LIST 2. 
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Figure 2-12. Example from PN model in Snoopy representing PR upregulated proteins.  
A) Graphical nodes build in Snoopy., B) Window showing properties of the ATP1A1 place representing 
ATP1A1 upregulated by PR signalling. The protein is linked back to the reactions it is involved in, with the 
recon2 reaction ID (R_NaKt) written below LIST 1. ACTIVITY 10 represents an activity look up table with 10 
steps, which constrain the quasi steady state flux. The first column represents the concentation, the middle is the 
lower bounds for the reaction flux and the third the upper flux. As ATP1A1 is only associated with 
unidirectional reactions in Recon2, the bounds are set from 0 to a positive flux. The maximal flux through the 
reaction represents the potential upregulation of protein levels resulting from PR signalling. C) Window 
showing properties of the ACOT6 place representing ACOT6 upregulated by PR signalling. The protein is 
linked back to the reactions it is involved in, with the recon2 reaction IDs written below LIST 2. This represents 
only the unidirectional reactions ACOT6 influences within recon2. D) Window showing properties of the 
ACOT6r place representing ACOT6 upregulated by PR signalling. The protein is linked back to the reactions it 
is involved in, with the recon2 reaction IDs written below LIST 2. 
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 The Cell cycle model  
 
The cell cycle component of the full reconstruction was built directly in Petri net formalism 
using the Snoopy graphical interface. The model was a translation of Tyson and Novak’s 
model of the cell cycle encoded in SBML and available from Biomodels 
(https://www.ebi.ac.uk/biomodels-main/BIOMD0000000195) as BIOMD0000000195 - 
Tyson2001_Cell_Cycle_Regulation (Tyson and Novak, 2001). The model is a mathematical 
ordinary differential equation (ODEs) model of the cell cycle; specifically, the eukaryotic cell 
cycle in budding yeast. It is not a full reconstruction of the cell cycle, but uses twenty ODEs 
to represent synthesis, degradation and activation reactions written so as to encompass the 
molecular antagonism and hysteresis required for cell cycling.  
 
The method of translating this model to an extended Petri net formalism using the QSSPN 
algorithm was an iterative process: the model was reconstructed in PN formalism and then 
simulations undertaken until the simulated cell cycle output matched that obtained when 
directly running Tyson and Novak’s model as published in 2001. For validation, the sbml 
version of the original model available from: https://www.ebi.ac.uk/biomodels-main 
/BIOMD0000000195 was run directly through COPASI and this output compared to the 
published output and the output from the QSSPN reconstruction. 
 
Each ODE from the Tyson and Novak model was examined in turn and the relevant nodes 
created in Snoopy. An example of this process is shown in Figure 2-13. The reaction as 
written in the Tyson and Novak model is studied and initially the key species are created as 
places, they key reactions are created as transitions and linked with a type of arc. Figure 2-13 
shows the stages of this, where B. provides the kinetic parameters for the synthesis of CycBt 
from Tyson and Novak’s model, C. shows this simple reaction recreated in Snoopy, with 
CycBt as a place and its synthesis reaction as a transition, with an arc connecting the two, and 
A. The comment for the transition in Snoopy contains the rate constant for this reaction, 
which matches the rate constant provided in the Tyson paper (Tyson and Novak, 2001). The 
table of rate constants are included in the supplementary material (Appendix 5). 
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Figure 2-13. The equation of CycBt synthesis incorporated into the petri net model in Snoopy.   
This is an example of the method used to incorporate the cell cycle equations as written by Tyson et al (Tyson and Novak, 2001) into the 
dynamic petri net model. B. represents the equation as taken from the Tyson paper, C. shows the equation built from nodes and transitions in 
the petri net and A. shows the properties of the transition (square), with RATE 0.04 representing the rate constant as given in the Tyson 
paper.  
 
 
Figure 2-14 shows a more complex example; the degradation of CycBt via Cdc20a. As with 
Figure 2-13, B. presents the kinetic parameters from Tyson and Novak’s model, C. is the 
reaction recreated in Snoopy, with two places (CycBt and Cdc20a) and two transitions 
(CycBt synthesis and degradation). Cdc20a is required for the degradation of CycBt, but its 
levels are not changed by the reaction (i.e. it is an activator); to reflect this, Cdc20a is 
connected to the CycBt degradation transition via a read arc. Finally, A. presents the 
properties of the degradation transition, taken from the rate constant provided in the Tyson 
paper (Tyson and Novak, 2001). 
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Figure 2-14. The equation of CycBt degradation via Cdc20a incorporated into the petri net model in Snoopy. 
This is an example of the method used to incorporate the cell cycle equations as written by Tyson et al (Tyson 
and Novak, 2001) into the dynamic petri net model. B. represents the equation as taken from the Tyson paper, 
C. shows the equation built from nodes and transitions in the petri net and A. shows the properties of the 
transition (square), with RATE 1 representing the rate constant as given in the Tyson paper. The table of rate 
constants are included in the supplementary material (Appendix 5). 
 
 
In isolation, these transitions appear uncomplicated, however, in this instance alone there are 
further places required to accurately model CycBt synthesis. For example, the levels of 
Cdc20 are controlled by the rate of its activation and degradation and whether it is inhibited. 
Cdc20 activation is dependent upon the levels of a molecule IEP and Cdc20 inhibition is 
controlled by the levels of another species; Mad. This is shown in Figure 2-15. 
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Figure 2-15. Cdc20 activation reconstructed from Tyson's model into a petri net model. A. shows a table from 
Tyson and Novak’s model published in 2001. A shows a sample table from the paper’s supplementary material. 
It includes the reaction through which Cdc20t is formed in the model. Modifiers refer to species within the 
reaction that alter Cdc20a, either increasing or decreasing the rate of production. B shows the reconstruction of 
this reaction within a Petri net model. Cdc20a is represented as a node and its activation as a transition. IEP (a 
modifier) is represented as a node linked to the Cdc20a activation transition.  
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Within the QSSPN control file (supplementary material, Appendix 6), the initial conditions 
for each species is assigned. These conditions were taken directly from the Tyson and Novak 
model. 
 
The cell cycle component is linked to the GSMN as a modifier of biomass shown in  
Figure 2-16, the objective function. Additionally, it has protein levels altered through the 
ER/PR gene and signalling regulatory network as an input.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-16. Biomass reaction from Recon 2 (Thiele and Palsson, 2010). The biomass reaction in Recon 2 
accounts for the macromolecular synthesis requirement of a cell for: DNA, RNA, protein, lipids and 
carbohydrates. The reaction was written assuming cellular composition of: protein 70.6%, DNA 1.4%, RNA 
5.8%, carbohydrates 7.1%, lipids 9.7%, others 5.4% and in addition vitamins, ions, cofactors. The carbohydrate 
fuel of choice was assumed to be Glucose-6-Phosphate. The cellular weight was assumed as 500x10-12 g per 
cell. The fractional contribution of each amino acid was assumed to be L-alanine 7.6%, Larginine 5.4%, L-
asparagine 4.2%, L-aspartate 5.3%, L-cysteine 0.7%, L-glutamine 4.9%, L-glutamate 5.8%, L-glycine 8.1%, L-
histidine 1.9%, L-isoleucine 4.3%, Lleucine 8.2%, L-lysine 8.9%, L-methionine 2.3%, L-phenylalanine 3.9%, 
L-proline 6.2%, L-serine 5.9%, L-threonine 4.7%, L-tryptophan 0.2%, L-tyrosine 2.4%, and valine 5.3%. The 
fraction contribution of each nucleotide triphosphate to RNA was assumed to be ATP 29.4%, CTP 21.4%, GTP 
19.8%, and UPT 29.3%. The fractional contribution of each deoxynucleotide triphosphate to DNA was assumed 
to be dATP 28.9%, dCTP 20.7%, dGTP 21.7%, and dTTP 28.7%. The data for lipid contribution was obtained 
from (Sheikh et al., 2005): cholestorol 7%, cardiolipin 4%, phosphatidylinositol 8%, phosphatidylcholine 53%, 
phosphatidylethanolamine 19%, phosphatidylglycerol 1%, sphingomyelin 6%, and phosphatidylserine 2%. The 
following energy requirements for translational processes were assumed: 4 ATP per peptidyl bond and an 
average protein length of 333 amino acids. This biomass reaction is a coarse-grained approximation of 
metabolic precursors required and was tailored for lymphocytes when data was available (Thiele and Palsson, 
2010). 
 
 
 
 
 
 
 
0.505626 M_ala_L_c + 0.35926 M_arg_L_c + 0.279425 M_asn_L_c + 0.352607 
M_asp_L_c + 20.704451 M_atp_c + 0.020401 M_chsterol_c + 0.011658 M_clpn_hs_c + 
0.039036 M_ctp_c + 0.046571 M_cys_L_c + 0.013183 M_datp_n + 0.009442 M_dctp_n + 
0.009898 M_dgtp_n + 0.013091 M_dttp_n + 0.275194 M_g6p_c + 0.325996 M_gln_L_c + 
0.385872 M_glu_L_c + 0.538891 M_gly_c + 0.036117 M_gtp_c + 20.650823 M_h2o_c + 
0.126406 M_his_L_c + 0.286078 M_ile_L_c + 0.545544 M_leu_L_c + 0.592114 
M_lys_L_c + 0.153018 M_met_L_c + 0.023315 M_pail_hs_c + 0.154463 M_pchol_hs_c + 
0.055374 M_pe_hs_c + 0.002914 M_pglyc_hs_c + 0.259466 M_phe_L_c + 0.412484 
M_pro_L_c + 0.005829 M_ps_hs_c + 0.392525 M_ser_L_c + 0.017486 M_sphmyln_hs_c 
+ 0.31269 M_thr_L_c + 0.013306 M_trp_L_c + 0.159671 M_tyr_L_c + 0.053446 
M_utp_c + 0.352607 M_val_L_c = 20.650823 M_adp_c + 20.650823 M_h_c + 20.650823 
M_pi_c 
Chapter 3 
 
164 
 
 
For those reactions with more complicated rates or kinetics, the full ODE is incorporated into 
the control file. Figure 2-17 B. shows the equation for Cdc20 inhibition as written into the 
control file.  
 
Figure 2-17. The equation for Cdc20a inhibition. For more complex transitions, the entire equations are written 
directly into the QSSPN control file. A. shows the equation for Cdc20a inhibition from Tyson’s model, which 
represents the inhibition of Cdc20a through a reaction that required the modifier ‘Mad’ to occur. B. shows this 
equation written into the QSSPN control file.  
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Notably, the original Tyson model does not only contain simple ODEs representing mass 
action and Michaelis-Menten kinetics. In addition to this, there are more complex ODEs 
including the Goldbeter-Koshland kinetics (Goldbeter and Koshland, 1981) to describe total 
Cdh1 concentration, the equation is shown in Figure 2-18. These are much more difficult to 
represent using Petri net formalism, therefore these equations were broken down into several 
smaller steps, which were then optimised to reach the same outcome.  
 
 
Figure 2-18. Goldbeter Koshland Function forms part of the Tyson model of the cell cycle used to describe the 
total concentration of Cdh1 in the model. Goldbeter Koshland kinetics allows Cdh1 production to be modelled 
as a zero-order-ultra-sensitive switch (Goldbeter and Koshland, 1981). 
 
Goldbeter-Koshland kinetics are used to describe a steady state solution for a biological 
system with two states. The conversion between the two states it described is performed by 
enzymes with opposing effects (kinase and phosphatase), such with phosphorylation and 
dephosphorylation. The use of this equation allows Cdh1 in the model to act as a ‘zero-order 
ultra-sensitive switch’, which occurs when the aforementioned enzymes are present together 
and the protein substrate concetration is far higher than the Km of the enzyme. This 
behaviour of Cdh1 is important to the characteristic of hysteresis in the model, which refers 
to the dependence of the model on previous effects (Goldbeter and Koshland, 1981).  
 
The full petri net reconstruction of the cell cycle model is shown in Figure 2-19. The 
corresponding QSSPN control file can be seen in the supplementary materials (Appendix 6). 
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Figure 2-19. Full Petri net reconstruction of the Tyson and Novak model of the cell cycle.  
The full QSSPN control file is included in the supplementary materials (Appendix 6).  
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 Constraining the GSMN 
As discussed in section 1.14.4.1, it is necessary to reduce the solution space for CBM in order 
to generate biologically meaningful predictions. This is usually achieved through the 
introduction of constraints to the system, which limit aspects of the model and thus reduce 
the solution space. One of the simplest constraints is the objective function, which was set to 
biomass within this thesis as a common trait of cancer cells is to proliferate. In addition, the 
reconstruction was further constrained through the available exchange reactions for the 
GSMN and the overlay of transcriptomic data to ‘personalise’ the models to target breast 
cancer cell lines. 
 
 Exchange reactions 
Exchange reactions are those that represent the transfer of molecules between the cell and the 
extracellular space. As CBM relies on the assumption of a steady-state these reactions are 
important as they balance production/consumption of metabolites within the cell with 
metabolite influx/efflux such that the net gain is zero.  
 
Initially, Recon2 has the bounds for all exchange reactions set as fully open LB/UB:-
1000/1000). As the reconstruction is designed to reproduce cell line behavoiurs, the exchange 
reactions were first constrained to represent the transfer of only those metabolites present in 
cell culture medium. Where a metabolite is present in medium, the bounds of relevant exchange 
reaction is left at -1, 1000, representing limited uptake but unlimited production flux; otherwise 
the reaction is closed with bounds set to 0,0. This is shown in Figure 2-20, and the full exchange 
set constrained to represent specific cell line medium is shown in section 4.2. 
 
Setting consumption fluxes to -1 is highly conservative as it represents a rate of metabolite 
uptake that is unlikely to be reached in vitro. As such, it allows all possible molecular 
requirements to be met from the medium exchange set. A more realistic scenario would be to 
constrain the uptake and efflux fluxes to biologically realistic values. This was achieved 
using experimentally derived flux values from two sources. The first is from de novo 
generated experimental data from this project, specifically for the molecules glucose, 
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glutamate and lactate as detailed in 4.3.5.1. The second was from a database of consumption 
and release data (CORE) generated by Jain et al in 2012. The group generated the database 
using liquid chromatography-tandem mass spectrometry (LC-MSMS) to generate CORE data 
for 140 metabolites across sixty primary human cancer cell lines (Jain et al., 2012). This data 
is available from https://dtp.cancer.gov/databases_tools/data_search.htm. The sixty cell lines 
are part of the National Cancer Institute database and which includes of key interest to this 
model, MCF-7 and MDA-MB-231 breast cancer lines (Shoemaker, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-20: Illustration of how bounds of exchange reactions in GSMN are constrained using program Jymet. 
a) This is the unconstrained GSMN with the bounds of all reactions fully open. b) The first stage is to close the 
bounds for any exchange reaction where the given molecule is not available to the cells. c) Bounds were 
changed from -1000/1000 to 0/0. For those reactions whose bounds remain open, if the exchange reaction is 
reversible the bounds were left as -1000/1000 and irreversible reactions were changed to either -1000/0 or 
0/1000 depending on the directionality. d) The final constraint added to individual reactions is then the rate 
taken from the CORE measurements of the NCI60 data. This was completed for all exchange reactions that 
involved metabolites included in the NCI60 dataset. For those exchange reactions where metabolites are present 
in the medium but for which there was no CORE data available, the flux was constrained to a level in the same 
range as other exchange reactions; -1/1 as opposed to -1000/1000. Following this, the bounds were reduced as 
low as possible before the rate of biomass production was affected. This was achieved through an iterative 
process of changing bounds and testing.  
a b 
c d 
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 Overlay microarray data 
 
In addition to constraining the bounds for the exchange reactions, the congruency approach 
was employed to integrate ~omics data with Recon2. Briefly, the congruency approach 
predicts a flux distribution for a GSMN using an expression dataset as the objective function. 
Fluxes through reactions mapped to proteins marked as absent in the omics dataset are 
minimized, based on the assumption that if no mRNA/protein is present then these reactions 
should not occur. The output therefore creates a scenario specific version of the GSMN, in 
this case representing specific breast cancer cell lines. It should be noted that all reactions 
encoded in the GSMN are used for optimization. In this project, both metabolism and 
transport (from Recon2) and ER non-genomic signaling (hard coded in the project) are 
optmised. This is a distinct advantage of coding the regulatory network into the GSMN as it 
allows a more refined context-specific GSMN to be created.   
 
Creation of context-specific GSMNs can be achieved using several different approaches; 
here, the Integrative Metabolic Analysis Tool (iMAT), and its derivative fastiMAT are 
utilised through the MuFINS program. The tool is based on a method developed by Shlomi et 
al. (Shlomi et al., 2008; Zur et al., 2010) 
  
Before gene expression data is overlain onto the GSMN, it is necessary to decide which 
transcripts are expressed (present) and which are not expressed (absent). Rather than an 
arbitrary threshold, this project uses the A/P calls from the initial analysis of arrays. This data 
is then collated into a tab delimited table such as in Figure 2-21. Tab delimited table 
produced from iMAT analysis of microarray data, showing whether transcripts are expressed 
‘1’, or not expressed ‘-1’. This method was initially formulated to generate ‘tissue-specific 
models’, the columns are labelled as ‘Tissue*’ in the JyMet interface. Columns are tab-
delimited, with ‘NA’ denoting an empty value. 
 
iMAT enables the integration of genomic data with a GSMN presented in SBML format. 
Once integrated, the tool allows metabolic flux to be explored in a range of conditions. The 
output of iMAT is flux state for each individual reaction, which, where possible is presented 
as active or inactive and corresponding confidence levels. For some reactions, the number of 
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alternative flux pathways with similar overall outputs through the network are too great to 
predict a unique activity state for a particular reaction.  
The final output incorporates confidence values and activity flux for particular genes and can 
be exported as a .sfba file for use within the model as a whole. An example script for the 
iMAT workflow is provided in the supplementary materials (Appendix 7).  
 
 
 
 
 
 
 
  
Figure 2-21. Tab delimited table produced from iMAT analysis of microarray data, showing whether transcripts 
are expressed ‘1’, or not expressed ‘-1’. This method was initially formulated to generate ‘tissue-specific 
models’, the columns are labelled as ‘Tissue*’ in the JyMet interface. Columns are tab-delimited, with ‘NA’ 
denoting an empty value.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
Gene        Tissue1    Tissue2 
g1         1             1 
g2         1            -1 
g3        -1             1 
… 
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 Generate predictions of potential drug targets 
 Gene Essentiality Scan 
 
For the identification of potential drug targets within the network described above, a scan of 
essential reactions was carried out through MuFINS. This works by constraining the flux of 
each reaction in turn to 0, one at a time, and observing the effect on the maximal value 
achieved for a given objective function. Any reactions whose constraint to 0 results in a value 
of 0 for the objective function are said to be essential. The objective function selected for this 
simulation is the biomass reaction as detailed in Figure 2-16. 
 
The output of the essential reactions scan is a list of essential reactions. The list of reactions 
was further refined in a number of ways to generate two key reactions for exploration in 
vitro. The essential reactions analysis was carried out for three different models specifically 
representing MCF-7, MDA-MB-231 and MCF-10A cells. The selection process firstly 
involved a comparison of the list of essential reactions between these models. Those 
reactions that were essential in MCF-7 and MDA-MB-231 cells and not essential in MCF-
10A cells were selected. MCF-10A cells represent normal breast cells, thus perturbations to 
those reactions essential in the cancer cell lines and not in a non-cancerous cell line have a 
higher likelihood of specifically targeting or preferentially affecting the cancer cell lines. This 
has the benefit of fewer off target effects and toxicities.  
 
The list of reactions was further refined by examining those that could be blocked with a 
pharmacological inhibitor. The two most common ways of perturbing a reaction in vitro or in 
vivo are via a pharmacological inhibitor or by using short interfering RNA (siRNA). Two 
benefits of a pharmacological inhibitor are that it is easier to optimise cell survival assays and 
therefore generate data to validate model predictions, especially considering time constraints 
of the project. Furthermore, utilisation of a pre-existing pharmacological inhibitor allows the 
exploration of the concept of drug repositioning. This has the advantage that the drug likely 
has already been subject to clinical trials and is safe for treatment. 
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3 Examination of the effect of metabolism 
modulating drugs in combination with 
chemotherapeutic agents in vitro 
 
 
 
3.1 Summary 
 
The majority of cancers are treated with a combination of surgery and/or radiotherapy, 
followed by a combination of chemotherapeutic agents. This allows both the point treatment 
of identified tumours and a systemic treatment to target residual/unidentified tumour tissue. 
For a full review of treatment paradigms, see introduction section 1.8. This chapter focusses 
on the concept of combination therapies; specifically, the combination of cancer 
chemotherapeutic agents with other drugs.  
 
The heterogeneity of breast cancer is now widely characterised, both the level of the 
individual (i.e. different people have tumours with different molecular signatures, and any 
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individual may possess multiple tumours with different molecular signatures) and the tumour 
(i.e. within a single tumour, there are cells with different molecular signatures). This 
heterogeneity is thought to be a key reason why a number of cancers, including breast, 
remain unresponsive to conventional chemotherapeutic treatments (Henry et al., 2016). In 
essence, each tumour, or sub-section of a tumour, may be seen as an individual entity for 
which there is an optimal treatment regimen. To achieve effective treatment of an 
individual’s cancer, it is necessary to design a treatment regimen that will be effective against 
all these sub-types of tumour.  
 
 
A central paradigm in drug development is that drugs are designed to target particular 
molecular features. On this basis and given the known intra-individual heterogeneity of breast 
cancer it is unlikely that any single drug will be fully effective. This has motivated the 
development of combination therapies, using multiple drugs together to increase the efficacy 
against all cancer cell types within an individual. The utilisation of drug combinations for the 
more effective treatment of cancer has long been ulitised as a means for improving treatment 
outcomes (DeVita et al., 1975).  
 
In this chapter, the efficacy of combinations containing classic cancer chemotherapeutics 
(tamoxifen, doxorubicin, cisplatin) and GW4064, an FXR ligand and metabolic disrupter, as 
a cancer chemotherapeutic will be explored.  
 
Combination therapies, their justification and design as well as the concept of synergy are all 
explored in detail in section 1.14. Below these concepts are briefly mentioned to 
contextualise the methods and results of this chapter. 
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3.2 Justification for combination therapies 
 
 Reduction in the potential for drug resistance  
 
Resistance to chemotherapeutic agents is a long-standing phenomenon, with clear references 
back to the 1950s, and the first mechanisms underpinning resistance elucidated by the early 
1960s (Brockman, 1963). However, despite this early characterisation the issue of resistance 
has continued to limit efficacy of anti-cancer treatments to the present day, where it still 
causes significant clinical issues. Resistance can be seen as intrinsic (i.e. an initial feature of 
the tumour) or acquired (i.e. exposure of cancer cells to a drug causes them to become 
resistant to this drug (Housman et al., 2014). Acquired drug resistance in breast cancer is 
explored in full detail in the introduction section 1.9. Briefly, resistance occurs due to the 
presence of salvage pathways that allow the cell to maintain its processes critical for survival 
and proliferation by circumventing the pathway blocked by the individual drug (Khdair et al., 
2010).  A common issue with chemotherapeutics is that they fail to target cancer stem cells 
(CSCs), meaning these cells often persist during treatment and possess the potential for new 
tumour growth. Combination therapies can be designed to include an agent that targets the 
CSCs directly (Takebe et al., 2015). 
 
One obvious solution to the challenge of drug resistance was the development of effective 
combination therapies, on the basis that using multiple drugs reduces the risk of a tumour cell 
being resistant to all of them. In a number of cancers including breast cancer, combination 
therapy now represents a cornerstone of cancer therapy. A particular issue is the emergence 
of multidrug resistance, where a tumour becomes resistant to two or more agents vastly 
reducing treatment options, and is usually associated with poor patient prognosis (Gottesman, 
2002). However, whilst multidrug resistance can occur, a tumour is more likely to develop 
resistance to monotherapy treatment (Bayat Mokhtari et al., 2017). On this basis, there is still 
an active pursuit of novel combination therapies, which should increase the probability of 
survival for cancer patients.  
 
 
Chapter 3 
 
175 
 Increase in efficacy through synergistic drug interactions 
 
Clinically, drug combinations are often used as a means to decrease toxic liability while 
maintaining efficacy, rather than to directly increase efficacy. The reason for this is that 
utilising a synergistic drug combination will mean that lower concentrations of each 
individual drug can be administered whilst maintaining the same potency and efficacy. At 
these lowered concentrations, the primary benefit is to reduce toxic liability of a treatment to 
a patient. Any drug will have a toxic liability associated with its use, most commonly due to 
over-activity at the target receptor (e.g. digoxin), off-target activity (e.g. terfenadine), or the 
formation of toxic adducts (e.g. paracetamol). Partridge et al explored side effects 
experienced by women with early-stage breast cancer finding short-term effects to include 
myalgia, thromboembolism, alopecia, nausea and emesis. Potential long-term effects suffered 
included cardiac dysfunction, premature menopause, and an increased likelihood of the 
development of leukaemia and myelodysplastic syndrome (Partridge, Burstein and Winer, 
2001).  The use of drugs in combination does not remove the potential for toxicity, but it can 
reduce the risk of toxicity occurring at a clinically effective dose of the combined agents 
(Bayat Mokhtari et al., 2017).  
 
     
3.3 Network Targeting drugs 
 
As explored in the previous section, synthetic lethality targets two (or more) biological 
entities that perform a similar function, removing resistance through biological redundancy. 
However, this concept can be extended to encompass targeting biological functions that are 
complementary but not necessarily redundant – this is the concept of network targeting drugs 
(Kolodkin et al., 2012). In general, network targeting looks to identify areas of fragility, 
where a combination of minor perturbations can radically change efficacy. An extension of 
network targeting is the concept of synthetic lethality, which looks to mitigate the inherent 
robustness of a network, this concept is detailed in section 1.14.1.2.  
 
There are a number of advantages to a network targeting approach, but also a number of 
challenges that must be overcome. 
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Advantages: 
(i) Increases the potential for repurposing drugs, as identified drug targets may not be 
those traditionally associated with cancer chemotherapy 
(ii) Potential for decreased toxic liability through targeted exploitation of drug 
synergy  
(iii) Genetic mapping of individual tumours raises the prospect of designing 
combinations specific for an individual 
 
Challenges:  
(i) A good knowledge of network biology is required to predict the emergent 
phenotype of targeting seemingly unrelated biological systems  
(ii) To robustly predict novel combinations, it is necessary to understand what 
biological targets (both on- and off-target) a drug interacts with 
 
 
 
3.4 Drugs that modulate the metabolic activity of cells  
 
As noted in the introduction, for cells to divide there is an energy cost associated with the 
production of building blocks for cell division (e.g. amino acids, nucleotides, lipids etc.).  As 
cancer is, essentially, a disease of uncontrolled cell division, there is a high energy demand to 
drive this cell division. On this basis, a network targeting approach could be to use traditional 
chemotherapeutics alongside metabolic disruptors. Reducing the energy available to a cell 
will (i) slow the rate of division, and (ii) make the cell more fragile to energy demands. 
 
Here, the potential of two metabolic disruptors (GW4064 and metformin) is explored in 
combination with traditional cancer chemotherapeutics to target breast cancer cell lines.   
 
 GW4064 
 
The mechanism of GW4064 is detailed in the introduction, section 1.11.1.The potential of a 
combination treatment using tamoxifen and GW4064 has been explored, with a synergistic 
Chapter 3 
 
177 
effect identified in breast cancer cell lines (Mohan et al.,2015)Tamoxifen has been used 
clinically for more than 30 years as a treatment for breast cancer (Jordan, 1992) but there are 
a number of issues with its use (Ring and Dowsett, 2004). These include resistance 
development during treatment with Tamoxifen, potential for disease relapse, and 
ineffectiveness of Tamoxifen treatment in breast cancers without ER (Dorssers et al., 2001; 
Shastry and Yardley, 2013). Separately, GW4064 and Tamoxifen have been shown to induce 
concentration-dependent cell death in both MCF-7 and MDA-MB-231 cells, through 
induction of ROS-mediated apoptosis (Kallio et al., 2005; Mohan et al.,2015). The pairwise 
combination of GW4064 and Tamoxifen has been shown to induce cell death in MCF-7 and 
MDA-MB-231 cell lines in a strongly synergistic manner (Mohan et al., 2015) 
 
The efficacy of a combination of GW4064 and Tamoxifen in cell lines suggests this as a 
promising alternative to Tamoxifen treatment alone and could provide therapeutic benefits in 
treating both ER-positive and ER-negative breast cancers (Mohan et al.,2015).  
 
 
 Metformin 
 
The identification of the protective effect of long-term metformin exposure against cancers 
including breast cancer, coupled with the identification of a number of putative mechanisms 
by which the drug inhibits cancer growth and stimulates apoptosis mean metformin is a 
promising novel treatment for breast cancer. This concept and the mechanism of action of 
metformin is explored in detail in section 1.11.2. However, the concentrations utilised in cell-
line experimentation are often not clinically viable. Thus, the potential for the utilisation of 
metformin in combination with conventional chemotherapeutics is explored here in MCF-7 
and MDA-MB-231 cell lines. If synergy is achieved, concentrations of both drugs can be 
lowered to achieve efficacy at clinically tractable concentrations, as well as limiting toxic 
liability. 
 
Metabolically, tumour cells differ from normal cells as detailed above and in the introduction. 
These differences, surrounding increased demand for energy, result in tumour cells having a 
higher sensitivity to metabolic disruptions such as changing energy homeostasis (Bost et al, 
2016). 
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3.5 Results and Discussion 
 
The overarching objective of this chapter was to assess the responsiveness of three breast cell 
lines to a selection of conventionally used chemotherapeutics either alone or in combination 
with the metabolism modifying agents GW4064 and metformin.  
 
The effect of these drugs on cell survival and proliferation was determined using both an 
MTT cell viability assay and a clonogenic cell survival assay. The cell lines used are MCF-7, 
an ER-positive breast cancer cell line; MDA-MB-231, a triple negative breast cancer cell 
line; and, MCF-10A, a non-transformed breast cell line. 
 
For combination studies, R-synergyfinder is used. Following examination of the three 
different methods of determining synergy, there was broadly agreement across Bliss, HSA 
and ZIP. For clarity, only ZIP output is presented.  
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 Effect of single chemotherapeutic agents on breast cancer cell 
line survival, proliferation and cell energy phenotype 
 
 Cell viability and clonogenic cell survival 
 
Figure 3-2. The effect of chemotherapeutic agents Tamoxifen (i), Cisplatin (ii) and Doxorubicin (iii) on the cell 
viability and clonogenic cell survival of MCF-7, MDA-MB-231 and MCF-10A cell lines.  Cells were exposed 
to varying concentrations of the agents for 24h. Cell viability was assayed by MTT (A) and cell survival 
determined by clonogenic assay, cells exposed to drug for 24h then removed and incubated for 14 days to form 
colonies (B). Data are relative to vehicle (≤ 1% DMSO) and are shown as mean ±SEM; n=6 for MTT and n=3 
for clonogenic assays. Ordinary one-way ANOVA with Dunnett’s test post hoc was performed to detect 
statistically significant differences between treatment conditions and vehicle denoted as * p < 0.05, ** p < 0.01, 
*** p < 0.001 and **** p < 0.0001.  
i. 
ii
. 
ii
i. 
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Across the three conventional chemotherapeutics tested, treatment with Tamoxifen had the 
greatest impact on viability in the breast cancer cell lines used as measured by MTT assay. 
 
Cell viability detected by MTT assay (Figure 3-2A) was greatly compromised by Tamoxifen 
treatment in all three cell lines tested, although the concentration-response profile for the 
three cell lines was different. MCF-10A cells showed the greatest sensitivity to lower 
concentrations of the drug. The lowest concentration tested, 1 μM Tamoxifen, caused a 
significant 21% reduction in viability of MCF-10A cells relative to DMSO vehicle (p < 
0.05), but no reduction in cell viability of MCF-7 or MDA-MB-231 cells was observed. Cell 
viability in these cell lines was not significantly compromised until Tamoxifen concentration 
was at least 10 μM (p ≤ 0.0001), resulting in a 78% and 89% reduction in viability in MCF-7 
and MDA-MB-231 cells, respectively. At the highest concentration tested in all three cell 
lines, 15 μM Tam, MDA-MB-231 cells showed the highest sensitivity; 91% reduction in cell 
viability, MCF-7 cells showed and 85% reduction and MCF-10A saw only a 52% reduction 
relative to vehicle. To determine whether the differential sensitivity between MCF-7 and 
MDA-MB-231 cells to Tamoxifen remained at higher concentrations, the concentration range 
was increased for MCF-7 and MDA-MB-231 cells up to 100μM. The observed pattern of 
MDA-MB-231 cells exhibiting higher sensitivity to Tamoxifen than MCF-7 cells continued 
at higher concentrations with the response of both cell lines across this extended 
concentration range being found to be significantly different (p < 0.01). The IC50s for MCF-
7, MDA-MB-231 and MCF-10A cells are 7μM, 5μM and 13μM respectively. Clonogenic 
assays, however, show only MDA-MB-231 cells are significantly affected by treatment with 
Tamoxifen (Figure 3-2B). These results followed the same pattern as the MTT assay, but 
with a greater sensitivity to dose. Consistent with the MTT assay, MDA-MB-231 show 
greater sensitivity to these concentrations of Tamoxifen, with 24-hour treatment with 2μM 
Tamoxifen resulting in a significant reduction to clonogenic cell survival (p=0.0151) but no 
significant effect in MCF-7 cells. All concentrations above 2μM resulted in 100% cell killing 
with no colonies forming in the experimental period (14 days).   
 
In contrast to the response to Tamoxifen, only MDA-MB-231 cell viability was significantly 
compromised in response to cisplatin. The responses of MCF-7 and MDA-MB-231 to 
treatment with cisplatin were found to be statistically significantly different (p≤0.0001). 
Overall, MCF-7 cells were sensitive to cisplatin exposure, while MDA-MB-231 cells were 
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less so. MCF-7 cell viability detected by MTT assay (Figure 3-2) was reduced by cisplatin 
treatment in a concentration-dependent manner. The lowest concentration of cisplatin to 
statistically reduce cell viability in MCF-7 cells was 20μM, with a 37% reduction relative to 
DMSO vehicle (p < 0.05). The largest effect on cell viability was detected after 24h 
treatment with 500μM Cis, resulting in an 86% reduction in viability relative to vehicle (p < 
0.0001). In contrast, none of the tested concentrations (2.5μM to 1mM) resulted in significant 
reductions in the viability of MDA-MB-231 cells; there was a trend toward reduced cell 
viability at Cisplatin concentrations greater than 600μM, but this was not statistically 
significant.  
 
Concentrations of 2.5μM and 50μM cisplatin were selected for clonogenic cell survival 
assays using MCF-7 and MDA-MB-231 cell lines (Figure 3-2B). MCF-7 cell survival 
detected by clonogenic assay followed the same pattern as the MTT assay, with a 
concentration-dependent detrimental effect on survival. In contrast to the MTT assay, MDA-
MB-231 cells show sensitivity these concentrations of cisplatin. Cell survival of MCF-7 cells 
was only significantly affected by treatment with 50μM cisplatin (p < 0.001), whereas 
treatments of 24h with both 2.5μM and 50μM cisplatin resulted in significant reductions in 
MDA-MB-231 cell survival (p < 0.05 and p < 0.01 respectively). 
 
Of the three drugs tested, doxorubicin had the least impact on viability across the cell lines as 
measured by MTT assay. Cell viability (Figure 3-2A) was not significantly affected by any of 
the doxorubicin (Dox) concentrations tested (0.3μM -20μM), relative to vehicle control. 
Concentrations of 0.1μM, 0.2μM and 1.0μM Dox were selected for detection of cell survival 
by clonogenic assay in MCF-7 and MDA-MB-231 cell lines (Figure 3-2B). In contrast to the 
MTT results, all tested concentrations of Doxorubicin resulted in significantly reduced cell 
survival. MCF-7 cells show greater sensitivity to Doxorubicin in this assay, with 0.2μM and 
1.0μM resulting in 80% and 85% reduction in cell survival compared with treatment with 
vehicle. For the same concentrations, MDA-MB-231 cells suffered only a 50% and 70% 
reduction in cell viability, respectively. Differences in response of these cell lines in MTT 
and clonogenic assays are likely observed because Doxorubicin prevents DNA replication but 
does not directly kill cells. MTT assays measure mitochondrial function, which may not be 
affected by Dox within 24 hours. In contrast, the clonogenic assay measures proliferation 
directly and over a longer time period (14 days); this time period is likely sufficient to 
observe the impact of slowed proliferation caused by Doxorubicin.  
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 Energy phenotype analysis 
 
For cisplatin and doxorubicin, further analysis of the effect of these agents on MCF-7 and 
MDA-MB-231 with regard to energy producing pathways in these cells was undertaken using 
the Energy Phenotype test (Figure 3-3). This approach simultaneously measures the two 
major energy producing pathways of the cell, mitochondrial respiration and glycolysis, under 
baseline and stressed conditions. Basal measurements of OCR (representing mitochondrial 
respiration) and ECAR (representing glycolysis) were taken for control and 25μM Cisplatin 
treated cells. MCF-7 cells under control conditions utilise a balance of glycolytic and 
mitochondrial respiration to generate energy. As shown in Figure 3-3(i)D. the net result is a 
shift toward a more energetically active cell, utilising both increased mitochondrial 
respiration and glycolysis. Following treatment with Cisplatin, there is minimal difference in 
OCR and ECAR under baseline or stressed conditions when compared with cells under 
control conditions. Figure 3-3(i)D. suggests a greater reliance on glycolysis than 
mitochondrial respiration following exposure to Cisplatin. 
 
Treatment with doxorubicin reduced the basal level of glycolysis but not mitochondrial 
respiration in MCF-7 cells compared with untreated (Figure 3-4(i)D, open symbols). 
Exposure of MCF-7 cells to doxorubicin increases the ability of the cells to respond to a 
stressor when compared with untreated cells. Figure 3-4 A and B show that in response to a 
stressor, ECAR and OCR in untreated cells remains the same, whereas in doxorubicin treated 
cells, both ECAR and OCR increase by 37% and 19%, respectively. This increase suggests 
that the cells are responding to an increased energy demand primarily by increased utilisation 
of glycolysis, and secondarily mitochondrial respiration. MDA-MB-231 cells see an increase 
in baseline activity, both ECAR and OCR increase (Figure 3-4(ii)D, open symbols) in 
response to treatment with Doxorubicin compared with cells in control condition, percentage 
increases of 100% and greater than 600%, respectively. As seen with MCF-7 cells, when 
exposed to the cell stressor mix, Doxorubicin-treated cells showed an increased utilisation of 
both mitochondrial and glycolytic pathways compared to the control. However, in this case 
the energy demand is met primarily through increased mitochondrial respiration (44% 
increase), and secondarily through glycolysis (12% increase). This is compared with an OCR 
increase of 13% for control cells and no change in ECAR. 
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Figure 3-3.  Energy phenotype test for MCF-7 (i) and MDA-MB-231 (ii) cells treated with cisplatin. The test 
measures the two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under 
baseline and stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline 
Phenotype, Stressed Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count 
in wells after assay completion. The Energy Phenotype Test was run on MCF-7 and MDA-MB-231 cells using 
the Agilent Seahorse XFp analyser. Basal measurements of OCR and ECAR are taken from each well 
representing different conditions: vehicle (V, ≤1% DMSO) or 25μM cisplatin (solubilised in DMSO at ≤1%). C 
is metabolic potential, the response of cells under different conditions to an induced energy demand. D shows 
the cell energy potential. The relative utilisation of the two energy pathways of a cell population is determined 
under both baseline (Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) 
conditions.   
MCF-7 - Cisplatin 25μM 
  
MDA-MB-231 - Cisplatin 25μM 
  
i. 
ii. 
A B 
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Figure 3-4. Energy phenotype test for MDA-MB-231 cells treated with doxorubicin. The test measures the two 
major energy producing pathways of the cell - mitochondrial respiration and glycolysis under baseline and 
stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline Phenotype, Stressed 
Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count in wells after assay 
completion. The Energy Phenotype Test was run on MCF-7 cells using the Agilent Seahorse XFp analyser. 
Basal measurements of OCR and ECAR are taken from each well representing different conditions: vehicle (V, 
≤1% DMSO) or 20μM doxorubicin (solubilised in DMSO at ≤1%). C is metabolic potential, the response of 
cells under different conditions to an induced energy demand. D shows the cell energy potential. The relative 
utilisation of the two energy pathways of a cell population is determined under both baseline (Baseline 
Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) conditions. 
MCF-7 - Doxorubicin 20μM 
  
MDA-MB-231 - Doxorubicin 20μM 
  
i. 
ii. 
Cell Energy Potential 
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 Effect of single metabolism modulating drugs on breast cancer 
cell line survival, proliferation and cell energy phenotype 
 
 Cell viability and clonogenic cell survival 
 
MCF-7, MDA-MB-231 and MCF-10A cell viability detected by MTT assay (Figure 3-13A) 
was greatly compromised by metformin treatment. MCF-10A cells showed the greatest 
sensitivity, with 5mM metformin causing a significant 59% reduction in viability of MCF-
10A cells relative to vehicle (p < 0.0001), compared to only a 10% reduction in viability of 
MDA-MB-231 cells (p < 0.05), and no reduction in cell viability of MCF-7 cells. As 
concentration increased, however, the impact on cell viability became greater for MCF-7 and 
MDA-MB-231 cells.  A maximal reduction in cell viability of 75% was observed for MCF-
10A cells, observed with all concentrations greater than 10mM metformin. In contrast, cell 
viability continued to decrease below 25% with metformin concentrations greater than 80mM 
for both MCF-7 and MDA-MB-231 cells. 
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Figure 3-5. The effect metabolism modulating drugs metformin and GW4064 on the cell viability and 
clonogenic cell survival of MCF-7, MDA-MB-231 and MCF-10A cell lines. Cells were exposed to varying 
concentrations of metformin for 24h. Cell viability was assayed by MTT and cell survival determined by 
clonogenic assay. Data are relative to vehicle (≤1% DMSO or H2O accordingly) and are shown as mean ±SEM; 
n=6. Ordinary one-way ANOVA with Dunnett’s test post hoc was performed to detect statistically significant 
differences between treatment conditions and vehicle denoted as * p < 0.05, ** p < 0.01, *** p < 0.001 and 
**** p < 0.0001.  
 
 
Concentrations of 5mM and 20mM Met were selected for detection of cell survival by 
clonogenic assay in MCF-7 and MDA-MB-231 cell lines (Figure 3-5C). MDA-MB-231 and 
MCF-7 cell survival detected by clonogenic assay appears to follow the same pattern as the 
MTT assay. Statistical analysis using a two-way ANOVA found that 5mM metformin did not 
significantly decrease cell survival whereas 20mM metformin resulted in statistically 
significant difference to cell survival relative to vehicle. No significant difference was found 
in the responsiveness of the two cell lines to these concentrations of metformin in the 
clonogenic assay, consistent with the observations from the MTT assay. 
 
(mM) 
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MDA-MB-231 and MCF-10A cell viability detected by MTT assay (Figure 3-5B) was 
greatly reduced by GW4064 treatment and MDA-MB-231 cell survival was compromised by 
GW4064 as seen in the clonogenic assay. MCF-10A cells showed the greatest sensitivity to 
lower concentrations of the drug, with the lowest concentration examined, 20μM GW4064 
causing a significant 63% reduction in viability of MCF-10A cells relative to vehicle (p < 
0.001) but no reduction in cell viability of MCF-7 or MDA-MB-231 cells. Treatment with 
GW4064 has a detrimental effect on cell viability of MDA-MB-231 cells detected by MTT at 
concentrations of 30μM and greater. The maximal reduction in viability were observed after 
24-hour treatment with GW4064 at 30μM for MCF-10A cells and 95μM for MDA-MB-231 
cells, resulting in reductions in cell viability relative to vehicle of 78% and 70%, respectively 
(p < 0.01). Across the same concentration range, 20μM-95μM, cell viability of MCF-7 cells 
was not significantly affected by GW4064. The concentration range was extended to 400μM 
for these cells, but no significant alteration in cell viability was observed. In contrast, cell 
survival was affected by GW4064 at 1μM and 25μM as shown in the clonogenic assay Figure 
3-5D. 
 
 Energy phenotype analysis 
 
Investigation into the effect of GW4064 on the utilisation of different respiratory pathways in 
MCF-10A and MCF-7 cells in shown in Figure 3-6. An energy phenotype test was carried 
out for untreated MCF-10A cells and those treated with GW4064. Basal measurements of 
OCR and ECAR are taken from each well representing different conditions: vehicle or 
115μM GW4064, Figure 3-6 A and B. Untreated MCF-10A cells preferentially utilise 
mitochondrial over glycolytic respiration, with a ratio of approximately 8:1. Treatment of 
MCF-10A cells with GW4064 results in a dramatic reduction in baseline OCR activity but no 
significant effect on ECAR.  
 
In comparison, MCF-7 untreated cells utilise both mitochondrial respiration and glycolysis 
equally. For MCF-7 cells, GW4064 treatment reduces the baseline utilisation of both the 
mitochondrial and glycolytic pathways, but the effect on OCR is much less dramatic (Figure 
3-6 D, open symbols). As seen with MCF-10A cells, treatment with GW4064 impaired the 
ability of cells to respond to the stressor, with neither mitochondrial respiration nor glycolytic 
pathway utlisation effected by the stressor 
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Figure 3-6. Energy phenotype test for MCF-10A and MCF-7 cells treated with GW4064. The test measures the 
two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under baseline and 
stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline Phenotype, Stressed 
Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count in wells after assay 
completion. The Energy Phenotype Test was run on MCF-10A and MCF-7 cells using the Agilent Seahorse 
XFp analyser. Basal measurements of OCR and ECAR are taken from each well representing different 
conditions: vehicle (V, ≤1% DMSO) or 115μM GW4064 (solubilised in DMSO at ≤1%). C is metabolic 
potential, the response of cells under different conditions to an induced energy demand. D shows the cell energy 
potential. The relative utilisation of the two energy pathways of a cell population is determined under both 
baseline (Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) conditions. 
MCF-10A – GW4064 115μM 
  
MCF-7 – GW4064 115μM 
  
A B 
i. 
ii. 
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Treatment 
(24h) 
Cell line 
Response Energy phenotype changes 
Cell Viability Clonogenic cell survival Alterations in respiration 
Ability to respond to a 
stressor 
Tam  
0-100µM 
MCF-7 
Significantly reduced at 
doses >10µM 
ns ↓ in at 1 or 2µM N/A N/A 
 MDA-MB-231 
Significantly reduced at 
doses >10µM 
Significant ↓ at 2µM N/A N/A 
 MCF-10A 
Significantly reduced at 
doses >1µM 
N/A N/A N/A 
Cis  
0-500µM 
MCF-7 
Significantly reduced at 
doses >15µM 
Significant ↓ at 2.5µM and 
50µM 
Minimal change Minimal change 
 
Cis  
0-1mM 
MDA-MB-231 
ns ↓ with doses  
up to 1mM 
Significant ↓ at 2.5µM and 
50µM 
Reduced glycolysis  
Increased ox phos  
Minimal change 
 MCF-10A N/A N/A N/A 
N/A 
 
Dox 
0-15µM 
MCF-7 
ns ↓ with doses 
up to 15mM 
Significant ↓ at 0.1µM, 
0.2µM, 1.0µM 
Reduced glycolysis no 
change to ox phos 
Increased utilisation of 
both pathways in response 
to a stressor 
 MDA-MB-231 
ns ↓ with doses  
up to 15mM 
Significant ↓ at 0.1µM, 
0.2µM, 1.0µM 
Increased glycolysis and 
ox phos 
Increased utilisation of 
both pathways in response 
to a stressor 
 MCF-10A 
ns ↓ with doses 
 up to 15mM 
Significant ↓ at 0.1µM, 
0.2µM, 1.0µM  
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Met  
0-150mM 
MCF-7 
Significantly reduced at 
doses >5mM 
Significant ↓ at 20mM N/A N/A 
Met  
0-15mM 
MDA-MB-231 
Significantly reduced at 
doses >5mM 
Significant ↓ at 20mM N/A N/A 
 MCF-10A 
Significantly reduced at 
doses >5mM 
N/A N/A N/A 
GW4064  
0-400µM 
MCF-7 
ns ↓ with doses up to 
400µM 
Significant ↓ at 1µM and 
25µM 
N/A N/A 
GW4064  
0-100µM 
MDA-MB-231 
Significantly reduced at 
doses >15µM 
Significant ↓ at 1µM and 
25µM 
N/A N/A 
GW4064 
 0-100µM 
MCF-10A 
Significantly reduced at 
doses >15µM 
N/A N/A N/A 
 
Table 3-1. Table summarising results from chapter three for MCF-7, MDA-MB-231 and MCF-10A cells treated with three chemotherapeutic agents and two metabolism 
modulating agents as individual treatments. n.s = non-significant, Tam = Tamoxifen, Cis = Cisplatin, Dox = Doxorubicin, Met = Metformin, LiCl = Lithium Chloride. 
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 Effect of drug combinations on breast cancer cell line survival, 
proliferation and cell energy phenotype 
 
Chemotherapy has been the primary treatment for treating breast cancer for decades. 
However, the importance of exploring alternative  approaches for treating breast cancer are 
highlighted by the aforementioned limitations of chemotherapy, including the development of 
resistance to a particular agent or agents (Ring and Dowsett, 2004). For the synergy analysis 
presented in this chapter, the ZIP model was used. 
 
 GW4064 synergises with tamoxifen and enhances its negative effect on 
cell viability in MCF-7 breast cancer cell line.  
 
The effect of a treatment combination of Tamoxifen and GW4064 was investigated by 
Mohan et al in 2015 (Mohan et al., 2015). This was further explored here, using MCF-7 and 
MDA-MB-231 cells to determine whether the findings from Mohan et al could be replicated.  
 
Alterations to MCF-7, MDA-MB-231 and MCF-10A cell viability in response to treatment 
by Tamoxifen and GW4064 combination treatments as detected by MTT assay is shown in 
Figure 3-7. This treatment combination greatly affected cell viability of MCF-7 and MDA-
MB-231 cells but not MCF-10A cells relative to treatment with 10μM Tamoxifen alone. The 
greatest impact on cell viability in MDA-MB-231 cells observed following 24h treatment 
with 10μM Tamoxifen and 50μM GW4064. The effect was a 62% reduction in viability 
relative to 10μM Tamoxifen alone. For MCF-7 cells, the most detrimental effect to cell 
viability was observed in the treatment condition of 10μM Tamoxifen and 95μM GW4064. 
This treatment condition caused a 92% reduction in viability relative to 10μM Tamoxifen 
alone. None of the tested treatment conditions significantly affected MCF-10A cell viability, 
although there was an overall trend for a decrease in viability.  
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Figure 3-7. The effect of chemotherapeutic agent Tamoxifen in combination with GW4064 on the cell viability 
and clonogenic cell survival of MCF-7, MDA-MB-231 and MCF-10A cell lines. Cells were exposed to single 
concentration of Tamoxifen and a range of concentrations of GW4064 for 24 hours. Cell viability was assayed 
by MTT and cell survival determined by clonogenic assay. Data are relative to vehicle (≤1% DMSO or H2O 
accordingly) and are shown as mean ±SEM; n=3-6. Ordinary one-way ANOVA with Dunnett’s test post hoc 
was performed to detect statistically significant differences between treatment conditions and vehicle denoted as 
* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.  
 
 
 
 
Figure 3-8. Graphical representation of the output from the synergy analysis for drug combinations of GW4064 
with Tamoxifen. R-package SynergyFinder was used to analyse the pairwise drug combinations explored here 
using the ZIP method. The method examines the effect of each drug alone and compares this with the effect of 
the drug in combination. The Synergy Score denotes whether a particular pairwise combination is antagonistic, 
additive or synergistic. A positive score (denoted in red) reflects a synergistic interaction, while antagonistic and 
additive interactions are indicated with green and white, respectively.  
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Alterations to MCF-7 and MDA-MB-231 cell survival following treatment with 
Tamoxifen+GW4064 was detected by clonogenic assay (Figure 3-7B). The response 
followed the same pattern as the MTT assay, but with greater sensitivity to dose. Consistent 
with the MTT assay, with the combination has a concentration dependent negative effect on 
cell viability in both cell lines.  
 
To explore the type of interaction between the two drugs, and quantify its effect, a pairwise 
comparison was analysed with SynergyFinder. The output from SynergyFinder is shown in 
Figure 3-9 and shows that the pairwise combination of Tamoxifen and GW4064 has an 
antagonistic effect in MDA-MB-231 cells at all GW4064 concentrations explored with the 
exception of the lowest concentration (10μM), where an additive effect is seen. In MCF-7 
cells, a synergistic interactions is seen, with the synergy score greater than 0 across all 
concentrations of GW4064 tested.  
 
 
 
 GW4064 synergises with cisplatin and enhances its negative effect on 
cell viability in breast cancer cell line MCF-7. 
 
MCF-7, MDA-MB-231 and MCF-10A cell viability detected by MTT assay (Figure 3-9A) 
was greatly compromised by the combination treatment with cisplatin and GW4064 relative 
to treatment with 25μM cisplatin alone. MCF-10A cells showed the highest sensitivity to this 
combination with MCF-7 cells also greatly affected by this treatment combination. Cell 
viability of both of these cell lines was significantly reduced (p < 0.0001) by treatment with 
25μM cisplatin and all concentrations of GW4064 (20-115μM). The most detrimental effect 
to cell viability observed in MCF-10A cells is a 72% reduction in viability in response to 24h 
treatment with 25μM cisplatin and 70μM GW4064. In MCF-7 an 87% reduction to viability 
is observed in response to the highest concentration combination tested. MDA-MB-231 cell 
viability detected by MTT assay was less greatly compromised by this combination 
treatment. Two concentration combinations of cisplatin and GW4064 (25μM cisplatin + 
70μM GW4064 and 25μM cisplatin + 115μM GW4064) significantly reduced cell viability 
relative to treatment with 25μM cisplatin alone by 23% (p < 0.05) and 31% (p < 0.01) 
respectively. 
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Figure 3-9. The effect of chemotherapeutic agent cisplatin in combination with GW4064 on the cell viability 
and clonogenic cell survival of MCF-7, MDA-MB-231 and MCF-10A cell lines. Cells were exposed to single 
concentration of cisplatin and a range of concentrations of GW4064 for 24 hours. Cell viability was assayed by 
MTT and cell survival determined by clonogenic assay. Data are relative to vehicle (≤1% DMSO or H2O 
accordingly) and are shown as mean ±SEM; n=3-6. Ordinary one-way ANOVA with Dunnett’s test post hoc 
was performed to detect statistically significant differences between treatment conditions and vehicle denoted as 
* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.  
 
 
 
 
Figure 3-10. Graphical representation of the output from the synergy analysis for drug combinations of 
GW4064 with cisplatin. R-package SynergyFinder was used to analyse the pairwise drug combinations explored 
here using the ZIP method. The method examines the effect of each drug alone and compares this with the effect 
of the drug in combination. The Synergy Score denotes whether a particular pairwise combination is 
antagonistic, additive or synergistic. A positive score (denoted in red) reflects a synergistic interaction, while 
antagonistic and additive interactions are indicated with green and white, respectively. 
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MCF-7 cell survival following combination treatment with cisplatin and GW4064 detected 
by clonogenic assay (Figure 3-9B) followed the same pattern as the MTT assay, with the 
combination having a concentration dependent negative effect on cell viability. In contrast to 
the MTT, however, the differential effect of cisplatin and GW4064 between MDA-MB-231 
and MCF-7 cells is not observed. MDA-MB-231 cell survival detected by clonogenic assay 
(Figure 3-9B), is greatly affected by treatment with cisplatin at 2.5μM and GW4064 at 20μM. 
The different patterns of effect observed between MTT and clonogenic assay are likely due to 
differences between the assay types and a reflection of the lower resolution of clonogenic 
assays with few concentration conditions compared with MTT assays. 
 
To quantify the interaction between GW4064 and cisplatin, the MTT data was analysed using 
SynergyFinder. Figure 3-10 shows the graphical output of the program for this pairwise 
combination. The interaction of cisplatin and GW4064 in MDA-MB-231 cells is 
antagonistic; the effect of the combination results in a lesser impact on cell viability than the 
effect of the drugs alone. This could mean that one drug offers a protective effect over the 
efficacy of the other. For MCF-7 cells, contrastingly, a high level of synergy is observed 
between GW4064 and cisplatin. The combined effect is greater than the sum of the individual 
drug effects. Synergy is observed at all concentrations of 25μM cisplatin combined with any 
concentration of GW4064, with greater synergy observed at lower concentrations of 
GW4064. 
 
Investigation into the effect of the combination treatment of GW4064+Cisplatin on the 
utilisation of different respiratory pathways was undertaken in MCF-7 and MDA-MB-231 
cells Figure 3-12 and Figure 3-13. The results from the energy phenotype test for MCF-7 
cells are shown in Figure 3-12(i) treated with 25μM cisplatin + 115μM GW4064 and Figure 
3-11(ii) 25μM cisplatin + 50μM GW4064 respectively. When treated with the lower 
condition, the effects are non-significant. When treated with the higher concentration 
combination, MCF-7 cells see a reduction in baseline OCR, representing mitochondrial 
respiration, (open symbols) in response to treatment with a combination of 
GW4064+cisplatin compared with cells in control condition. This concentration combination 
does not greatly impact the ability of these cells to respond to a stressor.  
 
 
Chapter 3 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. Energy phenotype test for MCF-7 cells treated with GW4064+cisplatin –first with lower then 
higher concentration combination. The test measures the two major energy producing pathways of the cell - 
mitochondrial respiration and glycolysis under baseline and stressed conditions, to reveal the three key 
parameters of cell energy metabolism: Baseline Phenotype, Stressed Phenotype, and Metabolic Potential. 
Output from the assay is normalised to final cell count in wells after assay completion. The Energy Phenotype 
Test was run on MCF-7 cells using the Agilent Seahorse XFp analyser. Basal measurements of OCR and ECAR 
are taken from each well representing different conditions: vehicle (V, ≤1% DMSO) or 25μM cisplatin + 
115μM GW4064 (solubilised in DMSO at ≤1%). C is metabolic potential, the response of cells under different 
conditions to an induced energy demand. D shows the cell energy potential. The relative utilisation of the two 
energy pathways of a cell population is determined under both baseline (Baseline Phenotype, open symbols) and 
stressed (Stressed Phenotype, closed symbols) conditions. 
MCF-7 – 25μM cisplatin + GW4064 50μM   
  
MCF-7 – 25μM cisplatin + GW4064 115μM   
A B 
A B 
C D 
C D 
i. 
ii. 
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Examination of the effect of 25μM cisplatin + 50μM GW4064 on the energy phenotype of 
MDA-MB-231 cells, Figure 3-12, finds that, in contrast to the response of MCF-7 cells, this 
treatment resulted in no change in basal respiration or the ability of these cells to respond to a 
stressor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12. Energy phenotype test for MDA-MB-231 cells treated with GW4064+cisplatin. The test measures 
the two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under baseline 
and stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline Phenotype, 
Stressed Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count in wells 
after assay completion. The Energy Phenotype Test was run on MCF-7 cells using the Agilent Seahorse XFp 
analyser. Basal measurements of OCR and ECAR are taken from each well representing different conditions: 
vehicle (V, ≤1% DMSO) or 25μM cisplatin + 50μM GW4064 (solubilised in DMSO at ≤1%). C is metabolic 
potential, the response of cells under different conditions to an induced energy demand. D shows the cell energy 
potential. The relative utilisation of the two energy pathways of a cell population is determined under both 
baseline (Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) conditions. 
  
 
 
 
 
 
 
 
 
 
Cell Energy Potential 
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 GW4064 and doxorubicin combination is additive in breast cancer cell 
lines MCF-7 and MDA-MB-231. 
 
MDA-MB-231 cell viability detected by MTT assay (Figure 3-15A) was compromised by 
24h treatment with a combination of Doxorubicin and GW4064. All but one treatment 
condition (Doxorubicin at 20μM and GW4064 at 10μM) resulted in a significant reduction in 
cell viability when compared with treatment with 20μM Dox alone. The most detrimental 
effect to cell viability was detected after 24h treatment with 20μM Dox and 95μM GW4064, 
resulting in a 63% reduction in viability relative to treatment with Dox alone. In contrast, 
none of the tested concentrations (doxorubicin at 20μM and GW4064 at 10-115μM) resulted 
in significant reductions in the viability of MCF-7 cells. Analysis with an ordinary one-way 
ANOVA found the response of MCF-7 and MDA-MB-231 to these treatment conditions to 
be significantly different. This aligns with the data from MTT assays examining the effect of 
GW4064 alone on the two cell lines. MCF-7 cells show little sensitivity to GW4064, with no 
significant reduction in cell viability observed even at the highest concentration tested, 
115μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13. The effect of chemotherapeutic agent doxorubicin in combination with GW4064 on the cell 
viability and clonogenic cell survival of MCF-7, MDA-MB-231 and MCF-10A cell lines. Cells were exposed to 
a single concentration of the doxorubicin and a range of concentrations of GW4064 for 24 hours. Cell viability 
was assayed by MTT and cell survival determined by clonogenic assay. Data are relative to vehicle (≤1% 
DMSO or H2O accordingly) and are shown as mean ±SEM; n=3-6. Ordinary one-way ANOVA with Dunnett’s 
test post hoc was performed to detect statistically significant differences between treatment conditions and 
vehicle denoted as * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.  
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Figure 3-14. Graphical representation of the output from the synergy analysis for drug combinations of 
GW4064 with doxorubicin. R-package SynergyFinder was used to analyse the pairwise drug combinations 
explored here using the ZIP method. The method examines the effect of each drug alone and compares this with 
the effect of the drug in combination. The Synergy Score denotes whether a particular pairwise combination is 
antagonistic, additive or synergistic. A positive score (denoted in red) reflects a synergistic interaction, while 
antagonistic and additive interactions are indicated with green and white, respectively. 
 
MDA-MB-231 cell survival detected by clonogenic assay (Figure 3-15B) followed the same 
pattern as the MTT assay, but with greater sensitivity to dose. A number of concentrations 
were selected; however, concentrations above Dox at 0.25μM and GW4064 at 1μM or 20μM 
resulted in 100% cell killing with no colonies forming in the experimental period (14 days). 
Consistent with the MTT assay, MDA-MB-231 cells are detrimentally affected by Dox and 
GW4064 combination treatment in a concentration-dependent manner. 24h treatment with 
0.25μM Dox with 1μM GW4064 caused a 67% reduction in cell survival relative to vehicle 
(p=0.0035) and 0.25μM Dox with 25μM GW4064 caused almost a complete inhibition of 
cell survival in MDA-MB-231 cells. In contrast to the MTT, however, the differential effect 
of Doxorubicin and GW4064 between MDA-MB-231 and MCF-7 cells is not observed. 
MCF-7 cell survival detected by clonogenic assay (Figure 3-15B), is greatly affected by 
treatment with Doxorubicin at 0.25μM and GW4064 at 1μM and 20μM, resulting in an 82% 
and close to 100% reduction relative to vehicle (p < 0.0001). As seen with treatment of 
MCF-7 and MDA-MB-231 cells with GW4064 alone (Figure 3-5A and B) the different 
patterns of effect observed between MTT and clonogenic assay are likely due to differences 
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between the assay types. In the clonogenic assays, the fact that only two concentrations are 
compared and the time period examined is long (14 days), means the assay may not have 
sufficient resolution to observe cell line differences.  
 
Figure 3-14 shows the graphical output from SynergyFinder, exploring the type of interaction 
between GW4064 and Doxorubicin. The interaction of the drugs in MDA-MB-231 cells is 
additive; a synergy score of 0 is observed. This is aligned with the observation that treatment 
with GW4064 is effective in reducing cell viability in MDA-MB-231 cells and the same 
reduction in viability is achieved in addition to any reductions in cell viability resulting from 
treatment with doxorubicin.  
 
SynergyFinder output for the same combination in MCF-7 cells shows largely an additive 
effect across most concentrations of GW4064. However, at the lowest concentration of 
GW4064 examined, the combination with 20μM doxorubicin did show low levels of synergy; 
a synergy score of >0. The low sensitivity of MCF-7 cells mean that any reductions in cell 
viability observed in the combination treatments compared with treatment with 20μM 
doxorubicin alone likely result from synergy between the tested drugs. There was not a 
significant reduction in cell viability following combination treatment above treatment with 
doxorubicin alone, however, meaning the level of synergy is low.  
 
Investigation into the effect of GW4064+doxorubicin on the utilisation of different 
respiratory pathways was undertaken in MCF-10A, MCF-7 and MDA-MB-231 cells, Figure 
3-15, Figure 3-16 and Figure 3-17 through an Energy Phenotype Test. Examining MCF-10A 
cells, Figure 3-15, basal measurements of OCR and ECAR are taken from each well 
representing different conditions: Vehicle and a combination of: 115μM GW4064 + 20μM 
Doxorubicin. Treatment of MCF-10A cells with GW4064+Doxorubicin results in a reduction 
in baseline activity of MCF-10A cells and a reduced ability to increase mitochondrial 
respiration or glycolysis in response to a stressor when compared with untreated cells (Figure 
3-16 D, open symbols). GW4064+doxorubicin inhibits the ability of cells to respond to a 
stressor by increasing mitochondrial respiration or glycolysis (Figure 3-15 D, closed 
symbols). MCF-10A untreated cells appear to primarily utilise mitochondrial respiration over 
glycolysis (See Figure 3-15 A vs B). This contrasts the energy phenotype of MDA-MB-231 
cells, which use glycolysis primarily, and MCF-7 cells, which use a balanced combination of 
glycolysis and mitochondrial respiration.  
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Figure 3-15. Energy phenotype test for MCF-10A cells treated with GW4064+doxorubicin. The test measures 
the two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under baseline 
and stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline Phenotype, 
Stressed Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count in wells 
after assay completion. The Energy Phenotype Test was run on MCF-7 cells using the Agilent Seahorse XFp 
analyser. Basal measurements of OCR and ECAR are taken from each well representing different conditions: 
vehicle (V, ≤1% DMSO) or 115μM GW4064 + 20μM Doxorubicin (solubilised in DMSO at ≤1%). C is 
metabolic potential, the response of cells under different conditions to an induced energy demand. D shows the 
cell energy potential. The relative utilisation of the two energy pathways of a cell population is determined 
under both baseline (Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) 
conditions. 
  
 
 
MCF-7 measurements of basal OCR and ECAR are reduced slightly in response to treatment 
with the combination of 20μM doxorubicin + 50μM GW4064 compared with cells in control 
condition, Figure 3-16 A and B. This treatment did not greatly affect the ability of the cells to 
respond to a stressor. Untreated MCF-7 cells appear to utilise a balance of mitochondrial and 
glycolytic respiration.  
 
 
MCF-10A – 20μM Doxorubicin + GW4064 115μM 
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Figure 3-16. Energy phenotype test for MCF-7 cells treated with GW4064+doxorubicin.The test measures the 
two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under baseline and 
stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline Phenotype, Stressed 
Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count in wells after assay 
completion. The Energy Phenotype Test was run on MCF-7 cells using the Agilent Seahorse XFp analyser. 
Basal measurements of OCR and ECAR are taken from each well representing different conditions: vehicle (V, 
≤1% DMSO) or 20μM doxorubicin + 50μM GW4064(solubilised in DMSO at ≤1%). C is metabolic potential, 
the response of cells under different conditions to an induced energy demand. D shows the cell energy potential. 
The relative utilisation of the two energy pathways of a cell population is determined under both baseline 
(Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) conditions. 
 
For MDA-MB-231 cells, basal measurements of OCR and ECAR are taken from each well 
representing different conditions: Control and 20μM doxorubicin + 50μM GW4064, Figure 
3-17. Treatment with this combination results in a decrease in baseline activity of MDA-MB-
231 cells, the impact on the level of glycolysis is greater than the impact on mitochondrial 
respiration. This suggests that the combination reduces the ability of these cells to utilise the 
glycolytic pathway. Treatment with GW4064 in combination with doxorubicin did not affect 
the way the cells responded to a stressor.  
 
MCF-7 – 20μM Doxorubicin + GW4064 50μM 
  
C D 
A B 
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Figure 3-17. Energy phenotype test for MDA-MB-231 cells treated with GW4064+doxorubicin.The test 
measures the two major energy producing pathways of the cell - mitochondrial respiration and glycolysis under 
baseline and stressed conditions, to reveal the three key parameters of cell energy metabolism: Baseline 
Phenotype, Stressed Phenotype, and Metabolic Potential. Output from the assay is normalised to final cell count 
in wells after assay completion. The Energy Phenotype Test was run on MCF-7 cells using the Agilent Seahorse 
XFp analyser. Basal measurements of OCR and ECAR are taken from each well representing different 
conditions: vehicle (V, ≤1% DMSO) or 20μM doxorubicin + 50μM GW4064 (solubilised in DMSO at ≤1%). C 
is metabolic potential, the response of cells under different conditions to an induced energy demand. D shows 
the cell energy potential. The relative utilisation of the two energy pathways of a cell population is determined 
under both baseline (Baseline Phenotype, open symbols) and stressed (Stressed Phenotype, closed symbols) 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDA-MB-231 – 20μM Doxorubicin + GW4064 50μM 
  
Cell Energy Potential             
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 GW4064 synergises with metformin and enhances its negative effect on 
cell viability in breast cancer cell line MCF-7. The combination is 
additive in MDA-MB-231 cells. 
 
MCF-7 and MDA-MB-231 cell viability detected by MTT assay was greatly compromised 
by the combination treatment with Met and GW4064 relative to treatment with 50mM 
Metformin (Figure 3-19). No significant difference was found in the sensitivity of MCF-7 
and MDA-MB-231 cells to this treatment combination. The greatest impact on cell viability 
was observed in MCF-7 cells following treatment with 50mM Met and 400μM GW4064 and 
in MDA-MB-231 cells following treatment with 50mM Met and 500μM GW4064.  This 
resulted in a decrease in viability relative to Metformin alone of 93% and 83% (p < 0.0001) 
in MCF-7 and MDA-MB-231 cells respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18. The effect of metabolism modulating drug metformin in combination with GW4064 on the cell 
viability and clonogenic cell survival of MCF-7 and MDA-MB-231 cell lines. Cells were exposed to 50mM 
metformin (Solubilised in H2O) and a range of concentrations of GW4064: 20μM-500μM (solubilised in DMSO 
at ≤1%) for 24 hours. Cell viability was assayed by MTT. Data are relative to vehicle (≤1% DMSO or H2O 
accordingly) and are shown as mean ±SEM; n=3-6. Ordinary one-way ANOVA with Dunnett’s test post hoc 
was performed to detect statistically significant differences between treatment conditions and vehicle denoted as 
* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.  
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Figure 3-19. Graphical representation of the output from the synergy analysis for drug combinations of 
GW4064 with metformin. R-package SynergyFinder was used to analyse the pairwise drug combinations 
explored here using the ZIP method. The method examines the effect of each drug alone and compares this with 
the effect of the drug in combination. The Synergy Score denotes whether a particular pairwise combination is 
antagonistic, additive or synergistic. A positive score (denoted in red) reflects a synergistic interaction, while 
antagonistic and additive interactions are indicated with green and white, respectively. 
 
The MTT data was analysed to look for synergy between the two drugs using SynergyFinder 
(Figure 3-19). In MDA-MB-231 cells, there is no synergy observed, the interaction of 
metformin and GW4064 is purely additive. Contrastingly, in MCF-7 cells, at concentrations 
of GW4064 above 25μM, synergy is observed between the two drugs.  
 
For MCF-7 cells, the synergy score at low concentrations of GW4064 (1μM to 20μM) is 0, 
and shows that the combination of metformin and GW4064 at these concentrations is 
additive. At higher concentrations of GW4064 the synergy score is >0, showing the 
combinations at these concentrations interact in a synergistic manner.  
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 Metformin synergises with doxorubicin and enhances its negative effect 
on cell viability in MDA-MB-231 cells 
 
MDA-MB-231  
 
The initial combination explored in this subset of experiments is that of doxorubicin (0-
10μM) and metformin (0-75mM) in MDA-MB-231 cells. Cell viability assayed using MTT 
assay was used to generate concentration response curves for each drug individually and for 
the combination and this data was analysed using SynergyFinder.  
 
Figure 3-20 shows the graphical output of the synergy analysis using SynergyFinder with 
four different reference models, all discussed in the introduction to this chapter; a) Bliss, b) 
ZIP, c) HAS and d) Loewe. For each of these analyses, the average synergy score is greater 
than 0, demonstrating a synergistic relationship exists between Doxorubicin and metformin at 
some combination of concentrations. There are, however clear differences in the analysis of 
synergy across the four models, most particularly the Loewe approach. There is a range in the 
average synergy scores from 1.052; output from the Loewe reference model to 9.564; output 
from the HSA model. Bliss and ZIP scores fall within this range; 2.726 and 3.231 
respectively. Furthermore, the distribution of synergy across the matrix differs between each 
model, suggesting the analysis from each different reference model detects synergy between 
different concentration combinations of doxorubicin and metformin. ZIP and Bliss 
distributions are similar, showing greatest synergy at low concentrations of metformin and 
doxorubicin. HAS output reproduces this effect, but also supports high levels of synergy at 
all most concentration combinations aside from at the highest concentrations of metformin 
combined with low doxorubicin concentrations. The Loewe model output shows synergy is 
observed across all concentrations of metformin when combined with the highest 
concentrations of doxorubicin.  
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Figure 3-20. 2D and 3D Graphical representation of the output from the synergy analysis for drug combinations 
of metformin with doxorubicin in MDA-MB-231 cells. R-package SynergyFinder was used to analyse the 
pairwise drug combination metformin (0-75mM) and doxorubicin (0-10μM) explored in MTT cell viability 
assays performed by undergraduate project students working in the laboratory. The method examines the effect 
of each drug alone and compares this with the effect of the drug in combination. The Synergy Score denotes 
whether a particular pairwise combination is antagonistic, additive or synergistic. Four synergy reference 
models were used a) Bliss, b) ZIP, c) HAS and d) Loewe. A positive score (denoted in red) reflects a synergistic 
interaction, while antagonistic and additive interactions are indicated with green and white, respectively. 
 
 
 
 
 
As discussed in detail in the introduction, the four models are based on different assumptions 
(Ianevski et al., 2017), which could explain the differences observed in the degree of synergy 
concluded. The comparison is therefore important to reduce bias in determining the way in 
which two drugs interact. The highest average synergy score for this combination is observed 
in the output from SynergyFinder using the HSA reference model. This reference model is 
useful in comparing a single agent against a combination, but cannot distinguish whether 
there is an improved effect of the combination compared with the additive effect expected 
when combining two agents (Foucquier and Guedj, 2015). This considered, it could be 
concluded that the HSA synergy score is an overestimate and not a true reflection of the 
interaction between Doxorubicin and metformin. The Bliss reference model assumes that 
both drugs have exponential concentration response curves. As presented in Figure 3-20, 
across the concentrations tested, doxorubicin does have an exponential concentration 
response curve but metformin does not, therefore, for this particular combination, results 
using the Bliss reference model may not provide an accurate picture of the synergy 
landscape. The Loewe model assumes a constant potency ratio across the concentrations 
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tested, which again is unlikely in this scenario. Where there is not a constant potency ratio 
across all concentrations, the ZIP reference model is likely the most accurate measure of 
synergy. The synergy landscape generated using the reference model here shows an average 
synergy score of 2.726, with the greatest synergy observed at doxorubicin concentrations 
<5μM and metformin concentrations <30mM. 
 
MCF-7 
 
The same combination of Doxorubicin and metformin was explored in MCF-7 cells. Figure 
32 shows the concentration response curves for the individual drug treatments and the 
concentration response matrix for the range of concentrations combined.  
 
The output of SynergyFinder for this combination in MCF-7 cells is shown in Figure 3-21 a-d 
Overall, the level of synergy seen between Doxorubicin and metformin is much lower in 
MCF-7 cells than in the MDA-MB-231 cell line. The average synergy scores across the 
outputs from each different reference model are all less than zero, scores of -10.41, -4.514, -
11.15, and -9.486 for Bliss, HSA, Loewe and ZIP respectively. These scores suggest that the 
relationship between the two drugs in MCF-7 cells is, at the majority of concentrations, 
antagonistic. At particular concentration combinations, in the Bliss, HSA and Zip models, 
some synergy is observed. In these three reference models, the strongest antagonistic 
interaction between the two agents is observed at the highest concentrations tested. The Bliss 
landscape of synergy shows some low level of this at very low concentrations of Doxorubicin 
across all concentrations of metformin. For the HSA model, the combination of doxorubicin 
at a concentration of 2.5μM with metformin 65mM or 70mM is synergistic, as well as 
Doxorubicin at 1μM and metformin at 20mM. The landscape output from the ZIP model 
shows some synergy between the two drugs at 1μM doxorubicin and 10mM metformin.  
 
 
 
 
 
 
 
Chapter 3 
 
209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-21. 2D and 3D graphical representation of synergy scores for the combination of metformin and 
doxorubicin in MCF-7 cells.  
R-package SynergyFinder was used to analyse the pairwise drug combination metformin (0-75mM) and 
doxorubicin (0-10μM) explored in MTT cell viability assays performed by undergraduate project students 
working in the laboratory. The method examines the effect of each drug alone and compares this with the effect 
of the drug in combination. The Synergy Score denotes whether a particular pairwise combination is 
antagonistic, additive or synergistic. Four synergy reference models were used a) Bliss, b) ZIP, c) HAS and d) 
Loewe. A positive score (denoted in red) reflects a synergistic interaction, while antagonistic and additive 
interactions are indicated with green and white, respectively. 
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 Metformin synergises with Tamoxifen and enhances its negative effect 
on cell viability in MDA-MB-231 cells 
 
MDA-MB-231  
 
The next drug combination investigated is Tamoxifen (0-40μM) with metformin (0-75mM). 
Again, this was tested in both MDA-MB-231 cells and MCF-7 cells. Initially, the MDA-MB-
231 results will be examined. Output from three of the four reference models; Bliss, HSA and 
ZIP, shown in Figure 3-22, have positive synergy scores from 5-10, showing overall in 
MDA-MB-231 cells, there is a synergistic relationship between Tamoxifen and metformin at 
the concentrations investigated.  SynergyFinder output using the Loewe model shows an 
average synergy score of negative 9.474, suggesting overall an antagonistic relationship 
between Tamoxifen and metformin across this concentration range. Differences in the output 
using the Loewe reference model could be due to assumptions made by this reference model. 
It assumes a constant potency ratio across the concentrations tested, which may not be the 
case in reality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22. 2D and 3D graphical representation of synergy scores for the combination of metformin and 
Tamoxifen in MDA-MB-231 cells. R-package SynergyFinder was used to analyse the pairwise drug 
combination metformin (0-75mM) and Tamoxifen (0-40μM) explored in MTT cell viability assays performed 
by undergraduate project students working in the laboratory. The method examines the effect of each drug alone 
and compares this with the effect of the drug in combination. The Synergy Score denotes whether a particular 
pairwise combination is antagonistic, additive or synergistic. Four synergy reference models were used a) Bliss, 
b) ZIP, c) HAS and d) Loewe. A positive score (denoted in red) reflects a synergistic interaction, while 
antagonistic and additive interactions are indicated with green and white, respectively.  
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MCF-7 
 
The same combination of doxorubicin and Tamoxifen was explored in MCF-7 cells.  Figure 
3-23 a-d shows the landscapes of the SynergyFinder analysis using different reference 
models for comparison, as well as their respective average synergy scores. The outputs from 
these models vary largely, for this cell line, the average synergy scores for Tamoxifen and 
doxorubicin are 1.492 when using the Bliss model, 3.579 when using the HSA model, -0.83 
for Loewe and -0.125 when the ZIP reference model is used. According to these scores, the 
Bliss and HSA model results, present the combination of Tamoxifen and metformin across 
these concentrations as being synergistic, whereas Loewe and ZIP reference models give 
scores suggesting the combination overall is antagonistic. Despite this, the Loewe model 
shows an area of particularly high synergy between 1µM and 20µM tamoxifen and above 
50mM Metformin. In reality, across the synergy landscapes, for all four reference models, 
there are concentration combinations that show synergy and other concentration 
combinations where the drugs interact antagonistically. According to all four reference 
models, at high concentrations of metformin and low concentrations of Tamoxifen, some 
synergy is observed between the two drugs. The Bliss and HSA models also show synergy at 
low concentrations of metformin with low concentrations of Tamoxifen, where this is not 
observed in the output from the Loewe and ZIP models. As discussed above, the Bliss 
reference model does not allow distinction between additive or synergistic effects of a 
pairwise combination and is thus prone to overestimating synergy between drugs. 
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Figure 3-23. 2D and 3D graphical representation of synergy scores for the combination of metformin and 
Tamoxifen in MCF-7 cells. R-package SynergyFinder was used to analyse the pairwise drug combination 
metformin (0-75mM) and Tamoxifen (0-40μM) explored in MTT cell viability assays performed by 
undergraduate project students working in the laboratory. The method examines the effect of each drug alone 
and compares this with the effect of the drug in combination. The Synergy Score denotes whether a particular 
pairwise combination is antagonistic, additive or synergistic. Four synergy reference models were used a) Bliss, 
b) ZIP, c) HAS and d) Loewe. A positive score (denoted in red) reflects a synergistic interaction, while 
antagonistic and additive interactions are indicated with green and white, respectively.
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Treatment 
(24h) 
Cell line 
Response Synergy 
Energy phenotype 
changes 
Cell Viability 
Clonogenic cell 
survival 
  Alterations in respiration 
Tam 10µM 
GW4064 
10µM-115µM 
MCF-7 
Signif ↓ in viability at 
doses >25µM GW4064 
 
 
Signif ↓ in clonogenic cell 
survival at Tam 2µM and 
GW4064 20µM 
 
Predominantly antagonistic effect 
of the drugs in combination 
N/A 
 MDA-MB-231 
Signif ↓ in viability at 
doses >10µM GW4064 
 
 
Signif ↓ in clonogenic cell 
survival at Tam 2µM and 
GW4064 1µM and at Tam 
2µM and GW4064 20µM 
 
Combination synergistic at all 
concentrations of GW4064 
N/A 
 MCF-10A n.s. effect on cell viability    N/A 
Cis 25µM 
GW4064 
20µM-200µM 
MCF-7 
Significant ↓ in cell 
viability at all doses tested 
 
Significant ↓ in clonogenic cell 
survival at Cis 2.5µM and 
GW4064 20µM 
Predominantly antagonistic effect 
of the drugs in combination 
Cis 25µM and GW4064 50µM 
resulted in a ↓ of both mitochondrial 
respiration and glycolysis 
 MDA-MB-231 
Significant ↓ in cell 
viability at 40µM and 
115µM 
 
 
Significant ↓ in clonogenic cell 
survival at Cis 2.5µM and 
GW4064 20µM 
Combination synergistic at all 
concentrations of GW4064 
n.s. effect on glycolysis of 
mitochondrial respiration or glycolysis 
of Cis 25µM and GW4064 50µM 
 MCF-10A 
Significant ↓ in cell 
viability at all doses tested 
   
Dox 20µM 
GW4064 10-
115µM 
MCF-7 
n.s. effect on cell viability  
 
Significant ↓ in clonogenic cell 
survival at Dox 0.25µM and 
GW4064 1µM and Dox 
0.25µM and GW4064 20µM 
Additive effect across all 
concentrations tested 
Dox 20µM GW4064 50µM ↓ in both 
mitochondrial respiration and 
glycolysis 
 MDA-MB-231 
Significant ↓ in viability at 
doses >25µM 
 
Significant ↓ in clonogenic cell 
survival at Dox 0.25µM and 
GW4064 1µM and Dox 
0.25µM and GW4064 20µM 
Additive effect across all 
concentrations tested 
Dox 20µM GW4064 50µM ↓ in both 
mitochondrial respiration and 
glycolysis 
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 MCF-10A    
Dox 20µM GW4064 115µM resulted 
in a large ↓ of mitochondrial 
respiration 
Met 50µM 
GW4064 
15µM-400µM 
MCF-7 
Significant ↓ in cell 
viability at concentrations 
>24µM GW4064 
 
Antagonistic at GW4064 
concentrations >30µM 
Additive at GW4064 
concentrations <30µM 
 
 MDA-MB-231 
Significant ↓ in cell 
viability at concentrations 
>15µM GW4064 
 
Additive at all concentrations 
tested 
 
Met 
0-75mM 
Dox 
0-10µM 
MCF-7   
Different patterns depending on 
model used but generally 
Synergistic at doses >2.5µM Dox 
and >20mM Met 
 
 MDA-MB-231   
Different patterns depending on 
model used but some synergy 
seen at doses of Met >25mM 
across different concentrations of 
Dox 
 
Met 
0-75mM Tam 
0-40µM 
 
MCF-7 
  
High levels of synergy >60mM 
Met and below 20µM Tam 
 
  
 
 
MDA-MB-231 
  
All methods of synergy analysis 
aside from Loewe find the 
combination to be antagonistic 
across most concentration 
combinations. Loewe finds at 
high doses of Tam and Met there 
is synergy 
 
 
 
Table 3-2. Table summarising results from chapter three for MCF-7, MDA-MB-231 and MCF-10A cells treated with three chemotherapeutic agents and two metabolism 
modulating agents as combination treatments ie. GW4064 with Tamoxifen, Doxorubicin and Cisplatin and Metformin with Tamoxifen, Doxorubicin and Cisplatin. n.s = non-
significant, Tam = Tamoxifen, Cis = Cisplatin, Dox = Doxorubicin, Met = Metformin, LiCl = Lithium Chloride.  
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3.6 Discussion 
 
Breast cancer is the most prevalent cancer in women worldwide and correspondingly is the 
most common cause of cancer deaths for females globally (Ghoncheh, Pournamdar and 
Salehiniya, 2016). Treatment development is complicated by the heterogeneity of breast 
cancer tumours. While effective treatments have been developed for hormone receptor 
positive tumours, TNBCs remain unresponsive to many current treatments (Masoud and 
Pagès, 2017).  
 
The overarching aim of this chapter is the investigation of the effect of combinatorial 
treatments on different breast cancer cell lines. Initially, the effects of individual 
chemotherapeutic drugs and agents on the model cell lines were assayed.  
 
 Individual treatment 
 
Tamoxifen is shown here to significantly affect the viability of all three breast cancer cell 
lines investigated, with MDA-MB-231 cells overall showing greatest sensitivity to this drug, 
an observation confirmed by clonogenic cell survival assay.  
 
Understanding the differences between these cell lines aids the understanding of differential 
responses to drug treatment. MCF-7 cells are classified as Luminal A breast cancer and have 
an immunoprofile of ER-positive, PR-positive or negative and HER2-negative. Additionally, 
these cells express low levels of Ki-67 protein, a marker for proliferation, are endocrine 
responsive and generally responsive to chemotherapy (Holliday and Speirs, 2011b). They are 
used as a model cell line for hormone receptor positive breast cancer (Soule et al., 1990). 
MDA-MB-231 cells are classified as Claudin-low breast cancer. The cells are triple negative 
for ER, PR and HER2. The cells express low levels of Ki-67 and low levels of E-cadherin, a 
tumour suppressor gene. The responsiveness to chemotherapy is intermediate (Holliday and 
Speirs, 2011b). MDA-MB-231 cells are widely utilised as a model cell line for hormone 
receptor negative breast cancers (Chavez, Garimella and Lipkowitz, 2010). MCF-10A cells 
are non-tumorigenic mammary epithelial cells. They were generated through prolonged 
culture in serum-free, low calcium medium (Soule et al., 1990). They are representative here 
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of a normal breast cell line and are utilised in this experiment to determine differential 
sensitivities of breast cancer and normal cell lines. 
 
Tamoxifen is a non-steroidal anti-estrogen that has been used clinically for more than 30 
years (Jordan, 1992). Its principle mechanism of action is achieved through its binding to the 
estrogen receptor and thus inhibiting the action of estrogen on the cell. Tamoxifen has been 
used widely in the treatment of ER positive breast cancer (Robert, 1997) and more recently as 
a preventative agent for these cancers (Fisher et al., 2005). This treatment when utilised to 
treat ER-positive breast cancers in early trials resulted in response rates of 50% (Robert, 
1997). The ER status of a tumour is a strong predictor of the clinical efficacy of Tamoxifen. 
The majority of trials and the Early Breast Cancer Trialists' Collaborative Group define ER-
positivity as 10 fmol/mg cytosol protein determined by ligand binding assay (EBCTCG, 
2005) and accordingly, ER levels of 10-19 fmol/mg cytosol protein proved to have 
substantial benefit with regard to tamoxifen efficiency (EBCTCG et al., 2011). MCF-7 are a 
useful model cell line which represent ER-positive breast cancer (Lee, Oesterreich and 
Davidson, 2015) with quantified levels of ER of more than 10-fold greater than the minimum 
required to be defined as ER-positive (Brandes and Hermonat, 1983; Saceda et al., 1988). As 
these cells are ER-positive, their responsiveness to treatment with Tamoxifen is in line with 
the literature and clinical expectations (Seeger et al., 2004) (Gonzalez-Malerva et al., 2011). 
The inhibitory concentration for 50% of MCF-7 cells as determined by MTT assay for 24-
hour treatment with Tamoxifen is 7 μM, which largely aligns with literature findings of IC50 
values in the range of 5μM-27μM (Seeger et al., 2004; Gonzalez-Malerva et al., 2011; Valle 
et al., 2011). Contrastingly, the findings from the cell survival analysis by clonogenic assay 
contradicts literature findings. The results here show that following 24-hour treatment of 
MCF-7 cells with 1μM and 2μM Tamoxifen, no significant reduction in cell survival was 
observed. Similar studies by other groups found Tamoxifen significantly reduces clonogenic 
cell survival at concentrations of 1 μM and above (Nagelkerke et al., 2014) and at lower 
concentrations of 0.1μM and above (Zhou et al., 2012). In the assay development during the 
work presented here, a range of concentrations were explored, however, concentrations 
greater than 2 μM resulted in 100% cell killing and therefore these experiments could not be 
quantified. A shorter exposure to higher concentrations of Tamoxifen could have allowed 
measurements of clonogenic cell survival in MCF-7 cells to be accurately quantified.  
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Tamoxifen is clinically widely used for the treatment of ER-positive but not ER-negative cell 
lines. Its clinical limitations in treating these breast cancers are one of the issues with the use 
of this SERM. The potential to, through combination of Tamoxifen with other agents, 
improve its efficacy in MDA-MB-231 cells, stimulated the investigation of combination 
therapeutics in this chapter. Despite limited clinical usefulness and the fact that the ER status 
of a tumour is a strong predictor of the clinical efficacy of tamoxifen (EBCTCG, 2005), the 
results presented here show that Tamoxifen has a significant negative impact on the cell 
viability and cell survival of MDA-MB-231 and MCF-10A cells. More surprisingly, in these 
experiments, MDA-MB-231 cells show greater sensitivity to 24-hour treatment with 
Tamoxifen than MCF-7 cells in both clonogenic and MTT assays and MCF-10A show the 
greatest sensitivity to low doses of Tamoxifen. MCF-10A sensitivity to Tamoxifen has been 
seen previously (Yaacob and Ismail, 2014) and a number of other studies have shown MDA-
MB-231 cells are sensitive to treatment with Tamoxifen (Majumdar, 2010), with cell viability 
affected by concentrations comparable to MCF-7 cells, 7μM and 5μM respectively (Zheng, 
Kallio and Härkönen, 2007). The observation that MDA-MB-231 cells show greater 
sensitivity to Tamoxifen than MCF-7 cells is in line with some of the literature (Darakhshan 
et al., 2015). Following four days exposure to Tamoxifen, Seeger et al find cellular 
proliferation in both MCF-7 and MDA-MB-231 cells is impacted, with calculated IC50 
values of 27μM and 18μM respectively (Seeger et al., 2004). Contrastingly, a number of 
studies report higher sensitivity of ER-positive MCF-7 cells to Tamoxifen (Zheng, Kallio and 
Härkönen, 2007; Nagelkerke et al., 2014). 
 
Quantification of ER in MCF-7 and MDA-MB-231 cells by Subik et al confirm that MDA-
MB-231 and MCF-10A cells are ER-negative. The Allred score that classifies breast cancers 
using immunohistochemistry and takes into account both the proportion of cells positively 
stained and the intensity of the staining finds MCF-7 cells have an Allred score of 10, 
whereas MDA-MB-231 cells score 0 (Subik et al., 2010). Therefore, the sensitivity of MDA-
MB-231 cells is not related to the binding of Tamoxifen to the ER and inhibiting estrogen 
signalling.  
 
This suggests that there are additional mechanisms by which Tamoxifen reduces cell 
proliferation. It has been understood for several years that Tamoxifen is not highly selective 
and can, via a number of means, induce apoptosis in ER negative breast cancers. This effect 
has been explored in a number of ER negative breast cancer cell lines including MDA-MB-
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231, MDA-MB-468 and SK-BR-3, where Tamoxifen is found to concentration-dependently 
induce apoptosis. The mechanisms by which this occur are numerous. One such mechanism 
is the down regulation of the oncoprotein CIP2A, which is overexpressed in a number of 
breast cancers (Mumby, 2007) and resultant down regulation of p-Akt (C.-Y. Liu et al., 
2014), suggesting apoptosis is mediated via the CIP2A/PP2A/p-Akt pathway as shown in  
Figure 3-24. CIP2A levels are reduced through a Tamoxifen-dependent transcription down 
regulation both directly and through the inhibition of Elk1 which reduces CIP2A promoter 
activity (C.-Y. Liu et al., 2014).  
 
Another mechanism by which tamoxifen interacts with breast cancer cells in an ER-
independent mechanism is by inhibiting cellular proliferation through a reduction in a cells 
capacity to uptake glutamate (Todorova et al., 2011). As explored in the introduction, 
transformed cells are often metabolically highly reliant on glutamine and therefore inhibiting 
its uptake will have adverse effects on the cell. The understanding that Tamoxifen can exert 
an effect on ER negative breast cancers could explain the observations that MDA-MB-231 
cells tested in this experiment and in the work of additional groups observed in the literature, 
appear sensitive to treatment with Tamoxifen.  
 
 
Figure 3-24 Molecular mechanism of the pro-apoptotic effect of Tamoxifen via the CIP2A/PP2A/p-Akt 
pathway. p-Akt inhibits apoptosis. Tamoxifen indirectly inhibits CIP2A. In turn, there is less CIP2A available to 
inhibit PP2A. PP2A levels are elevated, which downregulate p-Akt and therefore limit its ability to inhibit 
apoptosis. 
 
 
 
Cisplatin is a chemotherapeutic agent approved for the treatment of a number of cancer types 
in the late 1970s (Dasari and Tchounwou, 2014a). Limiting the usefulness of this agent in 
cancer therapy is its off target undesirable side effects including compromised immunity, 
gastrointestinal disorders and kidney damage (Arany and Safirstein, 2003). Cisplatin has not 
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been a first line treatment for breast cancer for reasons including the aforementioned toxicity. 
Furthermore, ER-positive breast cancers have been found to be relatively insensitive to this 
agent compared to other breast cell lines (Yde and Issinger, 2006). In agreement with the 
literature, examination here of clonogenic cell survival in MCF-7 cells found that this was 
only affected by the highest tested dose of cisplatin, showing less sensitivity than in MDA-
MB-231 cells. Contrastingly, cell viability as detected by MTT assay is greatly compromised 
by cisplatin treatment in a dose dependent manner in MCF-7 cells and that in this assay, these 
cells show greater sensitivity to the chemotherapeutic agent than MDA-MB-231 cells.   
 
Having established differential sensitivities of MCF-7 and MDA-MB-231 cells to cisplatin, 
further experimentation was carried out to looking at the effect of the drug on energy 
producing pathways and metabolism of these cell lines. Notably, without treatment, the 
results presented in this chapter show that  basal energy phenotype of MCF-7 cells utilises a 
balance of mitochondrial and glycolytic respiration, Figure 3-3, whereas the basal energy 
phenotype of MDA-MB-231 cells primarily utilise glycolysis. A common feature of many 
cancer cells is the preferential use of glycolytic respiration as opposed to mitochondrial 
oxidative phosphorylation, however, not all cancers rely on glycolysis (Zu and Guppy, 2004; 
Herst and Berridge, 2007; Suganuma et al., 2010). MCF-7 cell lines have been found in a 
number of studies to gain the majority of cellular energy from oxidative phosphorylation. 
Guppy et al find MCF-7 gleans 80% of energy from oxidative phosphorylation and 
Rodríguez-Enríquez et al find this to be 91%. These values are significantly higher than the 
findings presented in this chapter, which suggest closer to 50% of energy is gained from 
oxidative phosphorylation. However, this difference could be due to the oxygen availability 
in the experiments. Rodríguez-Enríquez et al find that in hypoxic conditions, the energy 
gained from oxidative phosphorylation drops to 36% (Guppy et al., 2002; Rodríguez-
Enríquez et al., 2010). In the experimental conditions used for the experiments detailed in 
this chapter, there may be a limitation on available oxygen to the MCF-7 cells, limiting 
oxidative phosphorylation and increasing the proportion of energy gained from glycolysis. 
Future experiments monitoring oxygen levels in experimental conditions could confirm this. 
The findings here that MDA-MB-231 cells primarily use glycolysis is consistent with 
metabolic profiling of these cells in the literature (Robey et al., 2005). Pelicano et al observe 
a reduced capacity for mitochondrial respiration in TNBC cell lines including MDA-MB-231 
cells, which leaves them dependent on glycolysis and the inhibition of glycolysis is highly 
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effective in targeting TNBC cells despite their resistance to other anticancer agents (Pelicano 
et al., 2014a). Lanning et al observe the preferential use of glycolysis in MDA-MB-231 cells 
through an energy phenotype test (Lanning et al., 2017). 
 
Treatment with cisplatin slightly reduced levels of glycolysis and slightly increased levels of 
mitochondrial respiration compared with untreated cells. This treatment also appeared to 
reduce the ability of the cells to increase glycolytic respiration in response to an increase in 
energy requirements. Cisplatin also affects the energy phenotype of MDA-MB-231 cells, 
reducing basal levels of both mitochondrial and glycolytic respiration but having a greater 
effect of glycolysis. Additionally, as observed with MCF-7 cells, following treatment with 
cisplatin, the ability of MDA-MB-231 cells to upregulate glycolysis in response to a stressor 
is reduced. This suggests that cisplatin reduces glycolytic capacity of this cell line and is 
consistent with literature for MDA-MB-231 cells. Both Wang et al, and Alborzina et al 
observed reduced glycolysis in MDA-MB-231 in response to cisplatin treatment and a 
reduction in cell survival (Alborzinia et al., 2011; S. Wang et al., 2016). 
 
Consistent with the observations presented in this chapter, where cisplatin reduces the 
capacity of MCF-7 cells for glycolytic respiration, cisplatin-induced inhibition of glycolysis 
has been observed in several cancers. Additionally, in most of these studies, the inhibition of 
glycolysis reduces cell survival and proliferation, also in line with the findings shown here. 
Wang et al observe that cisplatin inhibits growth and proliferation of cervical and breast 
cancer cells through the inhibition of glycolysis. They found that by upregulating key 
enzymes involved in glucose metabolism, including GLUT1, could reduce the inhibition of 
glycolysis by cisplatin (S. Wang et al., 2016). Shirmanova et al, through monitoring the 
effect of cisplatin on cellular redox-ratios speculate that the drug is inhibiting glycolysis in 
HeLa cells and this is impacting proliferative capacity (Shirmanova et al., 2017). Decreases 
in mitochondrial respiration and glycolysis have also been observed following cisplatin 
treatment, examining a number of cancer cell lines, Alborzina et al find initially following 
cisplatin treatment mitochondrial respiration is reduced and at later time points glycolysis 
decreases (Alborzinia et al., 2011). This finding is also observed in a number of in vivo 
studies including research by Shah et al examining redox-ratios in xenografts. They see a 
reduction in glycolysis that proceeds a reduction of the tumour size (Shah et al., 2015). 
MDA-MB-231 cells are less sensitive to glycolytic inhibitors than MCF-7 cells as found by 
Xinataropoulou et al, which suggests that, consistent with the observations in this chapter, 
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this cell line performs higher levels of glycolysis (Xintaropoulou et al., 2015). In addition, in 
vitro metabolomics studies using LC-MS carried out by Yang et al compared relative 
utilisation of glycolysis in MDA-MB-231 cells compared with MDA-MB-468 cells. The 
group found MDA-MB-231 cells to utilise between 80% and 100% glycolysis to generate 
energy, whereas MDA-MB-468 cells use between 20% and 70%. These findings were 
supported by observations of significantly higher uptake of glucose >2-fold and higher 
production of lactate, with the lactate concentration in the media found to be almost 4-fold 
higher after only one hour (Yang et al., 2016).  
 
Doxorubicin is an anthracycline antibiotic that has been used in cancer treatment for more 
than 30 years. Individual treatment of MCF-7 cells with doxorubicin in this chapter found 
that the drug has a significant impact on clonogenic cell survival even at low doses Figure 
3-2ii(B). The same effect was not observed with the cell viability assay, however. In contrast 
to these findings, where even 20uM treatment with doxorubicin did not significantly impact 
cell viability Figure 3-2ii(A), many groups identify IC50s in the nanomolar range including 
Smith et al and Fang et al. However, these groups do not specify length of treatment with 
doxorubicin and may be greater than the 24-hour exposure used in the experiments presented 
here (Smith et al., 2006; Fang et al., 2014). Pilco-Ferreto and Calaf specify 48 and 24-hour 
incubations of MCF-7 and MDA-MB-23 cells with doxorubicin and find IC50 values 
between 4μM and 8μM, finding MCF-7 cells to show more resistance to the drug (Pilco-
Ferreto and Calaf, 2016). Similarly, utilising a Sulforhodamine B (SRB) cell viability assay, 
Oncul and Ercan determine a similar IC50 for MCF-7 cells of 8.3μM (Oncul and Ercan, 
2017). Single drug evaluation of doxorubicin in MDA-MB-231 cells follows a similar pattern 
to that observed in MCF-7 cells. Cell viability was unaffected by the doses tested, but 
clonogenic cell survival was significantly negatively affected, with a calculated IC50 of 
0.2μM for MDA-MB-231 cells. Similar investigations from other groups find cell viability is 
impacted by low doses of doxorubicin, with Oncul and Ercan calculating an IC50 for these 
cells of 7μM and in another group’s MTT investigation, IC50 for MDA-MB-231 cells is 
1μM (Pilco-Ferreto and Calaf, 2016; Oncul and Ercan, 2017). The effectiveness of 
doxorubicin has been and continues to be limited by off target dose-dependent toxicity 
(Lovitt, Shelper and Avery, 2018), therefore the effect on MCF-10A non-cancerous cell line 
was also analysed. The selected concentration range had no significant effect on MCF-10A 
cell viability. Prior research examining doxorubicin in this cell line found the cells are 
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sensitive to variable concentrations, Polco-Ferreto and Calaf calculate the IC50 to be 1μM 
and Abdullah et al find this to be in the nanomolar range. However, this is with cells treated 
for 48h and 72h respectively. At a shorter exposure time, cell viability is less affected by the 
same dose range (Pilco-Ferreto and Calaf, 2016).  
 
Doxorubicin altered the relative use of glycolytic and mitochondrial respiration pathways, 
reducing basal glycolysis but not mitochondrial respiration in MCF-7 cells. Doxorubicin 
treatment appears to enhance the ability of cells to respond to a stressor, with increases in 
both energy producing pathways exceeding that observed in untreated MCF-7 cells. 
Contrastingly, treatment with doxorubicin enhances the ability of MDA-MB-231 cells to 
utilise glycolytic and mitochondrial respiration pathways. This is observed under basal levels 
and following exposure to a stressor. The direct effects of doxorubicin on the main energy 
generating pathways of cells have not been well explored in cancer, but a number of studies 
identify the inhibition of doxorubicin as a method of sensitising cells to the drug (Pelicano et 
al., 2006; Bean et al., 2014). Strigun et al find doxorubicin reduces glycolysis in 
cardiomyocytes (Strigun et al., 2012).  
 
Cancer requires high levels of energy to drive uncontrolled cell division. Metabolically 
cancer cells differ from non-transformed cells (Willmann et al., 2015). Therefore, the 
potential of two metabolic disruptors (GW4064 and doxorubicin) is explored in combination 
with traditional cancer chemotherapeutics to target breast cancer cell lines. Metformin is 
currently the primary therapy used for the treatment of type 2 diabetes mellitus (TIIDM), 
reducing blood glucose levels (Gong et al., 2012). The cytotoxic effects of metformin and 
thus its potential for use as an adjuvant treatment for traditional chemotherapeutics has been 
noted in a number of different cancer types. These include neck squamous cell carcinoma, 
glioblastoma and breast cancer (Lee et al., 2014; Lin et al., 2014; Würth, Barbieri and Florio, 
2014). Marinello et al explored the effects of this drug on MCF-7 and MDA-MB-231 cells 
specifically. The group observe metformin significantly reduces cell viability of these cell 
lines, with MCF-7 cells showing greater sensitivity to the drug (Marinello et al., 2016). 
Metformin has also been found to inhibit colony forming ability of MCF-7 cells, Ariaans et 
al observed this with 3-4mM metformin proving sufficient to reduce colony formation by 
50% depending on glucose concentration in the medium (Ariaans et al., 2017). In line with 
the literature, results presented in this chapter show that MCF-7 cell viability is significantly 
affected by 24-hour treatment with metformin and this cell line is slightly more sensitive to 
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these effects than MDA-MB-231 cells. Additionally, metformin decreased clonogenic cell 
survival of MCF-7 cells, with 20mM metformin significantly reducing colony forming 
ability. The response in MDA-MB-231 cells follows the same pattern as in MCF-7 cell lines. 
The cell viability and ability to form colonies are significantly affected by the drug. Little 
difference is observed in the sensitivity of these two cell lines to metformin, which contrasts 
findings by Marinello et al. they observe similar patterns of response to metformin but 
greater sensitivity in MCF-7 cells (Marinello et al., 2016). Lanning et al, in an investigation 
into metabolic profiles of TNBC cell lines, examine the effect of metformin on cell viability 
and find that in agreement with data presented in this chapter, MDA-MB-231 cells are 
sensitive to this drug (Lanning et al., 2017). In addition to the effects of metformin on breast 
cancer cells, the drug has also been associated with offering protection against mammary 
tumour development in a number of longitudinal studies. Therefore, examination of the 
effects of this drug on a non-tumorigenic breast line is important to identify the effect the 
drug could have on cells prior to neoplastic transformation. Experiments in this chapter find 
metformin negatively affects cell viability for MCF-10A cells and that these cells display 
greatest sensitivity to metformin compared with breast cancer cell lines examined 
(Jiralerspong et al., 2009; Giovannucci et al., 2010). These findings are consistent with cell 
viability analysis undertaken by Zhu et al (Zhu et al., 2014). Isrow et al compared the 
mechanistic effect of metformin in MCF-10A and MCF-7 cells and found that the drug did 
not cause cytotoxicity in MCF-10A cells. Mechanistically the group propose that this occurs 
because metformin induces ROS in MCF-7 but not MCF-10A cells. The study examined 
short term exposure to metformin, less than a quarter of the length of the cell viability assay 
presented in this chapter (Isrow et al., 2016), suggesting effects of metformin on MCF-10A 
cells are time delayed in comparison with MCF-7 cells. 
 
The Farnesoid X receptor (FXR) is a ligand-activated transcription factor expressed at high 
levels in a number of human cells. Initially identified in the liver, where it regulated bile acid 
metabolism, in recent years, FXR expression has been identified in the breast, and 
specifically in ductal epithelial cells of both normal and cancerous breast tissue. More 
specifically, expression of FXR is observed in a number of breast cancer cell lines including 
MCF-7, MDA-MB-231 and MDA-MB-468 (Swales et al., 2006a; Alasmael et al., 2016).  
 
The mechanistic diversity of FXR has been studied by a number of groups, who find FXR 
involvement in cellular repair, glucose homeostasis and ROS generation (Cariou and Staels, 
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2007). The expression of FXR in a number of breast cancers, along with its potential to 
negatively impact on tumour growth has raised interest in the potential role of FXR as a 
therapeutic target (Swales et al., 2006). Here, the effect of FXR agonist GW4064 on the 
viability, colony forming ability and energy phenotype of MCF-7 cells is investigated. The 
drug reduced clonogenic cell survival significantly but did not affect the cell viability of this 
cell line, even at concentrations up to 400μM. The insensitivity of MCF-7 cell viability to 
GW4064 in contradicts observations from a number of groups who observe a dose dependent 
reduction in cell viability following GW4064 treatment at significantly lower concentrations, 
calculated IC50 values in the range of 5-30μM (Swales et al., 2006a; Giordano et al., 2011b; 
Singh et al., 2014). MDA-MB-231 sensitivity to GW4064 is greater in terms of cell viability 
and similar when examining clonogenic cell survival. FXR is found to be present in both 
breast carcinoma cells and the surrounding normal breast cells in vitro (Swales et al., 2006a). 
The effect of GW4064 on MCF-10A cells is therefore of interest. In the cell viability assays 
carried out here, this cell line shows greatest sensitivity to the drug compared with MCF-7 
and MDA-MB-231 cells.  
 
FXR has been associated in a number of studies with the suppression of glycolysis. Trabelsi 
et al also find that FXR inhibits glycolysis in enteroendocrine L cells (Trabelsi et al., 2015) 
and Jiao et al observe an FXR-mediated suppression of glycolysis in human hepatoma cells 
(Jiao, Lu and Li, 2015). These studies had not yet been carried out in breast cancer cell lines.  
 
Preferential use of glycolysis is associated with tumorigenic transformation. Thus, the effect 
of potential anti-neoplastic therapies to temper the use of this pathway is important to 
quantify. Energy phenotype test results indicate that under basal and stressed conditions, 
MCF-7 cells utilise glycolysis as their primary energy generating pathway. GW4064 
treatment reduces basal glycolysis but also basal mitochondrial respiration. Notably, 
GW4064 also reduces compensatory glycolysis, reducing the ability of cells to upregulate 
this pathway in response to a stressor. The implications of this are the potentially sensitising 
effect of GW4064 on MCF-7 cells to other chemotherapeutics. Further investigation into the 
energy phenotype involved examination of the relative utilisation of mitochondrial 
respiration and glycolysis. As mentioned in earlier assays, MCF-7 cells use a balance of 
mitochondrial and glycolytic respiration. GW4064 reduces basal levels of both of these 
pathways and reduces the ability of MCF-7 cells to respond to a stressor. As with the 
glycolytic rate assay, this suggests GW4064 sensitises cells to further treatment. The effect of 
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GW4064 on phenotypically distinct breast cancer cell lines has been observed previously by 
Alasmael et al, who show that activation of the nuclear receptor FXR leads to cell death in 
four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor 
positive), MDA-MB-231 and MDA-MB-468 (triple negative). The group propose that the 
mechanism of cell death is largely through the intrinsic apoptotic pathway (Alasmael et al., 
2016). However, despite similar responsiveness to breast cancer cell lines and observations 
that in part GW4064 functions in all of the above lines through the intrinsic apoptotic 
pathway, phenotypically and metabolically, these cells are very different from both MCF-7 
and MDA-MB-231 cells and therefore the mechanism of action may still be in part different. 
This may additionally have further implications when examining combination therapies. The 
energy phenotype of MCF-10A cells shows the cells primarily utilise mitochondrial 
respiration over glycolysis. Thus, inhibition of glycolysis is likely to be less damaging to 
these cells. GW4064 treatment reduces baseline activity overall and the ability to increase 
glycolysis or mitochondrial respiration in response to a stressor. This suggests GW4064 
action also impacts mitochondrial respiration.  
 
 Combination treatment 
 
The concepts of combination therapies and network targeting drugs to treat breast cancer 
have gained a lot of interest in recent years. The superiority of these approaches includes: 
potentially decreased toxic liability through exploitation of drug synergy and the potential to 
repurpose agents not traditionally used in cancer treatment. Additionally, the approach 
minimises potential for the development of drug resistance as cells are often incapable of 
concomitantly adapting to multiple toxic effects of a combination of therapeutics (Bayat 
Mokhtari et al., 2017; Chalakur-Ramireddy and Pakala, 2018).  
 
Related to this is the concept of metabolic reprogramming, where adjustments made to 
tumour cell metabolism through drug treatments sensitise cells to chemotherapeutic 
treatment. Metabolic reprograming can also reduce tumour growth and aggressiveness. 
Nuclear receptors are targets for metabolic reprogramming, due to their central role as a 
transcription factors controlling expression of metabolic proteins. The research in this chapter 
explores the FXR nuclear receptor as an adjuvant therapy for a number of chemotherapeutic 
agents.  
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FXR agonist GW4064 in combination with the SERM Tamoxifen significantly affects cell 
survival and colony forming ability of MCF-7 cells relative to treatment with equivalent 
doses of each drug individually. Furthermore, analysis with SynergyFinder determines that 
this pairwise combination is synergistic across the whole dose range tested. Previous 
experimentation by Mohan et al in agreement with these results, find this combination to be 
synergistic as determined using the Chou-Talay method (Chou, 2010; Mohan et al.,2015). 
While effective treatments have been developed for hormone receptor positive tumours, 
TNBCs remain unresponsive to many current treatments (Ding et al., 2017; Chalakur-
Ramireddy and Pakala, 2018). As discussed above, the benefits of combination therapeutics 
are numerous and have been utilised to tackle TNBC by many groups. FXR activation alters 
clonogenic cell survival, cell viability and cellular metabolism in the TNBC cell line MDA-
MB-231. Additionally, though Tamoxifen is historically not a first line treatment for TNCB 
as its primary mechanism of action surrounds inhibition of estradiol signalling through the 
estrogen receptor, the results shown in this chapter, in line with observations of other groups,  
show this drug does have efficacy in compromising cell viability in TNBC cell lines (Zheng, 
Kallio and Härkönen, 2007; Majumdar, 2010; Todorova et al., 2011; Darakhshan et al., 
2015). As in MCF-7 cells, MDA-MB-231 cells are negatively impacted by this combination. 
Cell viability and colony forming ability are significantly reduced. However, synergy 
analysis found this combination to be largely antagonistic. This is likely due to the individual 
response of MDA-MB2-231 cells to Tamoxifen. These cells are significantly more sensitive 
than MCF-7 cells. Thus, with such high sensitivity to Tamoxifen alone, already achieving 
more than 90% reduction in cell viability, the additional impact GW4064 could have is 
limited. To determine whether this is the reason synergy is not observed in MDA-MB-231 
cells, in addition to the range of GW4064 concentrations explored, a range of Tamoxifen 
concentrations could be tested. As individual treatments, MCF-10A cells are sensitive to both 
Tamoxifen and GW4064. 10μM Tamoxifen alone resulted in a 50% reduction in cell viability 
and GW4064 concentrations between 10μM and 100μM all significantly reduce MCF-10A 
cell viability by more than 50%. The treatment combination of 10 μM Tamoxifen and a range 
of GW4064 concentrations between 10μM and 100μM had no effect on the viability of MCF-
10A cells relative to treatment with tamoxifen alone. The combination of Tamoxifen and 
GW4064 is additive in MDA-MB-231 cells, synergistic in MCF-7 cells, however in MCF-
10A cells appears to be antagonistic. Mechanistically, more studies would be required to 
ascertain how this occurs. However, insensitivity of normal breast lines to this combination 
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where breast cancer cell lines highlights the possibility of this combination to reduce of target 
effects of the individual drugs.  Contrastingly, exploration of the combination of cisplatin 
with GW4064 significantly affected MCF-10A cells. Compared with MCF-7 and MDA-MB-
231 cells, MCF-10A cells show the greatest sensitivity to this combination. 
 
Doxorubicin is a key conventional treatment for breast cancer, whose efficacy is limited by 
dose-dependent toxicity and resistance development. Investigation into sensitising cells to 
Doxorubicin to improve responsiveness and overcome resistance has been carried out 
previously. For Bean et al this sensitisation is achieved using glycolysis inhibitors including 
3-bromopyruvate. The group find that treatment with doxorubicin and 3-bromopyruvate 
significantly decrease mean cell viabilities in wild type and dox-resistant neuroblastoma cell 
lines (Bean et al., 2014). The MCF-7 cell line shows little sensitivity to doxorubicin when 
used as an individual treatment. GW4064 reduces the capacity of MCF-7 cells to utilise 
glycolysis and therefore explore the combination of the anthracycline with GW4064. The 
results presented here show no effect of this combination on cell viability but significant 
effect on clonogenic cell survival. Analysis finds this combination is primarily additive 
across the dose range of GW4064 tested, but at low concentrations some synergy is observed. 
To elucidate the mechanism of effect on MCF-7 cells of this combination, the glycolytic 
metabolism of these cells following treatment was analysed. The absence of key hormone 
receptors renders TNBC insensitive to a large number of breast cancer therapies. Therefore, 
cytotoxic chemotherapeutic agents such as doxorubicin remain the mainstay of treatment for 
triple negative breast cancer (Isakoff, 2010). However, the use of therapeutic doses of 
doxorubicin is limited by the adverse effects to off-target tissues, meaning effectiveness of 
this treatment is reduced (Carvalho et al., 2009) . The examination of doxorubicin as an 
individual treatment in this chapter found the drug had little effect on cell survival and 
viability. MDA-MB-231 cells respond to the combination with reduced viability and colony 
forming ability. The combination is additive, there is no synergistic effect of the drugs in 
combination, but the co-treatment does not hamper the mechanism of either agent.  
 
The effect on the energy phenotype of MCF-7 cells of this combination is an overall 
reduction in basal activity, notably with proportionally a greater reduction in glycolysis than 
in mitochondrial respiration. This suggests the cells are being shifted back to a more normal 
cellular metabolism where glycolysis is not preferentially used under aerobic conditions 
(Lunt and Vander Heiden, 2011). The results in this chapter show that in agreement with the 
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literature, untreated MDA-MB-231 cells primarily utilise glycolysis over mitochondrial 
respiration for energy generation (Robey et al., 2005). The combination resulted in an 
increase in basal glycolysis but a reduction in the ability of these cells to upregulate 
glycolysis in response to a stressor. The inhibited ability to respond to increased energy 
demand is observed in these cells with GW4064 treatment alone.  Examination of the energy 
phenotype of MCF-10A cells was undertaken in response to doxorubicin+GW4064. 
Untreated MCF-10A cells primarily use mitochondrial respiration as opposed to glycolysis. 
This combination reduces baseline activity of MCF-10A cells and in addition reduces their 
ability to respond to increased energy requirements.  
 
 
The use of cisplatin as a first line treatment for breast cancer is confounded by adverse side 
effects and relative insensitivity of hormone receptor positive cell lines to this drug (Yde and 
Issinger, 2006). However, this is often used in the treatment of TNBC and is shown to have 
greater efficacy in these tumours as they often have compromised double-strand DNA break 
repair due to a lack of functional BRCA1 (Elstrodt et al., 2006; Wahba and El-Hadaad, 
2015). Individual treatment with this drug in the experiments here reduced clonogenic cell 
survival but not cell viability as measured using MTT assay. Cisplatin is combined with 
GW4064 to explore whether any synergy exists between the two drugs and whether GW4064 
could sensitise MDA-MB-231 cells to cisplatin. GW4064 as an agent to sensitise cells to 
chemotherapeutics has been investigated by Wang et al in biliary tract cancer cells, who 
performed in vitro and in vivo experiments co-treated these cells with cisplatin and GW4064. 
The group found GW4064 did sensitise cells to cisplatin and in vivo found the co-treatment to 
inhibit tumour growth in mice (Wang et al., 2016). Investion of this combination in MCF-7 
cell lines here, found the combination significantly reduces cell viability and cell survival. 
The combination is highly synergistic across all dose combinations, with greatest synergy 
observed at low GW4064 doses. The effect of this combination in MDA-MB-231 cells was 
very different. The combination negatively effects cell survival but not cell viability. The 
combination is antagonistic as analysed through synergyfinder, suggesting cisplatin offers a 
protective effect over the effects of GW4064 on this cell line. 
 
Cisplatin alone reduces basal levels of glycolysis in MCF-7 cells but did not hamper the 
ability of these cells to upregulate this pathway in response to a stressor. GW4064 reduced 
primarily basal glycolysis as well as mitochondrial respiration and also inhibited the ability of 
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MCF-7 cells to respond to increased energy requirements. In combination, GW4064 and 
cisplatin reduce mitochondrial respiration and the ability of cells to respond to energy 
demands. In MDA-MB-231 cells, the energy phenotype test showed following exposure to 
this combination, MDA-MB-231 cells maintain primarily glycolytic respiration.  
 
Testing the potential of two metabolic disruptors (GW4064 and metformin) in combination 
with traditional cancer chemotherapeutics to target breast cancer cell lines showed that a 
number of these combinations are synergistic. Following this, the combination effects of the 
two metabolic disruptors in combination on cell viability and proliferation in MCF-7 cells 
were explored. 
 
Both metformin and GW4064 are metabolism modulating drugs, neither of which are 
conventionally utilised for the treatment of breast cancer. The effect of metformin has been 
widely studied in breast cancer, from epidemiological studies noting long term metformin 
treatment reduces the likelihood of breast cancer development (Libby et al., 2009a) to short-
term administration of the drug providing anti-cancer properties (Dowling, Goodwin and 
Stambolic, 2011). In MCF-7 cells, the combination is found to be synergistic at all dose 
combinations tested aside from low levels of GW4064 <20μM, whereas in MDA-MB-231 
cells, only additivitiy is observed. There are overlapping mechanisms by which metformin 
and GW4064 exert their action on human cells. GW4064 is an FXR agonist. A link between 
FXR and diabetes was proposed by Duran-Sandoval et al, who found that the expression of 
FXR is related to glucose homeostasis (Duran-Sandoval et al., 2004). The study identified 
that FXR is down regulated in animal models of diabetes, suggesting perhaps the action of 
metformin, an anti-diabetic agent, would reverse the down regulation and result in an overall 
increase in FXR levels within a cell (Duran-Sandoval et al., 2004). If this was the case, FXR 
levels would be increased by the GW4064 and metformin actions within a cell, meaning the 
combination treatment of these two agents increases FXR on multiple levels, exacerbating the 
effect of these elevated levels on the breast cancer cells. Quantification of FXR levels in 
response to metformin would provide evidence as to whether this is the case. 
 
The combination of the metabolism modulating drug metformin with traditional 
chemotherapeutic agents was also explored. Metformin is combined with a classical 
treatment for hormone receptor positive breast cancer, Tamoxifen and with doxorubicin, a 
first line treatment for many TNBCs. 
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In MCF-7 cells, the combination of doxorubicin and metformin was found to be antagonistic 
at the majority of concentration combinations tested, with some synergy observed at lower 
concentrations. Where in MCF-7 cells, the combination of doxorubicin and metformin is 
antagonistic, in the TNBC model cell line, it is synergistic across the majority of doses tested. 
This could be due to the greater reported sensitivity of MDA-MB-231 cells to ROS. 
Generally, levels of reactive oxygen species (ROS) are higher and oxidative stress is greater 
in cancers compared with normal cells. Elevated ROS can aid tumour progression and cancer 
development, but beyond a certain level can result in ROS-mediated apoptosis. Therefore, 
accordingly, the antioxidant capacity of cancers and cancer cell lines is increased to provide 
protection against high levels of ROS (Liou and Storz, 2010). The balance of sufficient ROS 
to promote tumourigenesis yet no so much as to induce apoptosis is critical for cancer cell 
survival and accordingly many anticancer drugs seek to disrupt this balance. Research into 
oxidative damage in MDA-MB-231 cells and MCF-7 cells found that with matched exposure 
to ROS, MDA-MB-231 cells experienced more cellular damage than MCF-7 cells. As 
explored in detail in the introduction, a component of the mechanism of metformin in 
inhibiting breast cancer progression is the generation of ROS. Additionally, one of the two 
main mechanisms by which doxorubicin affects cancer cells is through the generation of ROS 
(Gewirtz, 1999). The two agents utilised in this pairwise combination can both alter the 
balance of ROS to antioxidants within a cell and increase the likelihood that the cells will 
experience ROS damage and resultant apoptosis. If MDA-MB-231 cells are generally more 
sensitive to damage by ROS than MCF-7 cells, the efficacy of the outlined combination 
treatment is likely to be higher. With particular concentrations of metformin or doxorubicin 
alone, the cells may be able to mediate the effects of the elevation of ROS with antioxidants. 
With the combination treatment, it could result in an elevation of ROS beyond a level that 
can be compensated for by antioxidants present in the cell.  
 
The analysis of the combination of Tamoxifen with metformin show that according to all four 
reference models, at high concentrations of metformin and low concentrations of Tamoxifen, 
some synergy is observed between the two drugs. The Bliss and HSA models also show 
synergy at low concentrations of metformin with low concentrations of Tamoxifen, where 
this is not observed in the output from the Loewe and ZIP models. As discussed above, the 
Bliss reference model does not allow distinction between additive or synergistic effects of a 
pairwise combination and is thus prone to overestimating synergy between drugs. In MDA-
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MB-231 cells, for the pairing of Tamoxifen with metformin, output from three of the four 
synergy analysis reference models; Bliss, HSA and ZIP have positive synergy scores from 5-
10, showing overall in MDA-MB-231 cells, there is a synergistic relationship between 
Tamoxifen and metformin at the concentrations investigated.  As individual treatments, 
MCF-10A cells are sensitive to both Tamoxifen and GW4064. 10μM Tamoxifen alone 
resulted in a 50% reduction in cell viability and GW4064 concentrations between 10μM and 
100μM all significantly reduce MCF-10A cell viability by more than 50%. The treatment 
combination of 10 μM Tamoxifen and a range of GW4064 concentrations between 10μM and 
100μM had no effect on the viability of MCF-10A cells relative to treatment with tamoxifen 
alone. The combination of Tamoxifen and GW4064 is additive in MDA-MB-231 cells, 
synergistic in MCF-7 cells, however in MCF-10A cells appears to be antagonistic. 
Mechanistically, more studies would be required to ascertain how this occurs. However, 
insensitivity of normal breast lines to this combination where breast cancer cell lines 
highlights the possibility of this combination to reduce of target effects of the individual 
drugs.  Contrastingly, exploration of the combination of cisplatin with GW4064 significantly 
affected MCF-10A cells. Compared with MCF-7 and MDA-MB-231 cells, MCF-10A cells 
show the greatest sensitivity to this combination.  
 
Examination of the energy phenotype of MCF-10A cells was undertaken in response to 
doxorubicin+GW4064. Untreated MCF-10A cells primarily use mitochondrial respiration as 
opposed to glycolysis. This combination reduces baseline activity of MCF-10A cells and in 
addition reduces their ability to respond to increased energy requirements.  
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3.7 Conclusion 
 
For several treatments and combinations, greater sensitivity is observed in clonogenic cell 
survival assays than in MTT cell viability assays. These differences are likely due to 
differences between the assay types. MTT assays measure mitochondrial function after 24-
hours of treatment. Therefore, the effect of agents that do not directly affect mitochondrial 
function or do not affect this within 24 hours may be missed by this assay. Clonogenic assays 
measure proliferation directly and over a longer time period (14 days), which is likely 
sufficient time to observe the impact of agents that may slow proliferation without directly 
impacting mitochondrial respiration.  
 
Additionally, cell line differences observed in MTT assay results are often not seen in the 
clonogenic assay. This again is likely due to differences in assay types. In the clonogenic 
assays, the fact that only two concentrations are compared, and the time period examined is 
long (14 days), means the assay may not have sufficient resolution to observe the cell line 
differences that an MTT can capture. 
 
Despite these inconsistencies, there are many consistent conclusions. As expected, consistent 
with literature, established SERM Tamoxifen causes a dose dependent reduction in cell 
survival and viability in MCF-7 ER-positive cell line. Surprisingly, TNBC cell line MDA-
MB-231 showed greater sensitivity to this treatment than MCF-7 cells. Efficacy of 
Tamoxifen in TNBC cells aligns with the results from a number of groups. Mechanistically, 
this is proposed to occur through pathways including a Tamoxifen-mediated inhibition of 
glutamate uptake and an inhibition of the CIP2A/PP2A/p-Akt pathway which inhibits 
apoptosis in cancer cells (Liu 2014). Furthermore, consistent with the literature, in the 
experiments here, non-transformed MCF-10A cells show sensitivity to Tamoxifen induced 
cytotoxicity (Yaacob., et al 2014).  
 
MCF-7 cells are sensitive to cisplatin and undergo a reduction in glycolytic respiration 
following treatment. The cell survival of MDA-MB-231 cells is negatively affected and these 
cells also undergo reduced glycolysis following cisplatin treatment. However, cell viability 
was unaffected across the dose range. 
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Single agent treatment with doxorubicin did not compromise cell viability in any of the cell 
lines tested here but did reduce clonogenic cell survival. This is likely observed as 
doxorubicin prevents DNA replication but does not directly kill cells. The cell viability 
assays measure mitochondrial function which may not be affected by doxorubicin within 24 
hours. Therefore, the effect of the drug is only seen in clonogenic assays which measure 
proliferation directly and over 14 days.  
 
Doxorubicin reduced glycolysis in MCF-7 cell but increased this in MDA-MB-231 cells. 
This suggests the drug does not affect the ability to cells to use this pathway and in MDA-
MB-231 cells may act as a stressor for cells to upregulate energy generating pathways. 
 
Metabolism modulating drug metformin alone significantly reduced cell viability in all cell 
lines examined and interacts synergistically with doxorubicin and Tamoxifen in MDA-MB-
231 cells across all concentrations tested. In MCF-7 cells these combinations are also 
synergistic but only at particular dose combinations.  
 
GW4064 alone reduces cell viability in MDA-MB-231 and MCF-10A cells and cell survival 
in MDA-MB-231 and MCF-7 cell lines. In each cell line, this drug reduces glycolytic 
respiration and overall ability of the cells to respond to increased energy requirements, likely 
sensitising these cells to further treatment.  
 
GW4064 combinations with traditional chemotherapeutics are synergistic in MCF-7 but not 
MDA-MB-231 cell lines. Notably, GW4064+Tamoxifen reduces cell survival in MCF-7 cell 
lines, is worse than Tamoxifen alone in MDA-MB-231 cells and has no effect on cell 
viability in non-transformed MCF-10A cells. This highlights a combination therapy that 
appears selective only for a particular subtype of cancer cells.  
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Chapter 4 
 
4 In Silico Model of Breast Cancer Cell 
Lines: Modelling and Validation 
 
 
 
 
Chemotherapeutics are the most common treatment for breast cancer; however, their off-
target toxicities, variable level of efficacy and the ability of breast cancer to develop 
resistance against them has vastly limited their usefulness as a long-term treatment strategy 
(Nounou et al., 2015; Yu et al., 2017). Due to this, there is a need for alternative approaches 
for breast cancer treatment to improve treatment outcomes for patients. One approach that 
has had good success is the use of combination treatment, where individuals are exposed to 
two (or more) cancer chemotherapeutics at the same time (Chalakur-Ramireddy and Pakala, 
2018). As shown in Chapter 3, such combinations have the potential to exhibit synergy, 
allowing an increase in drug efficacy, a reduction in adverse effect profile, and a reduction in 
the risk of drug resistance developing (Mokhtari et al., 2017). While highly successful, this 
approach has been limited to the use of currently developed chemotherapeutics in 
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combinations designed after the individual drugs are developed, rather than identifying an 
optimal combination of biological actions and then developing/re-purposing drugs to target 
these biological pathways.  In this chapter, such a network targeting method of tackling 
breast cancer is explored. The concept of synthetic lethality will be exploited, approaching 
both from an intuitive study of cancer biochemistry as well as through systems biology 
paradigm.  
 
 
4.1 Motivation for the use of Systems Biology in Cancer 
treatment development 
Cancer is a complicated, multi-stage, heterogeneous disease. This complexity means that 
reductionist approaches to understand the development and treatment of cancer are 
particularly limited. For example, cancer can arise as a result of a number of interactions 
between genes and proteins at the molecular level, between cell types and tissues at the 
cellular level, and is further complicated by individual patient differences (Rivenbark, 
O’Connor and Coleman, 2013). Therefore, the ability to create dynamic multi-scale models 
representing all stages of biological organisation increases the usefulness of computational 
models in understanding disease progression and predicting the effects of medical 
interventions on a system. 
 
At the genetic level, combinations of, or in rare instances individual, genetic aberrations can 
result in a cell escaping normal control of the cell cycle and evading tumour suppression 
(Land et al., 1983). Once such malignant transformation has occurred, alterations in the 
relative expression of genes arise, resulting in a number of differentially expressed genes 
(Chuang et al., 2007). Epigenetic alterations add another layer of complexity to the 
progression of cancer (Laird, 2005), and the interaction of genetic, epigenetic and the 
resulting emergent phenotypes are key reasons for the utility of multi-scale in silico models 
to explore this disease and its treatment.  
 
At the patient level, additional complexities arise from intra- and inter-tumour heterogeneity, 
as well as heterogeneity between patients. Again, a computational biology approach is 
advantageous here as it allows the incorporation of data on individual differences gathered 
from clinical datasets. The intracellular complexities described above are matched by tissue 
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level and cellular intricacies. This includes interactions within the tumour microenvironment 
that contribute to cancer progression, including: the stimulation of angiogenesis; alterations 
to the extracellular matrix (Wang et al., 2017); and, metabolic changes (Smallbone et al., 
2007). Furthermore, interactions with tissues outside of the direct tumour microenvironment 
contribute to the trajectory of cancer progression and likelihood of metastasis, a critical 
determining factor in patient prognosis (Smallbone et al., 2007). 
 
The aforementioned intricacies and heterogeneity of cancer render reductionist approaches to 
treatment development severely limited in scope. These complexities also present challenges 
in generating meaningful computational biology models. Despite this, many in silico models 
capturing parts of the cancer process have been generated, and these have provided novel 
insights into cancer biology. Furthermore, the generation (Lander et al., 2001) and increased 
availability of large -omics datasets has enabled the incorporation of multi levels of cancer 
complexity into single models (Edgar et al., 2002).  
 
Computational modelling of cancer biology has been used to explore a number of different 
scales of biological organisation, including: signalling networks incorporating metabolism 
and biochemical pathways modelled dynamically; reaction networks using statistics to 
determine interactions; tumour microenvironment; and, tissue level interactions modelled 
using agent-based models (Wijeratne and Vavourakis, 2019).  
 
4.2 Development of a dynamic multi-scale, computational model 
of breast cancer 
 
 
Here, a computational model of a breast cancer cell is reconstructed, integrating a genome-
scale metabolic model, key gene and signal regulatory components and a kinetic model of the 
cell cycle. Once this general model was reconstructed, it was constrained using literature and 
de novo generated data to represent specific breast cancer cell lines or subtypes. The model 
was validated against its ability to reproduce known biology of the breast cancer cell lines 
under study, and then used to explore metabolic chokepoints and vulnerabilities and to 
identify novel targets for breast cancer treatment. The model is represented in Figure 4-1. 
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Figure 4-1. Diagram representing components of the breast cancer model created, how they are linked to one 
another and how the model is constrained. The model comprises a genome scale metabolic model (GSMM) a 
fully kinetic model of the cell cycle built as a Petri net and representations of estrogen and progesterone receptor 
signalling within the GSMM and as a Petri net. The signalling network is linked to the GSMM and cell cycle 
components of the model through genes whose expression are differentially regulated in response to estrogen or 
progesterone, that exist within the cell cycle model or GSMM. The cell cycle component is linked to the GSMM 
through the biomass reaction, when there is modelled cell cycle progression, this stimulates biomass production. 
The model is constrained through the congruency approach and restriction bounds are restricted based on 
metabolomics CORE data and from experimental data. A gene essentiality scan is run on this completed model 
to identify reactions critical for biomass production as potential drug targets. 
 
The methods for the generation of this model are detailed in section 2.3.2.1 ‘Methods and 
Materials: Stages of Model Development’. Below the methods are described in brief, 
alongside the rationale behind incorporation of each model element.  
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 Model components 
 
The model comprises three critical elements, i) a genome-scale metabolic model, ii) a gene 
and signal regulatory network and iii) a cell cycle model. 
 
i) A genome-scale metabolic model (GSMM) is a mathematical representation that captures 
all possible metabolic interconnections within a cell. The GSMN used in the current model is 
Recon 2, the most comprehensive general reconstruction of human metabolism openly 
available. Recon 2 is open to continual curation, allowing both improving accuracy and 
growth (Swainston et al., 2011; Thiele et al., 2013). GSMNs represents the complete set of 
chemical reactions relating to metabolism that occur within a genome; they can either be 
general and contain all possible reactions (e.g. Recon2), or cell-type specific, containing only 
those reactions known to occur in a particular cell type (e.g. HepatoNet) (Gille et al., 2010). 
Capturing this entire set of metabolic reactions is critical for studying complex diseases, and 
have been used by a number of groups to study differential metabolism in cancer (Lewis and 
Abdel-Haleem, 2013) and to identify drug targets and the effects of drugs on a system 
(Folger et al., 2011). 
 
ii) A limitation of GSMNs is that such constraint-based modelling approaches represent the 
steady-state; as such, they are not able to explore the dynamic changes that occur within a 
cell upon drug exposure or disease transformation. To address this limitation, a number of 
approaches have been suggested, including the QSSPN approach developed at The 
University of Surrey (Fisher et al., 2013). As gene and signalling regulatory networks are part 
of the complexity of cancer progression and additionally provide potential points for drug 
targeting, it is important to include them in such models. The estrogen and progesterone 
receptors were selected for inclusion as there is clear evidence around the influence hormone 
receptor status has over breast cancer aggressiveness and therapeutic options. 
 
iii) A kinetic model of the cell cycle was also incorporated into the final model because: (1) 
dysregulation of cell cycling is a key phenotype of cancer; (2) a number of cell cycle proteins 
are known to be differentially regulated by ER and PR signalling; and, (3) a number of drugs 
are cell cycle specific and function at particular stages within the cell cycle or by inhibiting 
its progression. The cell cycle model was reconstructed in Petri net formalism from the 
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published model of Tyson and Novak and validated against the original model behaviour 
(Tyson and Novak, 2001). 
 
These are the three main components that make up this dynamic model of breast cancer. Each 
section is also parameterised and linked to the other components of the model as shown in 
Figure 4-1. 
 
 
 Parameterisation 
 
The reason to focus on parameterisation of the model is that context- and cell-type specific in 
silico models of biological systems should increase the accuracy of predicted emergent 
properties. For a completely unconstrained model, it is theoretically possible to achieve any 
solution; conversely, a fully constrained model (e.g. a series of ordinary differential 
equations) will be completely reproducible and have only one solution. When working with a 
mixture of formalisms constraints are used to reduce the solution space and thus increase the 
likelihood that predicted solutions will reflect  in vivo biology (Machado et al., 2012; Orth et 
al., 2010). 
 
All GSMNs have two basic constraints: reaction stoichiometry and thermodynamics (Orth et 
al., 2010). In addition, two further constraints were used within the current model: first, any 
reactions that are not active in the particular cell line or tumour being modelled are removed 
through the congruency approach; second exchange reactions were parameterised so that they 
represent known metabolite consumption rates.  
Both of these additional constraints are achieved using the MuFINs tool. The congruency 
approach was employed to integrate ~omics data with Recon2. Briefly, the congruency 
approach predicts a flux distribution for a GSMN using an expression dataset as the objective 
function. Fluxes through reactions mapped to proteins marked as absent in the omics dataset 
are minimized, based on the assumption that if no mRNA/protein is present then these 
reactions should not occur. The output therefore creates a scenario-specific version of the 
GSMN, in this case representing specific breast cancer cell lines. It should be noted that all 
reactions encoded in the GSMN are used for optimization; in this project, both metabolism 
and transport (from Recon2) and ER non-genomic signalling (hard coded in the project) are 
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optimised. This is a distinct advantage of coding the regulatory network into the GSMN as it 
allows a more refined context-specific GSMN to be created.  
Creation of context-specific GSMNs can be achieved using several different approaches; 
here, the Integrative Metabolic Analysis Tool (iMAT), and its derivative fastiMAT were 
utilised through the MuFINS program. The tool is based on a method developed by Shlomi et 
al (Shlomi et al., 2008; Zur, Ruppin and Shlomi, 2010). To inform the congruency approach, 
it is necessary to decide which transcripts are expressed (present) and which are not 
expressed (absent) in a given cell-type. Transcriptomic data for each cell line was used, and 
the affymetrix absence/present (A/P) calls used. This data is then collated into a tab delimited 
table. This serves as the input for fastiMAT, along with the Recon2 model with ER non-
genomic signalling included. A sample script for running iMAT is included in the 
supplementary material (Appendix 7). 
 
Parameterisation of exchange reactions is achieved through altering the reaction bounds. The 
method for this is described in 1.15.3. Here, a two-stage approach was taken: first, exchange 
reactions for nutrients unavailable in the particular context of the cell being modelled are 
completely closed (i.e. 0,0); second, the work of Jain et al presents production and 
consumption rates for 219 metabolites across the entire NCI60 cell line collection (Jain et al., 
2012) This production/consumption data is available from 
https://dtp.cancer.gov/databases_tools/data_search.htm. The sixty cell lines are part of the 
National Cancer Institute database, and includes MCF-7 and MDA-MB-231 breast cancer 
lines (Shoemaker, 2006). Presuming that these rates are at the upper end of physiological, as 
transformed cell lines have a high metabolic demand, it is possible to use them to limit the 
consumption flux (commonly the LB): for example, the glucose flux reaction can be changed 
from -1000,1000 to -1.723855,1000.  
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 Signalling and regulatory network incorporation 
 
This was achieved in two stages. 
i) The required signalling network was extracted, based on the literature and on the 
Reactome Pathway Knowledgebase (Fabregat et al., 2018). It represents the known 
molecular interactions included in the path from hormone receptor to transcription 
factor and to gene (for ER and PR). The network was written into a set of linear 
equations which were pasted directly into the GSMN.  
 
ii) Once activated, the ER and PR cause transcriptional activation of a set of target 
genes. This set of target genes was generated using microarray and ChIP-seq data. 
Initially, target genes were identified by examining genes differentially expressed in 
response to progesterone or estradiol treatment (microarray data). Next, ChIP-seq data 
was used to determine which of these differentially regulated genes contained binding 
sites for ER and PR (i.e. were direct targets of the receptor). Genes that were 
differentially regulated in response to these treatments and were binding sites for ER 
or PR were incorporated into the Petri-net model. 
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4.3 Results for in silico analysis 
 Linking gene and signalling regulatory network to GSMN 
 
 Microarray data analysis 
 
Data was selected from studies generating microarray data for MCF-7 and other ER-positive 
breast cancer cell lines in the presence and absence of estrogen or progesterone, or an 
analogue of these hormones. The details of the experiments and data used are presented in 
section 2.3.2.2, Table 2-6 and Table 2-7. Each dataset was paired with an appropriate control, 
and the two conditions compared in terms of the expression level of all genes. This analysis 
was carried out using the R Bioconductor package, including the tools: Biobase 2.30.0, 
GEOquery 2.36.0, limma 3.26.8 (Huber et al., 2015).  
 
The output of this analysis provides, for each gene measured by the array: the adjusted p-
value for the statistical analysis, the log fold change of gene expression between the control 
and experimental conditions, and annotations including gene symbol and title. Those genes 
with an adjusted p-value 0.05 or lower and displaying a fold change in expression of greater 
than two-fold were selected from each experiment. These were then sorted into either 
positive or negative fold changes and those genes that were differentially expressed across 
three or more microarray experiments were selected for comparison with ChIP-Seq analysed 
data. In this way, only the most consistent gene changes were carried forward, as these are 
most likely to be biologically-relevant  
 
Table 4-1 and Table 4-2 details those genes with an adjusted p-value 0.05 or lower and with a 
fold change of greater than two, and that are differentially expressed across three or more 
microarray experiments.  
  
 ChIPseq data analysis 
 
While DNA microarray analysis identifies changes in transcriptome level, it does not provide 
information on the cause of this change. For example, an increase in transcript level in 
response to progesterone could be a result of direct action of the activated progesterone 
receptor on the promoter of the target gene; alternatively, it could reflect an indirect action 
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where intermediary steps exist between the activated receptor and the impact on target gene 
transcription. To differentiate these two actions, chromatin immunoprecipitation (ChIP) data 
was used to identify direct links between proteins (e.g. progesterone receptor) and the 
genome (e.g. target gene promoters). ChIP assays can provide a picture of where a particular 
protein binds to DNA within a genome at a particular time point. The primary stages of this 
technique involve: (i) stabilisation of protein-DNA interactions via crosslinking, for example 
with formaldehyde or ethylene glycol bis-(succinimidyl succinate) (EGS). This allows the 
examination of unstable or transient protein-DNA interactions. (ii) cell lysis and differential 
centrifugation to isolate nuclear contents. (iii) fragmentation of isolated nuclear material via 
enzymatic digestion or shearing. (iv) immunoprecipitation using an antibody specific to the 
target protein isolates the DNA-protein complex of interest, which can then be affinity 
purified. (v) DNA-protein complexes are disrupted by reversal of cross-linking using 
proteinase K or extreme heating, allowing isolation of the DNA fragments. (vi) Finally, 
sequencing of the DNA fragments is used to identify all the regions within the genome that 
the target protein was bound to (Walker, 2009) (Wold and Myers, 2008).  
 
ChIP-Seq data was sourced from the NCBI database, through which SRR files were located 
and downloaded for analysis. Details of these are in the supplementary material (Appendix 
2). Analysis of these ChIP-Seq files was undertaken using bowtie2-2.2.9. This tool allows 
mapping of ChIP-Seq sequence reads to the human genome. Using the Python programming 
language, .SAM output files from bowtie2-2.2.9 were analysed using the MACS-1.4.2 tool to 
perform peak calling. Peak calling identifies areas within the genome enriched with aligned 
reads, which are the areas where a protein, in this case ER/PR interacts with the DNA (Zhang 
et al., 2008).   
 
Analysis was undertaken on microarray and chipseq data from at least three independent 
experiments, for both estradiol and progesterone treated cells, with the aim of detecting 
common transcriptome changes for each treatment. Appendix Tables 2A and 2B in the 
supplementary material details these experiments and the groups who performed them. 
Wherever possible, data was sourced from experiments with matched conditions including: 
cell line, duration of exposure to progesterone or estrogen, analysis platform and controls 
used. The sourcing and analysis of three separate experimental results and then calculating an 
average of these was undertaken to minimise the effect of any experiment-specific 
differences.  
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 Results from the microarray and ChIP-seq analysis  
 
 Identification of target genes 
 
Those genes differentially expressed following treatment of breast cancer cell lines with PR 
or ER ligands, as identified by microarray, are presented in Table 4-1. Likewise, those genes 
identified as having PR or ER protein binding by ChIP-Seq experiments are presented in 
Table 4-2. 
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Microarray data 
 
Microarray data for genes differentially regulated in response to progesterone or estrogen 
Progesterone Receptor Estrogen Receptor 
Upregulated Downregulated Upregulated Downregulated 
ABAT MPHOSPH10 ADM ACAT2 FABP5 NDC80 SMTNL2 ABCA1 NBEA 
ABHD12 MRFAP1 ANGPT1 ACOT7 FCMR NEMP1 SNX24 ABCC5 NEDD9 
ABLIM3 MSRB1 ANP32E ADORA1 FEN1 NPY1R SOX3 ABCG1 NPAS3 
ACOT6 MT1G ATP11A AREG FGFBP2 NPY1R SPAG5 AMIGO2 PIK3IP1 
ACSL1 MT2A BAMBI ARHGEF26 FHL2 NR5A2 SPATS2L APOD PIK3R3 
ADD3 NDRG1 BICD1 ASB13 FKBP4 NRIP1 SPC25 ARID5B POLQ 
AK4 NET1 CCL2 ATAD2 FMN1 OIP5 STC2 ARL4A PPP1R3C 
ANXA1 NFKBIA CCNO AURKB FOS OLFML3 SYBU ATP6V0A4 RAB20 
ARHGEF37 NUSAP1 EDN1 BLM FOXC1 ORC1 SYTL5 BCAR3 RAB27B 
ARL4A P4HA2 FOXA1 BUB1 GAB2 PBK TACC3 BIK RND3 
ARRB1 PACSIN1 IGSF3 BUB1B GINS1 PCNA TFF1 BLNK RNF144B 
ATAD2 PRICKLE1 KCNS3 C10orf2 GINS2 PCP4 TGFA BTG2 RNF43 
ATP1A1 PRR15L LMCD1 C14orf132 GINS3 PDLIM3 THBS1 CCNG2 RUNDC3B 
ATP1B1 RAB11FIP1 LYPD1 C8orf44-SGK3 GLA PDZK1 TIAM1 CDK6 SEMA4C 
BCL6 RBP2 MEGF9 C8orf46 GMNN PGR TIFA CDKN2B SGCG 
BMF RCAN1 MKX CA12 GREB1 PMAIP1 TIMELESS CORO2A SH3BP4 
CEBPD RHOU MMP1 CALCR HEY2 POLA2 TIPARP CRISPLD2 SHANK2 
CMTM7 RPS6KA5 PREX1 CAV1 HSPB8 POLE2 TIPIN CSTA SLIT2 
CNTNAP2 S100P SERPINB2 CCNA2 IGFBP4 PPM1K TMPO CTNND2 SMAD6 
CREB3L2 SCRG1 SOX2 CDC25A IGSF1 PRIM1 TMPRSS3 CYP1A1 ST8SIA4 
CSRNP1 SEC14L2 TGFB3 CDC45 IL17RB PRSS23 TPD52L1 DDIT4 SYTL2 
CTSH SERPINA3 TM4SF1 CDC6 IL20 PTGES TSKU DRAM1 TACC1 
DEGS1 SGK1 TRIM25 CDC7 IRS2 RAB31 TSPAN5 EFNA1 TBX3 
DLG5 SGPP2 ZBED5 CDCA3 ISG20 RAD51 TYMS ELF5 TFPI 
DUSP1 SLC22A23 ZNF385A CDK1 JAK2 RAD54L UGT2B15 EPAS1 TGFB2 
DYNLL1 SLC25A18  CDKN3 KCNH1 RAI14 WDHD1 FAM110B TM4SF1 
ELOVL5 SLC31A2  CELSR2 KCNK5 RAPGEFL1 XBP1 FGF13 TMPRSS2 
F3 SLC39A14  CENPI KCNK6 RARA  FILIP1L TNFRSF11B 
FAM105A SLC47A1  CENPM KCTD6 RBM24  FUT9 TP53INP1 
FJX1 SLPI  CENPN KIAA0226L RERG  GABBR2 TRERF1 
FKBP5 SRM  CENPQ KIF15 RET  GNAI1 UPK1A 
FOXO4 ST3GAL1  CHEK1 MAD2L1 RFC4  GRB14 ZBTB10 
FXYD3 STAT5A  CHST8 MCM10 RHOBTB1  HCAR3 ZNF467 
GGCT STOM  CKS1B MAD2L1 RHOBTB3  HES1  
GPR124 SYBU  CLIP4 MCM4 RNASEH2A  HILPDA  
GPSM2 TESC  CXCL12 MCM5 RRM2  HIVEP2  
GREB1 THBS1  DBF4 MCM6 SDC2  ID1  
GRHL2 TIPARP  DDX10 MCM7 SERPINB9  ID2  
HMGB2 TRNP1  DEPTOR MELK SFXN2  ID2B///ID2  
HMGB3 TSC22D3  DSCC1 MIR1908 SGK1  ID3  
HSD11B2 WDYHV1  EGR3 MKI67 SGK223  IL1R1  
HSPB11 ZIC2  ELOVL2 MPPED2 SIAH2  KLHL24  
KCNG1 ZNF689  ERCC6L MREG SLC22A5  L1CAM  
KIAA0040 ZNF812  ESPL1 MYB SLC26A2  LIMA1  
LCMT1   EXO1 MYBL1 SLC35F6  LMCD1  
FJX1   FABP5 MYC SLC39A8  LOC100505984  
LOC93622   FCMR NAV2 SLC7A5  MYO1B  
MAFB   EXO1 NCAPG SMOX  NAV3  
 
Table 4-1: List of genes found to be up or downregulated in response to progesterone or estrogen treatment in 
breast cancer cell lines in three or more separate studies. Genes selected for inclusion in this table have an 
adjusted p-value 0.05 or lower and display a fold change in expression of greater than two. 
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Chipseq data 
 
Genes identified as having progesterone or estrogen receptor binding 
Progesterone Receptor  Estrogen Receptor 
ABAT GGCT S100P ACAT2 
ABHD12 GPR124 SCRG1 ACOT7 
ABLIM3 GPSM2 SEC14L2 CA12 
ACOT6 GREB1 SERPINA3 CYP1A1 
ACSL1 GRHL2 SGK1 ELOVL2 
ADD3 HMGB2 SGPP2 FUT9 
AK4 HMGB3 SLC22A23 FASD1 
ANXA1 HSD11B2 SLC25A18 GLA 
ARHGEF37 HSPB11 SLC31A2 PIK3R3 
ARL4A KCNG1 SLC39A14 PTGES 
ARRB1 KIAA0040 SLC47A1 SLC22A5 
ATAD2 LCMT1 SLPI SLC26A2 
ATP1A1 FJX1 SRM SLC7A5 
ATP1B1 LOC93622 ST3GAL1 TYMS 
BCL6 MAFB STAT5A UGT2B15 
BMF MPHOSPH10 STOM DSCC1 
CEBPD MRFAP1 SYBU CHEK1 
CMTM7 MSRB1 TESC CDK1 
CNTNAP2 MT1G THBS1 CDC25A 
CREB3L2 MT2A TIPARP BUB1B 
CSRNP1 NDRG1 TRNP1 CCNA2 
CTSH NET1 TSC22D3 CDC7 
DEGS1 NFKBIA WDYHV1 CDCA3 
DLG5 NUSAP1 ZIC2 CDKN3 
DUSP1 P4HA2 ZNF689 CDC45 
DYNLL1 PACSIN1 ZNF812 ABCA1 
ELOVL5 PRICKLE1  ABCC5 
F3 PRR15L  ATP6VOA4 
FAM105A RAB11FIP1  BTG2 
FJX1 RBP2  CCNG 
FKBP5 RCAN1  CDC6 
FOXO4 RHOU  CDKN2B 
FXYD3 RPS6KA5  CDK6 
 
Table 4-2: Output from ChipSeq experiments. List of genes found to have direct PR or ER binding. Appendix 
Table 2A and 2B detail the experiments from which this data are sourced.  
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Those genes differentially expressed following treatment of breast cancer cell lines with ER 
or PR ligands, as identified by microarray, and identified as having PR/ER protein binding by 
ChIP-Seq experiments were classed as primary target genes, shown in Table 4-3. For all 
primary target genes, a search was undertaken to identify whether the encoded proteins were 
included in Recon 2, using the search function on the virtual metabolic human website 
(Noronha et al., 2018).  
 
 
 
Differentially regulated genes in response to progesterone or estrogen treatment with PR or ER 
binding that are included in Recon 2  
Progesterone Receptor Estrogen Receptor 
Upregulated Downregulated Upregulated Downregulated 
ABAT ABCB11 ACAT2 ABCA1 
ACOT6 ACOX2 ACOT7 ABCC5 
ACSL1 EIC2 CA12 ATP6VOA4 
AK4  CYP1A1 BTG2 
ATP1A1  ELOVL2 CCNG 
ATP1B1  FUT9 CDC6 
DEGS1  FASD1 CDKN2B 
ELOVL5  GLA CDK6 
GGCT  PIK3R3  
ITPKA  PTGES  
NAGK  SLC22A5  
PDE1C  SLC26A2  
PLGC1  SLC7A5  
P4HA2  TYMS  
SERPINA1    
ST3GAL1    
ST3GAL4    
 
Table 4-3: Differentially regulated genes in response to progesterone or estrogen treatment with ER binding 
that are included in Recon 2 and are incorporated into the Petri Net model. 
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 Target gene function 
The function of each of the proteins selected for inclusion in the model was examined using 
GeneCards (Weizmann Institute of Science, no date). Of the genes upregulated in response to 
progesterone (Figure 4-2), the largest proportion are involved in lipid metabolism (25% of 
total). Other areas of note are: maintenance of electrochemical gradients (13%) and 
nucleotide regulation (13%). The function of proteins downregulated in response to 
progesterone are mainly related to lipid metabolism (33%) and multidrug resistance (33%) 
(Figure 4-3). 
 
 
Figure 4-2. Proportion of genes upregulated in response to treatment with (A) estrogen or (B) progesterone 
associated with different cellular functions. This data is from ChipSeq and Microarray data (sources detailed in 
Appendix 2) which is seen compiled in Table 4-3. Labels on the pie chart refer to the actual number of genes in 
each categors e.g. 10 genes involved in Cell cycle regulation are upregulated in response to estrogen.  
25 genes in total are upregulated in response to estrogen, with ER binding and present in 
Recon 2.  
 
8 genes in total are downregulated in response to estrogen with ER binding and present in 
Recon 2.  
17 genes in total are upregulated in response to progesterone, with PR binding and present in 
Recon 2.  
3 genes in total are downregulated in response to progesterone, with PR binding and present 
in Recon 2.  
Chapter 4 - Modelling 
 
249 
 
 
 
 
Figure 4-3: Proportion of genes downregulated in response to treatment with (A) estrogen or (B) progesterone 
associated with different cellular functions. This data is from ChipSeq and Microarray data (sources detailed in 
Appendix 2) which is seen compiled in Table 4-3. Labels on the pie chart refer to the actual number of genes in 
each categors e.g. 2 genes involved in Transport are downregulated in response to estrogen.  
 
 
The majority of genes upregulated in response to estrogen and selected for inclusion into the 
model are involved in cell cycle regulation (38%) and lipid metabolism (19%), as shown in 
Figure 4-2. For down-regulated genes (Figure 4-3) cell cycle regulation (63%) and transport 
(25%) are the two major categories. 
Notably, for estadiol there are differentially regulated genes related to lipid metabolism in 
both the up and down-regulated lists. For genes differentially regulated in response to 
progesterone, those involved in cell cycle regulation are included in both up and down-
regulated lists.  
 
 Incorporation into the model 
 
Once genes were selected for inclusion into the model, the ER and PR signalling were 
incorporated to the model. This was achieved in two main stages to include indirect 
and direct signalling.  
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 Indirect signalling  
 
The indirect signalling of ER illustrated in Figure 4-4 is included directly into the GSMN. 
The pathways of ER and PR signalling were obtained from Reactome, a curated pathway 
knowledge base (Fabregat et al., 2018), (Croft et al., 2014). This information was used to 
write linear reactions using MuFINS formalism which is detailed in section 1.14.4.7 in the 
background (Wu et al., 2016). The set of reactions written is included in the supplementary 
material (Appendix 4) and was incorporated directly into the tailored GSMN. 
 
Figure 4-4. Representation of indirect signalling for estrogen receptor. The diagram represents the path from the 
receptor to transcription factor and gene. This pathway was written as a set of linear equations. Pathways for 
figure obtained from Reactome (Fabregat et al. 2018).  (ATP = Adenosine Triphosphate, ADP = Adenosine 
Diphosphate, SOS = Son of Sevenless, Akt = Protein Kinase B, Src = Src homology 2 domain-containing, CAM 
= , eNOS = Nitric oxide syntgase, PKA = Protein Kinas A, MEK = Mitogen-activated protein kinase kinase, 
JNK = c-Jun N-terminal kinases, ERK1/2 = proline-directed kinases, Nup155 = Nuclear Pore Complex, Acyp1 
= Acylphosphatase 1, Ppif = Peptidyl-prolyl cis-trans isomerase, Atad2 = ATPase Family AAA Domain 
Containing 2, Mcm4 = Minichromosome Maintenance Complex Component 4, Abca1 = ATP-binding cassette, 
Creb1 = CAMP responsive element binding protein 1, SP1 = Sp/KLF transcription factor , Stat1 = Signal 
transducer and activator of transcription 1). 
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 Direct signalling  
 
Direct ER and PR signalling refers to activated nuclear receptors binding to the DNA and 
resulting in alterations to the expression of target genes. This was modelled using the Petri-
net modelling program, Snoopy.  
 
ER and PR have an influence over a number of target genes, both as primary targets of 
ER/PR signally and secondary targets that are altered in response to the effects of the proteins 
encoded by the primary targets. In order to meaningfully include this receptor signalling into 
the model, it was critical to identify target genes for each receptor, and whether they were 
primary or secondary targets. This was achieved by examining microarray and ChIP-seq data 
for breast cancer cell lines treated with estradiol or progesterone. The methodology for this is 
detailed below in ‘Identification of ER/PR target genes via microarray analysis’. 
 
Once a list of differentially expressed genes in response to estradiol or progesterone treatment 
were identified, these were incorporated into Snoopy as shown in methods and materials 
section 2.3.2.1. 
 
 Cell cycle modelling simulation 
 
As described in section 2.3.3, the kinetic cell cycle model was adapted from a published 
model of Tyson and Novak’s model. To assess the effectiveness of the reproduction, the 
simulated levels of key cell cycle proteins from the Tyson paper and the output from the 
Snoopy reconstructed model are compared. This is shown in Figure 4-5. 
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Figure 4-5. Simulated levels of key cell cycle proteins from Tyson and Novak’s paper and the reconstructed 
Petri net model. A shows the published output from Tyson and Novak 2001. Displaying cycling levels of m, 
Cdh1, CycB, IEP, Cdc20T and Cdc20A. Tyson and Novak’s model was reconstructed as a Petri net model with 
the same kinetics maintained and B is the simulated output from this reconstruction, representing the same 6 
species.  
 
 Constraining the model 
 
The model is constrained in two main ways: 
 
1) The congruency approach was employed to integrate ~omics data with Recon2. The 
tools used to achieve this are: Integrative Metabolic Analysis Tool (iMAT), and its 
derivative fastiMAT are utilised through the MuFINS program (Shlomi et al., 2008; Zur, 
Ruppin and Shlomi, 2010). Detailed in methods and materials 2.3.4.2 and Appendix 7. 
 
2) Constraining the exchange reactions using metabolomics consumption and release data.  
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 Constraining the exchange reactions  
 
Creating a context-specific set of exchange reactions 
 
Within recon 2 there are a number of exchange reactions, representing metabolite flux into 
and out of the cell. For the cell-line specific models, this exchange set was initially 
constrained whereby only exchange reactions for metabolites available to the cell remained 
open. These included metabolites presence in the atmosphere of the incubator in which the 
cells were kept and those present in the medium. Those exchange reactions left open are 
shown in Table 4-4.  
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Table 4-4. Table of exchange reactions from the original Recon 2 model selected for inclusion in the cell-line 
specific models. The table includes the reaction name in Recon 2, the reaction as written in the GSMN and the 
metabolite being exchanged. In addition, where the bounds in both are open, the metabolite can move into and 
out of the cell. Where bounds are only open in one of the columns, this represents a metabolite that is only 
exported out of or into the cell. 
Reaction name Reaction Metabolite LB UB 
     
R_EX_Lcystin_LPAREN_e_RPAREN_ M_Lcystin_e = M_Lcystin_e_xt L-cysteine -1 1 
R_EX_ala_L_LPAREN_e_RPAREN_ M_ala_L_e = M_ala_L_e_xt Alanine -1 1 
R_EX_arachd_LPAREN_e_RPAREN_ M_arachd_e = M_arachd_e_xt Arachadonic acid -1 1 
R_EX_arg_L_LPAREN_e_RPAREN_ M_arg_L_e = M_arg_L_e_xt Argenine -1 1 
R_EX_asn_L_LPAREN_e_RPAREN_ M_asn_L_e = M_asn_L_e_xt Asparagine -1 1 
R_EX_asp_L_LPAREN_e_RPAREN_ M_asp_L_e = M_asp_L_e_xt Aspartic acid -1 1 
R_EX_ca2_LPAREN_e_RPAREN_ M_ca2_e = M_ca2_e_xt Calcium -1 1 
R_EX_chsterol_LPAREN_e_RPAREN M_chsterol_e = M_chsterol_e_xt Cholesterol 0 1 
R_EX_co2_LPAREN_e_RPAREN_ M_co2_e = M_co2_e_xt Carbon Dioxide 0 1 
R_EX_co_LPAREN_e_RPAREN_ M_co_e = M_co_e_xt Carbon monoxide -1 1 
R_EX_cys_L_LPAREN_e_RPAREN_ M_cys_L_e = M_cys_L_e_xt Cysteine -1 1 
R_EX_fe2_LPAREN_e_RPAREN_ M_fe2_e = M_fe2_e_xt Iron 2+ -1 1 
R_EX_fe3_LPAREN_e_RPAREN_ M_fe3_e = M_fe3_e_xt Iron 3+ -1 1 
R_EX_fol_LPAREN_e_RPAREN_ M_fol_e = M_fol_e_xt Folate -1 0 
R_EX_glc_LPAREN_e_RPAREN_ M_glc_D_e = M_glc_D_e_xt Glucose -1 1 
R_EX_gln_L_LPAREN_e_RPAREN_ M_gln_L_e = M_gln_L_e_xt Glutamine -1 1 
R_EX_glu_L_LPAREN_e_RPAREN_ M_glu_L_e = M_glu_L_e_xt Glutamate -1 1 
R_EX_gly_LPAREN_e_RPAREN_ M_gly_e = M_gly_e_xt Glycine -1 1 
R_EX_h2o_LPAREN_e_RPAREN_ M_h2o_e = M_h2o_e_xt Water -1 1 
R_EX_h_LPAREN_e_RPAREN_ M_h_e = M_h_e_xt Hydrogen -1 1 
R_EX_hco3_LPAREN_e_RPAREN_ M_hco3_e = M_hco3_e_xt Hydrogen carbonate -1 1 
R_EX_hdca_LPAREN_e_RPAREN_ M_hdca_e = M_hdca_e_xt Palmitic acid -1 1 
R_EX_hdcea_LPAREN_e_RPAREN_ M_hdcea_e = M_hdcea_e_xt Palmitoleic acid -1 1 
R_EX_his_L_LPAREN_e_RPAREN_ M_his_L_e = M_his_L_e_xt Histidine -1 1 
R_EX_i_LPAREN_e_RPAREN_ M_i_e = M_i_e_xt Iodine -1 1 
R_EX_ile_L_LPAREN_e_RPAREN_ M_ile_L_e = M_ile_L_e_xt Isoleucine -1 1 
R_EX_k_LPAREN_e_RPAREN_ M_k_e = M_k_e_xt Potassium -1 1 
R_EX_lac_L_LPAREN_e_RPAREN_ M_lac_L_e = M_lac_L_e_xt Lactate -1 1 
R_EX_leu_L_LPAREN_e_RPAREN_ M_leu_L_e = M_leu_L_e_xt Leucine -1 1 
R_EX_lnlc_LPAREN_e_RPAREN_ M_lnlc_e = M_lnlc_e_xt Linoleic acid -1 1 
R_EX_lys_L_LPAREN_e_RPAREN_ M_lys_L_e = M_lys_L_e_xt Lysine -1 1 
R_EX_meoh_LPAREN_e_RPAREN_ M_meoh_e = M_meoh_e_xt Methanol -1 1 
R_EX_met_L_LPAREN_e_RPAREN_ M_met_L_e = M_met_L_e_xt Methionine -1 1 
R_EX_na1_LPAREN_e_RPAREN_ M_na1_e = M_na1_e_xt Sodium -1 0 
R_EX_ncam_LPAREN_e_RPAREN_ M_ncam_e = M_ncam_e_xt Niacinamide -1 0 
R_EX_nh4_LPAREN_e_RPAREN_ M_nh4_e = M_nh4_e_xt Ammonia -1 0 
R_EX_nifedipine_LPAREN_e_RPAREN M_nifedipine_e = M_nifedipine_e_xt Nifedipine 0 0 
R_EX_no2_LPAREN_e_RPAREN_ M_no2_e = M_no2_e_xt Nitrogen dioxide -1 1 
R_EX_o2_LPAREN_e_RPAREN_ M_o2_e = M_o2_e_xt Oxygen -1 0 
R_EX_ocdcea_LPAREN_e_RPAREN_ M_ocdcea_e = M_ocdcea_e_xt Oleic acid -1 1 
R_EX_phe_L_LPAREN_e_RPAREN_ M_phe_L_e = M_phe_L_e_xt Phenylalanine -1 1 
R_EX_pi_LPAREN_e_RPAREN_ M_pi_e = M_pi_e_xt Phosphatidylinositol -1 1 
R_EX_pnto_R_LPAREN_e_RPAREN_ M_pnto_R_e = M_pnto_R_e_xt Pantothenic acid -1 0 
R_EX_pro_L_LPAREN_e_RPAREN_ M_pro_L_e = M_pro_L_e_xt Proline -1 1 
R_EX_ps_hs_LPAREN_e_RPAREN_ M_ps_hs_e = M_ps_hs_e_xt Phosphatidylserine -1 1 
R_EX_pydxn_LPAREN_e_RPAREN_ M_pydxn_e = M_pydxn_e_xt Pyridoxine -1 0 
R_EX_ribflv_LPAREN_e_RPAREN_ M_ribflv_e = M_ribflv_e_xt Riboflavin -1 0 
R_EX_ser_L_LPAREN_e_RPAREN_ M_ser_L_e = M_ser_L_e_xt Serine -1 1 
R_EX_so4_LPAREN_e_RPAREN_ M_so4_e = M_so4_e_xt Sulphate -1 1 
R_EX_strdnc_LPAREN_e_RPAREN_ M_strdnc_e = M_strdnc_e_xt Stearidonic acid -1 1 
R_EX_thr_L_LPAREN_e_RPAREN_ M_thr_L_e = M_thr_L_e_xt Threonine -1 1 
R_EX_trp_L_LPAREN_e_RPAREN_ M_trp_L_e = M_trp_L_e_xt Tryptophan -1 1 
R_EX_tyr_L_LPAREN_e_RPAREN_ M_tyr_L_e = M_tyr_L_e_xt Tyrosine -1 1 
R_EX_urate_LPAREN_e_RPAREN_ M_urate_e = M_urate_e_xt Urate 0 1 
R_EX_urea_LPAREN_e_RPAREN_ M_urea_e = M_urea_e_xt Urea 0 1 
R_EX_val_L_LPAREN_e_RPAREN_ M_val_L_e = M_val_L_e_xt Valine -1 1 
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Constraining specific exchange reactions  
 
Once the set of specific exchange reactions was selected for inclusion into the model, the 
bounds of metabolite influx and efflux were constrained. 
 
Published production/consumption rates for 219 metabolites were used to constrain the 
exchange bounds of the GSMN. These consumption and release (CORE) values were derived 
from the work of by Jain et al, which included data from MCF-7 and MDA-MB-231 cell 
lines (Jain et al., 2012). However, it is known that cell lines in culture can develop unique 
phenotypes, moving away from the parental cell lines supplied by, for example, ECACC. To 
check that the cell lines used in the current study had similar consumption rates to those 
present in the NCI-60 cell lines, the consumption rate of key energy sources were measured 
in MCF-7 and MDA-MB-231 cell lines, namely: glucose, glutamate and lactate.  shows a 
representative plot of the consumption of each metabolite from medium for each cell line,  
shows both in silico and in vitro data for glucose, glutamate and lactate uptake and release, 
while Table 4-5 provides an overview of the results. LC-MSMS production/consumption rates 
from Jain et al were converted from femtomole (fmol/cell/h) per cell per hour to millimole 
per grams of dry weight per hour (mmol/gDW/h) using a value for cell density obtained from 
Recon 2 paper of 500 x 10-12gDW/cell (Calzone et al., 2008) . Therefore, 1 fmol/cell/h = 1 x 
10-12 mmol/500 x 10-12 gDW/h = 0.002 mmol/gDW/h. 1 fmol/cell/h = 0.002 mmol/gDW/h. 
Importantly, for glucose, lactate and glutamate, there was found to be no significant 
difference between the values obtained by Jain et al., and those obtained here. This provides 
some confidence to use the entire set of consumption rates from Jain et al (Jain et al., 2012).  
 
 
 
Table 4-5: CORE data for glucose, glutamate and lactate in MCF-7 and MDA-MB-231 cell lines. 
The table shows the CORE data for glucose, lactate and glutamate in MCF-7 and MDA-MB-231 cells as well as 
the error levels for their calculation. This is shown for experimentally calculated values using Abcam assay kits 
and data from the NCI60 dataset calculated using HPLC-MS/MS. There was found to be no significant 
difference for any of the CORE results between assay kit determined and NCI60 generated data (n.s.)  
Cell 
line 
Molecule 
NCI60 data 
(mmol/gDW/h) 
+/-10% 
Lower 
estimate 
(mmol/gDW/h) 
Upper 
estimate 
(mmol/gDW/h) 
Assay kit 
(mmol/gDW/h) 
+/-20% 
Lower 
estimate 
(mmol/gDW/h) 
Upper 
estimate 
(mmol/gDW/h) 
MCF-7 
Glucose -0.310 -0.279 -0.341 -0.498 -0.398 -0.598 
Glutamate 0.008 0.0072 0.0088 0.0275 0.022 0.077 
Lactate 0.104 0.0936 0.114 0.155 0.124 0.186 
MDA-
MB-231 
Glucose -0.618 -0.556 -0.68 -0.706 -0.635 -0.777 
Glutamate 0.026 0.0234 0.0286 0.032 0.0256 0.0384 
Lactate 0.428 0.385 0.471 0.361 0.288 0.43 
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Figure 4-6. Consumption of glucose from and the accumulation of l-lactate and glutamate in complete medium 
over 24h 78h and 55h respectively as measured using Abcam assay kits detailed in the methods in MCF-7 cells 
(ABC) and MDA-MB-231 cells (DEF). The data points and error bars for glucose and lactate represent 
means ± SEM (n = 3), a runs test confirmed that there was no significant deviation from linearity.  For 
glutamate, n=2. 
These time course assays were run as simulations using the parameterised model. Figure 4-7 
shows a comparison of the output from the simulations and in vitro measurements for lactate 
and glucose in MCF-7 cells (A and C) and MDA-MB-231 cells (B and D). In each of the 
graphs, no significant difference was found between the lines representing experimental vs in 
silico data.  
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Figure 4-7. In silico and in vitro time course assay measuring l-lactate accumulation or glucose depletion from 
the medium by MCF-7 (A and C) and MDA-MB-231 (B and D) cells. Consumption of glucose from and the 
accumulation of l-lactate in complete medium over 24h and 78h respectively as measured using Abcam assay 
kits detailed in the methods in MCF-7 cells (ABC) and MDA-MB-231 cells (DEF). The data points and error 
bars for glucose and lactate represent means ± SEM (n = 3). Linear regression was run and the best-fit 
line plotted with 95% confidence bands. A runs test confirmed that there was no significant deviation 
from linearity.   
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4.4 Gene essentiality scan and model predictions 
 
Upon completion of the different components of the model, their linking to one another and 
the constraints placed onto the GSMN, the model was explored to identify potential drug 
targets.  
 
For the identification of potential drug targets within the network described above, a scan of 
essential reactions was carried out through MuFINS, a Gene Essentiality Scan (Wu et al., 
2016). Gene essentiality is a computational technique to predict which reactions in a model 
are essential to reach a given objective. Such reactions can be envisaged as fragile points 
within the network, representing points where critical failure can be achieved: as such, they 
represent potential drug targets. This works by constraining the flux of each reaction in turn 
to 0, one at a time, and observing the effect on the maximal value achieved for a given 
objective function. Any reactions whose constraint to 0 results in a value of 0 for the 
objective function are said to be essential. The objective function selected for this simulation 
is the biomass reaction as detailed in Figure 2-16.  
 
The output of the essential reactions scan is a list of essential reactions. The list of reactions 
was further refined in a number of ways to generate two key reactions for exploration in 
vitro. The essential reactions analysis was carried out for three different models specifically 
representing MCF-7, MDA-MB-231 and MCF-10A cells. The selection process firstly 
involved a comparison of the list of essential reactions between these models. Those 
reactions that were essential in MCF-7 and MDA-MB-231 cells and not essential in MCF-
10A cells were selected. MCF-10A cells represent normal breast cells, thus perturbations to 
those reactions essential in the cancer cell lines and not in a non-cancerous cell line have a 
higher likelihood of specifically targeting or preferentially affecting the cancer cell lines. This 
has the benefit of fewer off target effects and toxicities.  
 
The list of reactions was further refined by examining those that could be blocked with a 
pharmacological inhibitor. The two most common ways of perturbing a reaction in vitro or in 
vivo are via a pharmacological inhibitor or by using short interfering RNA (siRNA). Two 
benefits of a pharmacological inhibitor are that it is easier to optimise cell survival assays and 
therefore generate data to validate model predictions, especially considering time constraints 
Chapter 4 - Modelling 
 
259 
of the project. Furthermore, utilisation of a pre-existing pharmacological inhibitor allows the 
exploration of the concept of drug repositioning. This has the advantage that the drug likely 
has already been subject to clinical trials and is safe for treatment. 
 
The output of the essential reactions scan is a list of essential reactions, 62 reactions are 
identified as essential, including R_biomass_reaction. This list was further refined in a 
number of ways to generate reactions for exploration in vitro.  
 
(i) First, those reactions essential in MCF-7 and MDA-MB-231 cells, but not 
essential in MCF-10A cells were selected. This is because MCF-10A cells 
represent normal breast cells; therefore, essential reactions in the cancer cell lines 
but not in the normal cell line have an increased likelihood of fewer adverse 
effects. 
(ii) The list of reactions was further refined by identifying those where the catalysing 
protein could be targeted with a pharmacological inhibitor. This provides focus on 
proteins most likely to be ‘druggable’ targets. In addition, this opens up the 
possibility of drug repositioning, decreasing the time required to get an effective 
treatment to the clinic. 
 
 
The two reactions selected for perturbation are involved in the production of serotonin and 
inositol monophosphate (R_ MI1PP). Within the models, the reactions associated with these 
molecules are shown in Table 4-8: Results from gene essentiality scan. Two molecules, their 
associated reactions in Recon2 and the associated PMID *as published in the VMH database 
(Noronha et al., 2018).. The pharmacological inhibitors available for each of these proteins 
are: for serotonin, Carbidopa; and, for inositol monophosphate, lithium. 
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The process of in silico modelling to selection of two potential drug targets for in vitro 
exploration is summarised in Figure 4-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. Diagram showing the use of the fully constrained model (shown in Figure 4-1) to perform Gene 
Essentiality Scan and identify ‘essenial’ reactions and how this list is constrained to represent reactions essential 
in MCF-7 and MDA-MB-231 cell models but not in MCF-10A cell models. Targets are then selected for 
exploration in vitro as those with available pharmacological inhibitors. Serotonin and Inositol monophosphate 
are selected as targets.  
 
To better understand the role of these genes within the model and biologically, the reactions 
they are involved in within Recon2 are identified and listed in the tables below. Additionally, 
the biological role of these was researched and summarised in the next section. 
Gene essentiality scan 
In turn perturb each reaction in GSMN and record effect on biomass production 
Identify 62 essential reactions  
Selectively target modelled cancer cells 
Select those that are only essential in MDA-MB-231 and MCF-7 iterations of the model not the MCF-10A iteration 
Select targets that can be perturbed pharmacologically  
Select those reactions that can be inhibited using pharmacological inhibitors 
Serotonin Inositol  
monophosphate 
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Essential reaction identified from Recon 2: Inositol monophosphate production 
Pharmacological inhibitor: Lithium Chloride 
Reactions involving Serotonin relate to: Inositol phosphate metabolism  
Recon 2 reaction MI1PP h2o[c] + mi1p_D[c] ->inost[c] + pi[c] 
Description Myo-Inositol 1-Phosphatase 
Reference (PubMed ID) 1377913, 2906139, 9322233 
Recon 2 reaction MI1PS g6p[c] -> mi1p_D[c] 
Description Myo-Inositol-1-Phosphate Synthase 
Reference (PubMed ID) 12941308 
Recon 2 reaction MI13PP h2o[c] + mi13p[c] -> mi1p_D[c] + pi[c] 
Description Inositol-1, 3-Bisphosphate 3-Phosphatase 
Reference (PubMed ID) 2906139 
Recon 2 reaction MI14P4Ph2o[c] + mi14p[c] -> mi1p_D[c] + pi[c] 
Description Inositol-1, 4-Bisphosphate 4-Phosphatase 
Reference (PubMed ID) 2906139 
Recon 2 reaction PIPLC h2o[c] + pail_hs[c] -> dag_hs[c] + h[c] + mi1p_D[c] 
Description Phosphatidylinositol Phospholipase C 
Reference (PubMed ID) 10702670, 10702683, 10760467, 11022047 ** 
Recon 2 reaction HMR_0663 h2o[c] + pail_hs[c] -> h[c] + HC02059[c] + mi1p_D[c] 
Description Phosphoinositide, Phospholipase C 
Reference (PubMed ID)  11509606; 7356635 
Recon 2 reaction 
HMR_9536 h2o[c] + M02911[c] -> glyc[c] + h[c] + mi1p_D[c] 
Description Sn-Glycero-3-Phospho-1-Inositol, Inositolphosphohydrolase 
Reference (PubMed ID)  
**continued 11022048, 11118617, 12117804, 12213492, 12416999, 13333955, 15140260, 1644792, 2167438, 7607669, 7612006, 7633416, 7789993, 7835906, 7849701, 
7890667, 8530101, 9345909 
 
Figure 4-9. Inositol monophosphate is identified as essential from the gene essentiality scan, its 
pharmacological inhibitor is LiCl. The table shows within Recon 2, the list of reactions associated with Inositol 
Monophosphate and the references for these linked reactions (PubMed IDs). 
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Essential reaction identified from Recon 2: Serotonin  
Pharmacological inhibitor: Carbidopa 
Reactions involving Serotonin relate to: Tryptophan Metabolism  
Recon 2 reaction 5HLTDL 5htrp[c] + h[c] -> co2[c] + srtn[c] 
Description 5-Hydroxy-L-Tryptophan Decarboxy-Lyase 
Reference (PubMed ID) 1540578 
Recon 2 reaction 5HOXINOXDA h2o[c] + o2[c] + srtn[c]  -> 5hoxindact[c] + h2o2[c] + nh4[c] 
Description 5-Hydroxytryptamine, Oxygen Oxidoreductase 
Reference (PubMed ID) 11134050, 15035803, 8920635, 9653080 
Recon 2 reaction SRTN23OX o2[c] + srtn[c] -> f5hoxkyn[c] 
Description 5-Hydroxytryptamine, Oxygen 2, 3-Dioxygenase 
Reference (PubMed ID)  
Recon 2 reaction SRTNACT accoa[c] + srtn[c]  -> coa[c] + h[c] + Nacsertn[c] 
Description Acetyl Coenzyme A:Aralkylamine N-Acetyltransferase 
Reference (PubMed ID) 1061163 
Recon 2 reaction SRTNMTXamet[c] + srtn[c] -> ahcys[c] + h[c] + nmthsrtn[c] 
Description S-Adenosyl-L-Methionine:Amine N-Methyltransferase (Srtn) 
Reference (PubMed ID) 8661026 
 
Figure 4-10. Serotonin is identified as essential from the gene essentiality scan, its pharmacological inhibitor is 
Carbidopa. The table shows within Recon 2, the list of reactions associated with Serotonin and the references 
for these linked reactions (PubMed IDs). 
 
 
 
 
 Inositol monophosphatase – model prediction 
 
Myo-inositol monophosphatase 
 
One of the reactions highlighted in the gene essentiality scan was MI1PP which is catalysed 
by the enzyme myo-inositol monophosphatase (IMPase), which is essential in inositol 
phosphate metabolism. IMPase catalyses step two of the pathway that ultimately generates 
myo-inositol in the phosphatidylinositol signalling pathway (Singh et al., 2012). The enzyme 
can utilise a number of different substrates including: myo-inositol monophosphates; 
fructose-1-phosphate; and, 2’AMP and glucose-1-phosphate (Parthasarathy, Parthasarathy 
and Vadnal, 1997).  
 
In humans, the enzyme is encoded by a gene on chromosome 8, covering 8q21.13 to q21.3 
(Sjøholt et al., 1997). There are three transcript variants, the gene is transcribed to form: 
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predominantly transcript variant 1, a 3369 bp mRNA, transcript variant 2, a 3597 bp mRNA 
and transcript variant 3, a 3287 bp mRNA. These are then translated to form 277, 336 and 198 
amino acid proteins. Each IMPase protein is structured as a series of alpha helices and beta-
pleated sheets in the formation αβαβα. The enzyme functions as a homodimer, with subunits 
linked by a number of hydrogen bonds (Bone, Springer and Atack, 1992). Each homodimer 
contains two metal binding sites (one per monomer), and magnesium (Mg2+) is required as a 
cofactor for effective enzyme activity (Hallcher and Sherman, 1980). IMPase is an important 
enzyme in the phosphatidylinositol pathway (PI), which is part of the phosphoinositide cycle 
summarised in Figure 4-11.  
 
 
Figure 4-11: Signalling pathways affected by Lithium.  
The figure shows PI/PKC and GSK-3β signalling as well as the phosphoinositide cycle with highlighted 
phosphatidylinositol pathway in grey. Ligand binding to G-protein coupled receptors activates PLC and 
hydrolyses PIP2 to IP3 + DAG which go onto stimulate calcium release and activate DAG-dependent PKC 
respectively. Lithium directly inhibits the enzyme inositol monophosphatase which results in a depleteion of 
inositol and DAG accumulates. In addition, Lithium inhibits GSK-3, which results in beta-catenin stabilisation 
and the activation of a lithium responsive gene network (genes responsive to LEF (lymphoid enhancer 
element)/TCF(T cell factor- 1) family transcription factors).  
 
 
The link between the PI pathway and IMPase is as follows. Phosphatidylinositol-4,5-
bisphosphate (PIP2) is broken down into two metabolites (inositol-1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG)) by phospholipase C, and these act as cellular messengers in 
apoptotic pathways, cell proliferation and growth (Toker, 2002). Phosphorylation of DAG 
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generates phosphatidic acid and cytidine mono-phosphorylphosphatidate, which binds to 
myo-inositols and forms PI. Hydrolysis of IP3 forms inositol diphophosphates, which are 
then hydrolysed to form inositol phosphate by IMPase. Inositol polyphosphate 1-phosphatase 
(IPPase) then converts inositol monophosphate to inositol. Myo-inositol molecules are then 
converted back into PIP2, completing the cycle (Ferruz et al., 2016).  
 
All inositol lipids and phosphates are derived from myo-inositol. In humans, myo-inositol is 
obtained in cells in a number of ways: Inositol phosphates can be recycled to generate 
inositol catalysed by two enzymes IMPase and IPPase (Balla, 2013); cells can uptake 
exogenous inositol from the environment (Kwon et al., 1992); or, myo-inositol can be 
synthesised within cells in a process catalysed in part by IMPase (Chen and Charalampous, 
1966).  
 
 Pharmacological inhibitors of IMPase 
 
Given the importance of IMPase in cell signalling, it is not surprising that work has been 
undertaken to identify pharmacological inhibitors of this enzyme. Lithium chloride is an un-
competitively inhibitor, preventing the resynthesisis of inositol from inositol-1-phosphate. 
The effect of this is an overall slowing of the phosphoinositol cycle (Berridge, Downes and 
Hanley, 1989). Lithium chloride (LiCl) is a salt of the compound lithium, a monovalent 
cation (Finley, 2016). Lithium was historically used in the treatment of a number of different 
ailments including gout, but was stopped due to its toxic liability providing, a negative risk-
benefit (Marmol, 2008). However, decades after its initial discovery, LiCl is still a front-line 
treatment for bipolar disorder, where it acts as a mood stabiliser and slows cyclic period and 
amplitude (Allison et al., 1976; Goodwin and Ghaemi, 1999).  
 
Lithium in the treatment of bipolar disorder is generally administered as a carbonate salt and 
the therapeutic dose ranges from 0.4 to 2.0 grams daily (Oruch et al., 2014a). The peak 
concentration is experienced between one and two hours after administration (Burton, 2006) 
and the drug is easily and evenly distributed through the body. The half-life of Lithium 
present in serum is on average 24 hours and (Luisier, Schulz and Dick, 1987) elimination of 
Lithium from the body is via the kidneys, as the drug is not metabolised (Koomans et al., 
1989).  
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As noted above, LiCl is an un-competitive inhibitor of IMPase, with a Ki of ~1mM (Hallcher 
and Sherman, 1980; Leech et al., 1993). However, it should be noted that this is not its only 
action on the body. Indeed, LiCl has multiple biological actions, including: serotonin release, 
PI pathway; and, Wnt signalling. 
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 Serotonin – Model Prediction 
 
Serotonin, also known as 5-hydroxytryptamine, is a biogenic amine that was first 
characterised in the late 1940s by Rapport and Page (Rapport et al., 1948). Serotonin is 
expressed in a range of tissues including the brain, gastrointestinal tract, platelets and, 
importantly, breast. Serotonin has a number of biological effects, primarily through its 
functions as a neurotransmitter (Brodie and Shore, 1957) and hormone. These biological 
roles are diverse and at times opposing, but are all actioned through serotonin receptors (5-
HT receptors), of which there are 13 subtypes in humans (Hoyer et al., 1994), the majority of 
which are G-protein coupled receptors (Hoyer et al., 1994). 
 
Within the central nervous system, serotonin is implicated in the regulation of sleep, 
temperature and appetite. The critical nature of serotonin is highlighted by examining the 
effects of decreased availability in the central nervous system (CNS). This leads to a number 
of anxiety disorders, as well as mania (Kandel, Schwartz and Jessell, 2001). The majority of 
drugs developed to effect serotonin are those intended to increase levels within the CNS, such 
as the selective serotonin reuptake inhibitors (SSRIs), which block serotonin reuptake 
transporters, increasing the serotonin levels available for receptor binding at the synaptic 
junction (Owens, 1996). 
 
Serotonin also has a role in the vasoconstriction of arteries, veins and venules, which is 
mediated by serotonin receptors present in the smooth muscle walls of these blood vessels 
(Vanhoutte, 1987). Related to this is the contribution of serotonin to mammalian 
hypertension, which was first observed in 1987 with antagonism of two serotonin receptors; 
5-HT1 and 5-HT2 resulting in a reduction in hypertension (Saxena, Bolt and Dhasmana, 
1987). A number of studies have elucidated a role for serotonin in promoting the aggregation 
of platelets. The molecule acts as an amplifier of the process once stimulated by 
Thromboxane A. The importance of serotonin in this process is evidenced by the strong 
inhibitory effect 5-HT2 antagonists have on the aggregation of platelets (Hilton and Cumings, 
1971; Cerrito et al., 1993). 
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 Pharmacological inhibitors of Serotonin 
 
Carbidopa is an inhibitor of the enzyme DOPA decarboxylase (DDC), an aromatic-L-amino 
acid decarboxylase. DDC is key in the synthesis of serotonin from L-tryptophan and the 
synthesis of dopamine from L-DOPA. The inhibition of DDC by Carbidopa therefore reduces 
levels of serotonin and dopamine (Bertoldi, 2014). The two reactions catalysed by DDC are 
shown in Figure 4-12: 
 
Figure 4-12: Serotonin and dopamine biosynthetic pathways. Figure adapted from (Hare and Loer, 2004). 
Serotonin and dopamine are synthesised in two stages, firstly, the enzymes tryptophan hydroxylase or tyrosine 
hydroxylase catalyse the transformation of tryptophan and tyrosine respectively into 5-hydroxytryptophan and 
L-Dopa. The second stage in this conversion for both serotonin and dopamine generation, utilises the L-amino 
acid decarboxylase enzyme (AADC). AADC is also referred to as 5-hydroxytryptophan decarboxylase or dopa 
decarboxylase. This enzyme decarboxylates 5-hydroxytryptophan and L-Dopa into Serotonin and dopamine, 
respectively (Clark, Weissbach and Udenfriend, 1954). 
 
The physiological role of DDC is to synthesise neurotransmitters required by the mammalian 
body, primarily serotonin and dopamine (Bertoldi, 2014). The synthesis and metabolism of 
these two neuromodulators are closely related, with alterations to one pathway generally 
impacting the other. For example, depletion of serotonin results in a number of mental health 
issues including depression and anxiety, while a lack of dopamine is associated with reduced 
motivation (Crisp and Mesce, 2004). Dysregulation of  DDC synthesis or altered enzyme 
activity have been shown to result in significant impacts on physical coordination (Marder 
and Eisen, 1984) and neuropsychiatric health (Reith et al., 1994). DDC is located both in 
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non-neuronal and neuronal tissues in humans and is part of the family of aminotransferases. 
The catalytic activity requires a coenzyme, pyridoxal 5’-phosphate (John, 1995) and a 
tyrosine residue-containing loop (Komori et al., 2012) which form part of the overall 
structure of a functional dimer. The dimer can exist as an open or closed conformation (apo 
or holo, respectively), according to binding of different substrates and coenzymes (Dunathan, 
1966). 
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4.5 Effect of drug combinations on breast cancer cell lines in 
vitro 
 
 Effect of individual drug treatments in vitro 
 
The overarching objective of this chapter was to identify novel drug combinations for the 
treatment of breast cancer. To achieve this, metabolic chokepoints that preferentially targeted 
breast cancer cell lines over a normal breast cell line were first identified using a gene 
essentiality scan as depicted in Figure 4-8. The targets identified are inositol monophoshate 
and serotonin. The effect of perturbing these reactions in vitro is explored here using the 
pharmacological inhibitors LiCl and carbidopa and observing the effect on cell viability 
through an MTT cell viability assay.  
 
The effect of these drugs in combination with a selection of conventionally used 
chemotherapeutics was also examined through MTT cell viability assays to explore the 
potential for synergy. 
 
For combination studies, R-synergyfinder is used. Following examination of the three 
different methods of determining synergy, there were notable differences between the outputs 
of the different methods for some combinations, therefore, output from Bliss, HSA and ZIP 
are presented.  
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 Cell Viability 
MCF-7, MDA-MB-231 and MCF-10A cells were exposed for 24 hours to vehicle or a range 
of doses of lithium chloride (50μM-200μM) or Carbidopa (1μM-150μM). At the end of the 
treatment period, cell viability was measured using the MTT technique, the results are shown 
in Figure 4-13.  
For lithium chloride, all three cell lines showed a concentration-dependent decrease in cell 
viability. The overall sensitivity of MDA-MB-231 cells to LiCl is lower across this range of 
concentrations tested compared to MCF-7 and MCF-10A cells, with MCF-10A cells showing 
the highest sensitivity: this difference between cell lines found to be statistically significantly 
(p≤0.001).  
For Carbidopa, no significant alteration in cell viability was observed at any of the 
concentrations tested, for any of the cell lines. Furthermore, the response of the three cell 
lines was not found to be statistically significantly different (p≤0.001).  
 
 
 
 
 
 
Figure 4-13: Response of MCF-7, MDA-MB-231 and MCF-10A cells to treatment with lithium chloride (A) 
and Carbidopa (B) for 24 h. Cell viability was determined using the MTT assay detailed in the methods section. 
MCF-7, MDA-MB-231 and MCF-10A cells treated for 24h with (A) a range of LiCl doses 50μM-200μM 
(solubilised in reverse osmosis (RO) H2O at ≤1%) or (B) a range of Carbidopa doses 1μM-100μM (solubilised 
in DMSO at ≤1%). Data are relative to the mean cell viability of either MCF-7 or MDA-MB-231 cells in control 
conditions as measured in three separate MTT assays. Data here are shown as mean ±SEM; n=3. A two-way 
ANOVA with Dunnett’s test post hoc was performed to detect statistically significant differences between 
treatment conditions and vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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 Discussion for individual treatments 
 
LiCl, a pharmacological inhibitor of the enzyme IMPase is found in the above experiments to 
negatively affect cell viability at doses greater than 130μM in estrogen receptor positive, 
triple negative and non-cancerous breast cell lines. While the impact of lithium exposure has 
been investigated for cancer in general, there have been limited studies exploring any link 
with breast cancer. Some studies on lithium exposure and general cancer incidence do stratify 
results to tissue, including breast, but the resultant patient numbers are sufficiently small that 
such sub-analyses are difficult to interpret (Martinsson, L et al., 2016). A study in MDA-MB-
231 cells has shown that treatment with myo-inositol reduced the invasive capacity and 
motility of this cell line through increasing levels of E and N-cadherins by up to seven-fold. 
Furthermore, this treatment reduced activity of the PI3K/Akt pathway, a pathway critical for 
cancer cell survival and proliferation. The expression of filopodia, generally utilised in cell 
motility, was also downregulated (Dinicola et al., 2016).  
Rouhani et al found that 24-hour treatment of breast cancer cells with 20mM LiCl in 
monolayer and spheroid cell culture sensitised the cells to ionising radiation. This radio-
sensitisation is believed, in part, to be due to a reduction in the Mre11 protein, a key 
component of the double stranded DNA repair process (Rouhani et al., 2014). 
In contrast, a number of previous studies have observed that treatment of ER+ breast cancer 
cell lines with LiCl results in mitogenic activation. For example, Welshons and colleagues 
observed proliferation of MCF-7 cells exposed to LiCl (Welshons et al., 1995). However, 
there are a number of key differences between the experimental conditions of these two 
studies that may underpin the different observations. First, the concentration range of LiCl 
tested by Welshon et al. was 1-5mM, which approximates the plasma concentration achieved 
clinically during the treatment of bipolar disorder. Here, concentrations used are three orders 
of magnitude lower, being in the micromolar range. It is unclear what the tissue 
concentrations achieved by 1-5mM plasma concentrations of LiCl, but they are likely to be 
lower for the majority of tissues. This is especially true of fatty tissues such as the breast 
given the relatively hydrophilicity of LiCL. Second, the duration of cell exposure to LiCl was 
four days in the Welshons study, but 24 hours here. Third, Welshons et al found that to 
observe a mitogenic effect, no estrogen could be present in the cell medium, or antiestrogens 
had to be added (Welshons et al., 1995). Other studies examining the effect of LiCl on ER+ 
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cell lines confirm that the dose of LiCl is likely to be a critical factor in determining the 
response of MCF-7 cells. Experiments carried out by Suganthi et al, found that the response 
of MCF-7 cells to LiCl was biphasic (Suganthi et al., 2012). In their study 1-10mM, LiCl 
promoted cell survival, whereas a 50-100mM (Suganthi et al., 2012) induces apoptosis, in 
part through the inhibition of anti-apoptotic proteins such as cyclin D1, Bcl-2, β-catenin, and 
Akt.  
Although all cells show reduced viability in response to treatment with LiCl, there were 
differences in sensitivity, with MCF-10A cells showing greatest sensitivity and MDA-MB-
231 cells the least. In order to understand these differences, research into intrinsic differences 
in these cell lines was explored. Kim et al published a study comparing metabolic and 
lipidomic profiling of MDA-MB-231, MCF-7 and MCF-10A cell lines. The group found a 
number of differences between the three cell lines when examined using gas chromatography 
mass spectrometry (GC-MS) and direct infusion mass spectrometry (DI-MS). Levels of a 
number of compounds within the cell lines differed including myo-inositol, which was 
significantly higher in MDA-MB-231 cells than in MCF-7 cells (Kim et al., 2016). This is 
potentially important as LiCl is known to interfere with the phosptatidyl inositol pathway 
(Silverstone, McGrath and Kim, 2005). Higher levels of myo-inositol in MDA-MB-231 cells 
could indicate an increased level of inositol monophosphatase (Vadnal and Ranganathan 
Parthasarathy, 1995). Under the assumption that MDA-MB-231 cells possess more IMPase 
than MCF-7 cells, it would be predicted that for a given concentration of LiCl, MDA-MB-
231 cells would have more active IMPase molecules than MCF-7 cells, which could account 
for the reduced sensitivity of this cell line to LiCl treatment.  
 
LiCl does not only inhibit IMPase, but has other cellular effects including PKC inhibition and 
alteration of Wnt signalling (De Meyer et al., 2011). Following the logic above, the fact that 
increased expression and activity of PKC is observed in the MDA-MB-231 cell lines may 
also contribute to the reduced sensitivity of this cell line to treatment (Zarate and Manji, 
2009). Lithium has been shown to be an activator of the Wnt and PI3K/Akt signalling 
pathways. It can thus propagate cell survival signals even in the absence of critical signalling 
molecules such as beta catenin, which are usually required for signal propagation (Sinha et 
al., 2005). Likewise, differences in Wnt signalling between cell lines could explain the 
differential sensitivity. Little direct comparison of Wnt signalling activity has been 
undertaken between MCF-7 and MDA-MB-231 cells, although no Wnt ligands are found in 
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MCF-7 cells (Klemm et al., 2011). Rather than a direct action on Wnt signalling, it is 
possible that the differential sensitivity is due to an indirect effect via the ER. There is known 
crosstalk between the Wnt/β-Catenin signalling pathways and Estrogen Receptor signalling. 
As MCF-7 cells are ER-positive and MDA-MB-231 cells are ER-negative, this crosstalk can 
only occur in MCF-7 cells (Gao et al., 2013). Activation of ER signalling increases Wnt 
signalling in a synergistic manner, with the effect inhibited by Tamoxifen (Gao et al., 2013). 
Further interactions postulated between these signalling pathways include the direct 
interaction of ER-alpha and beta-catenin in breast cancer cells and cell lines. Using 
immunoprecipitation, Kouzmenko et al observed co-immunoprecipitation of ER-alpha and 
beta-catenin; presence of a ligand is not obligate for co-immunoprecipitation, but the 
presence of estrogen does increase the association (Kouzmenko et al., 2004). Kouzmenko et 
al explored the implication of this physical interaction and showed a transcriptional 
association using an ER-alpha-linked luciferase reporter gene. The group observed that co-
recruitment of these proteins to response elements of target genes, and that over-expression 
of beta-catenin in MCF-7 cells increased the reporter gene expression (Kouzmenko et al., 
2004).  
 
In an equivalent paradigm to that detailed in the study of lithium use in bipolar disorder, 
longitudinal studies of patients with Parkinson’s disease (PD) have noted a differential cancer 
risk than in individuals without Parkinson’s disease (Bajaj, Driver and Schernhammer, 2010). 
For example, one study using the National Health Insurance System data from Taiwan 
examined close to 5000 patients with PD, each patient was randomly matched by age and 
gender with four people from the general population without PD. The results showed that the 
overall risk of cancer development is significantly lower in patients with PD than for the 
general population (RR=0.88 95% CI 0.78 to 0.99) (Sun et al., 2011). However, it should be 
noted that these findings are not consistent in the literature: for example, the correlation 
between PD and prostate cancer has been reported both as PD patients having lower risk of 
developing prostate cancer (Jespersen, Nørgaard and Borre, 2016) and that there is no 
significant correlation between these two morbidities (Ong, Goldacre and Goldacre, 2014). 
To better understand this relationship, a meta-analysis of 110 studies was undertaken. The 
analysis found that in Western populations, the risk of PD patients developing prostate cancer 
was significantly lower than in people without PD. The results was further subject to meta-, 
sensitivity and subgroup analysis, strengthening the robustness of the results (Chen, Zheng 
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and Hu, 2017). Conversely, PD is associated with a higher risk of melanoma development, 
but the aetiology is currently not understood (Disse et al., 2016). 
 
The association between PD and cancer has been attributed in part to the treatments used for 
PD. It has been proposed that Carbidopa, in isolation from Levodopa, may have anti-cancer 
properties. Treatment of pancreatic cancer cell lines  in vivo and in vitro with Carbidopa 
resulted in a reduction in cell proliferation (Ogura et al., 2017). The molecular basis for this 
inhibition has been proposed to be through the activation of aryl hydrocarbon receptor (AhR) 
signalling, which is promoted at therapeutically achievable concentrations of Carbidopa. 
Carbidopa is an AhR agonist, acting by binding to AhR and promoting binding of AhR to the 
promoter of the CYP1A1 gene and activating transcription (Safe, Qin and McDougal, 1999).  
 
 
Carbidopa is an inhibitor of the enzyme DOPA decarboxylase (DDC), an aromatic-L-amino 
acid decarboxylase. DDC is key in the synthesis of serotonin from L-tryptophan and the 
synthesis of dopamine from L-DOPA. The inhibition of DDC by Carbidopa therefore reduces 
levels of serotonin and dopamine (Bertoldi, 2014). Experiments examining the effect of 
carbidopa on viability in breast cell lines in this chapter finds there is no significant effect on 
viability in any of the three lines tested across the concentration range explored. This 
contrasts some research into the effect of Carbidopa on different cancer cell lines, where it is 
found to inhibit cell proliferation. Treatment of pancreatic cancer cell lines  in vivo and in 
vitro with Carbidopa resulted in a reduction in cell proliferation (Ogura et al., 2017). The 
molecular basis for this inhibition has been proposed to be through the activation of aryl 
hydrocarbon receptor (AhR) signalling, which is promoted at therapeutically achievable 
concentrations of Carbidopa. Carbidopa is an AhR agonist, acting by binding to AhR and 
promoting binding of AhR to the promoter of the CYP1A1 gene and activating transcription 
(Safe, Qin and McDougal, 1999).  
 
 
This effect of Carbidopa has also been observed in liver cancer cells (Ogura et al., 2017). 
However, this is contentious as activation of AhR is commonly associated with tumour 
growth and immune evasion (Dietrich and Kaina, 2010) (Negri et al., 2003), which appears 
to be the contrary of the biological effects of carbidopa. One possible reason for this apparent 
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contradiction is the potential for crosstalk between AhR and the estrogen receptor. This 
crosstalk has been extensively studied, with a number of groups using environmental toxin 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to activate AhR. The crosstalk has been shown 
to be inhibitory both in vivo and in vitro. In rats, treatment with TCDD inhibits E2-dependent 
breast cancer development following exposure to carcinogens (Holcomb and Safe, 1994; 
McDougal et al., 2001). Additionally, Gierthy et al observed that the growth of MCF-7 cells 
and MCF-7 xenografts in mice is inhibited by TCDD treatment (Gierthy et al., 1993). In 
breast cancer cell lines, TCDD-mediated AhR activation inhibits the ER and prevents 
estradiol-induced DNA synthesis, cell proliferation and expression of estradiol target genes 
(Safe, 1995). The suggested mechanisms by which active AhR inhibits ER action are 1) 
through proteasomal degradation of the receptor (Wormke et al., 2000), 2) inducing an 
upregulation of estradiol metabolising enzymes, thus reducing available estradiol (Gierthy et 
al., 1988)and 3) reduction in E2:ER-mediated gene expression by direct binding of AhR to 
elements within E2 responsive genes (Gillesby et al., 1997). Carbidopa is an AhR ligand, and 
AhR agonists have been found to activate this crosstalk which, in turn, inhibits proliferation 
of tumours in the human breast (McDougal et al., 2001). Reasons that the experiments here 
contrast findings by other groups may be due to the assays used. For example, Ogura et al use 
clonogenic assays to measure cell viability, where MTT assays are used here. MTT measures 
the metabolism of a cell and therefore findings that viability is not compromised could be 
explained by the fact that carbidopa has inhibited cell proliferation but the cells are still 
metabolically active (Ogura et al., 2017). Work my McDougal et al finds AhR agonists 
inhibit breast cancer cell proliferation, however this group do not use carbidopa. Therefore, 
the conflict with the observations in this chapter could be because the effects of carbidopa on 
breast cancer cells are greater than through AhR (McDougal et al., 2001). 
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4.6 Effect of combination drug treatments in vitro 
 
 Lithium chloride + Tamoxifen 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 2μM Tamoxifen, plus a range 
of concentrations of lithium chloride from 50μM-200μM. Cells were exposed for 24 hours 
before cell viability was measured by MTT assay.  
 
As expected, LiCl resulted in a concentration-dependent decrease in cell line viability. Cell 
viability was found to significantly differ from the cell viability when treated with 2μM 
Tamoxifen alone. Figure 4-14 B and C show MCF-7 and MDA-MB-231 cells with LiCl 
alone and LiCl in combination with 2μM Tamoxifen. These figures demonstrate the 
difference in effect of the individual versus the combination treatment in the two cell lines. 
The overall sensitivity of MDA-MB-231 cells to this drug combination is slightly higher than 
the sensitivity of MCF-7 cells. The response of the two cell lines was found to be statistically 
significantly different (p≤0.0001). The overall sensitivity of MDA-MB-231 cells to LiCl is 
lower across this concentration range than observed for MCF-7 cells. The cell viability of 
MCF-7 cells differs significantly from vehicle conditions at doses of 125μM or greater and 
the viability of MDA-MB-231 cells differs significantly from vehicle only at doses of 150μM 
and 200μM. Likewise, treatment with 150μM and 200μM LiCl caused an 80% reduction in 
MCF-7 cells and only a 75% reduction in viability of MDA-MB-231 cells. 
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Figure 4-14. Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of lithium chloride 
and Tamoxifen. Cell viability was determined using the MTT assay detailed in the methods section. (A) MCF-7 
and MDA-MB-231 cells treated for 24h with a combination of 2μM Tamoxifen (solubilised in DMSO at ≤1%) 
and a range of LiCL doses 50μM-200μM (solubilised in reverse osmosis (RO) H2O at ≤1%) Data are relative to 
the mean cell viability of either MCF-7 or MDA-MB-231 cells when treated with 2μM Tamoxifen as measured 
in three separate MTT assays. (B) Comparison of the effect of LiCl alone and LiCl+Tamoxifen on cell viability 
of MCF-7 cells. Cells are treated with LiCl alone (grey) and a combination of 2μM Tamoxifen (solubilised in 
DMSO at ≤1%) and a range of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) (green). (C) 
Comparison of the effect of LiCl alone and LiCl+Tamoxifen on cell viability of MDA-MB-231 cells. Cells are 
treated with LiCl alone (grey) and a combination of 2μM Tamoxifen (solubilised in DMSO at ≤1%) and a range 
of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) (green). Data are relative to the mean cell viability 
of either MCF-7 or MDA-MB-231 cells when treated with 1μM Doxorubicin as measured in three separate 
MTT assays OR mean cell viability of either MCF-7 or MDA-MB-231 cells in control conditions. Data here are 
shown as mean ±SEM; n3-6. The line is a non-linear fit log(inhibitor) vs. response – Variable slope (four 
parameters) Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). A two-way ANOVA with Dunnett’s 
test post hoc was performed to detect statistically significant differences between treatment conditions and 
vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
 
 
 
Figure 4-14 demonstrates that the co-exposure of breast cancer cell lines to Tamoxifen and 
LiCl results in a decrease in cell viability. However, such an analysis cannot determine if the 
nature of any interaction between the two drugs results; namely, additive, synergistic or 
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antagonistic. To formally assess the mode of interaction, the R-package SynergyFinder was 
utilised. SynergyFinder can assess interactions using Bliss, HSA, ZIP and Loewe 
methodologies, each of which has its own underlying assumptions and limitations (see 
(Yadav et al., 2015) for a review of these). 
 
Figure 4-15  and Figure 4-16 show the output from SynergyFinder for MDA-MB-231 and 
MCF-7 cell lines, respectively. Red is indicative of a synergistic interaction, white additive 
and green antagonistic. Synergy is observed across the dose range of LiCl tested when 
combined with Tamoxifen at 2μM for both MDA-MB-231 and MCF-7 cell lines. For both 
cell lines, the degree of synergy increases along with LiCl concentration.  
 
 
 
Figure 4-15. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of lithium chloride and Tamoxifen. The program was used to analyse the pairwise 
drug combination of Tamoxifen at 2μM and lithium chloride at a range of doses from 50-200μM in MDA-MB-
231 cells. a, b and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The 
synergy score denotes whether a particular combination is antagonistic, additive or synergistic. For all three 
methods used, the combination of lithium chloride across the dose range explored, with Tamoxifen at 2μM is 
synergistic, with higher levels of synergy observed at higher doses of lithium chloride. 
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Figure 4-16. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated 
with a combination of lithium chloride and Tamoxifen. The program was used to analyse the pairwise drug 
combination of Tamoxifen at 2μM and lithium chloride at a range of doses from 50-200μM in MCF-7 cells. a, b 
and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of lithium chloride across the dose range explored, with Doxorubicin at 1μM is synergistic, with 
higher levels of synergy observed at higher doses of lithium chloride. 
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 Lithium chloride + Doxorubicin 
 
 Cell Viability 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 1μM Doxorubicin, plus a range 
of lithium chloride from 50μM-200μM. Cells were exposed to the conditions for 24 hours 
before cell viability was measured. The response of the two cell lines was found to be 
statistically significantly different (p≤0.01) as shown in Figure 4-17.  
 
The overall sensitivity of MDA-MB-231 cells to this drug combination is higher than the 
sensitivity of MCF-7cells. At each treatment condition for MDA-MB-231 cells, the cell 
viability was found to significantly differ from the cell viability in when treated with 
Doxorubicin at 1μM alone. For MCF-7 cells, the cell viability was only significantly lower 
than that of cells in the vehicle condition at the highest dose of LiCl (200μM) combined with 
Doxorubicin. Furthermore, at the highest dose of LiCl, MDA-MB-231 cells saw a reduction 
in cell viability of 90% where MCF-7 cells saw a reduction of only 55%. 
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Figure 4-17. Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of lithium chloride 
and doxorubicin. Cell viability was determined using the MTT assay detailed in the methods section. (A) MCF-
7 and MDA-MB-231 cells treated for 24h with a combination of 1μM Doxorubicin (solubilised in DMSO at 
≤1%) and a range of LiCL doses 50μM-200μM (solubilised in reverse osmosis (RO) H2O at ≤1%) Data are 
relative to the mean cell viability of either MCF-7 or MDA-MB-231 cells when treated with 1μM Doxorubicin 
as measured in three separate MTT assays. (B) Comparison of the effect of LiCl alone and LiCl+doxorubicin on 
cell viability of MCF-7 cells. Cells are treated with LiCl alone (grey) and a combination of 1μM doxorubicin 
(solubilised in DMSO at ≤1%) and a range of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) 
(green). (C) Comparison of the effect of LiCl alone and LiCl+doxorubicin on cell viability of MDA-MB-231 
cells. Cells are treated with LiCl alone (grey) and a combination of 1μM doxorubicin (solubilised in DMSO at 
≤1%) and a range of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) (blue). Data are relative to the 
mean cell viability of either MCF-7 or MDA-MB-231 cells when treated with 1μM doxorubicin as measured in 
three separate MTT assays OR mean cell viability of either MCF-7 or MDA-MB-231 cells in control conditions. 
Data here are shown as mean ±SEM; n=2-3. The line is a non-linear fit log(inhibitor) vs. response – Variable 
slope (four parameters) Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).  A two-way ANOVA 
with Dunnett’s test post hoc was performed to detect statistically significant differences between treatment 
conditions and vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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 Synergy Analysis 
 
To analyse the pairwise drug combinations for level of interaction in different cell lines, the 
R-package described in the introduction was utilised to analyse the results from the cell 
viability assays. Figure 4-18 and Figure 4-19  show the graphical output from the program. 
Synergy is observed between this combination in MDA-MB-231 cells across the whole 
concentration range tested of lithium chloride.  Synergy is observed between this 
combination in MCF-7 cells but only at the highest concentrations of lithium chloride tested.  
At LiCl concentrations of 125μM and below, the combination is contrastingly antagonistic.  
 
MCF-7 cells are more sensitive to individual treatment with lithium chloride than MDA-MB-
231 cells, seeing a significant reduction in cell viability from doses 125μM and above in 
comparison with treatment with vehicle. 
 
 
Figure 4-18. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of lithium chloride and Doxorubicin. The program was used to analyse the pairwise 
drug combination of Doxorubicin at 1μM and lithium chloride at a range of doses from 50-200μM in MDA-
MB-231 cells. a, b and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. 
The synergy score denotes whether a particular combination is antagonistic, additive or synergistic. For all three 
methods used, the combination of lithium chloride across the dose range explored, with Doxorubicin at 1μM is 
synergistic, with higher levels of synergy observed at higher doses of lithium chloride. 
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Figure 4-19. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated 
with a combination of lithium chloride and Doxorubicin. The program was used to analyse the pairwise drug 
combination of Doxorubicin at 1μM and lithium chloride at a range of doses from 50-200μM in MCF-7 cells. a, 
b and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of lithium chloride at 150μM and 200μM with Doxorubicin at 1μM is synergistic. At doses of 
125μM lithium chloride and below, the combination is contrastingly antagonistic. The scores calculated using 
the ZIP method show lower levels of additivity. 
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 Lithium chloride + Cisplatin 
 
 Cell Viability 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 10μM Cisplatin, plus a range of 
concentrations of lithium chloride (50μM-200μM). Cells were exposed to the conditions for 
24 hours before cell viability was measured. The response of the two cell lines was found to 
be statistically significantly different (p≤0.01). Across the dose range of LiCl tested, MDA-
MB-231 cells showed higher sensitivity than the MCF-7 cells. At doses of 100μM and above, 
the cell viability of MDA-MB-231 cells was significantly reduced compared with the 
Cisplatin at 10μM alone condition. For MCF-7 cells, viability was not significantly impacted 
until the dose of LiCl was 150μM or 200μM. The maximum impact on cell viability for both 
cells was seen with 10μM Cisplatin and the highest LiCl dose tested; 200μM. For MCF-7 
cells this was a 60% reduction and for MDA-MB-231 cells an 85% reduction.  
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Figure 4-20. Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of lithium chloride 
and Cisplatin. Cell viability was determined using the MTT assay detailed in the methods section. MCF-7 and 
MDA-MB-231 cells treated for 24h with a combination of 10μM Cisplatin (solubilised in DMSO at ≤1%) and a 
range of LiCl doses 50μM-200μM (solubilised in reverse osmosis (RO) H2O at ≤1%) Data are relative to the 
mean cell viability of either MCF-7 or MDA-MB-231 cells when treated with 10μM Cisplatin as measured in 
three separate MTT assays. (B) Comparison of the effect of LiCl alone and LiCl+cisplatin on cell viability of 
MCF-7 cells. Cells are treated with LiCl alone (grey) and a combination of 10μM cisplatin (solubilised in 
DMSO at ≤1%) and a range of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) (green). (C) 
Comparison of the effect of LiCl alone and LiCl+cisplatin on cell viability of MDA-MB-231 cells. Cells are 
treated with LiCl alone (grey) and a combination of 10μM cisplatin (solubilised in DMSO at ≤1%) and a range 
of LiCl doses 50μM-200μM (solubilised in RO H2O at ≤1%) (blue). Data are relative to the mean cell viability 
of either MCF-7 or MDA-MB-231 cells when treated with 10μM cisplatin as measured in three separate MTT 
assays OR mean cell viability of either MCF-7 or MDA-MB-231 cells in control conditions. Data here are 
shown as mean ±SEM; n=3-6. The line is a non-linear fit log(inhibitor) vs. response – Variable slope (four 
parameters) Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). A two-way ANOVA with Dunnett’s 
test post hoc was performed to detect statistically significant differences between treatment conditions and 
vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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 Synergy Analysis 
 
To analyse the pairwise drug combinations for level of interaction in different cell lines, the 
R-package described in the introduction was utilised to analyse the results from the cell 
viability assays. Figure 4-21 and Figure 4-22 show the graphical output from the program. 
 
The combination of Cisplatin and lithium chloride in MDA-MB-231 cells is largely 
synergistic for doses of lithium chloride of 100μM and above. This pattern is very similar in 
MCF-7 cells. With synergy observed above 100μM LiCl, but only additivity with LiCl 
concentrations below this (doses of 75μM and 50μM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-21. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of lithium chloride and Cisplatin. The program was used to analyse the pairwise drug 
combination of Cisplatin at 10μM and lithium chloride at a range of doses from 50-200μM in MDA-MB-231 
cells. a, b and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The 
synergy score denotes whether a particular combination is antagonistic, additive or synergistic. For all three 
methods used, the combination of lithium chloride at doses higher than 75μM with Cisplatin at 10μM is 
synergistic. For doses 75μM and 50μM of lithium chloride, no synergy is observed and calculations using the 
Bliss and HSA methods suggest low levels of antagonism.  
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Figure 4-22. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated 
with a combination of lithium chloride and Cisplatin. The program was used to analyse the pairwise drug 
combination of Cisplatin at 10μM and lithium chloride at a range of doses from 50-200μM in MCF-7 cells. a, b 
and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of lithium chloride at doses higher than 100μM with Cisplatin at 10μM is synergistic. For doses 
75μM and 50μM of lithium chloride, no synergy is observed and calculations using the Bliss and HSA methods 
suggest low levels of antagonism.  
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 Carbidopa + Tamoxifen 
 
 Cell Viability 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 2μM Tamoxifen, plus a range 
of concentrations of Carbidopa from 1μM-100μM. Cells were exposed to the conditions for 
24 hours before cell viability was measured. The response of the two cell lines was not found 
to be statistically significantly different. Furthermore, there was no significant difference 
found in the cell viability for any treatment condition in any of the two cell lines.  
 
 
Figure 4-23. Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of Carbidopa and 
Tamoxifen. Cell viability was determined using the MTT assay detailed in the methods section. MCF-7 and MDA-MB-231 
cells treated for 24h with a combination of 2μM Tamoxifen (solubilised in DMSO at ≤1%) and a range of Carbidopa doses 
1μM-100μM (solubilised in DMSO at ≤1%). Data are relative to the mean cell viability of either MCF-7 or MDA-MB-231 
cells when treated with 2μM Tamoxifen as measured in three separate MTT assays. (B) Comparison of the effect of 
carbidopa alone and carbidopa+Tamoxifen on cell viability of MCF-7 cells. Cells are treated with carbidopa alone (grey) and 
a combination of 2μM Tamoxifen (solubilised in DMSO at ≤1%) and a range of carbidopa doses 1μM-100μM (solubilised in 
DMSO at ≤1%) (green). (C) Comparison of the effect of carbidopa alone and carbidopa+Tamoxifen on cell viability of 
MDA-MB-231 cells. Cells are treated with carbidopa alone (grey) and a combination of 2μM Tamoxifen (solubilised in 
DMSO at ≤1%) and a range of carbidopa doses 1μM-100μM (solubilised in DMSO at ≤1%) (blue). Data are relative to the 
mean cell viability of either MCF-7 or MDA-MB-231 cells when treated with 1μM Doxorubicin as measured in three 
separate MTT assays OR mean cell viability of either MCF-7 or MDA-MB-231 cells in control condition. Data here are 
shown as mean ±SEM; n=3-4. A two-way ANOVA with Dunnett’s test post hoc was performed to detect statistically 
significant differences between treatment conditions and vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** 
P < 0.0001. 
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 Synergy Analysis 
 
To analyse the pairwise drug combinations for level of interaction in different cell lines, the 
R-package described in the introduction was utilised to analyse the results from the cell 
viability assays. Figure 4-24 and Figure 4-25 show the graphical output from the program. 
The combination of Tamoxifen and Carbidopa in MDA-MB-231 cells is largely additive 
across the dose range of Carbidopa tested. Synergy in this combination is only observed at 
the highest dose of Carbidopa tested (100μM). It should also be noted that the synergy score 
range is less than for all other combinations, further supporting the minimal impact of this 
combination. 
  
The combination of Tamoxifen and Carbidopa in MCF-7 cells shows some synergy at doses 
of 5μM, 25μM and 100μM tested, but the synergy scores are minimal compared to those 
achieved with previous combinations, no synergy is observed at 1μM of Carbidopa with 
Tamoxifen or at 50μM Carbidopa with tamoxifen. The pattern of synergy of this pairwise 
combination is different in the two cell lines examined, with overall greater synergy being 
observed in MCF-7 cells. Notably, even though statistically synergy is occurring, there is no 
significant difference between the effect of single agent and the combinations explored here. 
Therefore, the synergy observed is not biologically relevant.  
 
There is no significant difference in the effect Carbidopa has on cell viability between MDA-
MB-231 and MCF-7 cells. For both cell lines, the dose range of 1-100μM has no significant 
impact on cell viability compared with the control. However, for Tamoxifen, in both cell 
viability and clonogenic assays, MDA-MB-231 cell lines show greater sensitivity to 
Tamoxifen. This increased sensitivity to the individual drug could account for the reduced 
synergy observed in the pairwise combination.  
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Figure 4-24. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of Carbidopa and Tamoxifen. The program was used to analyse the pairwise drug 
combination of Tamoxifen at 2μM and Carbidopa at a range of doses from 1-100μM in MDA-MB-231 cells. a, 
b and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of 100μM Carbidopa and 2μM Tamoxifen is synergistic, whereas doses of 5μM Carbidopa with 
2μM Tamoxifen are antagonistic. 
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Figure 4-25. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated 
with a combination of Carbidopa and Tamoxifen. The program was used to analyse the pairwise drug 
combination of Tamoxifen at 2μM and Carbidopa at a range of doses from 1-100μM in MCF-7 cells. a, b and c 
represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score denotes 
whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of 100μM Carbidopa and 2μM Tamoxifen show the highest synergy. Some synergy is also seen 
between the drugs at 25μM and 5μM of Carbidopa and 2μM Tamoxifen when calculated using the Bliss and 
HSA models, however, this is not observed when calculated using the ZIP method. 
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 Carbidopa + Doxorubicin 
 Cell Viability 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 2μM Tamoxifen, plus a range 
of concentrations of Carbidopa from 1μM-100μM. Cells were exposed to the conditions for 
24 hours before cell viability was measured. The response of the two cell lines was found to 
be statistically significantly different (p<0.0001). For MDA-MB-231 cells, there was no 
significant difference found in the cell viability for any treatment condition tested compared 
with Doxorubicin 1μM alone. For MCF-7 cells, at the highest two doses of Carbidopa 
combined with Doxorubicin at 1μM, cell viability was significantly increased when 
compared with Doxorubicin treatment at 1μM alone (p<0.05). 
 
 
Figure 4-26. Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of Carbidopa and 
Doxorubicin Cell viability was determined using the MTT assay detailed in the methods section. MCF-7 and MDA-MB-
231 cells treated for 24h with a combination of 1μM doxorubicin (solubilised in DMSO at ≤1%) and a range of Carbidopa 
doses 1μM-100μM (solubilised in DMSO at ≤1%).  (B) Comparison of the effect of carbidopa alone and 
carbidopa+doxorubicin on cell viability of MCF-7 cells. Cells are treated with carbidopa alone (grey) and a combination of 
1μM doxorubicin (solubilised in DMSO at ≤1%) and a range of carbidopa doses 1μM-100μM (solubilised in DMSO at ≤1%) 
(green). (C) Comparison of the effect of carbidopa alone and carbidopa+doxorubicin on cell viability of MDA-MB-231 
cells. Cells are treated with carbidopa alone (grey) and a combination of 1μM doxorubicin (solubilised in DMSO at ≤1%) 
and a range of carbidopa doses 1μM-100μM (solubilised in DMSO at ≤1%) (blue). Data are relative to the mean cell 
viability of either MCF-7 or MDA-MB-231 cells when treated with 1μM doxorubicin as measured in three separate MTT 
assays OR mean cell viability of either MCF-7 or MDA-MB-231 cells in control condition. Data here are shown as mean 
±SEM; n=3-4. A two-way ANOVA with Dunnett’s test post hoc was performed to detect statistically significant differences 
between treatment conditions and vehicle denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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 Synergy Analysis 
 
To analyse the pairwise drug combinations for level of interaction in different cell lines, the 
R-package described in the introduction was utilised to analyse the results from the cell 
viability assays. Figure 4-27 and Figure 4-28 show the graphical output from the program. 
The output from the Synergy analysis for MDA-MB-231 cells treated with a combination of 
Carbidopa and Doxorubicin shows some synergy between the combination at all doses of 
Carbidopa. The greatest synergy is seen when Doxorubicin is combined with the highest 
tested doses of Carbidopa (100μM). 
 
The output from the Synergy analysis for MCF-7 cells treated with a combination of 
Carbidopa and Doxorubicin shows some synergy between the combination at intermediate 
doses of Carbidopa; 10μM. At the highest tested doses of Carbidopa (100μM), the 
combination is strongly antagonistic. At the lowest tested doses of Carbidopa, 1μM, some 
additivity is seen from the output using Bliss and HSA methods. There is a difference in the 
pattern of interaction between doxorubicin and Carbidopa seen in MDA-MB-231 cells versus 
MCF-7 cells. This cannot be due to differences in responsiveness to Carbidopa as there is no 
significant difference in the effect Carbidopa has on cell viability between MDA-MB-231 
and MCF-7 cells. For both cell lines, the dose range of 1-100μM has no significant impact on 
cell viability compared with the control. Even though statistically synergy is occurring, there 
is no significant difference between the effect of single agent and the combinations explored 
here, meaning the synergy observed is not biologically relevant. Within cell viability assays 
for doxorubicin, however, MCF-7 cells are less responsive to the concentration range of 
doxorubicin tested than MDA-MB-231 cells.  
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Figure 4-27. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of Carbidopa and Doxorubicin.  Graphical representation of the output from R-
package SynergyFinder. The program was used to analyse the pairwise drug combination of Doxorubicin at 
1μM and Carbidopa at a range of doses from 1-100μM in MDA-MB-231 cells. a, b and c represent Synergy 
scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score denotes whether a 
particular combination is antagonistic, additive or synergistic. For all three methods used, across the dose range 
of Carbidopa, the combination of 100μM Carbidopa with 1μM Doxorubicin shows the highest level of synergy, 
with some synergy observed at all dose combinations. 
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Figure 4-28. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated 
with a combination of Carbidopa and Doxorubicin. The program was used to analyse the pairwise drug 
combination of Doxorubicin at 1μM and Carbidopa at a range of doses from 1-100μM in MCF-7 cells. a, b and 
c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, the 
combination of 10μM Carbidopa and 1μM Doxorubicin is synergistic, whereas doses of 50μM and 100μM 
Carbidopa with 1μM Doxorubicin are antagonistic. For the Bliss and HSA methods, there is also antagonism 
seen at doses of 1μM Carbidopa with Doxorubicin. The ZIP method shows a similar pattern of interaction 
between the two drugs but overall shows lower levels of antagonism and synergy.  
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 Carbidopa + Cisplatin 
 
 Cell Viability 
 
MCF-7 and MDA-MB-231 cells were treated with vehicle or 2μM Tamoxifen, plus a range 
of concentrations of Carbidopa from 1μM-100μM. Cells were exposed to the conditions for 
24 hours before cell viability was measured. The response of the two cell lines was not found 
to be statistically significantly different. Furthermore, there was no significant difference 
found in the cell viability for any treatment condition in any of the two cell lines compared 
with treatment with Cisplatin at 10μM alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-29.Response of MCF-7 and MDA-MB-231 cells to treatment with a combination of Carbidopa and 
Cisplatin. Cell viability was determined using the MTT assay detailed in the methods section. MCF-7 and MDA-MB-231 
cells treated for 24h with a combination of 10μM Cisplatin (solubilised in DMSO at ≤1%) and a range of Carbidopa doses 
1μM-100μM (solubilised in DMSO at ≤1%). (B) Comparison of the effect of carbidopa alone and carbidopa+cisplatin on 
cell viability of MCF-7 cells. Cells are treated with carbidopa alone (grey) and a combination of 10μM cisplatin (solubilised 
in DMSO at ≤1%) and a range of carbidopa doses 1μM-100μM (solubilised in DMSO at ≤1%) (green). (C) Comparison of 
the effect of carbidopa alone and carbidopa+cisplatin on cell viability of MDA-MB-231 cells. Cells are treated with 
carbidopa alone (grey) and a combination of 10μM cisplatin (solubilised in DMSO at ≤1%) and a range of carbidopa doses 
1μM-100μM (solubilised in DMSO at ≤1%) (blue). Data are relative to the mean cell viability of either MCF-7 or MDA-
MB-231 cells when treated with 10μM cisplatin as measured in three separate MTT assays OR mean cell viability of either 
MCF-7 or MDA-MB-231 cells in control condition. Data here are shown as mean ±SEM; n=3-6. A two-way ANOVA with 
Dunnett’s test post hoc was performed to detect statistically significant differences between treatment conditions and vehicle 
denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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 Synergy Analysis 
 
To analyse the pairwise drug combinations for level of interaction in different cell lines, the 
R-package described in the introduction was utilised to analyse the results from the cell 
viability assays. Figure 4-30 and Figure 4-31 shows the graphical output from the program. 
The interaction of the drugs in MDA-MB-231 cells is antagonistic at high concentrations of 
Carbidopa (50μM and 100μM); a synergy score of <0 is observed. At lower doses of 
Carbidopa combined with 10μM Cisplatin, the combination is synergistic, with highest levels 
of synergy observed with 1μM Carbidopa. As with the combination of Carbidopa and 
Tamoxifen, the dynamic range of the synergy scores is low, suggesting that any synergy is 
minimal. 
 
SynergyFinder output for the same combination in MCF-7 cells shows largely a synergistic 
effect across most doses of Carbidopa. In contrast to the pattern observed in MDA-MB-231 
cells, in MCF-7 cells, the greatest degree of synergy is observed with the highest doses of 
Carbidopa. Again, the dynamic range of the synergy scores is low. MCF-7 cells are more 
sensitive to treatment with Cisplatin in terms of reductions to cell viability across a dose 
range from 2.5μM-200μM. There is no significant difference in the effect Carbidopa has on 
cell viability between MDA-MB-231 and MCF-7 cells. For both cell lines, the dose range of 
1-100μM has no significant impact on cell viability compared with the control. Notably, even 
though statistically synergy is occurring, as seen in Figure 4-29, there is no significant 
difference between the effect of single agent and the combinations explored here. Therefore, 
the synergy observed is not biologically relevant. 
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Figure 4-30. Graphical representation of the output from R-package SynergyFinder for MDA-MB-231 cells 
treated with a combination of Carbidopa and Cisplatin. The program was used to analyse the pairwise drug 
combination of Cisplatin at 10μM and Carbidopa at a range of doses from 1-100μM in MDA-MB-231 cells. a, b 
and c represent Synergy scores calculated using Bliss, HSA and ZIP methods respectively. The synergy score 
denotes whether a particular combination is antagonistic, additive or synergistic. For all three methods used, 
across the dose range of Carbidopa, the combination of 1μM Carbidopa with 10μM Cisplatin shows the highest 
level of synergy, with high levels also seen at 10μM and 25μM Carbidopa. Contrastingly, at concentrations of 
50μM and 100μM Carbidopa, the combination with Cisplatin is antagonistic when the Bliss and HSA methods 
are used and additive as calculated using the ZIP method. 
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Figure 4-31. Graphical representation of the output from R-package SynergyFinder for MCF-7 cells treated with 
a combination of Carbidopa and Cisplatin. Graphical representation of the output from R-package 
SynergyFinder. The program was used to analyse the pairwise drug combination of Cisplatin at 10μM and 
Carbidopa at a range of doses from 1-100μM in MCF-7 cells. a, b and c represent Synergy scores calculated 
using Bliss, HSA and ZIP methods respectively. The synergy score denotes whether a particular combination is 
antagonistic, additive or synergistic. For all three methods used, across the dose range of Carbidopa, the 
combination of 100μM Carbidopa with 10μM Cisplatin shows the highest level of synergy, with high levels also 
seen at 25μM Carbidopa. At lower concentrations of Carbidopa, the combination with Cisplatin is less 
synergistic. 
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Treatment 
(24h) 
Cell line 
Response 
Synergy 
Cell Viability 
LiCl 
50µM-200µM 
MCF-7 
Significant ↓ in cell viability at concentrations >125µM 
 
 
MDA-MB-231 
Significant ↓ in cell viability at concentrations >150µM 
 
 
MCF-10A Significant ↓ in cell viability at concentrations >70µM  
Carbidopa 
1µM-100µM 
MCF-7 n.s. effect on cell viability across all concentrations  
MDA-MB-231 n.s. effect on cell viability across all concentrations  
MCF-10A n.s. effect on cell viability across all concentrations  
Tam 2µM 
LiCl 50µM-200µM 
MCF-7 Significant ↓ in cell viability across all concentrations tested Antagonistic across all combinations 
MDA-MB-231 Significant ↓ in cell viability across all concentrations tested Antagonistic across all combinations 
 MCF-10A    
Dox 1µM 
LiCl 50µM-200µM 
MCF-7 Significant ↓ in cell viability at 200µM LiCl 
Synergistic at LiCl concentrations <125µM 
Antagonistic at higher LiCl concentrations 
MDA-MB-231 Significant ↓ in cell viability at doses >70µM LiCl Antagonistic across all combinations 
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Cis 10µM 
LiCl 50µM-200µM 
MCF-7 Significant ↓ in cell viability at doses >125µM LiCl 
Antagonistic at concentrations of lithium >75µM some 
synergy with 50µM LiCl and 10µM Cis 
MDA-MB-231 Significant ↓ in cell viability at doses >100mM LiCl 
Antagonistic at concentrations of lithium >75µM some 
synergy with 50µM LiCl and 10µM Cis 
Tam 2µM Carbidopa 
1µM-100µM 
 
MCF-7 
n.s. ↓ in cell viability across any concentrations tested 
Predominantly antagonistic but not biologically relevant as 
n.s. change to viability 
 
MDA-MB-231 
n.s. ↓ in cell viability across any concentrations tested 
Some synergy but not biologically relevant as n.s. change to 
viability 
Dox 1µM Carbidopa 
1µM-100µM 
MCF-7 Significant increase in cell viability at >40µM Carbidopa Some synergy 
 MDA-MB-231 n.s. ↓ in cell viability across any concentrations tested 
Predominantly antagonistic but not biologically relevant as 
n.s. change to viability 
Cis Carbidopa 1µM-
100µM 
MCF-7 n.s. ↓ in cell viability across any concentrations tested 
Predominantly antagonistic but not biologically relevant as 
n.s. change to viability 
MDA-MB-231 n.s. ↓ in cell viability across any concentrations tested 
Antagonistic at <25µM carbidopa 
Synergy at 50µM Cis 
not biologically relevant as n.s. change to viability 
 
Table 4-6. Summarising results from chapter four for MCF-7, MDA-MB-231 and MCF-10A cells treated with three chemotherapeutic agents and two pharmacological 
inhibitors of potential targets as identified through a gene essentiality scan. Lithium Chloride and Carbidopa. These agents are examined individually and as combination 
treatments with Tamoxifen, Dox and Cisplatin. n.s = non-significant, Tam = Tamoxifen, Cis = Cisplatin, Dox = Doxorubicin, Met = Metformin, LiCl = Lithium Chloride. 
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 Discussion for combination treatments 
  
 Lithium chloride combinations 
 
The pairwise combination of LiCl and Tamoxifen significantly affected cell viability of 
MDA-MB-231 and MCF-7 cells when compared to treatment with either compound alone. 
Formal interaction analysis demonstrates that this interaction is synergistic, particularly at 
higher concentrations of LiCl. MDA-MB-231 cells are less sensitive to LiCl treatment alone 
than MCF-7 cells but are slightly more sensitive to treatment with Tamoxifen than MCF-7 
cells at high concentrations. However, at the concentration of Tamoxifen used for the 
combination studies (2 μM) there is no significant difference in the impact on cell viability 
between the two cell lines. A reason that the combination of Tamoxifen and LiCl has a 
greater impact on cell viability in MDA-MB-231 than MCF-7 cells could be a differential 
reliance on PKC signalling. As noted earlier, MDA-MB-231 cells express higher levels of 
PKC than MCF-7 cells, meaning that for any given concentration of PKC inhibitor there 
would be a higher number of uninhibited PKC molecules in MDA-MB-231 compared to 
MCF-7 cells, as inhibition is expressed as a percentage of the total number of molecules and 
not an absolute. Treatment with Tamoxifen or LiCl alone at the range of concentrations tested 
could leave sufficient PKC available for the MDA-MB-231 cells to function. However, the 
combination of the two PKC inhibitors has a greater chance of inhibiting sufficient PKC 
molecules to impact viability. In addition, it can be hypothesised that as MDA-MB-231 cells 
have more PKC, the cells are more reliant on this signalling pathway than MCF-7 cells. If 
this is correct, successful inhibition could be more detrimental to MDA-MB-231 cells than 
MCF-7 cells.  
 
Mechanistically, LiCl and Tam are protein kinase C (PKC) inhibitors. PKC overexpression is 
associated with a number of different cancers (Borner et al., 1995). In breast cancer cells, 
overexpression of PKC has been shown experimentally to increase proliferation rates and 
tumourigenesis (Ways et al., 1995). Additionally, PKC overexpression in breast cancer 
cells are positively correlated with tumour aggressiveness and poor responsiveness to 
endocrine therapies (Lønne et al., 2010). Assender et al showed that an overexpression of 
PKC reduces the expression of ER in breast cancer cells, which compromises the 
responsiveness of cells to endocrine therapy such as Tamoxifen (Assender et al., 2007). PKC 
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inhibitors such as Tamoxifen have been used in the treatment of breast cancer for a number 
of years. Many of the available inhibitors, however, are non-specific, which may account for 
their mixed effectiveness (Marengo et al., 2011). The combination of two PKC inhibitors 
likely results in a more complete PKC inhibition, which would result in an additive effect. 
Here, however, synergy is observed, which suggests that there are differential mechanistic 
effects between the drugs. These could be the impact on different sub-sets of PKC molecules, 
or activation of related pathways including IMPase and Wnt signalling. Activation of these 
related pathways highlights both direct and indirect cellular effects modulated by the ER. 
Where two mechanisms impart a reaction on a pathway at different points to achieve drug-
drug interaction.  
 
The combination of LiCl and Tamoxifen has been explored in the treatment of mania both in 
animal models (Valvassori et al., 2017) and in children and adolescents (Fallah et al., 2016). 
In animal models, the combination was found to mediate behavioural changes associated with 
mania and change PKC signalling pathways. A randomised, placebo-controlled clinical trial 
study conducted by Fallah et al found adding Tamoxifen to a treatment condition of lithium 
alone resulted in a reduction of symptoms of mania (Fallah et al., 2016). Synergy analysis 
was not conducted, and the authors did not suggest whether the combination was additive or 
synergistic. Although these studies relate to the treatment of bipolar disorder and mania, they 
serve to show that the two drugs are targeting the same signalling pathway which, in part, 
likely explains the synergy observed in these experiments. 
 
The concentrations of LiCl utilised in the above combination treatments are far lower than 
those clinically used in the treatment of bipolar (M vs mM). However, it should be noted 
that the clinical concentrations reflect plasma concentration and not local concentration. 
Given the high water solubility of LiCl, it is likely that the concentration in fatty tissues such 
as breast are orders of magnitudes lower. However, this could also show that here a 
synergistic effect can be achieved between LiCl and Tamoxifen with sub-clinical 
concentrations on LiCl. This would then have the benefit of reducing the potential of adverse 
side effect, which is particularly important given the potential toxicities of LiCl (detailed in 
section 4.4.1.2) 
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When examining the effect of the combination of LiCl and Doxorubicin on cell viability, 
MDA-MB-231 cells display significantly more sensitivity than MCF-7 cells (p≤0.01). The 
IC50 doses are 1uM Dox with 66uM LiCl and 1μM Dox with 191μM LiCl for MDA-MB-
231 and MCF-7 cells, respectively. Furthermore, the maximum decreases in cell viability are 
90% for MDA-MB-231 cells, but only 55% for MCF-7 cells. Tang et al examined 
combinations of GSK3 with conventional treatments for osteocarcinoma, including 
Doxorubicin, finding that the combination resulted in a significant reduction in cell viability 
compared with treatment with LiCl or Doxorubicin alone (Tang et al., 2012). Synergy 
analysis was not performed, so it is unknown whether the interaction between the 
combinations was found to be additive or synergistic. Further research into this combination 
has been undertaken in prostate cancer (Hossein, Zavareh and Fard, 2012). LiCl treatment of 
the pancreatic cell line DU145 significantly compromised cell viability in a concentration-
dependent manner. Combination with a low, sub IC50, concentration of Doxorubicin resulted 
in increased cytotoxicity, observed as a significantly higher proportion of cells in Sub-G1 
phase of the cell cycle; at the IC50 dose of Doxorubicin, the proportion of cells in Sub-G1 
phase was greater than 10% more than the control, consistent with an increase in the 
proportion of cells undergoing apoptosis (Hossein, Zavareh and Fard, 2012). The group 
found that combining the IC50 dose of Doxorubicin with LiCl also significantly increased 
cell cycle arrest in S-phase (approximately 30%). This is consistent with the known mode of 
action of Doxorubicin: causing cell death or growth inhibition at different stages in the cell 
cycle by intercalating with DNA and inhibiting DNA topoisomerase II (Minotti et al., 2004), 
in a cell cycle non-specific manner (Thorn et al., 2011).  
 
Reasons for the increase in cytotoxicity as a result of the combination of LiCl and 
Doxorubicin is likely related to the ability of LiCl to cause cell cycle arrest at S-phase. This is 
consistent with literature observations that S-phase cell cycle arrest increases the sensitivity 
of cells to treatment with chemotherapeutic agents such as Doxorubicin that are cell cycle 
phase dependent (Balk and Knudsen, 2008). This is because LiCl-induced S-phase cell cycle 
arrest increases the proportion of the cell population in a phase where DNA is actively 
replicating (Hossein, Zavareh and Fard, 2012). Consistent with this, Erguven et al showed 
that when exposed to the IC50 dose of LiCl in combination with IC50 concentration of 
doxorubicin, the prostate cancer cell line DU145, result in a reduced percentage of cells in G1 
cell cycle phase and an increase in p53 levels when compared with treatment with LiCl alone 
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(Erguven et al., 2016). The combination of Doxorubicin and lithium has been explored in 
other cancers to reduce adverse side effects associated with chemotherapy. For example, 
lithium has been found to offer a protective effect against the adverse cardiotoxic effects of 
Doxorubicin in vivo (Rahimi_Balaei et al., 2010).  
 
The increased sensitivity of MDA-MB-231 cells over MCF-7 cells to this combination 
cannot be explained by the sensitivities of the cell lines to the individual drugs, as there is no 
significant difference in their responsiveness to Doxorubicin, and MDA-MB-231 cells are 
less sensitive to LiCl alone. Greater synergy is observed in MDA-MB-231 cells across all 
doses of LiCl combined with 1μM Doxorubicin. In MCF-7 cells, synergy is only observed at 
the highest dose of LiCl tested. At low doses of LiCl, conversely, the interaction between the 
drugs is antagonistic. This suggests that LiCl offers a protective effect against doxorubicin 
toxicity in MCF-7 cells. Assaying a full range of doxorubicin concentrations combined with 
LiCl concentrations would allow this to be explored further and further research required to 
determine the mechanism of this antagonism. One reason could be related to the opposing 
effects of LiCl and doxorubicin on membrane associated ion pumps. Lithium has been found 
to stimulate Na+-Li+ counter-transport activity, resulting in a significant increase in sodium 
influx following treatment with the drug (Mallinger et al., 1987). Doxorubicin, in contrast 
inhibits membrane-associated ion pumps through its major metabolite doxorubicinol (Boucek 
et al., 1987). Inhibition of membrane ion pumps can result in apoptosis (Yeo et al., 2004), 
therefore, if the inhibitory effects of Doxorubicin on this can be tempered by LiCl-mediated 
stimulation, the cellular effect would be lessened. Direct measurement of ion channel 
function through voltage clamp and patch clamp methodologies would provide a means to 
determine the effect of each drug on this function and the effect of the combination. 
 
For cisplatin and lithium, there is a statistically significant difference between the effect on 
cell viability of MDA-MB-232 and MCF-7 cell lines: Despite being less sensitive to 
treatment with the individual drugs, MDA-MB-231 cells are more sensitive to the 
combination of LiCl and Cis. This is reflected in the IC50 values for the combinations: 10μM 
Cis with 95μM and 10μM Cis with 132μuM LiCl, respectively. In addition, the highest 
reduction in cell viability was achieved for MCF-7 cells at the highest concentration 
combination tested, but this is 25% lower than that achieved in MDA-MB-231 cells. A 
synergistic relationship is observed between the drugs at the highest concentrations of LiCl 
tested, for both cell lines. 
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The mechanism of action of Cisplatin is explained in detail in section 1.8.2.1. One mode of 
action is the ability for the molecule to form cross links between purine bases, which impairs 
replication and repair mechanisms (Dasari and Tchounwou, 2014b). In a similar way that 
increasing the number of cells in S-phase can increase the efficacy of doxorubicin, increasing 
the proportion of cells actively dividing can increase the effect cisplatin has. Hence, the 
synergistic interaction between lithium and Cisplatin may be due to the action of lithium on 
cell-cycling, as proposed for Doxorubicin.  
 
The interaction of LiCl and Cisplatin has also been explored in vivo following observations 
that treatment with cisplatin affected serum levels of lithium in patients taking lithium as a 
treatment for manic depressive or other psychiatric disorders. Beijnen et al found that in the 
first course of cisplatin-based chemotherapy, there was no effect on serum lithium 
concentration, but following rounds of chemotherapy resulted in an increase in lithium 
concentration. The group postulate this is due to a deterioration in kidney function, reducing 
the rate of lithium metabolism as opposed to direct interaction of the two drugs (Beijnen et 
al., 1992).  Lithium has also been used to mitigate adverse side effects of cisplatin treatment 
in patients with colon cancer, most notably acute kidney injury. Bao et al demonstrated that 
the use of lithium as a rescue therapy in patients receiving Cisplatin treatment could improve 
kidney repair and function (Bao et al., 2014). In addition, this group reported that 24- or 48-
hour lithium treatment of the SW480 colon cancer cell line resulted in a 20% reduction in 
cellular growth and enhanced the efficacy of Cisplatin toxicity (Bao et al., 2014). Potential 
mechanisms for this observed effect are the activation of caspase-3, which was observed for 
cisplatin pre-treated non pre-treated cells (Bao et al., 2014).  
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 Carbidopa combinations  
 
The response of MDA-MB-231 and MCF-7 cells to Carbidopa and Tamoxifen were not 
statistically significantly different. In addition, SynergyFinder analysis found little evidence 
for synergy between these two agents, with additivity or antagonism more probable. As such, 
it is unlikely that this combination has much potential to be further explored. 
 
In contrast, the interaction of Carbidopa with doxorubicin resulted in cell viability profiles 
that were significantly different between the two cell lines. None of the dose combinations 
tested resulted in a change in cell viability for MDA-MB-231 cells. For MCF-7 cells, the two 
highest doses of Carbidopa combined with 1μM doxorubicin resulted in a significant increase 
in cell viability compared with treatment with 1μM dox alone by up to 30% over doxorubicin 
alone. Further analysis demonstrated clear synergy for this combination of drugs, although 
there was a difference in the pattern of interaction observed in MDA-MB-231 cells versus 
MCF-7 cells. For MDA-MB-231 cells, for all three methods used, the combination of 100μM 
Carbidopa with 1μM doxorubicin showed the highest level of synergy, although some 
synergy was observed at all combinations tested.  
 
For MCF-7 cells, for all three methods used, the combination of 10μM Carbidopa and 1μM 
doxorubicin was synergistic, whereas doses of 50μM and 100μM Carbidopa with 1μM 
doxorubicin are antagonistic. For the Bliss and HSA methods, there is also antagonism seen 
at doses of 1μM Carbidopa with doxorubicin. The ZIP method shows a similar pattern of 
interaction between the two drugs but overall shows lower degrees of antagonism and 
synergy. The differences between the two cell lines in their response to this combination 
treatment cannot be due to differences in responsiveness to Carbidopa as there is no 
significant difference in the effect of the drug when applied alone, with no significant impact 
on cell viability compared with the control over the concentration range tested (1-100μM).  
 
We do observe a difference in sensitivity of the two cell lines to doxorubicin: MCF-7 cell 
viability is not significantly affected by any of the concentrations tested, whereas MDA-MB-
231 cell viability is.  Consistent with research investigations presented in this thesis into the 
efficacy of doxorubicin for MCF-7 cells, a number of groups find they are relatively less 
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sensitive than other breast cancer cell lines (Lovitt, Shelper and Avery, 2018). However, in 
contrast to findings in this thesis, where even 20uM treatment with doxorubicin did not 
significantly impact cell viability, many groups identify IC50s in the nanomolar range 
including Smith et al and Fang et al. However, these groups do not specify length of 
treatment with doxorubicin and may be greater than the 24-hour exposure used in the 
experiments detailed here (Smith et al., 2006; Fang et al., 2014). Pilco-Ferreto and Calaf used 
48 and 24-hour incubations of MCF-7 and MDA-MB-23 cells with doxorubicin, determining 
IC50 values between 4μM and 8μM and finding MCF-7 cells to show more resistance to the 
drug (Pilco-Ferreto and Calaf, 2016).  
 
 
While the effects of doxorubicin and carbidopa alone on MCF-7 cell viability are minimal, 
the combination effect of these two drugs results in cell viability greater than when the cells 
are 1) treated with 1μM doxorubicin and 2) untreated. The antagonistic effect of Carbidopa 
and Dox in combination is therefore the output from the SynergyFinder analysis as the 
combination appears, in fact, to stimulate cell growth. In these experiments, a range of doses 
of Carbidopa are combined with a fixed doxorubicin concentration. Examinations of a full 
concentration response matrix, varying levels of both drugs could identify further differences 
in response of MCF-7 and MDA-MB-231 cells. 
 
The response of MDA-MB-231 and MCF-7 cells to Carbidopa and Cisplatin was not 
statistically significantly different between the cell lines, and none of the combinations tested 
resulted in a significant reduction to cell viability compared with treatment using Cisplatin 
alone. However, under formal analysis, some synergy was detected in a cell line specific 
manner: in MDA-MB-231 cells, the combination is antagonistic at high concentrations of 
Carbidopa (50μM and 100μM), but synergistic at low concentrations (maximal synergy 
observed with 1μM Carbidopa). MCF-7 cells show largely synergistic effect with most 
concentrations of Carbidopa tested. In contrast to the pattern observed in MDA-MB-231 
cells, in MCF-7 cells the greatest degree of synergy is observed with the highest doses of 
Carbidopa (100μM). MCF-7 cells are more sensitive to treatment with Cisplatin in terms of 
reductions to cell viability across a dose range from 2.5μM-200μM. There is no significant 
difference in the effect Carbidopa has on cell viability between MDA-MB-231 and MCF-7 
cells. For both cell lines, the dose range of 1-100μM has no significant impact on cell 
viability compared with the control. 
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Carbidopa has been found to be cytotoxic to lung carcinoma cells (Gilbert et al., 2000). The 
group found there to be a central role for hydrogen peroxide (H2O2) in this cytotoxicity 
(Gilbert et al., 2004). The group noted that cells able to degrade H2O2 show less sensitivity to 
cytotoxic effects of Carbidopa. Notably, these cytotoxic effects were tempered by pyruvate, a 
product of aerobic glycolysis observed in a number of cancer cells (Baggetto, 1992). This is 
consistent with the findings from other groups, who observe pyruvate preventing H2O2 
mediated apoptosis (Andrae, Singh and Ziegler-Skylakakis, 1985; Ramakrishnan et al., 
1998). Observed in these experiments and in agreement with literature, MDA-MB-231 cells 
have a more glycolytic energy phenotype than MCF-7 cells (Robey et al., 2005; Pelicano et 
al., 2014b) and therefore may have a higher cellular level of pyruvate, conferring protection 
against free radicals generated by the autooxidation of Carbidopa. 
 
One mechanism by which this drug combination could be synergistic may be related to free 
radical-mediated apoptosis. Carbidopa’s autooxidation results in cell-damaging free radicals. 
Cisplatin reduces the ability of both cell lines to respire glycolytically, meaning the level of 
protective antioxidant pyruvate may be reduced. Thus, with this combination, the cell is 
subject to free radicals with reduced capacity to protect against these, which result in a 
synergistic effect of the two drugs observed.  
 
Overall, this combination displays more synergy in MCF-7 than MDA-MB-231 cells. 
Following treatment with cisplatin, levels of glycolytic respiration are still higher in MDA-
MB-231 cells, as shown in section 6.1.2.2 of GW4064. Therefore, it could be proposed that 
these cells maintain a higher level of pyruvate and the ability to reduce the effect of free 
radicals present. Assaying levels of pyruvate and H2O2 would help confirm the mechanism 
by which this combination functions differentially in MCF-7 and MDA-MB-231 cells. 
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4.7 Conclusion 
 
Here, a computational model of a breast cancer cell is built, integrating a genome-scale 
metabolic model, key gene and signal regulatory components and a kinetic model of the cell 
cycle. Once this general model was reconstructed, it was constrained using literature and de 
novo generated data to represent specific breast cancer cell lines or subtypes. The model was 
validated against its ability to reproduce known biology of the breast cancer cell line under 
study, effectively simulating the level of glucose accumulation and lactate depletion observed 
in in vitro time course assays. Following this, the model was used to explore metabolic 
chokepoints and vulnerabilities and to identify novel targets for breast cancer treatment. In 
silico investigations utilising this model highlighted two key reactions of interest: inositol 
monophosphatase and serotonin. Utilising pre-existing pharmacological inhibitors; lithium 
chloride and carbidopa, reactions for these molecules are perturbed in vitro and assay the 
effects of these on cell viability.  
 
In contrast to results from other groups (Taylor et al., 1995), here, individual treatment of 
MCF-7, MDA-MB-231 and MCF-7 causes a dose-dependent reduction in cell viability of 
these cell lines. The contradictions in MCF-7 cells, are likely due to the biphasic response of 
ER-positive cell lines to LiCl as found by (Suganthi et al., 2012). Greater sensitivity of MCF-
7 cells than MDA-MB-231 cell may be due to greater levels of IMPase, an indirect target of 
LiCl. Individual treatment with carbidopa had no effect on cell viability of the three cell lines 
assayed.  
 
As shown in Chapter 3, the use of combination treatment, where individuals are exposed to 
two (or more) cancer chemotherapeutics at the same time (Chalakur-Ramireddy and Pakala, 
2018) has the potential to exhibit synergy, allowing an increase in drug efficacy, a reduction 
in adverse effect profile, and a reduction in the risk of drug resistance developing (Mokhtari 
et al., 2017). However, this approach has been limited to the use of currently developed 
chemotherapeutics in ad hoc combinations. In this chapter, a network targeting method of 
tackling breast cancer is explored in order to exploit the concept of synthetic lethality, with 
combinations designed using systems biology methodologies.  
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The combination of LiCl with chemotherapeutic agents has been previously examined in 
prostate cancer (Freland and Beaulieu, 2012). Here, a synergistic effect between LiCl with 
Tamoxifen, cisplatin and doxorubicin is seen in both MCF-7 and MDA-MB-231 cell lines, 
with slightly higher levels of synergy observed in MDA-MB-231 cells across all 
combinations. Notably, synergy is achieved with sub-clinical doses of LiCl, suggesting 
inhibition of breast cancer growth could be achieved with minimal exposure to toxicities 
associated with higher doses of LiCl.  
 
Combinations of the same chemotherapeutic agents with carbidopa show some synergy 
across both cell lines. Carbidopa with Tamoxifen results in slight synergy at the highest doses 
of carbidopa tested, carbidopa with doxorubicin is synergistic in MDA-MB-231 cells only 
and the combination of carbidopa with cisplatin shows greater synergy in MCF-7 cells. This 
may be due to an increased ability of MDA-MB-231 cells to protect themselves against free 
radicals.  
 
Both predictions from this novel reconstruction of a breast cancer cell are validated in vitro. 
The inhibition of IMPase resulting in dose-dependent reduction in cell viability as an 
individual treatment and the inhibition of serotonin forming synergistic combinations with 
conventional chemotherapeutic agents. 
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Chapter 5 
 
5 Discussion and Conclusion 
 
 
 
5.1 Overview  
 
Breast cancer is the most prevalent cancer in women worldwide and in addition is the most 
common cause of female cancer deaths globally. Worldwide net 10-year survival rates for 
breast cancer have been improving year on year over the past four decades largely due to 
improvements in early diagnosis, screening programs and treatment developments. The rate 
of improvement to net survival has decreased, however, and is beginning to plateau. This 
leaves a proportion of breast cancers unresponsive to current treatments. The difference in 
responsiveness is due to the heterogeneity of breast cancer. There is a high degree of 
diversity both between and within breast cancer tumours, as well as amongst cancer bearing 
individuals. These differences contribute to differences in cancer aggressiveness, prognosis 
and therapeutic response, which complicates treatment.  
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Despite this, chemotherapy remains the mainstay for breast cancer treatment. However, 
issues with chemotherapeutic agents including off-target toxicities, variable levels of efficacy 
and the ability of breast cancer tumours to develop resistance against drugs, vastly limits their 
usefulness as a long-term treatment strategy. In this context, the aim of this work was to 
explore different means of targeting breast cancer. The approaches here include 1) an 
examination of novel combinations of metabolism modulating drugs and 2) the development 
of a dynamic, multi-scale computational model of a breast cancer cell, to identify potential 
targets within a cellular network for synergistic drug treatments and validate these predictions 
in vitro. 
 
5.2 Combining metabolism modulating drugs with traditional 
chemotherapeutic agents 
 
The observation that patient outcomes from conventional mono-chemotherapy are limited, 
led to the development of collaborative treatment strategies. The concept of combination 
therapy, co-administering two or more chemotherapeutic agents, was first utilised in 1965 to 
treat leukaemia (Frei et al., 1965). This approach has since been used in a range of different 
cancer types including breast cancer and has resulted in improvements in reducing both off 
target toxicities (Hu et al., 2016) and resistance development (Wei et al., 2016). Since first 
conceptualised, the use of combination chemotherapy has become more widespread, with the 
most common regimens used being anthracycline combinations (Camacho et al., 2016), 
methotrexate based combinations (Li et al., 2017) and paclitaxel combinations (Socinski et 
al., 2012). Specific examples of combinations chemotherapy used in breast cancer include 
doxorubicin with cisplatin to treat breast cancer tumour bearing mouse models (Wu et al., 
2017) and paclitaxel with methotrexate in breast cancer cell lines (Liu et al., 2015). Utilising 
drug combinations can allow mitigation of off target toxicity, through exploitation of 
potentially synergistic interactions between two agents. For example, synergistic 
combinations allow the reduction of individual drug concentration without reducing 
combined efficacy. Therefore, patients receive the therapeutic effect with lower doses of each 
drug (Wei, et al., 2016). However, treatment with two agent that possess only additive effects 
would more likely result in further toxicity.  
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The design of these initial combinations was based around three main criteria: namely, that 
the agents should have 1) minimal overlapping toxicities 2) different therapeutic mechanisms 
to minimise drug resistance development 3) similar solubility and permeation to aid delivery 
(Qin et al., 2018). These requirements, however, were not often all met ahead of clinical 
trials or their utilisation in patient treatment (Miles, von Minckwitz and Seidman, 2002). 
While these empirically designed combinations have shown some benefits to patient 
outcomes, toxicities remain an issue (Miles, von Minckwitz and Seidman, 2002). Therefore, 
to significantly improve patient outcomes, a more refined method of combination 
therapeutics is required.  
 
Forming an important part of the phenotype shared by a number of cancer types is 
unconstrained growth, which contributes to cancer invasiveness and potential metastasis. To 
maintain this unbridled growth and promote survival, cancer cells employ a number of 
metabolic alterations, referred to collectively as metabolic transformation (Cairns et al., 
2011). This allows the generation of ATP, production of macromolecules required for 
cellular growth and reduced effects of damaging reactive oxygen species (ROS) (Hanahan 
and Weinberg, 2011). The increased utilisation of aerobic glycolytic respiration over 
oxidative phosphorylation to meet cancer cell energy needs is a central tenet of this metabolic 
transformation. This meets a number of needs of cancer cells including 1) increased ATP 
generation, although this is less efficient than oxidative phosphorylation. 2) reduced ROS 
generation 3) aids adaptation to hypoxic tumour environments (Gillies et al., 2008). 
 
Given that metabolic transformation is so central to the phenotype of cancer, it has been 
targeted with anticancer therapeutics for a number of years. Early attempts to exploit this 
stimulated the development of antimetabolites (Farber et al., 1948), which are molecules 
resembling nucleotide metabolites that inhibit enzyme activity and impede nucleotide 
synthesis (Elion, 1989). Cancer cells possess increased demand for DNA replication and 
therefore nucleotide biosynthesis, resulting in clinical success of these antimetabolites 
(Luengo et al., 2017). They include purine analogues such as 6-mercaptopurine (Elion, 1989) 
and pyrimidine analogues including 5-fluorouracil, still utilised to treat a number of cancers 
today (Wagner et al., 2006). This class of drugs inhibits general proliferative metabolism, and 
while this is at the centre of the success of this class of chemicals, it also contributes to its 
limitations. These include surrounding toxicities to non-malignant, rapidly dividing cells 
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myeloid cells in the bone marrow (Brown et al., 2017). This, coupled with gastrointestinal 
toxicities, are dose-limiting factors for these drugs (Brown et al., 2017). The utilisation of 
antimetabolites served as a proof-of-concept for the therapeutic advantage of targeting 
meatbolism in breast cancer. Targeting proliferative metabolism alone appears to have a 
limited clinical window, however, stimulating the identification for other, more targeted 
metabolism modulating targets.  
 
Other metabolic signatures of cancer and specifically breast cancer include a reliance on 
glutamine catabolism, serine metabolism and a lipogenic phenotype (Mishra and Ambs, 
2015). Additionally, tumourigenic adaptations to stress distinguish transformed from non-
transformed cells. One key adaptations include the presence of ROS stimulating cancer cell 
growth (Liou and Storz, 2010; Weinberg et al., 2010), with oncogenes such as MYC 
stimulating ROS generation to contribute toward tumourigenicity. Increased production of 
ROS, however, requires the generation of antioxidants as a means to protect against the toxis 
effects of extreme levels of ROS which could still be damaging. Cancer cells are 
metabolically adapted to generate antioxidants. Primarily from reduced glutathione, 
generated in a reaction catalysed by glutathione and coenzyme NADPH. Late-stage tumours 
particularly, can reroute the products of the pentose phosphate pathway and glycolysis into 
this detoxification preferentially over biogenesis (Jerby et al., 2012). A number of the above 
metabolic signatures and adaptations are emerging as novel metabolic targets (Martinez-
Outschoorn et al., 2017), with a number of metabolism modulating drugs already being 
assessed in phase I and phase II clinical trials. In breast cancer glycolysis inhibitors including 
dichloroacetate have been shown to stabilise the disease during clinical trials (Sborov, 
Haverkos and Harris, 2015). Additionally, some initial combinations of metabolism 
modulating agents with traditional chemotherapeutics are currently in clinical trials, such as 
ATN 224, an angiogenesis inhibitor, with carboplatin (Sborov, Haverkos and Harris, 2015). 
 
Considering the benefits of combination therapies, and promising outcome of existing drugs 
altering cancer metabolism, a network targeting approach could be to use traditional 
chemotherapeutics alongside metabolic disruptors. Reducing the energy available to a cell 
will (i) slow the rate of division, and (ii) make the cell more fragile to energy demands. This 
approach thus far is relatively limited; therefore, explore the potential of two metabolic 
disruptors (GW4064 and Metformin) in combination with traditional cancer 
chemotherapeutics is explored to target breast cancer cell lines.   
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The Farnesoid X receptor (FXR), a ligand activated transcription factor was initially 
characterised in the liver. Subsequently, its presence in non-cancerous and cancerous breast 
tissue as well as in breast cancer cell lines: MCF-7 and MDA-MB-231 has been characterised 
(Swales et al., 2006b). This, combined with its characterisation as a prognostic marker for 
disease-free patient survival (Giaginis et al., 2017), make FXR an attractive target for breast 
cancer treatment. Absence of functional FXR has been associated with a spontaneous 
development of liver tumours in  FXR -/- knockout mice (Yang et al., 2007) and is described 
through mouse knockout studies as a tumour suppressor for colorectal cancer ( 
Bailey et al., 2014). Furthermore, in human colorectal cancer, FXR levels are silenced in 
stage I-IV carcinomas (De Gottardi et al., 2004; Bailey et al., 2014). Understanding the 
implications of a lack of active FXR highlights the potential for clinical benefits in increasing 
residual FXR activity. GW4064 is a pharmacological FXR agonist, confirmed to alter 
downstream FXR targets including small heterodimer protein (SHP) (Swales et al., 2006) and 
induce mitochondrial mediated apoptosis in breast cancer cell lines (Giordano et al., 2011b; 
Mohan et al., 2015).  
 
Ahead of the combination studies, the response of breast cancer cell lines to single agent 
treatment was characterised by examining cell survival and cell viability. In addition, as this 
thesis’ investigation surrounds metabolism modifying drugs, the effect of the drugs on the 
cell energy phenotypes of cell lines is investigated. GW4064, in line with existing research, 
was shown to inhibit clonogenic cell survival in MCF-7 and MDA-MB-231 cells and in 
addition to have a negative impact on cell viability in MDA-MB-231 cells and MCF-10A 
non-transformed cells. The effect of GW4064 on the cell energy phenotype was a reduction 
in both energy generating pathways as well as a reduction in metabolic potential, which 
suggests sensitisation to a stressor.   
 
Consistent with literature, the SERM Tamoxifen caused a concentration-dependent reduction 
in cell survival and viability in MCF-7 ER-postive cell line (Seeger et al., 2004; Gonzalez-
Malerva et al., 2011). Surprisingly, the TNBC cell line MDA-MB-231 showed greater 
sensitivity to this treatment than MCF-7 cells. However, such efficacy aligns with the results 
from a number of groups (Zheng, Kallio and Härkönen, 2007; Todorova et al., 2011; 
Darakhshan et al., 2015), and is proposed to occur through pathways including a Tamoxifen-
mediated inhibition of glutamate uptake (Todorova et al., 2011) and an inhibition of the 
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CIP2A/PP2A/p-Akt pathway which inhibits apoptosis in cancer cells (Liu 2014). 
Furthermore, non-transformed MCF-10A cells are sensitive to Tamoxifen induced 
cytotoxicity.  
 
MCF-7 cells are sensitive to cisplatin and undergo a reduction in glycolytic respiration 
following treatment. The cell survival of MDA-MB-231 cells is negatively affected and these 
cells also undergo reduced glycolysis following cisplatin treatment. However, cell viability 
was unaffected across the dose range. Single agent treatment with doxorubicin did not 
compromise cell viability in any of the cell lines tested here but did reduce clonogenic cell 
survival, which is likely due to the mechanism of doxorubicin. This is understanding as the 
drug prevents DNA replication but does not directly kill cells – hence toxicity would be as a 
result of cell arrest-mediated toxicity (Minotti et al., 2004), rather than a direct effect. 
Doxorubicin reduced glycolysis in MCF-7 cell but increased this in MDA-MB-231 cells. 
This suggests the drug does not affect the ability to cells to use this pathway and in MDA-
MB-231 cells may act as a stressor for cells to upregulate energy generating pathways. 
Biologically, the implications of this are increased cellular energy demands and a potential 
sensitisation to metabolism modulating drugs, highlighting doxorubicin as an agent of 
interest for further combination studies. 
 
We built on initial combination studies carried out by Mohan et al in 2015, who found 
GW4064 synergises with Tamoxifen in MCF-7 and MDA-MB-231 cells (Mohan et al., 
2015). Notably GW4064+Tamoxifen is synergistic in MCF-7 cells and reduces cell viability 
in MDA-MB-231 and MCF-7 cell lines, but not in non-transformed MCF-10A cells. This 
highlights a combination therapy that appears selective only for cancer cells. The benefits of 
a selective therapy include reduced off-target toxicities. Across the combination studies, 
GW4064 combinations with traditional chemotherapeutics are synergistic in MCF-7 but not 
MDA-MB-231 cell lines. The mechanisms for this remain to be elucidated.  
 
Continuing with the exploration of metabolism modulating drugs in combination with 
chemotherapeutic agents, the effect of Metformin on breast cancer cell lines is assayed. 
Metformin is currently the primary therapy used for the treatment of type 2 diabetes mellitus 
(TIIDM), where it acts to reduce blood glucose levels (Gong et al., 2012). Today, the drug 
has been used clinically for over 50 years and displays high levels of safety (Rena, Pearson 
and Sakamoto, 2013). Metformin has effects beyond its primary use, controlling TIIDM, for 
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example, long-term treatment with Metformin is associated with a reduction in the incidence 
of cardiovascular disease (Turner, 1998) (Griffin, Leaver and Irving, 2017).  
 
The mechanism of action of Metformin is multifaceted and is still not fully characterised 
(Rena, Pearson and Sakamoto, 2013). However, there is increasing evidence for Metformin 
offering a protective effect against cancer development. A number of longitudinal studies 
have identified a reduced risk of cancer development in patients taking Metformin at an 
average daily concentration of 1875mg, which is below the maximum prescribed dose 
(2000mg/day). Libby et al in 2009 performed an observational cohort study among people 
with type 2-diabetes and found that individuals who had taken Metformin for greater than 
three years were found to have a significant reduction in cancer risk (ORs with 95% CI 0.40; 
0.21 to 0.57, p=0.004); higher levels of exposure conferred a greater protective effect (Libby 
et al., 2009b). In breast cancer specifically, an epidemiological study carried out in 2009 
examined patients split into groups of diabetic patients taking Metformin, diabetic patients 
not taking Metformin and non-diabetic patients not taking Metformin. The responsiveness of 
each group to neoadjuvant therapy was examined, demonstrating that the pathological 
complete response of diabetic patients taking Metformin was 16% higher than diabetic 
patients not receiving Metformin and 8% higher than non-diabetic patients (p=0.02) 
(Jiralerspong et al., 2009).   
 
Numerous mechanisms by which Metformin acts upon breast cancer cells have been 
hypothesised and tested experimentally, but no definitive mechanism(s) have been 
established for its anti-cancer properties to date. In vitro, Metformin has been found to inhibit 
the growth of certain cell lines in culture. For example, Zhang et al demonstrated that  MCF-
7 and MDA-MB-231 exposure to 5-20mM Metformin for 48 hours significantly inhibited 
cell proliferation, invasion and migration as well as inducing apoptosis (J. Zhang et al., 
2017). 
 
The identification of the protective effect of long-term Metformin exposure against cancers 
including breast cancer, coupled with the identification of a number of putative mechanisms 
by which the drug inhibits cancer growth and stimulates apoptosis mean Metformin is a 
promising novel treatment for breast cancer. However, the concentrations utilised in cell-line 
experimentation are often not clinically viable. Thus, the potential for the utilisation of 
Metformin in combination with conventional chemotherapeutics is explored here in MCF-7 
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and MDA-MB-231 cell lines. If synergy is achieved, concentrations of both drugs can be 
lowered to achieve efficacy at clinically tractable concentrations, as well as limiting toxic 
liability.  
 
Characterisation of the effect of Metformin alone on the breast cell lines showed the drug has 
a significant negative impact on all three cell lines explored, with MCF-10A cell lines 
showing the greatest sensitivity to alterations in cell viability. This is perhaps surprising, as 
the normal breast cell line would be expected to have the lowest metabolic demands. The 
observation is likely a consequence of the varied effects of Metformin meaning cellular 
effects are defined by metabolic demand. The full combination matrices were completed by 
undergraduate students working with me. Where with GW4064 combinations synergistic 
effects of the explored combinations are seen predominantly in MCF-7 cells, with Metformin 
combinations, a higher degree of synergy is seen within MDA-MB-231 cells than in MCF-7 
cells.  
 
Given the negative effect of both GW4064 and Metformin on cell viability, the effect of these 
drugs in combination was assayed. A combination using no chemotherapeutic agents could 
have significant advantages such as a reduction resistance development, a reduction in 
toxicities associated with chemotherapeutics and potentially a more targeted treatment, 
affecting only the transformed metabolism of cancer cells. The combination is additive in 
MDA-MB-231 cells but synergistic in MCF-7 cells. This suggests that there is the potential 
for effective cancer treatments without using conventional chemotherapeutic agents, which 
could have positive impacts on patient wellbeing and survival.  
 
 
The work here confirms the hypothesis that metabolism modulating drugs can sensitise breast 
cancer cells to the effects of chemotherapeutic agents, with combination studies finding that 
these can be 1) synergistic and 2) cancer cell specific. In vitro investigation of Metformin 
combinations re-establishes the drug as a potential adjuvant therapeutic for breast cancer 
treatment and further highlights potential gains from repurposing drugs.  
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5.3 Develop of a dynamic, multiscale computational model of 
breast cancer and in vitro validation 
 
The results from the combination therapies of metabolism modulating drugs GW4064 and 
Metformin with conventional chemotherapeutics indicate that there is the potential to obtain 
synergistic effects from this type of combination therapy. In addition, the selective effect of 
Tamoxifen with GW4064 on breast cancer cell lines only highlight the potential for more 
directed targeting of cancer cells, sparing normal tissues from negative effects (Mokhtari et 
al., 2017). A means to predict novel targets for metabolism modulating drugs that could again 
be explored in combination with conventional chemotherapeutics was therefore desirable.  
 
Systems biology is a holistic method for understanding intricate biological systems and has 
its basis in the theory of emergent properties; essentially, the central premise is that as 
biological systems are combined, novel effects will emerge that would not be predicted by 
studying the systems in isolation (Bruggeman and Westerhoff, 2007). Practically, systems 
biology explores biological systems using mathematical techniques informed by, and 
validated through, in vitro and in vivo models. In one approach, computational models are 
built using well described pathways and interactions. These descriptive models can then be 
populated with known mathematical parameters gleaned from quantitative experimental 
techniques, ranging from individual measurements of enzyme kinetics to high-throughput 
proteomics and genomics screens. The models, once generated and parameterised can be 
used to run simulations and predict the aforementioned emergent properties of a system 
(Somvanshi and Venkatesh, 2014).  
 
Cancer is a complicated, multi-stage, heterogeneous disease. This complexity means that 
reductionist approaches to understand the development and treatment of cancer are 
particularly limited. For example, cancer can arise as a result of a number of interactions 
between genes and proteins at the molecular level, between cell types and tissues at the 
cellular level, and is further complicated by individual patient differences (Rivenbark, 
O’Connor and Coleman, 2013). Therefore, the ability to create dynamic multi-scale models 
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representing all stages of biological organisation increases the usefulness of computational 
models in understanding disease progression and predicting the effects of medical 
interventions on a system. The aforementioned intricacies and heterogeneity of cancer render 
reductionist approaches to treatment development severely limited in scope. These 
complexities also present challenges in generating meaningful computational biology models. 
Despite this, many in silico models capturing parts of the cancer process have been 
generated, and these have provided novel insights into cancer biology. Furthermore, the 
generation (Lander et al., 2001) and increased availability of large -omics datasets has 
enabled the incorporation of multi levels of cancer complexity into single models (Edgar, 
Domrachev and Lash, 2002).  
Computational modelling of cancer biology has been used to explore a number of different 
scales of biological organisation, including: signalling networks incorporating metabolism 
and biochemical pathways modelled dynamically; reaction networks using statistics to 
determine interactions; tumour microenvironment; and, tissue level interactions modelled 
using agent-based models. Here, a computational model of a breast cancer cell is generated, 
integrating a genome-scale metabolic model, key gene and signal regulatory components and 
a kinetic model of the cell cycle. Once this general model was reconstructed, it was 
constrained using literature and de novo generated data to represent specific breast cancer cell 
lines or subtypes. The model was validated against its ability to reproduce known biology of 
the breast cancer cell line under study, effectively simulating the level of glucose 
accumulation and lactate depletion observed in the in vitro time course assays. This model is 
limited by incomplete representation of signalling networks and incomplete parameterisation. 
Incorporation of additional gene and signalling regulatory networks may increase how 
closely the model represent specific cell lines or patient tumours. Further parameterisation of 
the GSMN using metabolomics data for all reactions as opposed to purely exchange 
reactions, would further shrink the solution space and increase the likelihood of correctly 
predicting emergent properties. This being said, this model represents multiple levels of 
biological complexity and more parameterisation than a number of systems biology models. 
Furthermore, useful predictions have been derived from in silico investigations, leading to the 
identification of potential new combination therapeutics.  
 
Following this, the model was used to explore metabolic chokepoints and vulnerabilities and 
to identify novel targets for breast cancer treatment. In silico investigations utilising this 
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model highlighted two key reactions of interest: inositol monophosphatase and serotonin. 
Utilising pre-existing pharmacological inhibitors; lithium chloride (LiCl) and carbidopa, the 
reactions for these molecules in vitro are perturbed and the effects of these on cell viability 
assayed.  
 
The model is distinct in terms of its combination of multiple scales of biological organisation 
and with its parameterisation. The usefulness of the model is enhanced by the ability to create 
multiple iterations representing patient specific data, which, critically, allows improved 
accuracy when predicting emergent properties and also a movement towards personalised 
treatment development. Utilising a gene essentiality scan, a number of genes essential to 
fulfilling the set objective function are identified: biomass production, representing cell 
growth. Selecting two genes of interest with pre-existing pharmacological inhibitors enabled 
the movement towards model validation. The use of gene essentiality scans to identify 
druggable metabolic nodes has been previously utilised by a number of groups. The approach 
is outlined by Penrod et al (Penrod et al., 2011) and has been used in combination with 
machine learning by Costa et al, who develop a system to give nodes ‘druggability scores’ 
(Costa et al., 2010). This has also been applied to combination therapeutics, with Tang et al 
using metabolic networks with drug treatment efficacies and binding affinities to predict 
multi-target combinations (Tang et al., 2013). 
 
In contrast to results from other groups (Taylor et al., 1995), here, individual treatment of 
MCF-7, MDA-MB-231 and MCF-10A with LiCl causes a concentration-dependent reduction 
in cell viability of these cell lines. The contradictions in MCF-7 cells, are likely due to the 
biphasic response of ER-positive cell lines to LiCl as found by Suganthi et al (Suganthi et al., 
2012). Greater sensitivity of MCF-7 cells than MDA-MB-231 cell may be due to greater 
levels of IMPase, a target of LiCl. These observations have implications for the potential use 
of LiCl in treating breast cancer. Given the biphasic response, ensuring the correct dose at the 
target site would be critical. Utilising approaches such as intra-tumoural chemotherapy 
delivery have improved patient outcome largely through a reduction in systemic toxicities 
(Brincker, 1993; Goldberg et al., 2002). This approach would lend itself to utilisation where 
there is a small therapeutic window for a drug such as LiCl. Given that differential efficacies 
may result from levels of IMPase present in a tumour, assaying patient genetic landscapes 
would enable a pre-treatment assessment of the potential usefulness of this drug in adjuvant 
chemotherapy. 
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Further exploring the effect of metabolism modulating drugs in combination with 
chemotherapeutics, the effect of these two drugs in combination with chemotherapeutic 
agents is examined. A a synergistic effect between LiCl with Tamoxifen, cisplatin and 
doxorubicin is seen in both MCF-7 and MDA-MB-231 cell lines, with slightly higher levels 
of synergy observed in MDA-MB-231 cells across all combinations. Notably, synergy is 
achieved with sub-clinical doses of LiCl, suggesting inhibition of breast cancer growth could 
be achieved with minimal exposure to toxicities associated with higher doses of LiCl. 
Furthermore, the higher levels of synergy observed in MDA-MB-231 cells suggest these 
combination treatments could tackle the treatment of triple negative breast cancer, for which, 
unlike other breast cancer subtypes, there are currently no targeted therapies (Anders and 
Carey, 2008).  
 
Combinations of the same chemotherapeutic agents with carbidopa show some synergy 
across both cell lines. Carbidopa with Tamoxifen results in slight synergy at the highest doses 
of carbidopa tested, carbidopa with doxorubicin is synergistic in MDA-MB-231 cells only 
and the combination of carbidopa with cisplatin shows greater synergy in MCF-7 cells. This 
may be due to an increased ability of MDA-MB-231 cells to protect themselves against free 
radicals (Robey et al., 2005; Pelicano et al., 2014a).  
 
Both predictions from this novel reconstruction of a breast cancer cell have been validated in 
vitro. The inhibition of IMPase resulting in concentration-dependent reduction in cell 
viability as an individual treatment and the inhibition of serotonin forming synergistic 
combinations with conventional chemotherapeutic agents. Thus, this work acts to not only 
explore novel combinations to treat breast cancer, but acts as a compelling proof-of-concept 
for the use of computational biology approaches in the development of network targeting 
drug combinations (Kolodkin et al., 2012).  
 
The model presented here provides important advancements in the area of computational 
cancer biology, generating a dynamic multi-scale model of breast cancer with novel 
components and context-specific iterations. Furthermore, this work demonstrates that in 
silico predictions of network drug targeting can be used to identify novel drug combinations, 
which can be validated in vitro.  
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5.4 Future work 
 
Novel combinations of metabolism modulating drugs with chemotherapeutic agents have 
been identified and assayed in this thesis with regard to effect on cell viability and survival. 
Despite favourable outcomes of these combinations, the mechanism of action of these 
combinations was explored in vitro. Future work determining the effect of these 
combinations on gene expression, target and downstream protein levels as well as on 
important pathways including apoptotic signalling pathways would enable a greater 
understanding of the observed effects. Performing western blot analysis on predicted targets 
would aid determination of the pathways utilised by the drugs explored in this work. LiCl and 
Metformin, particularly, have a number of targets and whilst some mechanisms are well 
characterised for these drugs, a number are poorly understood. Therefore, approaches such as 
microarray analysis would allow whole genome analysis of genetic alterations following 
these treatments and may allow identification of primary mechanistic pathways in different 
cell lines. 
 
Some analysis of energy phenotypes of breast cell lines was undertaken, expansion on this 
work and the alterations to energy generating pathways following combination therapeutics 
would aid further understanding of the effect of these combinations of the cell lines. A 
glycolytic rate assay designed by Agilent, would be a useful means by which to confirm 
differences in glycolytic utilisation of different breast cell lines. Further understanding of 
cancer cell metabolism and the effect of drug combinations tested in this work would aid the 
design of smart drug combinations.  
 
A key goal of combination therapeutics is the limitation of off target toxicities, to fully assess 
these effects, mouse xenograft models could be utilised. These models would enable 
assessment of systemic toxicities and also determine the distribution of drugs throughout the 
organism. To this point, recent research has postulated that the individual differential 
responses to certain treatments are related to the ability of different patient tumours to uptake 
drugs intracellularly. Differences observed in the response of MCF-7 and MDA-MB-231 
cells could be influenced by differential intracellular concentrations. Assays into these levels 
could enable a greater understanding of differential responses from different tumours and 
different patients.  
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The promising output of a number of the combination studies that 1) show synergy and 2) 
appear to selectively target cancer cells makes these ideal candidates to take forward for 
(pre)clinical trials. Specifically, Tamoxifen in combination with GW4064, which has lower 
efficacy in MCF-10A cells and Metformin in combination with chemotherapeutic agents 
which is synergistic in the triple negative breast cancer cell line, a typically hard to treat 
cancer subtype. As Metformin is well tolerated patients, the addition of this to an approved 
breast cancer treatment could improve patient outcomes with minimal added negative side 
effects.  
 
With regard to in silico investigations, to further investigate the intelligent design of drug 
combinations, flux variability analysis could be utilised. This algorithm allows the 
observation of whole metabolism effects following the perturbation of one reaction. The 
identification of potential compensatory pathways could allow combinations that are robust 
to resistance development. Additional alterations to the model would be to expand on the 
parameterisation of the GSMN using whole cell metabolomics data, as opposed to data for 
consumption and release reactions only. Further development of the signalling and regulatory 
network to include other important pathways that striate cancer subtypes could be undertaken 
to increase model iteration specificity. HER2 signalling, for example, has great effect on 
metastasis-free survival of patients (Adamczyk et al., 2017). The model presented in this 
thesis is a proof of concept, demonstrating validated novel drug target predictions. Future 
enhancements of the model would enable he utilisation of this model to become a key part of 
the drug development pipeline for breast cancer. 
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5.5 Conclusion 
 
The work presented here has confirmed the sensitivity of breast cancer cell lines to 
chemotherapeutic agents cisplatin, doxorubicin and Tamoxifen and metabolism modulating 
drugs Metformin and GW4064. In addition, the results identify a similar sensitivity of normal 
breast cell line MCF-10A to individual treatments. Metabolism as a target for breast cancer 
has gained traction in recent years and importantly, this work confirms the hypothesis that 
metabolism modulating drugs can sensitise cancer cells to treatment with chemotherapeutic 
agents in breast cancer cell lines (Gang et al., 2014; Long et al., 2016). Using MTT cell 
viability assays used to assay the effect on cell viability, complimented by clonogenic cell 
survival assays, the gold standard for measuring response of cells to novel agents and 
combinations, some synergy is seen across all combinations tested. Notably, differential 
responses are seen between the two breast cancer cell lines: MCF-7 cells see more synergy 
with GW4064 combinations and MDA-MB-231 cells see higher sensitivity with Metformin 
combinations, reiterating the importance of subtype and even patient-specific treatments 
(Yersal and Barutca, 2014).  
 
The work here represents important contributions to the use of computational cancer biology. 
The Multi Formalism Interaction Network Simulator (MuFINS) (Wu et al., 2016), was 
utilised to develop a novel reconstruction of a human breast cancer cell was developed, as a 
dynamic multi-scale computational model. This approach is recently gaining more traction, 
with use by groups examining diverse biological functions (Defontaine, Hernández and 
Carrault, 2004; Wu et al., 2016; Sier, Thumser and Plant, 2017). The model presented here 
uniquely combines a general human GSMN, an estrogen and progesterone gene and 
signalling regulatory network and a validated reconstruction of a fully kinetic published 
model of the cell cycle (Tyson and Novak, 2001).  
 
The GSMN is constrained firstly by cell line specific microarray data through the congruency 
approach (Zur, Ruppin and Shlomi, 2010)and then with literature sourced as well as de novo 
generated metabolomics data, contributing to the ever-growing body of work surrounding 
context-specific models (Becker and Palsson, 2008; Jerby, Shlomi and Ruppin, 2010; Wang, 
Eddy and Price, 2012).  
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Through this model, in silico investigations were carried out including a gene essentiality 
scan to identify genes required to meet the objective function of biomass production (cell 
growth) as potential novel drug targets. These in silico predictions were validated using in 
vitro breast cancer cell line models representing two diverse breast cancer subtypes, hormone 
receptor positive invasive ductal carcinoma and a triple negative adenocarcinoma (Holliday 
and Speirs, 2011a). Furthermore, combined targeting of these predicted drug targets with 
chemotherapeutic agents resulted in synergy observed across both cell lines. Notably, 
synergy of Tamoxifen with subclinical levels of LiCl is observed, identifying a potential 
combination therapy with reduced toxicities. This is particularly important given LiCl 
toxicities observed in its use to treat bipolar disorder (Gitlin, 2016).  
 
The work presented here has key findings that contribute to wider knowledge of breast 
cancer. Firstly, proof of concept studies combining metabolism modulating drugs with 
chemotherapeutic agents show that these can be 1) synergistic and 2) cancer cell specific. The 
clinical implications of this include reduced toxic liability through potential dose reductions, 
fewer off-target systemic effects and potentially a reduced likelihood of resistance 
development through pharmacologically reducing biological redundancy. In addition, the 
work provides important advancements in the area of computational cancer biology, 
generating a dynamic multi-scale model of breast cancer with novel components and context-
specific iterations. Furthermore, this work demonstrates that in silico predictions of network 
drug targeting can be used to identify novel drug targets that can then be combined with other 
drugs, the effects of which can be validated in vitro.  
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Appendix 1. Generalised R-scripts used for the microarray analysis.  
 
Generalised R-scripts for microarray data analysis 
# Version info: R 3.2.3, Biobase 2.30.0, GEOquery 2.36.0, limma 3.26.8 
# R scripts generated  Mon Oct 17 08:19:07 EDT 2016 
################################################################ 
#   Differential expression analysis with limma 
library(Biobase) 
library(GEOquery) 
library(limma) 
# load series and platform data from GEO 
gset <- getGEO("GSE59908", GSEMatrix =TRUE, AnnotGPL=FALSE) 
if (length(gset) > 1) idx <- grep("GPL15207", attr(gset, "names")) else idx <- 1 
gset <- gset[[idx]] 
# make proper column names to match toptable  
fvarLabels(gset) <- make.names(fvarLabels(gset)) 
# group names for all samples 
gsms <- "000111XXXXXXXXXXXXXXXXXX" 
sml <- c() 
for (i in 1:nchar(gsms)) { sml[i] <- substr(gsms,i,i) } 
# eliminate samples marked as "X" 
sel <- which(sml != "X") 
sml <- sml[sel] 
gset <- gset[ ,sel] 
# log2 transform 
ex <- exprs(gset) 
qx <- as.numeric(quantile(ex, c(0., 0.25, 0.5, 0.75, 0.99, 1.0), na.rm=T)) 
LogC <- (qx[5] > 100) || 
          (qx[6]-qx[1] > 50 && qx[2] > 0) || 
          (qx[2] > 0 && qx[2] < 1 && qx[4] > 1 && qx[4] < 2) 
if (LogC) { ex[which(ex <= 0)] <- NaN 
  exprs(gset) <- log2(ex) } 
# set up the data and proceed with analysis 
sml <- paste("G", sml, sep="")    # set group names 
fl <- as.factor(sml) 
gset$description <- fl 
design <- model.matrix(~ description + 0, gset) 
colnames(design) <- levels(fl) 
fit <- lmFit(gset, design) 
cont.matrix <- makeContrasts(G1-G0, levels=design) 
fit2 <- contrasts.fit(fit, cont.matrix) 
fit2 <- eBayes(fit2, 0.01) 
tT <- topTable(fit2, adjust="fdr", sort.by="B", number=250) 
tT <- subset(tT, 
select=c("ID","adj.P.Val","P.Value","t","B","logFC","GB_ACC","GI","Gene.Symbol","SPOT_ID")) 
write.table(tT, file=stdout(), row.names=F, sep="\t") 
################################################################ 
#   Boxplot for selected GEO samples 
library(Biobase) 
library(GEOquery) 
# load series and platform data from GEO 
gset <- getGEO("GSE59908", GSEMatrix =TRUE, getGPL=FALSE) 
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################################################################ 
#   Boxplot for selected GEO samples 
library(Biobase) 
library(GEOquery) 
# load series and platform data from GEO 
gset <- getGEO("GSE59908", GSEMatrix =TRUE, getGPL=FALSE) 
if (length(gset) > 1) idx <- grep("GPL15207", attr(gset, "names")) else idx <- 1 
gset <- gset[[idx]] 
# group names for all samples in a series 
gsms <- "000111XXXXXXXXXXXXXXXXXX" 
sml <- c() 
for (i in 1:nchar(gsms)) { sml[i] <- substr(gsms,i,i) } 
sml <- paste("G", sml, sep="")  set group names 
# eliminate samples marked as "X" 
sel <- which(sml != "X") 
sml <- sml[sel] 
gset <- gset[ ,sel] 
# order samples by group 
ex <- exprs(gset)[ , order(sml)] 
sml <- sml[order(sml)] 
fl <- as.factor(sml) 
labels <- c("CTRL","EXPT") 
# set parameters and draw the plot 
palette(c("#dfeaf4","#f4dfdf", "#AABBCC")) 
dev.new(width=4+dim(gset)[[2]]/5, height=6) 
par(mar=c(2+round(max(nchar(sampleNames(gset)))/2),4,2,1)) 
title <- paste ("GSE59908", '/', annotation(gset), " selected samples", sep ='') 
boxplot(ex, boxwex=0.6, notch=T, main=title, outline=FALSE, las=2, col=fl) 
legend("topleft", labels, fill=palette(), bty="n") 
  
https://www.ncbi.nlm.nih.gov/geo/geo2r/ 
 
 
  
https://www.ncbi.nlm.nih.gov/geo/geo2r/ 
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Appendix 2A 
ESTROGEN RECEPTOR – data files and details for ChIPseq analysis 
GSE 
Number 
GSM 
Number 
SRX SRR 
Number 
Cell 
Line 
Platform Experimental Control Treatment Chip 
antibody 
SAM files Reference 
GSE25710 GSM631494  ERX008601 ERR022054 MCF7 Illumina Genome 
Analyzer II / IIx 
  Input_control(v)  Input_DNA ERR022054.sam https://www.ncbi.nlm.nih. 
gov/geo/query/acc.cgi 
GSE25710 GSM631452   ERR022052 MCF7 Illumina Genome 
Analyzer II / IIx 
E2 treated    ER ERR022052.sam  
                    
GSE59530 
  
GSM1534712 SRX747767 SRR1635435 MCF7 Illumina HiSeq 
2500  
  Input_control(v) 
r1 
Vehicle Input_DNA SRR1635435.sam (Franco, Nagari and Kraus, 
2015) 
GSE59530 GSM1534713 SRX747768 SRR1635436 MCF7 Illumina HiSeq 
2500  
  Input_control(v) 
r2 
Vehicle Input_DNA SRR1635436.sam (Franco, Nagari and Kraus, 
2015) 
GSE59530 GSM1534722 SRX747777 SRR1635445 MCF7 Illumina HiSeq 
2500  
E2 treated r1   100 nM 17β-
estradiol 
ER-alpha SRR1635445.sam (Franco, Nagari and Kraus, 
2015) 
GSE59530 GSM1534723 SRX747778 SRR1635446 MCF7 Illumina HiSeq 
2500  
E2 treated r2   100 nM 17β-
estradiol 
ER-alpha SRR1635446.sam (Franco, Nagari and Kraus, 
2015) 
GSE59530 GSM1534714 SRX747769 SRR1635437 MCF7 Illumina HiSeq 
2500  
  Vehicle_control 100 nM 17β-
estradiol 
Input_DNA   (Franco, Nagari and Kraus, 
2015) 
                    
GSE54855 GSM1325253 SRX469400 SRR1167684 MCF7 Illumina HiSeq 
2000 (Homo 
sapiens) 
  Ns igg ip control 
(non-specific 
binding) 
100 nM estradiol IgG SRR1167684.sam (Guertin et al., 2014) 
GSE54855 GSM1325249 SRX469369 SRR1167678 MCF7 Illumina HiSeq 
2000 (Homo 
sapiens) 
E2 treated (10 
mins) 
  100 nM estradiol 
10 minutes 
ER   (Guertin et al., 2014) 
GSE54855 GSM1325251 SRX469398 SRR1167682 MCF7 Illumina HiSeq 
2000 (Homo 
sapiens) 
E2 treated 
(160 mins) 
  100nM estradiol 
160 minutes 
ER SRR1167682.sam (Guertin et al., 2014) 
 
Appendix 2A. Estrogen receptor – data files and details for ChIPseq analysis 
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PROGESTERONE RECEPTOR – data files and details for ChIPseq analysis 
GSE 
Number 
GSM Number SRX SRR Number Cell 
Line 
Platform Experimental Control Treatment Chip 
antibody 
SAM files Reference 
GSE68359 
GSE68355 
GSM1669020  SRX1012603 SRR2000691 T47D Illumina HiSeq 
2000 
  Input_control Full media None 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669021  SRX1012604 SRR2000692 T47D Illumina HiSeq 
2000 
 
Input_control Full media None 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669022 SRX1012605  T47D Illumina HiSeq 
2000 
 Input_control Full media None  (Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669035 SRX1012618  T47D Illumina HiSeq 
2000 
PR  3h 100nM 
Progesterone  
PR  (Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669036 SRX1012619  T47D Illumina HiSeq 
2000 
PR  3h 100nM 
Progesterone  
PR  (Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669037 SRX1012620  T47D Illumina HiSeq 
2000 
PR  3h 100nM 
Progesterone  
PR  (Mohammed et al., 2015) 
                    
GSE68359 
GSE68355 
GSM1669051 SRX1012634 
 
MCF7 Illumina HiSeq 
2000 
  Input_control Full media None 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669052 SRX1012635 
 
MCF7 Illumina HiSeq 
2000 
  Input_control Full media None 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669053 SRX1012636 
 
MCF7 Illumina HiSeq 
2000 
 
Input_control Full media None 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669070 SRX1012653 
 
MCF7 Illumina HiSeq 
2000 
PR   3h 100nM 
Progesterone  
PR 
 
(Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669071 SRX1012654 
 
MCF7 Illumina HiSeq 
2000 
PR 
 
3h 100nM 
Progesterone  
PR   (Mohammed et al., 2015) 
GSE68359 
GSE68355 
GSM1669072 SRX1012655  MCF7 Illumina HiSeq 
2000 
PR  3h 100nM 
Progesterone  
PR  (Mohammed et al., 2015) 
                    
GSE41617 
GSE41466 
GSM1017847 SRX193384 
 
T47D-
MTVL 
Agilent-014850 
Whole Human 
Genome 
Microarray 
4x44K G4112F 
  
 
Vehicle anti-PR 
 
(Ballaré et al., 2013) 
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Illumina 
Genome 
Analyzer 
GSE41617 
GSE41466 
GSM1017851 SRX193388 
 
T47D-
MTVL 
Agilent-014850 
Whole Human 
Genome 
Microarray 
4x44K G4112F 
Illumina 
Genome 
Analyzer 
  
10mM R5020  
360 minutes 
anti-PR   (Ballaré et al., 2013) 
GSE41617 
GSE41466 
GSM1017850 SRX193387 
 
T47D-
MTVL 
Agilent-014850 
Whole Human 
Genome 
Microarray 
4x44K G4112F 
Illumina 
Genome 
Analyzer 
 
  10mM R5020  
60 minutes 
anti-PR 
 
(Ballaré et al., 2013) 
GSE31129 GSM770760  SRX091826 SRR330988 AB32 Illumina 
Genome 
Analyzer IIx 
  Input_control 45 mins 10nM 
ORG2058 
Anti-PR 
 
(Clarke and Graham, 2012) 
GSE31129 GSM770761  SRX091827 SRR330989 AB32 Illumina 
Genome 
Analyzer IIx 
 
Input_control 45 mins 10nM 
ORG2058 
Anti-PR 
 
(Clarke and Graham, 2012) 
GSE31129 GSM770758 SRX091824 SRR330986 AB32 Illumina 
Genome 
Analyzer IIx 
PR-ChIP  45 mins 10nM 
ORG2058 
Anti-PR  (Clarke and Graham, 2012) 
GSE31129 GSM770759 SRX091825 SRR330987 AB32 Illumina 
Genome 
Analyzer IIx 
PR-ChIP  45 mins 10nM 
ORG2058 
Anti-PR  (Clarke and Graham, 2012) 
GSE31129 GSM770763 SRX091829 SRR330991 T47D Illumina 
Genome 
Analyzer IIx 
 Input_control 45 mins 10nM 
ORG2058 
Anti-PR  (Clarke and Graham, 2012) 
GSE31129 GSM770766 SRX091832 SRR330994 T47D Illumina 
Genome 
Analyzer IIx 
 Input_control 45 mins 10nM 
ORG2058 
Anti-PR  (Clarke and Graham, 2012) 
GSE31129 GSM770762 SRX091828 SRR330990 T47D Illumina 
Genome 
Analyzer IIx 
PR-ChIP  45 mins 10nM 
ORG2058 
Anti-PR 
 
(Clarke and Graham, 2012) 
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GSE31129 GSM770764 SRX091830 SRR330992 T47D Illumina 
Genome 
Analyzer IIx 
PR-ChIP  45 mins 10nM 
ORG2058 
Anti-PR 
 
(Clarke and Graham, 2012) 
GSE68355 GSM1669071 
 
 
SRR2000787 MCF7 Illumina HiSeq 
2000 
 
PR   3h 100nM 
Progesterone  
PR Antibody 
(H-190) 
 
(Mohammed et al., 
2015)(Mohammed <i>et 
al.</i>, 2015) 
GSE68355 GSM1669020 
 
SRR2000691 T47D Illumina HiSeq 
2000 
 
 
Input_control Full_Media 
 
none (input)   (Mohammed et al., 2015) 
GSE68355 GSM1669021 
 
 SRR2000692 T47D Illumina HiSeq 
2000 
 
 Input_control Full_Media 
 
none (input)  (Mohammed et al., 2015) 
GSE68355 GSM1669035 
 
 
SRR2000718 T47D Illumina HiSeq 
2000 
 
PR   100nM 
Progesterone  
3h 
PR Antibody 
(H-190) 
 
(Mohammed et al., 2015) 
GSE68355 GSM1669051 
 
 
SRR2000750 MCF7 Illumina HiSeq 
2000 
 
 
Input_control Full_Media 
 
none (input)   (Mohammed et al., 2015) 
GSE68355 GSM1669052 
 
 
SRR2000751 MCF7 Illumina HiSeq 
2000 
 
 
Input_control Full_Media 
 
none (input) 
 
(Mohammed et al., 2015) 
 
Appendix 2B. Progesterone receptor – data files and details for ChIPseq analysis 
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Appendix 4 
 
Reaction ID Reaction  
R_ER_EX_akt akt_e = akt_xt 
R_ER_53 creb1_n + 0.0 no_n = creb1p_n + 0.0 no_n 
R_ER_38 M_h_m + M_nadp_m = M_nadph_m 
R_ER_TRm_atp M_atp_m = M_atp_c 
R_ER_TR_akt akt_c = akt_e 
R_ER_TRm akt_m = akt_c 
R_ER_EX_pkg pkg_e = pkg_xt 
R_ER_TRm_ras|gdp ras|gdp_c = ras|gdp_m 
R_ER_EX_cav1 cav1_e = cav1_xt 
R_ER_EX_gc gc_e = gc_xt 
R_ER_TR_cgmp cgmp_c = cgmp_ca 
R_ER_16 & gc|no_c + gtp_c = cgmp_ca 
R_ER_TR_gc gc_c = gc_e 
R_ER_EX_shc shc_e = shc_xt 
R_ER_TRm_gc gc_c = gc_e 
R_ER_TR_cav1 cav1_c = cav1_e 
R_ER_TRm_cav1 cav1_m = cav1_c 
R_ER_45 
& er|estradiol|er|estradiol_m + src_m = 
er|estradiol|er|estradiol|src_m 
R_ER_39 a1 = b1 
R_ER_19 cam_m + enos|cav1_m = enos|cav1|cam_m 
R_ER_EX_arg arg_e = arg_xt 
R_ER_TRm_cam cam_m = cam_c 
R_ER_TR_arg arg_c = arg_e 
R_ER_15 gc_c + no_c = gc|no_c 
R_ER_18 cav1_c + enos_m = enos|cav1_m 
R_ER_TRm_arg arg_m = arg_c 
R_ER_EX_erk erk_e = erk_xt 
R_ER_TR_erk erk_c = erk_e 
R_ER_TRm_erk erk_m = erk_c 
R_ER_13 gdp_c + ras_c = ras|gdp_c 
R_ER_TR_pkg pkg_c = pkg_e 
R_ER_TRm_pkg pkg_m = pkg_c 
R_ER_23 
M_arg_L_c + & enos|cam|aktp_m + nadph_c + 
o2_c = M_citr_L_c + M_no_c 
R_ER_EX_M_estradiol M_estradiol_e = M_estradiol_xt 
R_ER_TR_shc shc_c = shc_e 
R_ER_TRm_shc shc_m = shc_c 
R_ER_EX_src src_e = src_xt 
R_ER_EX_pip2 pip2_e = pip2_xt 
R_ER_TR_src src_c = src_e 
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R_ER_TRm_src src_m = src_c 
R_ER_EX_adp adp_e = adp_xt 
R_ER_EX_er er_e = er_xt 
R_ER_EX_grb2 grb2_e = grb2_xt 
R_ER_TR_grb2 grb2_c = grb2_e 
R_ER_TRm_grb2 grb2_m = grb2_c 
R_ER_EX_pi3k pi3k_e = pi3k_xt 
R_ER_TR_pi3k pi3k_c = pi3k_e 
R_ER_TRm_pi3k pi3k_m = pi3k_c 
R_ER_52 dbd|rrm2_xt = dbd|rrm2_n 
R_ER_42 
M_atp_c + akt|pip3_m + & mtor_c = adp_c + 
aktp|pip3_m 
R_ER_TRm_akt akt_m = akt_c 
R_ER_EX_sos sos_e = sos_xt 
R_ER_TR_sos sos_c = sos_e 
R_ER_TRm_sos sos_m = sos_c 
R_ER_TR_er er_c = er_e 
R_ER_TRm_er er_m = er_c 
R_ER_TR_adp adp_c = adp_e 
R_ER_EX_mek mek_e = mek_xt 
R_ER_TRm_adp adp_m = adp_c 
R_ER_EX_cam cam_e = cam_xt 
R_ER_EX_gdp gdp_e = gdp_xt 
R_ER_TR_gdp gdp_c = gdp_e 
R_ER_TRm_enos|cam enos|cam_c = enos|cam_m 
R_ER_TR_atp M_atp_c = M_atp_e 
R_ER_27 mek_c = mekp_c 
R_ER_22 
M_atp_c + enos|cam|akt_m = M_adp_c + 
enosp|cam|aktp_m 
R_ER_17 cam_c + enos_c = enos|cam_c 
R_ER_TRm_gdp gdp_m = gdp_c 
R_ER_TR_pip2 pip2_c = pip2_e 
R_ER_TRm_pip2 pip2_m = pip2_c 
R_ER_EX_pdpk1 pdpk1_e = pdpk1_xt 
R_ER_TR_pkgp a2 = b2 
R_ER_59 
M_atp_n + creb1_n + & pkgp_n = adp_n + 
creb1p_c 
R_ER_TR_pdpk1 pdpk1_c = pdpk1_e 
R_ER_TRm_pdpk1 pdpk1_m = pdpk1_c 
R_ER_EX_ras ras_e = ras_xt 
R_ER_TR_ras ras_c = ras_e 
R_ER_TRm_ras ras_m = ras_c 
R_ER_EX_creb1 creb1_e = creb1_xt 
R_ER_TR_creb creb1_c = creb1_e 
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R_ER_TRn_creb1 creb1_n = creb1_e 
R_ER_62 & ac_m + atp_c = camp_c 
R_ER_TRm_creb1 creb1_m = creb1_c 
R_ER_EX_nadp M_nadp_e = M_nadp_xt 
R_ER_TR_nadp M_nadp_c = M_nadp_e 
R_ER_1 
2.0 M_estradiol_m + 2.0 er_m = 2.0 
er|estradiol_m 
R_ER_EX_msk1 msk1_e = msk1_xt 
R_ER_TRn_msk1 msk1_n = msk1_c 
R_ER_TR_msk1 msk1_c = msk1_e 
R_ER_TRm_msk1 msk1_m = msk1_c 
R_ER_TRn_M_estradiol M_estradiol_n = M_estradiol_c 
R_ER_TRe_M_estradiol M_estradiol_c = M_estradiol_e 
R_ER_TRm_M_estradiol M_estradiol_m = M_estradiol_c 
R_ER_EX_mtor mtor_e = mtor_xt 
R_ER_TR_mtor mtor_c = mtor_e 
R_ER_TRm_mtor mtor_m = mtor_c 
R_ER_TRn_mtor mtor_n = mtor_c 
R_ER_TRm_nadp M_nadp_m = M_nadp_c 
R_ER_26 erk_c + mek_c = mek|erk_c 
R_ER_33.1 ppmek_c = ppmek_xt 
R_ER_46 
& er|estradiol|er|estradiol|src_m + 
pi3k_m = 
er|estradiol|er|estradiol|src|pi3k_m 
R_ER_40 
2.0 M_estradiol_n + 2.0 er_m = 2.0 
er|estradiol_n 
R_ER_47 
er|estradiol|er|estradiol_m + shc_m = 
er|estradiol|er|estradiol|shc_m 
R_ER_3 
2.0 er|estradiol_m = 
er|estradiol|er|estradiol_m 
R_ER_51 
4.0 M_atp_n + & mapk_n + msk1_n = 4.0 
adp_n + msk1p_n 
R_ER_50 M_atp_n + msk1p_n = adp_n + creb1p_n 
R_ER_2 
2.0 M_estradiol_m + 2.0 er_m = 2.0 
er|estradiol_m 
R_ER_TRn_mapk|mapk mapk|mapk_n = mapk|mapk_c 
R_ER_29 erk_c + mekp_c = mekp|erk_c 
R_ER_24 erk_c = erkp_c 
R_ER_25 erkp_c = erkpp_c 
R_ER_4 akt_c + pip3_m = akt|pip3_m 
R_ER_14.1 crebp1_n = crebp1_xt 
R_ER_14 M_atp_n + creb1_n = adp_n + crebp1_n 
R_ER_7 
akt|pip3_m + pdpk1|pip3_m = 
akt|pdpk1|pip3_m 
R_ER_21 akt_m + enos|cam_m = enos|cam|akt_m 
R_ER_20 
enos|cav1|cam_m = & ca2 + cav1_c + 
enos|cam_m 
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R_ER_32 
2.0 M_atp_c + mekp|erk_c = 2.0 M_adp_c + 
mekp|erkp_c 
R_ER_35 
2.0 M_atp_c + & mekp|erk_c = 2.0 M_adp_c 
+ mekp|erkp_c 
R_ER_48 
& 
er|estradiol|er|estradiol|shc|grb2|sos_m 
+ gtp_c + ras|gdp_m = gdp_c + ras|gtp_m 
R_ER_44 & raf_m + ras|gtp_m = ras|gtp|raf_m 
R_ER_43 ~ pka_c + raf_c = rafp_c 
R_ER_34 erk_c + mekpp_c = mekpp|erk_c 
R_ER_33 mekpp|erk_c = pperk_c + ppmek_c 
R_ER_5.1 pip3_xt = pip3_m 
R_ER_9 
akt|pip3_m + pdpk1|pip3_m = 
akt|pdpk1|pip3_m 
R_ER_5 
M_atp_m + & pi3k_m + pip2_m = M_adp_m + 
pip3_m 
R_ER_60 
M_atp_n + aktp_n + creb1_n = adp_n + 
akt_n + creb1p_n 
R_ER_TR_aktp aktp_c = aktp_m 
R_ER_58 cgmp_c + pkg_c = pkgp_c 
R_ER_8 pdpk1_m + pip3_m = pdpk1|pip3_m 
R_ER_49 raf_c + ras|gtp|raf_m = ras|gtp|raf|raf_m 
R_ER_54 & creb1p_n + dbd|rrm2_n = rrm2_n 
R_ER_36 2.0 mapk_c = mapk|mapk_c 
R_ER_TRn_estradiol M_estradiol_n = M_estradiol_c 
R_ER_31 erk_c + mekp_c = mekp|erk_c 
R_ER_57 M_atp_c + aktp_c + bad_c = adp_c + badp_c 
R_ER_56 
akt|pdpk1|pip3_m + atp_m = adp_c + aktp_m 
+ pdpk1|pip3_m 
R_ER_6 
akt|pdpk1|pip3_m + atp_m = adp_c + aktp_m 
+ pdpk1|pip3_m 
R_ER_TRm_akt|pip3 akt|pip3_c = akt|pip3_m 
R_ER_11 
akt|pdpk1|pip3_m + atp_m = aktp_m + 
pdpk1|pip3_m 
R_ER_12 
atp_m + & pi3k_m + pip2_m = adp_m + 
pip3_m 
R_ER_EX_bad M_atp_c + aktp_c + bad_c = adp_c + badp_c 
R_ER_TR_bad bad_e = bad_xt 
R_ER_EX_pka pka_e = pka_xt 
R_ER_TR_pka pka_c = pka_e 
R_ER_TRm_pka pka_m = pka_c 
R_ER_TRm_bad bad_c = bad_e 
R_ER_10 bad_m = bad_c 
R_ER_EX_raf raf_e = raf_xt 
R_ER_TR_raf raf_c = raf_e 
R_ER_TRn_gc gc_n = gc_m 
R_ER_TRm_raf raf_m = raf_c 
R_ER_TRn_M_atp M_atp_n = M_atp_m 
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R_ER_EX_ca2 ca2_e = ca2_xt 
R_ER_TR_cam cam_c = cam_e 
R_ER_TR_ca2 ca2_c = ca2_e 
R_ER_TRm_ca2 ca2_m = ca2_c 
R_ER_EX_no no_e = no_xt 
R_ER_TR_no no_c = no_e 
R_ER_TRm_no no_m = no_c 
R_ER_TRn_no no_n = no_c 
R_ER_TR_gtp gtp_c = gtp_e 
R_ER_EX_gtp gtp_e = gtp_xt 
R_ER_TRm_gtp gtp_m = gtp_c 
R_ER_TR_mek mek_c = mek_e 
R_ER_TRm_mek mek_m = mek_c 
R_ER_30 
2.0 atp_c + mekp|erk_c = 2.0 adp_c + 
mekp|erkp_c 
R_ER_28 mekp_c = mekpp_c 
R_ER_EX_mapk mapk_e = mapk_xt 
R_ER_TR_mapk mapk_c = mapk_e 
R_ER_TRn_mapk mapk_n = mapk_c 
R_ER_TRm_mapk mapk_m = mapk_c 
R_ER_37 M_h_c + M_nadp_c = M_nadph_c 
R_ER_TRm_pkgp pkgp_m = pkgp_c 
R_ER_TRn_pkgp pkgp_n = pkgp_c 
R_ER_TRn_aktp aktp_n = aktp_c 
R_ER_EX_enos enos_e = enos_xt 
R_ER_TR_enos enos_c = enos_e 
R_PR_TRe_pg pg_m = pg_e 
R_PR_EX_p21 p21_e = p21_xt 
R_PR_TR_p21 p21_c = p21_e 
R_PR_TRm_p21 p21_m = p21_c 
R_PR_23.5 ksr1_c + mark3_c = ksr1|mark3_c 
R_PR_EX_mark3 mark3_e = mark3_xt 
R_PR_TR_mark3 mark3_c = mark3_xt 
R_PR_TRm_mark3 mark3_m = mark3_c 
R_PR_21.5 
p21_m + ras|gtp|raf|ywhab|ywhab_m = 
p21ras|gtp|raf|ywhab|ywhab_m 
R_PR_21 
raf|ywhab|ywhab_c + ras|gdp_m = 
ras|gtp|raf|ywhab|ywhab_m 
R_PR_EX_ksr1 ksr1_e = ksr1_xt 
R_PR_TR_ksr1 ksr1_c = ksr1_e 
R_PR_TRm_ksr1 ksr1_m = ksr1_c 
R_PR_22.5 ksr1_c + rafp_c = raf|ksr1_c 
R_PR_22 
p21ras|gtp|raf|ywhab|ywhab_m + raf|ksr1_c 
= p21ras|gtp|raf|raf_m 
R_PR_19.5 2.0 ywhab_c = ywhab|ywhab_c 
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R_PR_23 
2.0 M_atp_c + & ksr1|mark3_c = 2.0 
M_adp_c + ksr1p|mark3_c 
R_PR_EX_rafkinases rafkinases_e = rafkinases_xt 
R_PR_24 
ksr1p|mark3_c + ywhab|ywhab_c = 
ksr1p|mark3|ywhab|ywhab_c 
R_PR_25 
M_h20_c + ksr1p|mark3|ywhab|ywhab_c + & 
pp2a_c = ksr1|mark3|ywhab|ywhab_c + pi_c 
R_PR_26 
ksr1|mark3|ywhab|ywhab_c = ksr1|mark3_c + 
ywhab|ywhab_c 
R_PR_27 
4.0 M_atp_c + p21ras|gtp|raf|raf_m + & 
rafkinases_m = 4.0 M_adp_c + 
p21ras|gtp|raf|rafp_m 
R_PR_EX_map2k map2k_e = map2k_xt 
R_PR_TR_map2k map2k_c = map2k_e 
R_PR_TRm_map2k map2k_m = map2k_c 
R_PR_27.5 mapk_c + raf_c = raf|mapk_c 
R_PR_EX_il17rd il17rd_e = il17rd_xt 
R_PR_TR_il17rd il17rd_c = il17rd_e 
R_PR_TRm_il17rd il17rd_m = il17rd_c 
R_PR_TRgm_il17rd il17rd_gm = il17rd_c 
R_PR_31.5 
p21_m + ras|gtp|rafp_m = 
p21ras|gtp|rafp_m 
R_PR_TRm_ras|gtp|rafp ras|gtp|rafp_m = ras|gtp|rafp_c 
R_PR_28.5 M_gtp_c + rafp_c + ras_c = ras|gtp|rafp_c 
R_PR_28 
map2k_c + mapk_c + raf|mapk_c + 
ras|gtp|rafp_c = rafp|map2k|mapk_m 
R_PR_29 
2.0 M_atp_c + rafp|map2k|mapk_m = 2.0 
M_adp_c + rafp|map2kp|mapk_m 
R_PR_30 
2.0 M_atp_c + rafp|map2kp|mapk_m = 2.0 
M_adp_c + rafp|map2kp|mapkp_m 
R_PR_EX_rafp|map2kp|mapkp 
rafp|map2kp|mapkp_e = 
rafp|map2kp|mapkp_xt 
R_PR_31 
ab_c + rafp|map2kp|mapkp_m = map2kp_c + 
mapkp_c + p21ras|gtp|araf_m + raf|mapk_c 
R_PR_EX_adenylatecyclase adenylatecyclase_e = adenylatecyclase_xt 
R_PR_TR_adenylatecyclase adenylatecyclase_c = adenylatecyclase_e 
R_PR_TRm_adenylatecyclase adenylatecyclase_m = adenylatecyclase_c 
R_PR_5 
& adenylatecyclase_m + atp_c = camp_c + 
ppi_c 
R_PR_EX_gproteinbg gproteinbg_e = gproteinbg_xt 
R_PR_TR_gproteinbg gproteinbg_c = gproteinbg_e 
R_PR_TRm_gproteinbg gproteinbg_m = gproteinbg_c 
R_PR_6 
M_h2o_c + camp_c + & phosphodiesterase_c 
= amp_c 
R_PR_EX_gproteina gproteina_e = gproteina_xt 
R_PR_TR_gproteina gproteina_c = gproteina_e 
R_PR_TRm_gproteina gproteina_m = gproteina_c 
R_PR_EX_gproteinap gproteinap_e = gproteinap_xt 
R_ER_TRm_enos enos_m = enos_c 
R_PR_TR_pg pg_c = pg_e 
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R_PR_TRm_pg pg_m = pg_c 
R_PR_32 
map2k_c + mapk_c + mp1|p14_em + 
p21ras|gtp|rafp_m = 
mp1|p14|araf|map2k|mapk_em 
R_PR_33 
4.0 M_atp_c + mp1|p14|araf|map2k|mapk_em 
= 4.0 M_adp_c + 
mp1|p14|araf|map2kp|mapkp_em 
R_PR_EX_mp1|p14 mp1|p14_e = mp1|p14_xt 
R_PR_TR_mp1|p14 mp1|p14_c = mp1|p14_e 
R_PR_TRm_mp1|p14 mp1|p14_m = mp1|p14_c 
R_PR_TRem_mp1|p14 mp1|p14_em = mp1|p14_c 
R_PR_34.5 2.0 map2k_c = map2k|map2k_c 
R_PR_34 
il17rd_gm + map2k|map2k_c + mapk_c = 
il17rd|map2kp|mapk_gm 
R_PR_TRn_pka pka_n = pka_c 
R_PR_EX_pka pka_e = pka_xt 
R_PR_35 
2.0 M_atp_c + il17rd|map2kp|mapk_gm = 2.0 
M_adp_c + il17rd|map2kp|mapkp_gm 
R_PR_35.5 M_atp_c + mapk_c = M_adp_c + mapkp_c 
R_PR_36 2.0 mapkp_c = mapkp|mapkp_c 
R_PR_37 mapkp|mapkp_c = mapkp|mapkp_n 
R_PR_EX_pea15 pea15_e = pea15_xt 
R_PR_TR_pea15 pea15_c = pea15_e 
R_PR_TRm_pea15 pea15_m = pea15_c 
R_PR_38 
mapkp_c + mapkp|mapkp_c + 2.0 pea15_c = 
mapkp|pea15_c 
R_PR_7 gproteinap_m = gproteina_m + pi_c 
R_PR_11 pr|pg_c + src_c = pr|pg|src_c 
R_PR_12 pr|pg|src_c + shc_c = pr|pg|src|shc_c 
R_PR_13 
3.0 M_atp_c + pr|pg|src|shc_c = 
pr|pg|src|shcp_c 
R_PR_14 
grb2|sos1_c + pr|pg|src|shcp_c = 
pr|pg|src|shcp|grb2|sos1_c 
R_PR_EX_sos1 sos1_e = sos1_xt 
R_PR_TR_sos1 sos1_c = sos1_e 
R_PR_TRm_sos1 sos1_m = sos1_c 
R_PR_15 grb2_c + sos1_c = grb2|sos1_c 
R_PR_EX_p21ras p21ras_e = p21ras_xt 
R_PR_TR_p21ras p21ras_c = p21ras_e 
R_PR_TRm_p21ras p21ras_m = p21ras_c 
R_PR_16 
M_gtp_c + p21ras_m + & 
pr|pg|src|shcp|grb2|sos1_c = M_gdp_c + 
p21rasp_m 
R_PR_EX_ras|gef ras|gef_e = ras|gef_xt 
R_PR_TR_ras|gef ras|gef_c = ras|gef_e 
R_PR_TRm_ras|gef ras|gef_m = ras|gef_c 
R_PR_17 
M_gtp_c + ras|gdp_m + & ras|gef_c = 
M_gdp_c + ras|gtp_m 
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R_PR_EX_pp2a pp2a_e = pp2a_xt 
R_PR_TR_pp2a pp2a_c = pp2a_e 
R_PR_TRm_pp2a pp2a_m = pp2a_c 
R_PR_18 
M_h20_c + & pp2a_c + rafp|ywhab|ywhab_c = 
M_pi_c + raf|ywhab|ywhab_c 
R_PR_19 
rafp_c + ywhab|ywhab_c = 
rafp|ywhab|ywhab_c 
R_PR_20 raf|ywhab|ywhab_c = raf_c + ywhab|ywhab_c 
R_PR_8 
gproteina_m + gproteinbg_m = 
gproteinabg_m 
R_PR_9 
M_atp_n + creb1_n + & pka_n = M_adp_n + 
creb1p_n + pi_n 
R_PR_EX_pr pr_e = pr_xt 
R_PR_TR_pr pr_c = pr_e 
R_PR_TRm_pr pr_m = pr_c 
R_PR_10 pg_c + pr_c = pr|pg_c 
R_PR_2 
gproteinabg_m + parqr7|pg_m = 
parqr7|pg|gproteinabg_m 
R_PR_EX_pg pg_e = pg_xt 
R_PR_TR_parqr7 parqr7_c = parqr7_e 
R_PR_TRm_parqr7 parqr7_m = parqr7_c 
R_PR_EX_parqr7 parqr7_e = parqr7_xt 
R_PR_4 
adenylatecyclase_m + gproteinap_m = 
gproteinap|adenylatecyclase_m 
R_PR_TR_gproteinap gproteinap_c = gproteinap_e 
R_PR_TRm_gproteinap gproteinap_m = gproteinap_c 
R_PR_TRm_rafkinases rafkinases_m = rafkinases_c 
R_PR_TR_rafkinases rafkinases_c = rafkinases_e 
R_PR_EX_phosphodiesterase 
phosphodiesterase_e = 
phosphodiesterase_xt 
R_PR_TR_phosphodiesterase phosphodiesterase_c = phosphodiesterase_e 
R_PR_TRm_phosphodiesterase phosphodiesterase_m = phosphodiesterase_c 
R_ER_TRm_rafkinases a = b 
 
 
Appendix 4. Reactions written for indirect signalling of ER (R_ER_) and PR (R_PR_) and 
included in the GSMN. 
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Appendix 5 
 
 
Appendix 5. The table of rate constants for Tyson and Novak’s model of the cell cycle (Tyson and Novak, 2001).
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Ctrl file for cell cycle in MuFINS 
 
 
MODEL ./recon2_xt.PIPES.CORE.v2.sfba 
NUMBER_OF_SAMPLES 1 
 
SEED 761  
 
TIME_MAX 800 
MAXIMAL_TIMESTEP 0.01 
MAX_CHANGE 0.01  
 
OUTPUT ./output.xls 
LOG ./log.txt 
MONITOR 200 
PROGRESS 200 
 
INITIAL_STATE 
 
CycBt 0.001 
CycB 0.00062  
Cdc20a 0.001 
Cdc20t 0.001 
Cdh1 0.001 
CKIt 0.001 
IEP 0.001 
SK 0.001 
m 0.5 
Mad 1 
TF 0.029  
END 
 
PROPENSITY_FUNCTION Cdh1_synthesis 
((1+10*Cdc20a)*(1-Cdh1))/(0.04+1-Cdh1) 
END 
 
PROPENSITY_FUNCTION Cdh1_degradation 
(2*SK*Cdh1+35*m*CycB*Cdh1)/(0.04+Cdh1) 
END 
 
PROPENSITY_FUNCTION Cdc20t_synthesis 
0.005+((0.2*(CycB*m/0.3)^4)/(1+(CycB*m/0.3)^4)) 
END 
 
PROPENSITY_FUNCTION Cdc20_activation 
(1*IEP*(Cdc20t-Cdc20a))/(0.001+Cdc20t-Cdc20a) 
END 
 
PROPENSITY_FUNCTION Cdc20a_inhibition 
(0.5*Mad*Cdc20a)/(0.001+Cdc20a) 
END 
 
PROPENSITY_FUNCTION IEP_synthesis 
0.1*m*CycB*(1-IEP) 
END 
 
PROPENSITY_FUNCTION growth 
0.005*m*(1-m/10) 
END 
 
RESET_FUNCTION CycB_formation 
CycBt-
((2*CycBt*CKIt)/(CycBt+CKIt+1/1000+(((CycBt+CKIt+1/1000)^2
)-4*CycBt*CKIt)^0.5)) 
END 
 
RESET_FUNCTION TFv1 
1.5*m/1+0.05*SK/1 
END 
 
RESET_FUNCTION TFv2 
1+3*m/1*CycB/1 
END 
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RESET_FUNCTION CycB_formation 
CycBt-
((2*CycBt*CKIt)/(CycBt+CKIt+1/1000+(((CycBt+CKIt+1/1000)^2
)-4*CycBt*CKIt)^0.5)) 
END 
 
RESET_FUNCTION TFv1 
1.5*m/1+0.05*SK/1 
END 
 
RESET_FUNCTION TFv2 
1+3*m/1*CycB/1 
END 
 
RESET_FUNCTION TFB 
TF_v2-TF_v1+0.01*TF_v2+0.01*TF_v1 
END 
 
RESET_FUNCTION TF_formation 
(2*TF_v1*0.02)/(TF_B+(TF_B^2-4*(TF_v2-
TF_v1)*TF_v1*0.01)^0.5) 
END 
 
RESET_FUNCTION half_m  
0.5*m 
END 
 
*/ MONITORS */ 
 
PETRI_NET_MONITORS 
 
CycBt 
CycB 
Cdh1 
Cdc20a 
Cdc20t 
CKIt 
IEP 
m 
Mad 
SK 
TF 
TF_v1 
TF_v2 
TF_B 
CycB_is_up 
END 
 
SIMULATION 
 
 
Appendix 6: QSSPN control file for cell cycle model 
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Appendix 7 
An example script for the iMAT workflow  
 
 
Theory 
The integration of ~omics data with genome-scale metabolic networks has two distinct 
advantages: 
(i) the generation of context-specific genome-scale metabolic networks to allow examination 
of the emergent behavior of these metabolic landscapes during, for example, disease 
progression (REFS) 
(ii) the additional constraints placed that emerge through integration of ~omic datasets and 
genome-scale metabolic landscapes has been shown to improve the robustness of 
predictions made from thse ~omic datasets. 
  
MUFINS contains a number of different analysis methodologies to interpret ~omics data in 
the context of a GSMN, namely: Gene inactivity moderated by metabolism and expression 
(GIMME), iMAT and Fast iMAT. (REFS) 
  
This section will detail how to undertake these methods in MUFINS. Analysis can be 
undertaken through JyMet, but due to the time involved in most of these procedures it is 
more likely that jobs will be run on a remote server. Therefore, command line options are 
presented. 
  
Usage of iMAT method and alternatives. 
  
Synopsis 
  
./sfba  -i model_file  -X external_tag  -j gexp_file  -p problem_type  -b 
problem_file   [-o array] [-s solver] [-c] [-f output_file] 
  
where, 
  
-i model_file  :  input model file in MUFINS reaction table format. 
-j gexp_file  : input gene expression data file 
  
For iMAT and Fast iMAT methods (-p imat, -p fimat), gene expression data should be pre-
processed and discretized as 3 levels: highly (1), lowly (-1) and moderately expressed 
(0).  For  example: 
  
Gene        Tissue1    Tissue2 
g1         1         1 
g2         1        -1 
g3        -1         1 
… 
  
Where, the first column consists of gene names, and each of the following columns is 
associated with a gene expression profile for particular condition. Since this method was 
initially formulated to generate ‘tissue-specific models’, the columns are labelled as ‘Tissue*’ 
in the JyMet interface. Columns are tab-delimited, with ‘NA’ denoting an empty value.  The 
expression data can also be enzyme expression level (protein abundances) which is used in 
the same way as the gene expressions. For the GIMME methods (-p gimme and –p 
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gimmefva), the expressions are pre-processed absolute expression levels (positive 
numbers). 
  
-p problem_type :  analysis method 
The following methods are implemented: 
fimat: Fast iMAT approach (see MUFINS manuscript). 
  
-b problem_file  :  input problem file 
Problem file follows the format of FBA described in MUFINS manual (see sfba.pdf). The 
following parameters are specific to ~omics data analysis: 
![expression name]   - In ~omics data analysis approaches objective function represents 
congruency between data and flux distribution, rather than reaction flux. Thus we use the 
name of ~omics data sample (Tissue) in place as objective function. For gimme and 
gimmefva, the problem should define reaction bounds which define Required Metabolic 
Functionalities (RMF) that the cell is assumed to achieve, such as for example growth rate 
where the biomass reaction should be fixed at specific value. 
?[reaction name and gene name]  - perform analysis only for specific reactions and genes. If 
no reaction or gene designated, all reactions and genes will be investigated. Names are 
single space-delimited.   
  
-o array :  expression array 
Without the problem file you can directly specify which expression array column in 
expression table you would like to analyze. 
  
-s solver : solver and algorithms 
Both a GNU Linear Programming kit (GLPK) and Gurobi can be used as the solver. For the 
GLPK solver you can choosesimplex, exact or milp[,mip_gap] with mip_gap indicating the 
tolerance of the mixed integer linear programming (MILP: default mip_gap = 1e-6).  
To use the Gurobi solver, set options as -s grb[,tol[,foc]] where 2 parameters can be 
set. Parameter tol is used to set Dual&Primal feasibility tolerance for the Gurobi solver, 
tightening this tolerance can produce smaller constraint violations (default: 1e-6, Min: 1e-9, 
Max: 1e-2). Parameter foc is used to set MILP solution strategy, 4 integer values can be 
chosen which are  1: focus on finding feasible solutions quickly; 2: focus on proving 
optimality; 3: focus on moving objective bound; 0 (default): balancing between finding new 
feasible solutions and proving that the current solution is optimal. If MILP solver is very slow 
for a problem then try foc=3.  Because Gurobi’s MILP is much efficient than GLPK’s MILP, it 
is better choose Gurobi for problems which need MILP solver (such as imat and fimat) on 
big models. 
The default solver is GLPK simplex. 
  
Example 
Run the following commands: 
./sfba -i model.sfba -X _xt -j gexp -p fimat -o Tissue1 –s grb -c -f out_fimat 
   
  
Output for Fast iMAT (fimat): 
  
#666666: OPTIMAL (R1 + R1__r + R2 + -1 R3 + R4 + R5 + R5__r) 
Reac(direc)    Minimum        Maximum       Activity    State    Comment 
R1        500000: OPTIMAL    500000: OPTIMAL    1     1    #Reaction 1 
R1__r        0: OPTIMAL        0: OPTIMAL            -1     1    #R1:Reverse 
R2        500000: OPTIMAL    500000: OPTIMAL    1     1    #Reaction 2 
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R3        999999: OPTIMAL    999999: OPTIMAL    1     -1    #Reaction 3 
R4        333333: OPTIMAL    333333: OPTIMAL    1     1    #Reaction 4 
R5        333333: OPTIMAL    333333: OPTIMAL    1     1    #Reaction 5 
R5__r        0: OPTIMAL        0: OPTIMAL        -1     1    #R5:Reverse 
; 
  
The first row shows the maximized optimal flux 666666 and its state OPTIMAL on the 
objective function max(R1 + R1__r + R2 + -1 R3 + R4 + R5 + R5__r). 
Column  State denotes reaction state determined by genes expressions and rules and the 
coefficients are determined by these states. After fixing the nonzero-state reactions' fluxes, 
the normal FVA then be applied to each zero-state reaction. Let predicted flux range be 
[Fmin, Fmax], if Fmin >0 or Fmax<0 then reaction is predicted to be active (1); if Fmin = 
Fmax = 0 then reaction is predicted to be inactive (-1); otherwise reaction is predicted 
undetermined (0). By this reaction R1, R2, R3, R4 and R5 are active, and reverse 
reactions R1__r and R5__r are inactive which is consistent with the results of imat. Reactions 
with suffix ‘__r’ are split reverse reactions for nonzero state reversible reactions. 
  
  
  
Output for Gene inactivity moderated by metabolism and expression (gimme): 
  
#75: OPTIMAL (3 R6 + 3 R6__r) 
BIOMASS    50    0    #Biomass 
GROWTH        50    0    #Growth 
NR1        0    0    #Nutrient M1 
NR2        100    0    #Nutrient M2 
NR3        25    0    #Nutrient M3 
NR4        0    0    #Nutrient M4 
R1        50    100    #Reaction 1 
R2        25    100    #Reaction 2 
R2__r        0    100    #R2:Reverse 
R3        0    100    #Reaction 3 
R3__r        0    100    #R3:Reverse 
R4        0    0    #Reaction 4 
R5        25    200    #Reaction 5 
R5__r        0    200    #R5:Reverse 
R6        25    9    #Reaction 6 
R6__r        0    9    #R6:Reverse 
; 
  
The first row shows the minimized optimal flux 75 and its state OPTIMAL on the objective 
function minimize (3 R6 + 3 R6__r) under maximal growth (biomass fixed at 50). The 
value 75 is inconsistency score indicating the degree of disagreement between the gene 
expression data and the assumed objective function under specified required functionalities. 
Second column is non-unique flux for each reaction; third column is the reaction state 
determined by genes expressions and rules using the same mapping rule as iMAT method. 
Reactions with suffix ‘__r’ are split reverse reactions for all reversible reactions. 
 
Setting up the files for fast iMAT - R 
Procedure uses affy package to undertake normalisation, and then the panp package to make 
presenence-absence calls 
Initial set-up 
 setwd() to directory with cel files in 
 source("https://bioconductor.org/biocLite.R") #Set source for packages 
 biocLite("affy") 
 library(affy) 
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 biocLite("simpleaffy") 
 library(simpleaffy) 
 biocLite("panp") 
 library(panp) 
 biocLite("annotate") 
 Library(annotate) 
 biocLite("hgu133a2.db") #annotation information for HG-U133A_Plus_2 array 
 Library(hgu133a2.db) 
  
  
Preprocessing cel files 
 samples <- ReadAffy() #Reads all cel files in working directory in samples data structure 
 Saqc <- qc(samples) 
 Plot(saqc) #visual check of the quality of the cel files 
 samplesRMA <- rma(samples) # RMA preprocessing 
  
Panp 
 PA <- pa.calls(samplesRMA) #Carry out panp on pre-preocessed array data 
 PAcalls <- PA$Pcalls 
 write.csv(PAcalls, file = "PAcalls_rma.csv") #extract PA calls 
 Pvalues <- PA$Pvals 
 write.csv(Pvalues, file = "Pvals_rma.csv") #extract P values for PA calls 
  
Default will provide absent (A), present (P) and marginal (M). Take conservative approach and assign 
marginal -> present. Where you have multiple arrays, use the mode to decide assignment 
  
Extract probe data 
Panp provides a csv file of Affy_ID and expression level. For iMAT you need ENTREZID and expression 
level, to allow mapping to Recon2, which uses EntrezID for gene-reaction mapping 
 x <- hgu133a2ENTREZID #extract EntrezID information 
 mapped_probes <- mappedkeys(x) # mapp EntrezID to AffyID 
 GeneID.expression <- read.csv(file="PAcalls_rma.csv", sep=",") # load PA calls 
 GeneID.probeID <- as.data.frame(x[mapped_probes]) # load AffyID:EntrezID mapping 
 mrg <- merge(GeneID.expression, GeneID.probeID, by.x=1, by.y=1) # merge datasets by their 
commonalities 
 write.csv(mrg, file="merge.csv") # export result to .csv file 
Prepare input format for Fast iMAT 
 Open .csv file in Excel 
o Replace A,P and M with -1, 1 and 0, respectively 
o Remove row numbers column and swap affyID and Gene ID columns 
 merge <-read.csv("merge.csv") #read csv file into R 
 write.table(merge, file="mergetab.txt",sep="\t",row.names=FALSE) #ensures format is 
encoded correctly to  be read by JyMet 
 Open mergetab.txt in TextEdit and remove "" around col titles 
  
NOTE: check resultant .csv file for any values that are not (1) or (-1). Set these as -1. Can occur if 
match is not found 
Fast iMAT - terminal 
Initial set up 
In working directory ensure you have the following files 
 merge.txt #tab-delimited expression file from panp (above) 
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 sfba-glpk #program 
 Input sfba file (e.g. recon2_xt.PIPES.CORE.v2.sfba) 
o NOTE: you need to remove version number from GeneID to ensure that match is found 
 Open sfba file in Excel 
 Select the rule column and then Replace '.1' … '.n' with '' 
 Save file as tab-delimited and open in JyMet to check 
Command 
An example terminal line is shown here 
  
./sfba-grb -i recon2_xt.PIPES.CORE.v2.sfba -X _xt -j merge.txt -p fimat -o Tissue1 -s grb -f out_fimat 
  
Solution will solve in approx 20 minutes, with the following output 
  
Where min, max = FVA solution for this reaction; activity/state = active (1), undetermined (0) and 
inactive (-1) 
Open file in Excel and save as .csv to ensure correct reading in r 
 
Creation of final sfba file in R 
  
 Prepare sfba file for merge 
o create a copy and append .txt 
o Open in Excel and save as .csv file 
 Use makeSFBA8.R source script 
 Need to enter in blocks at present (does not work as a continuous script) 
o First block to line 13: Import/creation of structures 
o Second block 14-56: Loop to assign bounds for each reaction 
o Third block 57-59: Creation of output files 
 Check that the created .sfba file is different from the input .sfba file in JyMet to sanity check 
that the approach has worked 
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Control file for model 
 
 
 
MODEL ./RECON2_PIPES_NCI60_MCF7+ER.sfba 
 
 
 
 
NUMBER_OF_SAMPLES 1 
 
 
 
SEED 761  
 
 
 
 
 
 
 
TIME_MAX 10 
 
 
 
MAXIMAL_TIMESTEP 0.01 
 
 
 
MAX_CHANGE 0.01  
 
 
 
OUTPUT ./output.xls 
 
 
 
LOG ./log.txt 
 
 
 
 
 
 
 
MONITOR 2000 
 
 
 
PROGRESS 2000 
 
 
 
 
 
INITIAL_STATE 
 
 
 
 
 
CycBt 0.001 
 
CycB 0.00062 
 
Cdc20a 0.001 
 
Cdc20t 0.001 
 
Cdh1 0.001 
 
CKIt 0.001 
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IEP 0.001 
 
SK 0.001 
 
m 0.5 
 
Mad 1 
 
TF 0.029  
 
 
 
 
 
PR 0.1   
Progesterone 1 
ER 0.1 
Estrogen 0.16 
Tumour 1 
 
 
AK4 120 
ACSL1 111 
ST3GAL4 120 
NAGK 120 
SERPINA1 0 
GGCT 120 
ATP1A1 120 
ATP1B1 120 
PDE1C 120 
DEGS1 120 
ACOT6 112.1 
RRM2B 112.1 
ITPKA 111 
ELOVL5 111 
PLGC1 111 
P4HA2 111 
ABCB11 109 
EIC2 111 
ACOX2 109 
 
PIK3R3 112.5 
UGT2B15 112.5 
ACAT2 111 
ELOVL2 111 
FASD1 112.5 
CA12 112.5 
PTGES 112.5 
SLC26A2 112.5 
ACOT7 111 
GLA 111 
SLC22A5 111 
CYP1A1 111 
TYMS 112.5 
FUT9 112.5 
SLC7A5 111 
ABCA1 11 
ABCC5 11 
ATP6V0A4 11 
 
 
BUB1B 112.5 
CCNA2 0 
CDC25A 112.5 
CDC7 112.5 
CDK1 112.5 
CDCA3 112.5 
CDKN3 112.5 
CHEK1 112.5 
DSCC1 112.5 
CDC45 111 
 
BTG2 0 
CCNG2 0 
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CDC6 0 
CDK6 0 
CDKN2B 0 
 
 
 
*/ ER_ACTIVATES */ 
 
ER_target_gene_activated 0.83 
ER_target_mRNA_activated 0.0666075 
 
 
*/ PR_ACTIVATES */ 
 
PR_target_gene_activated 0.83 
PR_target_mRNA_activated 0.0666075 
 
 
END 
 
 
 
*/ ER REGULATED GENE EXPRESSION */ 
 
PROPENSITY_FUNCTION ER_activation 
Estrogen*ER*360 
END 
 
PROPENSITY_FUNCTION ER_deactivation 
ER_act*360*75 
END 
 
 
*/ ER ACTIVATION OF TRANSCRIPTION */ 
 
PROPENSITY_FUNCTION ERtarget_transcription_basal 
ER_target_gene_activated*0.1926 
END 
 
PROPENSITY_FUNCTION ERtarget_transcription_ER 
ER_target_gene_activated*ER_act*12 
END 
 
PROPENSITY_FUNCTION ER_activated_target_mRNA_degradation 
ER_target_mRNA_activated*2.4 
END 
 
 
*/ ER INHIBITION OF TRANSCRIPTION */ 
 
PROPENSITY_FUNCTION ER_repressor_transcription 
0.0162-(0.0154*ER_act) 
END 
 
PROPENSITY_FUNCTION ER_inactivated_target_mRNA_degradation 
ER_target_mRNA_inhibited*2.4 
END 
 
 
*/ PR REGULATED GENE EXPRESSION */ 
 
PROPENSITY_FUNCTION PR_activation 
Progesterone*PR*360 
END 
 
PROPENSITY_FUNCTION PR_deactivation 
PR_act*360*75 
END 
 
 
 
*/ PR ACTIVATION OF TRANSCRIPTION */ 
 
PROPENSITY_FUNCTION PRtarget_transcription_basal 
PR_target_gene_activated*0.1926 
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END 
 
PROPENSITY_FUNCTION PRtarget_transcription_PR 
PR_target_gene_activated*PR_act*12 
END 
 
PROPENSITY_FUNCTION PR_activated_target_mRNA_degradation 
PR_target_mRNA_activated*2.4 
END 
 
 
 
 
*/ PR INHIBITION OF TRANSCRIPTION */ 
 
PROPENSITY_FUNCTION PR_repressor_transcription 
0.1572-(0.00131*PR_act) 
END 
 
PROPENSITY_FUNCTION PR_inactivated_target_mRNA_degradation 
PR_target_mRNA_inhibited*2.4 
END 
 
 
 
*/ TUMOUR MODULE */  
 
PROPENSITY_FUNCTION Tumour_Growth 
Tumour*0.0235 
END 
 
PROPENSITY_FUNCTION Death 
Tumour*0 
END 
 
 
 
 
 
 
*/ CELL CYCLE */ 
 
 
PROPENSITY_FUNCTION Cdh1_synthesis 
((1+10*Cdc20a)*(1-Cdh1))/(0.04+1-Cdh1) 
END 
 
 
PROPENSITY_FUNCTION Cdh1_degradation 
(2*SK*Cdh1+35*m*CycB*Cdh1)/(0.04+Cdh1) 
END 
 
PROPENSITY_FUNCTION Cdc20t_synthesis 
0.005+((0.2*(CycB*m/0.3)^4)/(1+(CycB*m/0.3)^4)) 
END 
 
 
PROPENSITY_FUNCTION Cdc20_activation 
(1*IEP*(Cdc20t-Cdc20a))/(0.001+Cdc20t-Cdc20a) 
END 
 
 
PROPENSITY_FUNCTION Cdc20a_inhibition 
(0.5*Mad*Cdc20a)/(0.001+Cdc20a) 
END 
 
 
PROPENSITY_FUNCTION IEP_synthesis 
0.1*m*CycB*(1-IEP) 
END 
 
 
PROPENSITY_FUNCTION growth 
0.005*m*(1-m/1000) 
END  
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RESET_FUNCTION CycB_formation 
CycBt-((2*CycBt*CKIt)/(CycBt+CKIt+1/1000+(((CycBt+CKIt+1/1000)^2)-4*CycBt*CKIt)^0.5)) 
END 
 
 
 
RESET_FUNCTION TFv1 
1.5*m/1+0.05*SK/1 
END 
 
 
 
RESET_FUNCTION TFv2 
1+3*m/1*CycB/1 
END 
 
 
 
RESET_FUNCTION TFB 
TF_v2-TF_v1+0.01*TF_v2+0.01*TF_v1 
END 
 
 
 
RESET_FUNCTION TF_formation 
(2*TF_v1*0.02)/(TF_B+(TF_B^2-4*(TF_v2-TF_v1)*TF_v1*0.01)^0.5) 
END 
 
 
 
RESET_FUNCTION half_m  
0.5*m 
END 
 
 
*/ MONITORS */ 
 
PETRI_NET_MONITORS 
 
PR_target_gene_activated 
PR_target_mRNA_activated 
ER_target_gene_inhibited 
ER_target_mRNA_inhibited 
 
ER_target_gene_activated 
ER_target_mRNA_activated 
ER_target_gene_inhibited 
ER_target_mRNA_inhibited 
PR 
ER 
Progesterone 
Estrogen 
PR_act 
ER_act 
 
AK4 
ACSL1 
ST3GAL4 
NAGK 
SERPINA1 
GGCT 
ATP1A1 
ATP1B1 
PDE1C 
DEGS1 
ACOT6 
RRM2B 
 
ABCB11 
EIC2 
ACOX2 
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PIK3R3 
UGT2B15 
ACAT2  
ELOVL2 
FASD1 
CA12 
PTGES 
SLC26A2 
ACOT7 
GLA 
SLC22A5  
CYP1A1  
TYMS 
FUT9 
SLC7A5 
ABCA1 
ABCC5 
ATP6V0A4 
ELOVL5 
 
 
BUB1B 
CCNA2 
CDC25A  
CDC7  
CDK1 
CDCA3 
CDKN3 
CHEK1 
DSCC1 
CDC45 
 
BTG2 
CCNG2 
CDC6 
CDK6 
CDKN2B 
 
 
ACOT7_deg 
GGCT_deg 
PIK3R3_deg 
SOLUTION1 
SOLUTION2 
 
 
CycBt 
 
CycB 
 
Cdh1 
 
Cdc20a 
 
Cdc20t 
 
CKIt 
 
IEP 
 
m 
 
Mad 
 
SK 
 
TF 
 
TF_v1 
 
TF_v2 
 
TF_B 
 
CycB_is_up 
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Tumour_growth 
 
Death 
 
Tumour 
 
PIK3R3_deg 
 
flux2glucose 
flux2biomass 
 
END 
 
 
 
SIMULATION 
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